OA16599A - Glucosylceramide synthase inhibitors. - Google Patents
Glucosylceramide synthase inhibitors. Download PDFInfo
- Publication number
- OA16599A OA16599A OA1201300399 OA16599A OA 16599 A OA16599 A OA 16599A OA 1201300399 OA1201300399 OA 1201300399 OA 16599 A OA16599 A OA 16599A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- formula
- methyl
- further relates
- invention further
- Prior art date
Links
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 title description 5
- 206010024579 Lysosomal storage disease Diseases 0.000 claims abstract description 44
- 102000031052 Ceramide glucosyltransferases Human genes 0.000 claims abstract description 40
- 108091000115 Ceramide glucosyltransferases Proteins 0.000 claims abstract description 40
- 150000001875 compounds Chemical class 0.000 claims description 498
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 295
- 239000001257 hydrogen Substances 0.000 claims description 199
- 229910052739 hydrogen Inorganic materials 0.000 claims description 199
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 178
- 125000003003 spiro group Chemical group 0.000 claims description 155
- 125000003118 aryl group Chemical group 0.000 claims description 152
- 125000001072 heteroaryl group Chemical group 0.000 claims description 150
- 229910052799 carbon Inorganic materials 0.000 claims description 115
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 113
- -1 isopropenyl phenyl Chemical group 0.000 claims description 101
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 99
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 75
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 60
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 56
- 102000004190 Enzymes Human genes 0.000 claims description 48
- 108090000790 Enzymes Proteins 0.000 claims description 48
- 238000002648 combination therapy Methods 0.000 claims description 39
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 34
- 239000000651 prodrug Substances 0.000 claims description 28
- 229940002612 prodrugs Drugs 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 19
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 18
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 18
- 230000002132 lysosomal Effects 0.000 claims description 18
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 14
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 230000037361 pathway Effects 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000005605 benzo group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 102000016871 Hexosaminidase A Human genes 0.000 claims description 5
- 108010053317 Hexosaminidase A Proteins 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims description 4
- 102000016870 Hexosaminidase B Human genes 0.000 claims description 4
- 108010053345 Hexosaminidase B Proteins 0.000 claims description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- 208000008425 Protein Deficiency Diseases 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 229910003844 NSO2 Inorganic materials 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 2
- 238000009256 replacement therapy Methods 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract description 91
- 230000002401 inhibitory effect Effects 0.000 abstract description 18
- 239000003112 inhibitor Substances 0.000 abstract description 15
- 208000008466 Metabolic Disease Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 182
- 239000007787 solid Substances 0.000 description 136
- 238000000034 method Methods 0.000 description 126
- 239000000203 mixture Substances 0.000 description 125
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 121
- 239000000243 solution Substances 0.000 description 113
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 108
- 238000005160 1H NMR spectroscopy Methods 0.000 description 105
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 98
- 238000006243 chemical reaction Methods 0.000 description 97
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 88
- 235000019439 ethyl acetate Nutrition 0.000 description 75
- 230000000875 corresponding Effects 0.000 description 64
- 201000010099 disease Diseases 0.000 description 63
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 59
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 56
- 238000002560 therapeutic procedure Methods 0.000 description 48
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 44
- 239000007832 Na2SO4 Substances 0.000 description 42
- 239000003921 oil Substances 0.000 description 42
- 235000019198 oils Nutrition 0.000 description 42
- 229910052938 sodium sulfate Inorganic materials 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 40
- 239000012044 organic layer Substances 0.000 description 39
- 229940088598 Enzyme Drugs 0.000 description 38
- 239000000758 substrate Substances 0.000 description 38
- 239000011541 reaction mixture Substances 0.000 description 35
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 33
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 31
- 210000002700 Urine Anatomy 0.000 description 30
- 239000000463 material Substances 0.000 description 29
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 29
- 206010018048 Gaucher's disease Diseases 0.000 description 28
- 238000009825 accumulation Methods 0.000 description 28
- 238000007792 addition Methods 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 23
- 230000002354 daily Effects 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 230000002829 reduced Effects 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 21
- 210000004556 Brain Anatomy 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 230000001225 therapeutic Effects 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- 238000003860 storage Methods 0.000 description 19
- 239000000725 suspension Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 18
- 229910052681 coesite Inorganic materials 0.000 description 18
- 229910052906 cristobalite Inorganic materials 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 229910052904 quartz Inorganic materials 0.000 description 18
- 238000010992 reflux Methods 0.000 description 18
- 229910052682 stishovite Inorganic materials 0.000 description 18
- 210000001519 tissues Anatomy 0.000 description 18
- 229910052905 tridymite Inorganic materials 0.000 description 18
- POQRWMRXUOPCLD-GZXCKHLVSA-N β-D-glucosyl-N-(tetracosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O POQRWMRXUOPCLD-GZXCKHLVSA-N 0.000 description 18
- 210000002381 Plasma Anatomy 0.000 description 17
- 210000004027 cells Anatomy 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 17
- 239000004576 sand Substances 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 16
- HHJTWTPUPVQKNA-JIAPQYILSA-N β-D-glucosylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HHJTWTPUPVQKNA-JIAPQYILSA-N 0.000 description 16
- 210000003734 Kidney Anatomy 0.000 description 15
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 15
- 239000004202 carbamide Substances 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 14
- 125000004429 atoms Chemical group 0.000 description 14
- 238000004166 bioassay Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 238000003818 flash chromatography Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 13
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 13
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229920002892 amber Polymers 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- 201000005603 Fabry disease Diseases 0.000 description 11
- 239000000010 aprotic solvent Substances 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- XJKNACDCUAFDHD-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonane Chemical compound C1CC2CCN1CCN2 XJKNACDCUAFDHD-UHFFFAOYSA-N 0.000 description 10
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 10
- 206010029331 Neuropathy peripheral Diseases 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 108090001123 antibodies Proteins 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 229920000045 Dermatan sulfate Polymers 0.000 description 9
- AVJBPWGFOQAPRH-FWMKGIEWSA-L Dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 9
- 102100018083 GBA Human genes 0.000 description 9
- 229920002971 Heparan sulfate Polymers 0.000 description 9
- VODZWWMEJITOND-OWWNRXNESA-N N-Stearoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-OWWNRXNESA-N 0.000 description 9
- 229940051593 dermatan sulfate Drugs 0.000 description 9
- 238000007910 systemic administration Methods 0.000 description 9
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 8
- WKPUACLQLIIVJJ-RHKLHVFKSA-M (2S,3R,4R,5S,6R)-4-hydroxy-3-methoxy-6-[(2S,3R,4S,5S,6R)-6-methoxy-4-oxido-5-(sulfooxyamino)-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylate Chemical compound [O-][C@H]1[C@H](NOS(O)(=O)=O)[C@H](OC)O[C@@H](COS(O)(=O)=O)[C@@H]1O[C@H]1[C@@H](OS(O)(=O)=O)[C@H](O)[C@@H](OC)[C@@H](C([O-])=O)O1 WKPUACLQLIIVJJ-RHKLHVFKSA-M 0.000 description 8
- VPQCVPFSCUZMQI-UHFFFAOYSA-N CC(C)(NC(=O)OC1CN2CCC1CC2)c1ccc(F)c(Br)c1 Chemical compound CC(C)(NC(=O)OC1CN2CCC1CC2)c1ccc(F)c(Br)c1 VPQCVPFSCUZMQI-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 8
- IQPQWNKOIGAROB-UHFFFAOYSA-N [N-]=C=O Chemical compound [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000004305 biphenyl Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000008079 hexane Substances 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000000185 intracerebroventricular Methods 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 7
- 210000003169 Central Nervous System Anatomy 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 7
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000003018 immunosuppressive agent Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 150000003408 sphingolipids Chemical class 0.000 description 7
- HFQKBOPMAOTAIR-TZSVBWBLSA-N α-D-galactosyl-(1->4)-β-D-galactosyl-(1->4)-β-D-glucosylceramide Chemical group O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HFQKBOPMAOTAIR-TZSVBWBLSA-N 0.000 description 7
- ZVEMLYIXBCTVOF-UHFFFAOYSA-N 1-(2-isocyanatopropan-2-yl)-3-prop-1-en-2-ylbenzene Chemical compound CC(=C)C1=CC=CC(C(C)(C)N=C=O)=C1 ZVEMLYIXBCTVOF-UHFFFAOYSA-N 0.000 description 6
- BGKCBZYMCDIZHZ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-(2-bromophenyl)carbamate Chemical compound BrC1=CC=CC=C1NC(=O)OC1C(CC2)CCN2C1 BGKCBZYMCDIZHZ-UHFFFAOYSA-N 0.000 description 6
- JLUOHHFAHYVFGJ-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)acetic acid Chemical compound C1CC2C(CC(=O)O)CN1CC2 JLUOHHFAHYVFGJ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 6
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 6
- 101710043468 atpP Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 230000002255 enzymatic Effects 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 201000004502 glycogen storage disease II Diseases 0.000 description 6
- 229960002127 imiglucerase Drugs 0.000 description 6
- 108010039650 imiglucerase Proteins 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 101710043458 oli Proteins 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 239000001184 potassium carbonate Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000002194 synthesizing Effects 0.000 description 6
- YPWZLBKKVGKDSH-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-(3-bromophenyl)carbamate Chemical compound BrC1=CC=CC(NC(=O)OC2C3CCN(CC3)C2)=C1 YPWZLBKKVGKDSH-UHFFFAOYSA-N 0.000 description 5
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 5
- 208000006515 AB Variant Tay-Sachs Disease Diseases 0.000 description 5
- 210000004185 Liver Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010028144 alpha-Glucosidases Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 5
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 5
- 230000002503 metabolic Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 230000003442 weekly Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- VQGHWWJDOZXTNL-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-(4-bromophenyl)cyclopropyl]carbamate Chemical compound C1=CC(Br)=CC=C1C1(NC(=O)OC2C3CCN(CC3)C2)CC1 VQGHWWJDOZXTNL-UHFFFAOYSA-N 0.000 description 4
- BQQQLNDIYUBIAI-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(3-methoxyphenyl)propan-2-yl]carbamate Chemical compound COC1=CC=CC(C(C)(C)NC(=O)OC2C3CCN(CC3)C2)=C1 BQQQLNDIYUBIAI-UHFFFAOYSA-N 0.000 description 4
- OJCLMSVFVVKWJX-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-[3-(4-fluorophenyl)phenyl]propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=CC=1C1=CC=C(F)C=C1 OJCLMSVFVVKWJX-UHFFFAOYSA-N 0.000 description 4
- LLZKAZNUCYYBQO-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(OCC=2C=CC=CC=2)=C1 LLZKAZNUCYYBQO-UHFFFAOYSA-N 0.000 description 4
- IQKKTIWXHJDLFL-UHFFFAOYSA-N 2-(4-bromophenyl)propan-2-amine Chemical compound CC(C)(N)C1=CC=C(Br)C=C1 IQKKTIWXHJDLFL-UHFFFAOYSA-N 0.000 description 4
- FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 4
- 108060000228 ADRM1 Proteins 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 4
- NOMQTCMMBHIIII-UHFFFAOYSA-N BrC=1C=CC(=C(C1)C(C)(C)NC(OC1CN2CCC1CC2)=O)F Chemical compound BrC=1C=CC(=C(C1)C(C)(C)NC(OC1CN2CCC1CC2)=O)F NOMQTCMMBHIIII-UHFFFAOYSA-N 0.000 description 4
- 210000000133 Brain Stem Anatomy 0.000 description 4
- 102100005833 CD68 Human genes 0.000 description 4
- 210000001638 Cerebellum Anatomy 0.000 description 4
- 101710010383 GAA Proteins 0.000 description 4
- 102100008255 GAA Human genes 0.000 description 4
- 102000001389 Glial Fibrillary Acidic Protein Human genes 0.000 description 4
- 108010093505 Glial Fibrillary Acidic Protein Proteins 0.000 description 4
- 229940096919 Glycogen Drugs 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 4
- 210000001320 Hippocampus Anatomy 0.000 description 4
- KXCLCNHUUKTANI-RBIYJLQWSA-N Keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 4
- 229920000288 Keratan sulfate Polymers 0.000 description 4
- 102100008175 MGAM Human genes 0.000 description 4
- 208000008955 Mucolipidosis Diseases 0.000 description 4
- YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(β-N-acetyl-D-glucosaminyl)-L-asparagine zwitterion Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 description 4
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 4
- 102000018740 N-Acetylgalactosamine-4-Sulfatase Human genes 0.000 description 4
- LKQLRGMMMAHREN-YJFXYUILSA-N N-stearoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC LKQLRGMMMAHREN-YJFXYUILSA-N 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 210000001103 Thalamus Anatomy 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 description 4
- 108040005465 acid sphingomyelin phosphodiesterase activity proteins Proteins 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001058 adult Effects 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- UXEWTESAMOZBGJ-JTQLQIEISA-N benzyl N-[(2S)-1-(methylamino)propan-2-yl]carbamate Chemical compound CNC[C@H](C)NC(=O)OCC1=CC=CC=C1 UXEWTESAMOZBGJ-JTQLQIEISA-N 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000004432 carbon atoms Chemical group C* 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000000295 complement Effects 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 201000010870 diseases of metabolism Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 210000000056 organs Anatomy 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- IVLICPVPXWEGCA-SSDOTTSWSA-N (3S)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@H](O)CN1CC2 IVLICPVPXWEGCA-SSDOTTSWSA-N 0.000 description 3
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 3
- BOPRNJPIGVEXLY-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[(3-bromophenyl)methyl]carbamate Chemical compound BrC1=CC=CC(CNC(=O)OC2C3CCN(CC3)C2)=C1 BOPRNJPIGVEXLY-UHFFFAOYSA-N 0.000 description 3
- QPTFCMGUUJRBIW-UHFFFAOYSA-N 2-(3-bromo-4-fluorophenyl)propan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)C1=CC=C(F)C(Br)=C1 QPTFCMGUUJRBIW-UHFFFAOYSA-N 0.000 description 3
- PCFPNAWEGXXSBU-UHFFFAOYSA-N 2-(5-bromo-2-fluorophenyl)propan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)C1=CC(Br)=CC=C1F PCFPNAWEGXXSBU-UHFFFAOYSA-N 0.000 description 3
- BLECELZYPLXLOT-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-1,2-thiazol-5-yl]propan-2-amine Chemical compound S1C(C(C)(N)C)=CC(C=2C=CC(F)=CC=2)=N1 BLECELZYPLXLOT-UHFFFAOYSA-N 0.000 description 3
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 3
- ZAZPDOYUCVFPOI-UHFFFAOYSA-N 2-methylpropylboronic acid Chemical compound CC(C)CB(O)O ZAZPDOYUCVFPOI-UHFFFAOYSA-N 0.000 description 3
- YZYQQJHFYIVWPS-UHFFFAOYSA-N 3,4,5,6-tetradehydrothiopyran Chemical group [CH]1SC#CC#C1 YZYQQJHFYIVWPS-UHFFFAOYSA-N 0.000 description 3
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-Aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 3
- 229940018563 3-aminophenol Drugs 0.000 description 3
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 3
- 229910014585 C2-Ce Inorganic materials 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-O CC[NH+](CC)CC Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 3
- 102100010331 CHIT1 Human genes 0.000 description 3
- 229940047120 Colony stimulating factors Drugs 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N Diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 102000004420 EC 2.7.3.2 Human genes 0.000 description 3
- 108010042126 EC 2.7.3.2 Proteins 0.000 description 3
- 102100011343 GLB1 Human genes 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 210000002216 Heart Anatomy 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 229940047124 Interferons Drugs 0.000 description 3
- 210000003712 Lysosomes Anatomy 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 210000001589 Microsomes Anatomy 0.000 description 3
- OCGZSNQBKMILAT-UHFFFAOYSA-N N-[2-(5-bromo-2-fluorophenyl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1CN(CC2)CCC2N1C(=O)NC(C)(C)C1=CC(Br)=CC=C1F OCGZSNQBKMILAT-UHFFFAOYSA-N 0.000 description 3
- 102100018748 NPC1 Human genes 0.000 description 3
- 108060005541 NPC2 Proteins 0.000 description 3
- 102100015915 NPC2 Human genes 0.000 description 3
- 208000002537 Neuronal Ceroid-Lipofuscinosis Diseases 0.000 description 3
- 108010021388 Niemann-Pick C1 Protein Proteins 0.000 description 3
- 201000000788 Niemann-Pick disease type C1 Diseases 0.000 description 3
- 201000000785 Niemann-Pick disease type C2 Diseases 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 3
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- SQXUKOJKIWCALK-AAXLQGCPSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate;(2S)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 SQXUKOJKIWCALK-AAXLQGCPSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000002393 azetidinyl group Chemical group 0.000 description 3
- 125000004069 aziridinyl group Chemical group 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 230000024881 catalytic activity Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 108010057052 chitotriosidase Proteins 0.000 description 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 3
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 3
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 230000002055 immunohistochemical Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 3
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 230000001868 lysosomic Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 230000003040 nociceptive Effects 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 230000000737 periodic Effects 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000003638 reducing agent Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 2
- JIMVRUCDZGFJRE-UHFFFAOYSA-N (3-ethylphenyl)boronic acid Chemical compound CCC1=CC=CC(B(O)O)=C1 JIMVRUCDZGFJRE-UHFFFAOYSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- PLFBGAXIQJPOEX-MRVPVSSYSA-N (3S)-3-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@](C)(N)CN1CC2 PLFBGAXIQJPOEX-MRVPVSSYSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- QCGBKSMEDBMKPI-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-naphthalen-2-ylpropan-2-yl)urea Chemical compound C1=CC=CC2=CC(C(C)(NC(=O)NC3C4CCN(CC4)C3)C)=CC=C21 QCGBKSMEDBMKPI-UHFFFAOYSA-N 0.000 description 2
- HDCDCJKHZPGOSU-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(3-methoxyphenyl)propan-2-yl]urea Chemical compound COC1=CC=CC(C(C)(C)NC(=O)NC2C3CCN(CC3)C2)=C1 HDCDCJKHZPGOSU-UHFFFAOYSA-N 0.000 description 2
- VIORSCWKBMHCBI-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(3-propan-2-ylphenyl)propan-2-yl]urea Chemical compound CC(C)C1=CC=CC(C(C)(C)NC(=O)NC2C3CCN(CC3)C2)=C1 VIORSCWKBMHCBI-UHFFFAOYSA-N 0.000 description 2
- OWUXVWPHYONVOA-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-benzylurea Chemical compound C1N(CC2)CCC2C1NC(=O)NCC1=CC=CC=C1 OWUXVWPHYONVOA-UHFFFAOYSA-N 0.000 description 2
- ALEZWDWARSRIRW-UHFFFAOYSA-N 1-(3-propan-2-ylphenyl)cyclopropan-1-amine Chemical compound CC(C)C1=CC=CC(C2(N)CC2)=C1 ALEZWDWARSRIRW-UHFFFAOYSA-N 0.000 description 2
- PGTDLVUAYUMZNU-UHFFFAOYSA-N 1-(4-bromophenyl)cyclopropan-1-amine Chemical compound C=1C=C(Br)C=CC=1C1(N)CC1 PGTDLVUAYUMZNU-UHFFFAOYSA-N 0.000 description 2
- JVTJGVRWCIELLU-UHFFFAOYSA-N 1-(4-phenylmethoxyphenyl)cyclopropan-1-amine Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1C1(N)CC1 JVTJGVRWCIELLU-UHFFFAOYSA-N 0.000 description 2
- FGFRLPUTEXUVNL-UHFFFAOYSA-N 1-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]-1-methyl-3-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)urea Chemical compound C1N(CC2)CCC2C1(C)NC(=O)N(C)C1(C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)CC1 FGFRLPUTEXUVNL-UHFFFAOYSA-N 0.000 description 2
- IPSWQNYZUPFBSZ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl (4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1C(CC2)CCN2C1 IPSWQNYZUPFBSZ-UHFFFAOYSA-N 0.000 description 2
- LZGQJNDCZBAXNI-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-(1-phenylcyclobutyl)carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC=CC=2)CCC1 LZGQJNDCZBAXNI-UHFFFAOYSA-N 0.000 description 2
- RNCDNVPHNZMJSB-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-(1-phenylcyclohexyl)carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC=CC=2)CCCCC1 RNCDNVPHNZMJSB-UHFFFAOYSA-N 0.000 description 2
- RZGSDGBRIISTBT-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-(2-naphthalen-1-ylpropan-2-yl)carbamate Chemical compound C1=CC=C2C(C(C)(NC(=O)OC3C4CCN(CC4)C3)C)=CC=CC2=C1 RZGSDGBRIISTBT-UHFFFAOYSA-N 0.000 description 2
- DFXBNTJBUYGYMU-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(2-methoxyphenyl)propan-2-yl]carbamate Chemical compound COC1=CC=CC=C1C(C)(C)NC(=O)OC1C(CC2)CCN2C1 DFXBNTJBUYGYMU-UHFFFAOYSA-N 0.000 description 2
- RWMGRIPJVJJTFF-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(3-bromo-2-fluorophenyl)propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C1=CC=CC(Br)=C1F RWMGRIPJVJJTFF-UHFFFAOYSA-N 0.000 description 2
- PIFSMRKOVIECOH-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(4-propan-2-ylphenyl)propan-2-yl]carbamate Chemical compound C1=CC(C(C)C)=CC=C1C(C)(C)NC(=O)OC1C(CC2)CCN2C1 PIFSMRKOVIECOH-UHFFFAOYSA-N 0.000 description 2
- HMHPQGKZSUGBQO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(4-tert-butylphenyl)propan-2-yl]carbamate Chemical compound C1=CC(C(C)(C)C)=CC=C1C(C)(C)NC(=O)OC1C(CC2)CCN2C1 HMHPQGKZSUGBQO-UHFFFAOYSA-N 0.000 description 2
- FOCHMTABQMLPEL-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-N-[2-(4-bromophenyl)propan-2-yl]acetamide Chemical compound C1N(CC2)CCC2C1CC(=O)NC(C)(C)C1=CC=C(Br)C=C1 FOCHMTABQMLPEL-UHFFFAOYSA-N 0.000 description 2
- ARXJQOLRRUGZIH-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)propan-2-amine Chemical compound CC(C)(N)C1=CC=CC(Br)=C1F ARXJQOLRRUGZIH-UHFFFAOYSA-N 0.000 description 2
- UXGIUUWHZBFBAK-UHFFFAOYSA-N 2-(3-bromophenyl)propan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)C1=CC=CC(Br)=C1 UXGIUUWHZBFBAK-UHFFFAOYSA-N 0.000 description 2
- XJRLZIBKKHJOHI-UHFFFAOYSA-N 2-(3-methoxyphenyl)propan-2-amine Chemical compound COC1=CC=CC(C(C)(C)N)=C1 XJRLZIBKKHJOHI-UHFFFAOYSA-N 0.000 description 2
- YEWPZESCQGOKSW-UHFFFAOYSA-N 2-(3-propan-2-ylphenyl)propan-2-amine Chemical compound CC(C)C1=CC=CC(C(C)(C)N)=C1 YEWPZESCQGOKSW-UHFFFAOYSA-N 0.000 description 2
- MBUKEKSGKCTXIN-UHFFFAOYSA-N 2-(5-bromothiophen-3-yl)propan-2-amine Chemical compound CC(C)(N)C1=CSC(Br)=C1 MBUKEKSGKCTXIN-UHFFFAOYSA-N 0.000 description 2
- GJSBUQQWJJUJGC-UHFFFAOYSA-N 2-(5-bromothiophen-3-yl)propan-2-ol Chemical compound CC(C)(O)C1=CSC(Br)=C1 GJSBUQQWJJUJGC-UHFFFAOYSA-N 0.000 description 2
- NQRPHVIWLGEPOQ-UHFFFAOYSA-N 2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CSC(C=2C=CC(F)=CC=2)=N1 NQRPHVIWLGEPOQ-UHFFFAOYSA-N 0.000 description 2
- DVULFGRGRDRWTF-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)-1,2-thiazol-5-yl]propan-2-ol Chemical compound S1C(C(C)(O)C)=CC(C=2C=CC(F)=CC=2)=N1 DVULFGRGRDRWTF-UHFFFAOYSA-N 0.000 description 2
- BHTUBVZDBCKLFO-UHFFFAOYSA-N 2-[3-(cyclopropylmethoxy)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(OCC2CC2)=C1 BHTUBVZDBCKLFO-UHFFFAOYSA-N 0.000 description 2
- OZGYMYWIHRWIEE-UHFFFAOYSA-N 2-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-methylpropanoic acid Chemical compound S1C(C(C)(C(O)=O)C)=NC(C=2C=CC(F)=CC=2)=C1 OZGYMYWIHRWIEE-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- ZOXOBTGYOUSMIA-UHFFFAOYSA-N 2-naphthalen-1-ylpropan-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(C(C)(N)C)=CC=CC2=C1 ZOXOBTGYOUSMIA-UHFFFAOYSA-N 0.000 description 2
- YVPPUVZWMHWCQE-UHFFFAOYSA-N 2-naphthalen-2-ylpropan-2-amine Chemical compound C1=CC=CC2=CC(C(C)(N)C)=CC=C21 YVPPUVZWMHWCQE-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XWYOPVIODQBPPI-UHFFFAOYSA-N 3-(2-methylpropoxy)aniline Chemical compound CC(C)COC1=CC=CC(N)=C1 XWYOPVIODQBPPI-UHFFFAOYSA-N 0.000 description 2
- REZHUZDZDPKIIS-UHFFFAOYSA-N 3-(4-fluorophenyl)-5-prop-1-en-2-yl-1,2-thiazole Chemical compound S1C(C(=C)C)=CC(C=2C=CC(F)=CC=2)=N1 REZHUZDZDPKIIS-UHFFFAOYSA-N 0.000 description 2
- BUXURAOEFDKRGG-UHFFFAOYSA-N 3-(cyclopropylmethoxy)aniline Chemical compound NC1=CC=CC(OCC2CC2)=C1 BUXURAOEFDKRGG-UHFFFAOYSA-N 0.000 description 2
- WVFQAXXFCPVSED-UHFFFAOYSA-N 3-amino-1-azabicyclo[2.2.2]octane-3-carbonitrile Chemical compound C1CC2C(N)(C#N)CN1CC2 WVFQAXXFCPVSED-UHFFFAOYSA-N 0.000 description 2
- IEWKLMGEIQEKBG-UHFFFAOYSA-N 3-methyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2C(C)(O)CN1CC2 IEWKLMGEIQEKBG-UHFFFAOYSA-N 0.000 description 2
- LWYFMTMRWRGREZ-UHFFFAOYSA-N 3-propan-2-ylbenzonitrile Chemical compound CC(C)C1=CC=CC(C#N)=C1 LWYFMTMRWRGREZ-UHFFFAOYSA-N 0.000 description 2
- QMGBIPKOKCSUCL-UHFFFAOYSA-N 3-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=CC(N)=C1 QMGBIPKOKCSUCL-UHFFFAOYSA-N 0.000 description 2
- UDAOJHAASAWVIQ-UHFFFAOYSA-N 4-phenylmethoxybenzonitrile Chemical compound C1=CC(C#N)=CC=C1OCC1=CC=CC=C1 UDAOJHAASAWVIQ-UHFFFAOYSA-N 0.000 description 2
- JKYAIMMIAFYURA-UHFFFAOYSA-N 5-(4-fluorophenyl)-1,3,4-oxathiazol-2-one Chemical compound C1=CC(F)=CC=C1C1=NSC(=O)O1 JKYAIMMIAFYURA-UHFFFAOYSA-N 0.000 description 2
- PEXAZYDITWXYNJ-UHFFFAOYSA-N 5-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1F PEXAZYDITWXYNJ-UHFFFAOYSA-N 0.000 description 2
- 101700059763 ACD Proteins 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102100015004 ARSA Human genes 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N Adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 2
- 102000005922 Amidases Human genes 0.000 description 2
- 108020003076 Amidases Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010068220 Aspartylglucosaminuria Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 102100007539 CLN3 Human genes 0.000 description 2
- 101700082055 CLN3 Proteins 0.000 description 2
- 102100007535 CLN5 Human genes 0.000 description 2
- 108060001648 CLN5 Proteins 0.000 description 2
- 102100010237 CLN6 Human genes 0.000 description 2
- 101700052332 CLN6 Proteins 0.000 description 2
- 102100010236 CLN8 Human genes 0.000 description 2
- 101700032959 CLN8 Proteins 0.000 description 2
- 101700053596 COQ2 Proteins 0.000 description 2
- 241000238097 Callinectes sapidus Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical group [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108090000751 Ceramidases Proteins 0.000 description 2
- 102000004201 Ceramidases Human genes 0.000 description 2
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 description 2
- 229940049197 Cerezyme Drugs 0.000 description 2
- 108010022172 Chitinases Proteins 0.000 description 2
- 102000012286 Chitinases Human genes 0.000 description 2
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
- 229940119017 Cyclosporine Drugs 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 102100018428 DPAGT1 Human genes 0.000 description 2
- 108010084740 Daclizumab Proteins 0.000 description 2
- 229940049268 Euthasol Drugs 0.000 description 2
- 102100004985 GUSB Human genes 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 101700013413 HGC1 Proteins 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108010053927 Iduronate Sulfatase Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 229940047122 Interleukins Drugs 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 2
- 229940040461 Lipase Drugs 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 2
- 208000006249 Mannosidase Deficiency Disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- UQRORFVVSGFNRO-UTINFBMNSA-N Miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 2
- 229960001512 Miglustat Drugs 0.000 description 2
- 206010072927 Mucolipidosis type I Diseases 0.000 description 2
- 208000002678 Mucopolysaccharidosis Diseases 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 208000000149 Multiple Sulfatase Deficiency Disease Diseases 0.000 description 2
- FXZWPZMCZNJILD-UHFFFAOYSA-N N-[(6-bromopyridin-3-yl)methyl]ethanamine;hydrochloride Chemical compound Cl.CCNCC1=CC=C(Br)N=C1 FXZWPZMCZNJILD-UHFFFAOYSA-N 0.000 description 2
- DDOVBCWVTOHGCU-QMXMISKISA-N N-[(E,2S,3R)-3-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 2
- CMVSRCAHLFGGQR-UHFFFAOYSA-N N-[2-(3-bromo-4-fluorophenyl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1CN(CC2)CCC2N1C(=O)NC(C)(C)C1=CC=C(F)C(Br)=C1 CMVSRCAHLFGGQR-UHFFFAOYSA-N 0.000 description 2
- FSQLQZDESFHGME-UHFFFAOYSA-N N-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)N2C3CCN(CC3)CC2)=C1 FSQLQZDESFHGME-UHFFFAOYSA-N 0.000 description 2
- 210000000956 Olfactory Bulb Anatomy 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101700031082 PPT1 Proteins 0.000 description 2
- 102100000067 PPT1 Human genes 0.000 description 2
- 229960001412 Pentobarbital Drugs 0.000 description 2
- 229910019020 PtO2 Inorganic materials 0.000 description 2
- NHQSFWWRATVRND-UHFFFAOYSA-N S1C(Br)=CC(C2(CC2)NC(=O)OC2C3CCN(CC3)C2)=C1 Chemical compound S1C(Br)=CC(C2(CC2)NC(=O)OC2C3CCN(CC3)C2)=C1 NHQSFWWRATVRND-UHFFFAOYSA-N 0.000 description 2
- 101700061430 SAT19 Proteins 0.000 description 2
- 102100012779 STS Human genes 0.000 description 2
- 208000000828 Sialic Acid Storage Disease Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 108010087999 Steryl-Sulfatase Proteins 0.000 description 2
- 101700085115 TPP1 Proteins 0.000 description 2
- 102100016217 TPP1 Human genes 0.000 description 2
- 101700084264 TTPA Proteins 0.000 description 2
- 101700081234 TTR Proteins 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N Titanium isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N Tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- 108010024501 UDPacetylglucosamine-dolichyl-phosphate acetylglucosamine-1-phosphate transferase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 229960003122 alglucerase Drugs 0.000 description 2
- 108010060162 alglucerase Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 235000020127 ayran Nutrition 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cells Anatomy 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- PWEGVZDXTQLFLQ-UHFFFAOYSA-N dioxidoboron Chemical compound [O-][B][O-] PWEGVZDXTQLFLQ-UHFFFAOYSA-N 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- XARRDOFGRYXMLR-UHFFFAOYSA-N ethyl 2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)C1=CSC(C=2C=CC(F)=CC=2)=N1 XARRDOFGRYXMLR-UHFFFAOYSA-N 0.000 description 2
- IEPJVHULVDHSMD-UHFFFAOYSA-N ethyl 2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]acetate Chemical compound CCOC(=O)CC1=CSC(C=2C=CC(F)=CC=2)=N1 IEPJVHULVDHSMD-UHFFFAOYSA-N 0.000 description 2
- URARIFHORWEDFN-UHFFFAOYSA-N ethyl 2-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]-2-methylpropanoate Chemical compound S1C(C(C)(C)C(=O)OCC)=NC(C=2C=CC(F)=CC=2)=C1 URARIFHORWEDFN-UHFFFAOYSA-N 0.000 description 2
- CGUQDWFCFLYYIJ-UHFFFAOYSA-N ethyl 2-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]acetate Chemical compound S1C(CC(=O)OCC)=NC(C=2C=CC(F)=CC=2)=C1 CGUQDWFCFLYYIJ-UHFFFAOYSA-N 0.000 description 2
- CTBPHIUHURRPAL-UHFFFAOYSA-N ethyl 3-(4-fluorophenyl)-1,2-thiazole-5-carboxylate Chemical compound S1C(C(=O)OCC)=CC(C=2C=CC(F)=CC=2)=N1 CTBPHIUHURRPAL-UHFFFAOYSA-N 0.000 description 2
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 201000008049 fucosidosis Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002298 globosides Chemical class 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 108010089932 heparan sulfate sulfatase Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108090001060 lipase Proteins 0.000 description 2
- 102000004882 lipase Human genes 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-L lithium;dihydroxide Chemical compound [Li+].[OH-].[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-L 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BKODRUGPWSHWSW-UHFFFAOYSA-N methyl 2-(1-azabicyclo[2.2.2]octan-3-yl)acetate Chemical compound C1CC2C(CC(=O)OC)CN1CC2 BKODRUGPWSHWSW-UHFFFAOYSA-N 0.000 description 2
- ARPWWDBRSBYILL-UHFFFAOYSA-N methyl 2-(1-azabicyclo[2.2.2]octan-3-ylidene)acetate Chemical compound C1CC2C(=CC(=O)OC)CN1CC2 ARPWWDBRSBYILL-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 201000006033 mucosulfatidosis Diseases 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 2
- 201000007657 neuronal ceroid lipofuscinosis 5 Diseases 0.000 description 2
- 201000007655 neuronal ceroid lipofuscinosis 6 Diseases 0.000 description 2
- 201000007638 neuronal ceroid lipofuscinosis 8 Diseases 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 102000005327 palmitoyl-protein thioesterase Human genes 0.000 description 2
- 108020002591 palmitoyl-protein thioesterase Proteins 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000003169 placental Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 201000010138 pseudo-Hurler polydystrophy Diseases 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011232 storage material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000019798 tripotassium phosphate Nutrition 0.000 description 2
- 230000002485 urinary Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- KZHYEEVBTPEBPI-UHFFFAOYSA-N (1-isocyanatocyclohexa-2,4-dien-1-yl)benzene Chemical group C=1C=CC=CC=1C1(N=C=O)CC=CC=C1 KZHYEEVBTPEBPI-UHFFFAOYSA-N 0.000 description 1
- QQLRSCZSKQTFGY-UHFFFAOYSA-N (2,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1F QQLRSCZSKQTFGY-UHFFFAOYSA-N 0.000 description 1
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 1
- QSSPYZOSTJDTTL-UHFFFAOYSA-N (2-ethylphenyl)boronic acid Chemical compound CCC1=CC=CC=C1B(O)O QSSPYZOSTJDTTL-UHFFFAOYSA-N 0.000 description 1
- GNZLYIZLBODZNH-UHFFFAOYSA-N (2-phenylphenyl) 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate Chemical compound C1CN(CC2)CCC2N1C(=O)OC1=CC=CC=C1C1=CC=CC=C1 GNZLYIZLBODZNH-UHFFFAOYSA-N 0.000 description 1
- RTKSJZYDPYNKLS-UHFFFAOYSA-N (2-phenylphenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1C1=CC=CC=C1 RTKSJZYDPYNKLS-UHFFFAOYSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- SUYJXERPRICYRX-UHFFFAOYSA-N (3-bromophenyl)methanamine Chemical compound NCC1=CC=CC(Br)=C1 SUYJXERPRICYRX-UHFFFAOYSA-N 0.000 description 1
- STZHBULOYDCZET-KLXURFKVSA-N (3R)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@@H](N)CN1CC2 STZHBULOYDCZET-KLXURFKVSA-N 0.000 description 1
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3R)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 1
- PLFBGAXIQJPOEX-QMMMGPOBSA-N (3R)-3-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1CC2[C@@](C)(N)CN1CC2 PLFBGAXIQJPOEX-QMMMGPOBSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- GXYPITRJSPDNLU-UHFFFAOYSA-M (4-nitrophenyl)chloranuidylformate Chemical compound [O-]C(=O)[Cl-]C1=CC=C([N+]([O-])=O)C=C1 GXYPITRJSPDNLU-UHFFFAOYSA-M 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- PKRWWZCDLJSJIF-UHFFFAOYSA-N 1,3-benzodioxole-5-carbonitrile Chemical compound N#CC1=CC=C2OCOC2=C1 PKRWWZCDLJSJIF-UHFFFAOYSA-N 0.000 description 1
- VCIKVHACZDLJCT-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonan-3-one Chemical compound N1C(=O)CN2CCC1CC2 VCIKVHACZDLJCT-UHFFFAOYSA-N 0.000 description 1
- WFCWQIUYEUANRL-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-(1-naphthalen-1-ylethyl)urea Chemical compound C1=CC=C2C(C(NC(=O)NC3C4CCN(CC4)C3)C)=CC=CC2=C1 WFCWQIUYEUANRL-UHFFFAOYSA-N 0.000 description 1
- ZKHMKCGJFMCXIC-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-phenylpropan-2-yl)urea Chemical compound C1N(CC2)CCC2C1NC(=O)NC(C)(C)C1=CC=CC=C1 ZKHMKCGJFMCXIC-UHFFFAOYSA-N 0.000 description 1
- BSUUDHDZNAZEAY-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[1-(3-propan-2-ylphenyl)cyclopropyl]urea Chemical compound CC(C)C1=CC=CC(C2(CC2)NC(=O)NC2C3CCN(CC3)C2)=C1 BSUUDHDZNAZEAY-UHFFFAOYSA-N 0.000 description 1
- HPDTURATNMXEHQ-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(3-bromophenyl)propan-2-yl]urea Chemical compound C1N(CC2)CCC2C1NC(=O)NC(C)(C)C1=CC=CC(Br)=C1 HPDTURATNMXEHQ-UHFFFAOYSA-N 0.000 description 1
- WCLWNROKDIXTQD-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(3-phenylphenyl)propan-2-yl]urea Chemical compound C1N(CC2)CCC2C1NC(=O)NC(C)(C)C(C=1)=CC=CC=1C1=CC=CC=C1 WCLWNROKDIXTQD-UHFFFAOYSA-N 0.000 description 1
- GONOHGQPZFXJOJ-UHFFFAOYSA-N 1-(1-isocyanatoethyl)naphthalene Chemical compound C1=CC=C2C(C(N=C=O)C)=CC=CC2=C1 GONOHGQPZFXJOJ-UHFFFAOYSA-N 0.000 description 1
- KQIKMRHZEVFCCU-UHFFFAOYSA-N 1-(3-butyl-1-azabicyclo[2.2.2]octan-3-yl)-3-[4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl]urea Chemical compound C1N(CC2)CCC2C1(CCCC)NC(=O)NC(C)(C)C#CC1=CC=C(F)C=C1 KQIKMRHZEVFCCU-UHFFFAOYSA-N 0.000 description 1
- ZHGSELZNTJZWCJ-UHFFFAOYSA-N 1-(3-cyano-1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]urea Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)NC2(C3CCN(CC3)C2)C#N)=C1 ZHGSELZNTJZWCJ-UHFFFAOYSA-N 0.000 description 1
- PASVOXGCIDVUKF-UHFFFAOYSA-N 1-(3-ethyl-1-azabicyclo[2.2.2]octan-3-yl)-3-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]urea Chemical compound C1N(CC2)CCC2C1(CC)NC(=O)NC1(C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)CC1 PASVOXGCIDVUKF-UHFFFAOYSA-N 0.000 description 1
- VEJWNIYARKAHFI-UHFFFAOYSA-N 1-(3-methoxyphenyl)propan-2-amine Chemical compound COC1=CC=CC(CC(C)N)=C1 VEJWNIYARKAHFI-UHFFFAOYSA-N 0.000 description 1
- NEONCEXQRGZZMP-UHFFFAOYSA-N 1-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)-3-[2-methyl-2-(3-methylphenyl)propyl]urea Chemical compound CC1=CC=CC(C(C)(C)CNC(=O)NC2(C)C3CCN(CC3)C2)=C1 NEONCEXQRGZZMP-UHFFFAOYSA-N 0.000 description 1
- VSHZXOLHFRVZND-UHFFFAOYSA-N 1-(4-methoxyphenyl)propan-2-ylazanium;chloride Chemical compound Cl.COC1=CC=C(CC(C)N)C=C1 VSHZXOLHFRVZND-UHFFFAOYSA-N 0.000 description 1
- ZVFHVDNMPGRDDZ-UHFFFAOYSA-N 1-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)-3-[1-(5-phenylpyridin-2-yl)cyclopropyl]urea Chemical compound C1CN(CC2)CCC2C1(C)NC(=O)NC1(C=2N=CC(=CC=2)C=2C=CC=CC=2)CC1 ZVFHVDNMPGRDDZ-UHFFFAOYSA-N 0.000 description 1
- CORKPPLFQPYRLN-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)propan-2-amine Chemical compound CC(N)CC1=CC=C(C(C)C)C=C1 CORKPPLFQPYRLN-UHFFFAOYSA-N 0.000 description 1
- PYIVLZVGWKGCGG-UHFFFAOYSA-N 1-(4-tert-butylphenyl)propan-2-amine Chemical compound CC(N)CC1=CC=C(C(C)(C)C)C=C1 PYIVLZVGWKGCGG-UHFFFAOYSA-N 0.000 description 1
- RGZGRPPQZUQUCR-UHFFFAOYSA-N 1-Phenylcyclohexylamine Chemical compound C=1C=CC=CC=1C1(N)CCCCC1 RGZGRPPQZUQUCR-UHFFFAOYSA-N 0.000 description 1
- ONZMAEXKDOLEOZ-SFHVURJKSA-N 1-[(3R)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]urea Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)N[C@@H]2C3CCN(CC3)C2)=C1 ONZMAEXKDOLEOZ-SFHVURJKSA-N 0.000 description 1
- ONZMAEXKDOLEOZ-GOSISDBHSA-N 1-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]urea Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)N[C@H]2C3CCN(CC3)C2)=C1 ONZMAEXKDOLEOZ-GOSISDBHSA-N 0.000 description 1
- IJAYVJBOEWLXFK-HSZRJFAPSA-N 1-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]-3-[(3S)-3-methyl-1-azabicyclo[2.2.2]octan-3-yl]urea Chemical compound N([C@]1(C2CCN(CC2)C1)C)C(=O)NC1(C=2C=CC(=CC=2)C=2C=CC(F)=CC=2)CC1 IJAYVJBOEWLXFK-HSZRJFAPSA-N 0.000 description 1
- RYUPTWCEWSUXQZ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-3-ol Chemical compound C1CC2C(O)CN1C2 RYUPTWCEWSUXQZ-UHFFFAOYSA-N 0.000 description 1
- VZPRMKOCTSUHCR-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-3-one Chemical compound C1CC2C(=O)CN1C2 VZPRMKOCTSUHCR-UHFFFAOYSA-N 0.000 description 1
- KHAKFKRESWHJHB-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine;hydrochloride Chemical compound Cl.C1CC2C(N)CN1CC2 KHAKFKRESWHJHB-UHFFFAOYSA-N 0.000 description 1
- ZKMZPXWMMSBLNO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2C(=O)CN1CC2 ZKMZPXWMMSBLNO-UHFFFAOYSA-N 0.000 description 1
- QIXFWUDLGSAWGT-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-(3-phenylphenyl)carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 QIXFWUDLGSAWGT-UHFFFAOYSA-N 0.000 description 1
- FCGGPETWQSJLHJ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[(3-phenylphenyl)methyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NCC(C=1)=CC=CC=1C1=CC=CC=C1 FCGGPETWQSJLHJ-UHFFFAOYSA-N 0.000 description 1
- MZHQGQBYAKLCEH-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[(3-propan-2-yloxyphenyl)methyl]carbamate Chemical compound CC(C)OC1=CC=CC(CNC(=O)OC2C3CCN(CC3)C2)=C1 MZHQGQBYAKLCEH-UHFFFAOYSA-N 0.000 description 1
- SRXKAJZFWLJLLI-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[(3-pyrimidin-5-ylphenyl)methyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NCC(C=1)=CC=CC=1C1=CN=CN=C1 SRXKAJZFWLJLLI-UHFFFAOYSA-N 0.000 description 1
- UBHSXVWWJDXIBD-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[(4-phenoxyphenyl)methyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NCC(C=C1)=CC=C1OC1=CC=CC=C1 UBHSXVWWJDXIBD-UHFFFAOYSA-N 0.000 description 1
- OOUNAAUFCNXKQN-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-(3-propan-2-ylphenyl)cyclopropyl]carbamate Chemical compound CC(C)C1=CC=CC(C2(CC2)NC(=O)OC2C3CCN(CC3)C2)=C1 OOUNAAUFCNXKQN-UHFFFAOYSA-N 0.000 description 1
- IJUIXCKAATUKCR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-(4-phenylmethoxyphenyl)cyclopropyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC(OCC=3C=CC=CC=3)=CC=2)CC1 IJUIXCKAATUKCR-UHFFFAOYSA-N 0.000 description 1
- GLNZEZNEPZOWRE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-(4-phenylphenyl)cyclopropyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC(=CC=2)C=2C=CC=CC=2)CC1 GLNZEZNEPZOWRE-UHFFFAOYSA-N 0.000 description 1
- MXSXSBDZEHDSCR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-(4-pyridin-2-ylphenyl)cyclopropyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC(=CC=2)C=2N=CC=CC=2)CC1 MXSXSBDZEHDSCR-UHFFFAOYSA-N 0.000 description 1
- OBWKRKIGCPAESQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-(4-pyrimidin-5-ylphenyl)cyclopropyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC(=CC=2)C=2C=NC=NC=2)CC1 OBWKRKIGCPAESQ-UHFFFAOYSA-N 0.000 description 1
- ONKZHPRQDWJTOU-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[1-[4-(1,3-benzothiazol-5-yl)phenyl]cyclopropyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC1(C=2C=CC(=CC=2)C=2C=C3N=CSC3=CC=2)CC1 ONKZHPRQDWJTOU-UHFFFAOYSA-N 0.000 description 1
- XGKVTTVLAUFKNY-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(1,3-benzodioxol-5-yl)propan-2-yl]carbamate Chemical compound C1=C2OCOC2=CC(C(C)(NC(=O)OC2C3CCN(CC3)C2)C)=C1 XGKVTTVLAUFKNY-UHFFFAOYSA-N 0.000 description 1
- LMHXRSJVEJTYIY-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(2-ethylphenyl)phenyl]carbamate Chemical compound CCC1=CC=CC=C1C1=CC=CC=C1NC(=O)OC1C(CC2)CCN2C1 LMHXRSJVEJTYIY-UHFFFAOYSA-N 0.000 description 1
- LEUHZUXMAQAMET-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(2-methylphenyl)propan-2-yl]carbamate Chemical compound CC1=CC=CC=C1C(C)(C)NC(=O)OC1C(CC2)CCN2C1 LEUHZUXMAQAMET-UHFFFAOYSA-N 0.000 description 1
- QUCAPPQXIHRYMV-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(2-methylpropoxy)phenyl]carbamate Chemical compound CC(C)COC1=CC=CC=C1NC(=O)OC1C(CC2)CCN2C1 QUCAPPQXIHRYMV-UHFFFAOYSA-N 0.000 description 1
- ULVQTPQGKMUVBO-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(3-ethylphenyl)phenyl]carbamate Chemical compound CCC1=CC=CC(C=2C(=CC=CC=2)NC(=O)OC2C3CCN(CC3)C2)=C1 ULVQTPQGKMUVBO-UHFFFAOYSA-N 0.000 description 1
- AWXJAQGNQGXRPY-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(3-methoxyphenyl)phenyl]carbamate Chemical compound COC1=CC=CC(C=2C(=CC=CC=2)NC(=O)OC2C3CCN(CC3)C2)=C1 AWXJAQGNQGXRPY-UHFFFAOYSA-N 0.000 description 1
- VZPWHUQQSUFTNJ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]carbamate Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)OC2C3CCN(CC3)C2)=C1 VZPWHUQQSUFTNJ-UHFFFAOYSA-N 0.000 description 1
- BECHPKVZVSXCDR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(4-bromophenyl)propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C1=CC=C(Br)C=C1 BECHPKVZVSXCDR-UHFFFAOYSA-N 0.000 description 1
- MJSRIMPGTQEIMM-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-(4-pyrimidin-5-ylphenyl)propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=C1)=CC=C1C1=CN=CN=C1 MJSRIMPGTQEIMM-UHFFFAOYSA-N 0.000 description 1
- MMVDZVGPBITWFR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-[3-fluoro-4-(4-fluorophenyl)phenyl]propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=C1F)=CC=C1C1=CC=C(F)C=C1 MMVDZVGPBITWFR-UHFFFAOYSA-N 0.000 description 1
- KOVYXVXXJYWVKQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-[4-(1,3-benzothiazol-6-yl)phenyl]propan-2-yl]carbamate Chemical compound C1=C2N=CSC2=CC(C2=CC=C(C=C2)C(C)(NC(=O)OC2C3CCN(CC3)C2)C)=C1 KOVYXVXXJYWVKQ-UHFFFAOYSA-N 0.000 description 1
- NMVAAEYJGLSBJZ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[2-[5-(4-fluorophenyl)thiophen-3-yl]propan-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CSC=1C1=CC=C(F)C=C1 NMVAAEYJGLSBJZ-UHFFFAOYSA-N 0.000 description 1
- WZZVFNOQUUZUJE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[3-(2-ethylphenyl)phenyl]carbamate Chemical compound CCC1=CC=CC=C1C1=CC=CC(NC(=O)OC2C3CCN(CC3)C2)=C1 WZZVFNOQUUZUJE-UHFFFAOYSA-N 0.000 description 1
- YNBVSNKJYRLJAE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[3-(2-methoxyphenyl)phenyl]carbamate Chemical compound COC1=CC=CC=C1C1=CC=CC(NC(=O)OC2C3CCN(CC3)C2)=C1 YNBVSNKJYRLJAE-UHFFFAOYSA-N 0.000 description 1
- KNZXYAXXVIELEQ-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[3-(3-methoxyphenyl)phenyl]carbamate Chemical compound COC1=CC=CC(C=2C=C(NC(=O)OC3C4CCN(CC4)C3)C=CC=2)=C1 KNZXYAXXVIELEQ-UHFFFAOYSA-N 0.000 description 1
- JRALGKRLGSYVMC-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[3-[4-(4-fluorophenyl)phenyl]oxetan-3-yl]carbamate Chemical compound C1=CC(F)=CC=C1C1=CC=C(C2(COC2)NC(=O)OC2C3CCN(CC3)C2)C=C1 JRALGKRLGSYVMC-UHFFFAOYSA-N 0.000 description 1
- WKYLVNNRDQDAHM-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[3-[4-(4-fluorophenyl)phenyl]pentan-3-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(CC)(CC)C(C=C1)=CC=C1C1=CC=C(F)C=C1 WKYLVNNRDQDAHM-UHFFFAOYSA-N 0.000 description 1
- JFEYMBFKUPANIG-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C#CC1=CC=C(F)C=C1 JFEYMBFKUPANIG-UHFFFAOYSA-N 0.000 description 1
- XOIFLTCJVDCLCA-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[[3-(2-methylpropoxy)phenyl]methyl]carbamate Chemical compound CC(C)COC1=CC=CC(CNC(=O)OC2C3CCN(CC3)C2)=C1 XOIFLTCJVDCLCA-UHFFFAOYSA-N 0.000 description 1
- XTUVQIJHLUZSEK-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-yl N-[[3-(cyclopropylmethoxy)phenyl]methyl]carbamate Chemical compound C1N(CC2)CCC2C1OC(=O)NCC(C=1)=CC=CC=1OCC1CC1 XTUVQIJHLUZSEK-UHFFFAOYSA-N 0.000 description 1
- QLOVQJFVRRNQPK-UHFFFAOYSA-N 1-azabicyclo[3.2.2]nonan-4-one Chemical compound O=C1CCN2CCC1CC2 QLOVQJFVRRNQPK-UHFFFAOYSA-N 0.000 description 1
- SXYWRDIOSJZZGM-UHFFFAOYSA-N 1-azoniabicyclo[2.2.2]octane;hydroxide Chemical compound O.C1CC2CCN1CC2 SXYWRDIOSJZZGM-UHFFFAOYSA-N 0.000 description 1
- GOOVAYJIVMBWPP-UHFFFAOYSA-N 1-bromo-2-isocyanatobenzene Chemical compound BrC1=CC=CC=C1N=C=O GOOVAYJIVMBWPP-UHFFFAOYSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- ZRFJYAZQMFCUIX-UHFFFAOYSA-N 1-bromo-3-ethylbenzene Chemical compound CCC1=CC=CC(Br)=C1 ZRFJYAZQMFCUIX-UHFFFAOYSA-N 0.000 description 1
- VQVBCZQTXSHJGF-UHFFFAOYSA-N 1-bromo-3-isocyanatobenzene Chemical compound BrC1=CC=CC(N=C=O)=C1 VQVBCZQTXSHJGF-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BDQNKCYCTYYMAA-UHFFFAOYSA-N 1-isocyanatonaphthalene Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1 BDQNKCYCTYYMAA-UHFFFAOYSA-N 0.000 description 1
- IFVYFMNCNFMBGV-UHFFFAOYSA-N 1-phenylcyclobutan-1-amine;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C1(N)CCC1 IFVYFMNCNFMBGV-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-Crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- DGCOGZQDAXUUBY-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole Chemical compound C1=CC=C2OC(F)(F)OC2=C1 DGCOGZQDAXUUBY-UHFFFAOYSA-N 0.000 description 1
- UDCUVKCARSZDNG-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)propan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)C1=CC=C2OCOC2=C1 UDCUVKCARSZDNG-UHFFFAOYSA-N 0.000 description 1
- DYMNUSAQEHRZGE-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-N-[1-(3-propan-2-ylphenyl)cyclopropyl]acetamide Chemical compound CC(C)C1=CC=CC(C2(CC2)NC(=O)CC2C3CCN(CC3)C2)=C1 DYMNUSAQEHRZGE-UHFFFAOYSA-N 0.000 description 1
- JJWFQAZHNFHJGE-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-N-[1-(4-methylphenyl)cyclopropyl]acetamide Chemical compound C1=CC(C)=CC=C1C1(NC(=O)CC2C3CCN(CC3)C2)CC1 JJWFQAZHNFHJGE-UHFFFAOYSA-N 0.000 description 1
- NGEFCYVMAJERHS-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-N-[2-(2-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=CC=C1CCNC(=O)CC1C(CC2)CCN2C1 NGEFCYVMAJERHS-UHFFFAOYSA-N 0.000 description 1
- ZISBAAQXKXJVIW-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-N-[2-(3-methoxyphenyl)propan-2-yl]acetamide Chemical compound COC1=CC=CC(C(C)(C)NC(=O)CC2C3CCN(CC3)C2)=C1 ZISBAAQXKXJVIW-UHFFFAOYSA-N 0.000 description 1
- AXPSHPXXPNFNGH-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)-N-[2-(4-phenylphenyl)propan-2-yl]acetamide Chemical compound C1N(CC2)CCC2C1CC(=O)NC(C)(C)C(C=C1)=CC=C1C1=CC=CC=C1 AXPSHPXXPNFNGH-UHFFFAOYSA-N 0.000 description 1
- HCMSYUHZEXYCNS-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yl)acetic acid;hydrochloride Chemical compound Cl.C1CC2C(CC(=O)O)CN1CC2 HCMSYUHZEXYCNS-UHFFFAOYSA-N 0.000 description 1
- FWOQDWJPEBVSOT-UHFFFAOYSA-N 2-(1-azabicyclo[3.2.2]nonan-4-yl)-N-[1-(5-phenylpyridin-2-yl)cyclopropyl]acetamide Chemical compound C1CN(CC2)CCC2C1CC(=O)NC1(C=2N=CC(=CC=2)C=2C=CC=CC=2)CC1 FWOQDWJPEBVSOT-UHFFFAOYSA-N 0.000 description 1
- WSWPCNMLEVZGSM-UHFFFAOYSA-N 2-(2-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC=C1CCN WSWPCNMLEVZGSM-UHFFFAOYSA-N 0.000 description 1
- YRVVAFHIEPYATJ-UHFFFAOYSA-N 2-(2-methoxyphenyl)propan-2-amine Chemical compound COC1=CC=CC=C1C(C)(C)N YRVVAFHIEPYATJ-UHFFFAOYSA-N 0.000 description 1
- SVHFBAAZRDCASE-UHFFFAOYSA-N 2-(2-methylphenyl)propan-2-amine Chemical compound CC1=CC=CC=C1C(C)(C)N SVHFBAAZRDCASE-UHFFFAOYSA-N 0.000 description 1
- WXAFGTXOIBNLNB-UHFFFAOYSA-N 2-(3-bromophenyl)propan-2-amine Chemical compound CC(C)(N)C1=CC=CC(Br)=C1 WXAFGTXOIBNLNB-UHFFFAOYSA-N 0.000 description 1
- ZRFMJMFYMQAUDO-UHFFFAOYSA-N 2-(3-bromophenyl)propan-2-ol Chemical compound CC(C)(O)C1=CC=CC(Br)=C1 ZRFMJMFYMQAUDO-UHFFFAOYSA-N 0.000 description 1
- LEMRHTTWKDVQEI-UHFFFAOYSA-N 2-(3-phenoxyphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 LEMRHTTWKDVQEI-UHFFFAOYSA-N 0.000 description 1
- DWDJGSQWSMJSGV-UHFFFAOYSA-N 2-(3-prop-1-en-2-ylphenyl)propan-2-amine Chemical compound CC(=C)C1=CC=CC(C(C)(C)N)=C1 DWDJGSQWSMJSGV-UHFFFAOYSA-N 0.000 description 1
- ZRQHMGUMVCESKV-UHFFFAOYSA-N 2-(3-propan-2-yloxyphenyl)acetic acid Chemical compound CC(C)OC1=CC=CC(CC(O)=O)=C1 ZRQHMGUMVCESKV-UHFFFAOYSA-N 0.000 description 1
- PQEFTRZQYSHQQJ-UHFFFAOYSA-N 2-(3-propan-2-yloxyphenyl)propan-2-amine Chemical compound CC(C)OC1=CC=CC(C(C)(C)N)=C1 PQEFTRZQYSHQQJ-UHFFFAOYSA-N 0.000 description 1
- CJWUSPLLYDLICM-UHFFFAOYSA-N 2-(3-propan-2-yloxyphenyl)propan-2-amine;hydrochloride Chemical compound Cl.CC(C)OC1=CC=CC(C(C)(C)N)=C1 CJWUSPLLYDLICM-UHFFFAOYSA-N 0.000 description 1
- KMJLJHXKDTUCRP-UHFFFAOYSA-N 2-(4-bromophenyl)propan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)C1=CC=C(Br)C=C1 KMJLJHXKDTUCRP-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-Bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- FHYDGAOWKXCFHT-UHFFFAOYSA-N 2-[3-(2-methylpropoxy)phenyl]acetic acid Chemical compound CC(C)COC1=CC=CC(CC(O)=O)=C1 FHYDGAOWKXCFHT-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- ZJFWCELATJMDNO-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CBr)C=C1 ZJFWCELATJMDNO-UHFFFAOYSA-N 0.000 description 1
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- FMKOJHQHASLBPH-OUBTZVSYSA-N 2-iodopropane Chemical compound CC([13CH3])I FMKOJHQHASLBPH-OUBTZVSYSA-N 0.000 description 1
- VLJPCCPJHQAAQB-UHFFFAOYSA-N 2-methyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CN2C(C)C(O)C1CC2 VLJPCCPJHQAAQB-UHFFFAOYSA-N 0.000 description 1
- LGOHLIRGPFPGKT-UHFFFAOYSA-N 2-methyl-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(C)C2=O LGOHLIRGPFPGKT-UHFFFAOYSA-N 0.000 description 1
- QQOYEGNKIDORQP-UHFFFAOYSA-N 2-methyl-2-(3-methylphenyl)propan-1-amine;hydrochloride Chemical compound Cl.CC1=CC=CC(C(C)(C)CN)=C1 QQOYEGNKIDORQP-UHFFFAOYSA-N 0.000 description 1
- NHPWIWAGVOXDPU-UHFFFAOYSA-N 2-methylidene-1-azabicyclo[2.2.2]octan-3-one Chemical compound C1CC2CCN1C(=C)C2=O NHPWIWAGVOXDPU-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 1
- GHIUKPGFHXNXKL-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)phenyl]-3-methyl-N-(4-methyl-1-azabicyclo[3.2.2]nonan-4-yl)butanamide Chemical compound C1CN(CC2)CCC2C1(C)NC(=O)CC(C)(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1 GHIUKPGFHXNXKL-UHFFFAOYSA-N 0.000 description 1
- UVKURTLVTLRSSM-UHFFFAOYSA-N 3-bromo-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Br)=C1F UVKURTLVTLRSSM-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- BEDKJKABPPDZNB-UHFFFAOYSA-N 3-hydroxy-1-azabicyclo[2.2.2]octane-3-carbonitrile Chemical compound C1CC2C(O)(C#N)CN1CC2 BEDKJKABPPDZNB-UHFFFAOYSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- HHTWDQMTAADGQQ-UHFFFAOYSA-N 3-methyl-N-[2-(4-phenylphenyl)propan-2-ylsulfamoyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1N(CC2)CCC2C1(C)NS(=O)(=O)NC(C)(C)C(C=C1)=CC=C1C1=CC=CC=C1 HHTWDQMTAADGQQ-UHFFFAOYSA-N 0.000 description 1
- MUNOBADFTHUUFG-UHFFFAOYSA-N 3-phenylaniline Chemical compound NC1=CC=CC(C=2C=CC=CC=2)=C1 MUNOBADFTHUUFG-UHFFFAOYSA-N 0.000 description 1
- XNLWJFYYOIRPIO-UHFFFAOYSA-N 3-phenylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C=2C=CC=CC=2)=C1 XNLWJFYYOIRPIO-UHFFFAOYSA-N 0.000 description 1
- BDAQGUZTTPIATR-UHFFFAOYSA-N 3-propan-2-ylbenzamide Chemical compound CC(C)C1=CC=CC(C(N)=O)=C1 BDAQGUZTTPIATR-UHFFFAOYSA-N 0.000 description 1
- DLYVSJDCQZVKMD-UHFFFAOYSA-N 3-propan-2-ylbenzoic acid Chemical compound CC(C)C1=CC=CC(C(O)=O)=C1 DLYVSJDCQZVKMD-UHFFFAOYSA-N 0.000 description 1
- IIQOURMQVWTWII-UHFFFAOYSA-N 3-propan-2-ylbenzoyl chloride Chemical compound CC(C)C1=CC=CC(C(Cl)=O)=C1 IIQOURMQVWTWII-UHFFFAOYSA-N 0.000 description 1
- OYUCWSBVVRRERP-UHFFFAOYSA-N 3-propan-2-yloxybenzonitrile Chemical compound CC(C)OC1=CC=CC(C#N)=C1 OYUCWSBVVRRERP-UHFFFAOYSA-N 0.000 description 1
- LZHMNCJMXQKSBY-UHFFFAOYSA-N 4-(4-methoxyphenyl)butanoic acid Chemical compound COC1=CC=C(CCCC(O)=O)C=C1 LZHMNCJMXQKSBY-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- VHFLVGIMDGXALR-UHFFFAOYSA-N 4-Ethylamphetamine Chemical compound CCC1=CC=C(CC(C)N)C=C1 VHFLVGIMDGXALR-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- VNDHYTGVCGVETQ-UHFFFAOYSA-N 4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C=C1 VNDHYTGVCGVETQ-UHFFFAOYSA-N 0.000 description 1
- VQFOHZWOKJQOGO-UHFFFAOYSA-N 4-fluorobenzenecarbothioamide Chemical compound NC(=S)C1=CC=C(F)C=C1 VQFOHZWOKJQOGO-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RMJIPVJGTMAEOM-UHFFFAOYSA-N 5-(2-chloropropan-2-yl)-3-(4-fluorophenyl)-1,2-thiazole Chemical compound S1C(C(C)(Cl)C)=CC(C=2C=CC(F)=CC=2)=N1 RMJIPVJGTMAEOM-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical compound NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 101710028797 AFUA_4G13800 Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229940022705 Aldurazyme Drugs 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 108009000047 Alzheimers Disease Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000969130 Atthis Species 0.000 description 1
- 101710010421 BN863_22020 Proteins 0.000 description 1
- 101710010411 BN863_22030 Proteins 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N Benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- KESOSAIPFUGAHC-UHFFFAOYSA-M C(C)(C)OC=1C=C(C=CC1)C(C)(C)NC([O-])=O Chemical compound C(C)(C)OC=1C=C(C=CC1)C(C)(C)NC([O-])=O KESOSAIPFUGAHC-UHFFFAOYSA-M 0.000 description 1
- MJULVLVEBDMNKP-QMRHZFGWSA-N C1([C@@H]2C[C@H]2NC(=O)OC2C3CCN(CC3)C2)=CC=CC=C1 Chemical compound C1([C@@H]2C[C@H]2NC(=O)OC2C3CCN(CC3)C2)=CC=CC=C1 MJULVLVEBDMNKP-QMRHZFGWSA-N 0.000 description 1
- YEJMLXWBWPOAPW-UHFFFAOYSA-N C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=C(F)C=1C1=CC=CN=C1 Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=C(F)C=1C1=CC=CN=C1 YEJMLXWBWPOAPW-UHFFFAOYSA-N 0.000 description 1
- WEHYQUNCYPFJSG-UHFFFAOYSA-N C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=C(F)C=1C1=CC=NC=C1 Chemical compound C1N(CC2)CCC2C1OC(=O)NC(C)(C)C(C=1)=CC=C(F)C=1C1=CC=NC=C1 WEHYQUNCYPFJSG-UHFFFAOYSA-N 0.000 description 1
- OIGQJTOCSNWOJK-UHFFFAOYSA-N CC(=C)C1=CC=CC(C(C)(C)NC(=O)OC2(C3CCN(CC3)C2)C#N)=C1 Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)OC2(C3CCN(CC3)C2)C#N)=C1 OIGQJTOCSNWOJK-UHFFFAOYSA-N 0.000 description 1
- VQWDUGNUIRIWKV-UHFFFAOYSA-N CC(=C)C=CNC(N)=O Chemical compound CC(=C)C=CNC(N)=O VQWDUGNUIRIWKV-UHFFFAOYSA-N 0.000 description 1
- NNHHBCXYOSKAAK-UHFFFAOYSA-N CC(C)(NC(=O)OC1CN2CCC1CC2)c1ccc(F)c(c1)-c1cncnc1 Chemical compound CC(C)(NC(=O)OC1CN2CCC1CC2)c1ccc(F)c(c1)-c1cncnc1 NNHHBCXYOSKAAK-UHFFFAOYSA-N 0.000 description 1
- UBBFFDUGVYEAGL-UHFFFAOYSA-N CC(C)(NC(=O)OC1CN2CCC1CC2)c1cccc(Br)c1 Chemical compound CC(C)(NC(=O)OC1CN2CCC1CC2)c1cccc(Br)c1 UBBFFDUGVYEAGL-UHFFFAOYSA-N 0.000 description 1
- ANYWMNBBBHADKF-UHFFFAOYSA-N CC(C)(NC(=O)OC1CN2CCC1CC2)c1cccc(c1)C1CC1 Chemical compound CC(C)(NC(=O)OC1CN2CCC1CC2)c1cccc(c1)C1CC1 ANYWMNBBBHADKF-UHFFFAOYSA-N 0.000 description 1
- GJDNEFKOXNVBNU-UHFFFAOYSA-N CC(C)C1=CC=CC(C(C)(C)NC(=O)OC2C3CCN(CC3)C2)=C1 Chemical compound CC(C)C1=CC=CC(C(C)(C)NC(=O)OC2C3CCN(CC3)C2)=C1 GJDNEFKOXNVBNU-UHFFFAOYSA-N 0.000 description 1
- ZXOGOUWPAYCYIT-UHFFFAOYSA-N CC(C)CC1=CC=CC(C(C)(C)NC(=O)OC2C3CCN(CC3)C2)=C1 Chemical compound CC(C)CC1=CC=CC(C(C)(C)NC(=O)OC2C3CCN(CC3)C2)=C1 ZXOGOUWPAYCYIT-UHFFFAOYSA-N 0.000 description 1
- YQNHCCILOTXJJJ-UHFFFAOYSA-N CC(C)Cc1ccc(F)c(c1)C(C)(C)NC(=O)OC1CN2CCC1CC2 Chemical compound CC(C)Cc1ccc(F)c(c1)C(C)(C)NC(=O)OC1CN2CCC1CC2 YQNHCCILOTXJJJ-UHFFFAOYSA-N 0.000 description 1
- FLVOWOGNIQDHQG-UHFFFAOYSA-M CC(C)OC1=CC=CC=C1NC([O-])=O Chemical compound CC(C)OC1=CC=CC=C1NC([O-])=O FLVOWOGNIQDHQG-UHFFFAOYSA-M 0.000 description 1
- UBXYMQXJDIEIBN-UHFFFAOYSA-M CC1(C)OB(OC1(C)C)C1=CC=C(C=C1)C1(CC1)NC([O-])=O Chemical compound CC1(C)OB(OC1(C)C)C1=CC=C(C=C1)C1(CC1)NC([O-])=O UBXYMQXJDIEIBN-UHFFFAOYSA-M 0.000 description 1
- HRVNTCDPUJDDNZ-UHFFFAOYSA-N CCOC(=O)C1=CSN=C1C1=CC=C(F)C=C1 Chemical class CCOC(=O)C1=CSN=C1C1=CC=C(F)C=C1 HRVNTCDPUJDDNZ-UHFFFAOYSA-N 0.000 description 1
- 101700046984 CDK20 Proteins 0.000 description 1
- ASBFYQPHQOXMCA-UHFFFAOYSA-M COC1=CC=CC=C1C1=CC=CC=C1NC([O-])=O Chemical compound COC1=CC=CC=C1C1=CC=CC=C1NC([O-])=O ASBFYQPHQOXMCA-UHFFFAOYSA-M 0.000 description 1
- 101700003315 CSF3 Proteins 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- HTVDCXKQALQLCB-UHFFFAOYSA-M Cc1ccccc1C(C)(C)NC([O-])=O Chemical compound Cc1ccccc1C(C)(C)NC([O-])=O HTVDCXKQALQLCB-UHFFFAOYSA-M 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N Chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 210000003917 Chromosomes, Human Anatomy 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101710006640 DIT33 Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N Dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241001399795 Eusphalerum anale Species 0.000 description 1
- 229940014516 Fabrazyme Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N Felbinac Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 201000008892 GM1 gangliosidosis Diseases 0.000 description 1
- 208000009796 Gangliosidosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 206010020718 Hyperplasia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010031792 IGF Type 2 Receptor Proteins 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid zwitterion Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 102000019218 Mannose-6-phosphate receptor Human genes 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N Methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028095 Mucopolysaccharidosis IV Diseases 0.000 description 1
- 208000000690 Mucopolysaccharidosis VI Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- 229940103023 Myozyme Drugs 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- MLWZXVJUJQTLPH-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-2-(4-phenylphenyl)acetamide Chemical compound C1N(CC2)CCC2C1NC(=O)CC(C=C1)=CC=C1C1=CC=CC=C1 MLWZXVJUJQTLPH-UHFFFAOYSA-N 0.000 description 1
- MQDUBMOSAYRTMJ-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbenzamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(C=1)=CC=CC=1C1=CC=CC=C1 MQDUBMOSAYRTMJ-UHFFFAOYSA-N 0.000 description 1
- PLAUEYSOHOHDIW-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-4-(4-methoxyphenyl)butanamide Chemical compound C1=CC(OC)=CC=C1CCCC(=O)NC1C(CC2)CCN2C1 PLAUEYSOHOHDIW-UHFFFAOYSA-N 0.000 description 1
- WYMWPYUTQKSFJQ-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-4-(4-methylphenyl)butanamide Chemical compound C1=CC(C)=CC=C1CCCC(=O)NC1C(CC2)CCN2C1 WYMWPYUTQKSFJQ-UHFFFAOYSA-N 0.000 description 1
- NLYHSWZIYAWLGU-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-N'-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]oxamide Chemical compound C1=CC(F)=CC=C1C1=CC=C(C2(CC2)NC(=O)C(=O)NC2C3CCN(CC3)C2)C=C1 NLYHSWZIYAWLGU-UHFFFAOYSA-N 0.000 description 1
- VDOVBJUBHFAZNO-UHFFFAOYSA-N N-(2-naphthalen-1-ylpropan-2-yl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(C)(C)NC(=O)N1CCN2CCC1CC2 VDOVBJUBHFAZNO-UHFFFAOYSA-N 0.000 description 1
- NUEJNLGYOUWEJF-UHFFFAOYSA-N N-(2-phenylphenyl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1CN(CC2)CCC2N1C(=O)NC1=CC=CC=C1C1=CC=CC=C1 NUEJNLGYOUWEJF-UHFFFAOYSA-N 0.000 description 1
- SIXLKFFQGNAVOZ-UHFFFAOYSA-N N-(3-phenylphenyl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1CN(CC2)CCC2N1C(=O)NC(C=1)=CC=CC=1C1=CC=CC=C1 SIXLKFFQGNAVOZ-UHFFFAOYSA-N 0.000 description 1
- BYWLNTJDYHPXFR-RASHCRKMSA-N N-[(E,2S,3R)-3-hydroxy-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]formamide Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BYWLNTJDYHPXFR-RASHCRKMSA-N 0.000 description 1
- VJLLLMIZEJJZTE-KAQXTUTFSA-N N-[(E,2S,3R)-3-hydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VJLLLMIZEJJZTE-KAQXTUTFSA-N 0.000 description 1
- HRIPRKAKDXNLPE-UHFFFAOYSA-N N-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1=CC(F)=CC=C1C1=CC=C(C2(CC2)NC(=O)N2C3CCN(CC3)CC2)C=C1 HRIPRKAKDXNLPE-UHFFFAOYSA-N 0.000 description 1
- OJRDRYIRUGOQNL-UHFFFAOYSA-N N-[2-(3-bromophenyl)propan-2-yl]-2-chloroacetamide Chemical compound ClCC(=O)NC(C)(C)C1=CC=CC(Br)=C1 OJRDRYIRUGOQNL-UHFFFAOYSA-N 0.000 description 1
- NWXRSEPOXNXREC-UHFFFAOYSA-M N-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]carbamate Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC([O-])=O)=C1 NWXRSEPOXNXREC-UHFFFAOYSA-M 0.000 description 1
- YZYBWKDFJWKPCV-UHFFFAOYSA-N N-[2-(3-propan-2-yloxyphenyl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound CC(C)OC1=CC=CC(C(C)(C)NC(=O)N2C3CCN(CC3)CC2)=C1 YZYBWKDFJWKPCV-UHFFFAOYSA-N 0.000 description 1
- MTFNURZOHVNIJE-UHFFFAOYSA-N N-[2-(3-propan-2-ylphenyl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound CC(C)C1=CC=CC(C(C)(C)NC(=O)N2C3CCN(CC3)CC2)=C1 MTFNURZOHVNIJE-UHFFFAOYSA-N 0.000 description 1
- ZUKCRSDHRIJARO-UHFFFAOYSA-N N-[2-(4-fluoro-3-phenylphenyl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1CN(CC2)CCC2N1C(=O)NC(C)(C)C(C=1)=CC=C(F)C=1C1=CC=CC=C1 ZUKCRSDHRIJARO-UHFFFAOYSA-N 0.000 description 1
- WKNQIOPIWQONJC-UHFFFAOYSA-N N-[2-[2-fluoro-5-(2-methylpropyl)phenyl]propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound CC(C)CC1=CC=C(F)C(C(C)(C)NC(=O)N2C3CCN(CC3)CC2)=C1 WKNQIOPIWQONJC-UHFFFAOYSA-N 0.000 description 1
- QWTRUZKBHYEKAJ-UHFFFAOYSA-N N-[2-[4-(4-fluorophenyl)phenyl]propan-2-ylsulfamoyl]-3-methyl-1-azabicyclo[2.2.2]octan-3-amine Chemical compound C1N(CC2)CCC2C1(C)NS(=O)(=O)NC(C)(C)C(C=C1)=CC=C1C1=CC=C(F)C=C1 QWTRUZKBHYEKAJ-UHFFFAOYSA-N 0.000 description 1
- VMHWWQJKHRGIJY-UHFFFAOYSA-N N-[2-[4-fluoro-3-(4-fluorophenyl)phenyl]propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C1CN(CC2)CCC2N1C(=O)NC(C)(C)C(C=1)=CC=C(F)C=1C1=CC=C(F)C=C1 VMHWWQJKHRGIJY-UHFFFAOYSA-N 0.000 description 1
- NBALDKDFYJBBAZ-UHFFFAOYSA-N N-naphthalen-1-yl-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1NC(=O)N1CCN2CCC1CC2 NBALDKDFYJBBAZ-UHFFFAOYSA-N 0.000 description 1
- APDLCSPGWPLYEQ-WRBRXSDHSA-N N-octanoylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCC APDLCSPGWPLYEQ-WRBRXSDHSA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-M N-phenylcarbamate Chemical compound [O-]C(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-M 0.000 description 1
- YSGVHVXAZHQVJI-UHFFFAOYSA-N N12CC(C(CC1)CC2)OC(NC(C)(C)C2=C(C=CC(=C2)C2CC2)F)=O Chemical compound N12CC(C(CC1)CC2)OC(NC(C)(C)C2=C(C=CC(=C2)C2CC2)F)=O YSGVHVXAZHQVJI-UHFFFAOYSA-N 0.000 description 1
- GOYSZHZSNWIDNQ-UHFFFAOYSA-N N12CC(C(CC1)CC2)OC(NC(C)(C)C=2C=C(C(=CC2)F)C2=CC=C(C=C2)F)=O Chemical compound N12CC(C(CC1)CC2)OC(NC(C)(C)C=2C=C(C(=CC2)F)C2=CC=C(C=C2)F)=O GOYSZHZSNWIDNQ-UHFFFAOYSA-N 0.000 description 1
- BENIXRIDLPIJEN-UHFFFAOYSA-N N12CC(C(CC1)CC2)OC(NC(C)(C)C=2C=C(C=CC2)C2=CC=CC=C2)=O Chemical compound N12CC(C(CC1)CC2)OC(NC(C)(C)C=2C=C(C=CC2)C2=CC=CC=C2)=O BENIXRIDLPIJEN-UHFFFAOYSA-N 0.000 description 1
- KFUIBJGZYHKCRE-UHFFFAOYSA-N N12CC(C(CC1)CC2)OC(NC(C)(C)C=2C=C(C=CC2F)C2=CC=CC=C2)=O Chemical compound N12CC(C(CC1)CC2)OC(NC(C)(C)C=2C=C(C=CC2F)C2=CC=CC=C2)=O KFUIBJGZYHKCRE-UHFFFAOYSA-N 0.000 description 1
- DFWCZVVZMFFFLS-UHFFFAOYSA-N N12CC(C(CC1)CC2)OC(NC2(CC2)C2=CC=C(C=C2)C2=CC=C(C=C2)OC)=O Chemical compound N12CC(C(CC1)CC2)OC(NC2(CC2)C2=CC=C(C=C2)C2=CC=C(C=C2)OC)=O DFWCZVVZMFFFLS-UHFFFAOYSA-N 0.000 description 1
- XAAPLMDDLREXEY-OAQYLSRUSA-N N12C[C@H](C(CC1)CC2)OC(NC2(CC2)C2=CC=C(C=C2)C2=C(C=C(C=C2)F)F)=O Chemical compound N12C[C@H](C(CC1)CC2)OC(NC2(CC2)C2=CC=C(C=C2)C2=C(C=C(C=C2)F)F)=O XAAPLMDDLREXEY-OAQYLSRUSA-N 0.000 description 1
- 102100007814 NAGA Human genes 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- GGLCAWKTTCTJQV-LJQANCHMSA-N O1C(C)(C)C(C)(C)OB1C1=CC=C(C2(CC2)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C2(CC2)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 GGLCAWKTTCTJQV-LJQANCHMSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010034606 Peripheral neuropathy Diseases 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 208000009901 Polycystic Kidney Disease Diseases 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- MNOALXGAYUJNKX-UHFFFAOYSA-N S-chloro chloromethanethioate Chemical compound ClSC(Cl)=O MNOALXGAYUJNKX-UHFFFAOYSA-N 0.000 description 1
- JAQFTPUOJKELML-UHFFFAOYSA-N S1C(C(C)(N=[N+]=[N-])C)=CC(C=2C=CC(F)=CC=2)=N1 Chemical compound S1C(C(C)(N=[N+]=[N-])C)=CC(C=2C=CC(F)=CC=2)=N1 JAQFTPUOJKELML-UHFFFAOYSA-N 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000000587 Skeletal Muscle Fibers Anatomy 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- 229920002397 Thermoplastic olefin Polymers 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N Thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 230000037253 Total clearance Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N Triphenylphosphine oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-L UDP-α-D-glucose(2-) Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP([O-])(=O)OP([O-])(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-L 0.000 description 1
- 210000001835 Viscera Anatomy 0.000 description 1
- 229940099072 Zavesca Drugs 0.000 description 1
- DYUXVJAFBUZREW-VHSXEESVSA-N [(1S,2R)-2-isocyanatocyclopropyl]benzene Chemical compound O=C=N[C@@H]1C[C@H]1C1=CC=CC=C1 DYUXVJAFBUZREW-VHSXEESVSA-N 0.000 description 1
- VZPWHUQQSUFTNJ-SFHVURJKSA-N [(3R)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-(3-prop-1-en-2-ylphenyl)propan-2-yl]carbamate Chemical compound CC(=C)C1=CC=CC(C(C)(C)NC(=O)O[C@@H]2C3CCN(CC3)C2)=C1 VZPWHUQQSUFTNJ-SFHVURJKSA-N 0.000 description 1
- VQGHWWJDOZXTNL-OAHLLOKOSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[1-(4-bromophenyl)cyclopropyl]carbamate Chemical compound C1=CC(Br)=CC=C1C1(NC(=O)O[C@H]2C3CCN(CC3)C2)CC1 VQGHWWJDOZXTNL-OAHLLOKOSA-N 0.000 description 1
- VBXBBJFLPPESHN-OAQYLSRUSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[1-[4-(4-fluorophenyl)phenyl]cyclopropyl]carbamate Chemical compound C1=CC(F)=CC=C1C1=CC=C(C2(CC2)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 VBXBBJFLPPESHN-OAQYLSRUSA-N 0.000 description 1
- FHJZQSKPNPOVAK-HXUWFJFHSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[1-[4-(5-fluoropyridin-2-yl)phenyl]cyclopropyl]carbamate Chemical compound N1=CC(F)=CC=C1C1=CC=C(C2(CC2)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 FHJZQSKPNPOVAK-HXUWFJFHSA-N 0.000 description 1
- BECHPKVZVSXCDR-OAHLLOKOSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-(4-bromophenyl)propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C1=CC=C(Br)C=C1 BECHPKVZVSXCDR-OAHLLOKOSA-N 0.000 description 1
- OJPCEFRLJREIKO-QGZVFWFLSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[3-(4-fluorophenyl)-1,2-thiazol-5-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(SN=1)=CC=1C1=CC=C(F)C=C1 OJPCEFRLJREIKO-QGZVFWFLSA-N 0.000 description 1
- YWNHNGHBKVCLKM-QGZVFWFLSA-N [(3S)-1-azabicyclo[2.2.2]octan-3-yl] N-[2-[4-(4-fluorophenyl)-1,3-thiazol-2-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(SC=1)=NC=1C1=CC=C(F)C=C1 YWNHNGHBKVCLKM-QGZVFWFLSA-N 0.000 description 1
- GSGHEEGOQGSSLM-UHFFFAOYSA-N [1-[4-(4,4-difluorocyclohexyl)oxyphenyl]cyclopropyl] carbamate Chemical compound C=1C=C(OC2CCC(F)(F)CC2)C=CC=1C1(OC(=O)N)CC1 GSGHEEGOQGSSLM-UHFFFAOYSA-N 0.000 description 1
- DNZZMUUOQGHGBB-UHFFFAOYSA-N [N-]=C=O.C1CCOC1 Chemical compound [N-]=C=O.C1CCOC1 DNZZMUUOQGHGBB-UHFFFAOYSA-N 0.000 description 1
- YHFMAZGUIFPDFT-UHFFFAOYSA-M [O-]C(=O)NC1(CC1)C1=CC(OC2=CC=C(F)C=C2)=CC=C1 Chemical compound [O-]C(=O)NC1(CC1)C1=CC(OC2=CC=C(F)C=C2)=CC=C1 YHFMAZGUIFPDFT-UHFFFAOYSA-M 0.000 description 1
- MYTJGFBUAWALSE-UHFFFAOYSA-M [O-]C(=O)NC1(CC1)C1=NC(OC2=CC=C(F)C=C2)=CC=C1 Chemical compound [O-]C(=O)NC1(CC1)C1=NC(OC2=CC=C(F)C=C2)=CC=C1 MYTJGFBUAWALSE-UHFFFAOYSA-M 0.000 description 1
- JYGMGWYUOALHIN-UHFFFAOYSA-M [O-]C(=O)NC1(CC1)C1=NC=C(C=C1)C1=CC=C(F)C=C1 Chemical compound [O-]C(=O)NC1(CC1)C1=NC=C(C=C1)C1=CC=C(F)C=C1 JYGMGWYUOALHIN-UHFFFAOYSA-M 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001195 anabolic Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229940000635 beta-Alanine Drugs 0.000 description 1
- 102000007329 beta-Thromboglobulin Human genes 0.000 description 1
- 108010007638 beta-Thromboglobulin Proteins 0.000 description 1
- 230000002146 bilateral Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000002305 biomodulatory effect Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- ZWWQRMFIZFPUAA-UHFFFAOYSA-N dimethyl 2-methylidenebutanedioate Chemical compound COC(=O)CC(=C)C(=O)OC ZWWQRMFIZFPUAA-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- CEALXSHFPPCRNM-UHFFFAOYSA-L disodium;carboxylato carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OC([O-])=O CEALXSHFPPCRNM-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000003028 elevating Effects 0.000 description 1
- KUBARPMUNHKBIQ-VTHUDJRQSA-N eliglustat tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1.C([C@@H](NC(=O)CCCCCCC)[C@H](O)C=1C=C2OCCOC2=CC=1)N1CCCC1 KUBARPMUNHKBIQ-VTHUDJRQSA-N 0.000 description 1
- 229960000886 eliglustat tartrate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 101700043128 est Proteins 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- IBHOWDPRDYMIMO-UHFFFAOYSA-N ethyl 3-amino-3-sulfanylidenepropanoate Chemical compound CCOC(=O)CC(N)=S IBHOWDPRDYMIMO-UHFFFAOYSA-N 0.000 description 1
- LUYMKCLOYODOEI-UHFFFAOYSA-N ethyl 5-bromothiophene-3-carboxylate Chemical compound CCOC(=O)C1=CSC(Br)=C1 LUYMKCLOYODOEI-UHFFFAOYSA-N 0.000 description 1
- FMVJYQGSRWVMQV-UHFFFAOYSA-N ethyl propiolate Chemical compound CCOC(=O)C#C FMVJYQGSRWVMQV-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000032686 female pregnancy Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- CYEFKCRAAGLNHW-UHFFFAOYSA-N furan-3-ylboronic acid Chemical compound OB(O)C=1C=COC=1 CYEFKCRAAGLNHW-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000002254 galactosylceramides Chemical class 0.000 description 1
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 201000006440 gangliosidosis Diseases 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002305 glucosylceramides Chemical group 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 231100000986 in utero exposure Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000010136 inclusion-cell disease Diseases 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 101700009216 malA Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 108010031099 mannose receptor Proteins 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- DZUPFYGLKFFCPP-UHFFFAOYSA-N methyl 1-(2-methoxy-2-oxoethyl)-5-oxopyrrolidine-3-carboxylate Chemical compound COC(=O)CN1CC(C(=O)OC)CC1=O DZUPFYGLKFFCPP-UHFFFAOYSA-N 0.000 description 1
- BFNDBRHGXQREBC-UHFFFAOYSA-N methyl 1-(2-methoxy-2-oxoethyl)pyrrolidine-3-carboxylate Chemical compound COC(=O)CN1CCC(C(=O)OC)C1 BFNDBRHGXQREBC-UHFFFAOYSA-N 0.000 description 1
- SIGOIUCRXKUEIG-UHFFFAOYSA-N methyl 2-dimethoxyphosphorylacetate Chemical compound COC(=O)CP(=O)(OC)OC SIGOIUCRXKUEIG-UHFFFAOYSA-N 0.000 description 1
- KMFJVYMFCAIRAN-UHFFFAOYSA-N methyl 3-bromobenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1 KMFJVYMFCAIRAN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000002025 microglial Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 201000007769 mucolipidosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AZKDTTQQTKDXLH-UHFFFAOYSA-N naphthalene-2-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CC=C21 AZKDTTQQTKDXLH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- LBKLIYYMQBFROC-UHFFFAOYSA-N nonan-4-ol Chemical compound CC[CH]C(O)CCCCC LBKLIYYMQBFROC-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001979 organolithium group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-L pamoate(2-) Chemical class C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- ISYORFGKSZLPNW-UHFFFAOYSA-N propan-2-ylazanium;chloride Chemical compound [Cl-].CC(C)[NH3+] ISYORFGKSZLPNW-UHFFFAOYSA-N 0.000 description 1
- QIPHSSYCQCBJAX-UHFFFAOYSA-N propan-2-ylboronic acid Chemical compound CC(C)B(O)O QIPHSSYCQCBJAX-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 101700054498 such-1 Proteins 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 102000005262 sulfatase family Human genes 0.000 description 1
- 108060007951 sulfatase family Proteins 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000005306 thianaphthenyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 102000005488 thioesterase family Human genes 0.000 description 1
- 108020002982 thioesterase family Proteins 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
Abstract
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Description
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
O.A.P.I. - B.P. 887, YAOUNDE (Cameroun) - Tel. (237) 22 20 57 00- Fax: (237) 22 20 57 27- Site web: http:/www.oapi.int - Email: oapi@oapi.int
GLUCOSYLCERAMIDE SYNTHASE INHIBITORS BACKGROUND OF THE INVENTION Fîeld of the Invention
The présent invention relates generally to the field of therapeutics for cancer and metabolic diseases. More specifically, the invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
Summary of the Related Art
Glucosylceramide synthase (GCS) is a pivotai enzyme which catalyzes the initial glycosylation step in the biosynthesis of glucosylceramide-base glycosphingolipids (GSLs) namely via the pivotai transfer of glucose from UDP-glucose (UDP-GIc) to ceramide to form glucosylceramide (See Fig. 1). GCS is a transmembrane, type III intégral protein localized in the cis/medial Golgi. Glycosphingolipids (GSLs) are believed to be intégral for the dynamics of many cell membrane events, including cellular interactions, signaling and trafficking. Synthesis of GSL structures has been shown (see, Yamashita et al., Proc. Natl. Acad. Sci. USA 1999, 96(16), 91429147) to be essential for embryonic development and for the différentiation of some tissues. Ceramide plays a central rôle in sphingolipid metabolism and downregulation of GCS activity has been shown to hâve marked effects on the sphingolipid pattern with diminished expression of glycosphingolipids. Sphingolipids (SLs) hâve a biomodulatory rôle in physiological as well as pathological cardiovascular conditions. In particular, sphingolipids and their regulating enzymes appear to play a rôle in adaptive responses to chronic hypoxia in the néonatal rat heart (see, El Alwanit et al., Prostaglandins & Other Lipid Mediators 2005, 78(1-4), 249-263).
GCS inhibitors hâve been proposed for the treatment of a variety of diseases (see for example, W02005068426). Such treatments include treatment of glycolipid storage diseases (e.g., Tay Sachs, Sandhoffs, GM2 Activator deficiency, GM1 gangliosidosis and Fabry diseases), diseases associated with glycolipid accumulation (e.g., Gaucher disease; Miglustat (Zavesca), a GCS inhibitor, has been approved for therapy in type 1 Gaucher disease patients, see, Treiber et al., Xenobiotica 2007, 37(3), 298-314), diseases that cause rénal hypertrophy or hyperplasia such as diabetic nephropathy; diseases that cause hyperglycemia or hyperinsulemia; cancers in which glycolipid synthesis is abnormal, infectious diseases caused by organisms which use cell surface glycolipids as receptors, infectious diseases in which synthesis of glucosylceramide is essential or important, diseases in which synthesis of glucosylceramide is essential or important, diseases in which excessive glycolipid synthesis occurs (e.g., atherosclerosis, polycystic kidney disease, and rénal hypertrophy), neuronal disorders, neuronal injury, inflammatory diseases or disorders l
associated with macrophage recruitment and activation (e.g., rheumatoid arthritis, Crohn’s disease, asthma and sepsis) and diabètes mellitus and obesity (see, WO 2006053043).
In particular, it has been shown that overexpression of GCS is implicated in multi-drug résistance and disrupts ceramide-induced apoptosis. For example, Turzanski et al., (Experimental Hematology 2005, 33 (1 ), 62-72 hâve shown that ceramide induces apoptosis in acute myeloid leukemia (AML) cells and that P-glycoprotein (p-gp) confers résistance to ceramide-induced apoptosis, with modulation of the ceramide-glucosylceramide pathway making a marked contribution to this résistance in TF-1 cells. Thus, GCS inhibitors can be useful for treatment of proliférative disorders by inducing apoptosis in diseased cells.
SUMMARY OF THE INVENTION
The présent invention refers to a compound represented by the following structural formula,
or a pharmaceutically acceptable sait or prodrug thereof, wherein: n is 1,2 or 3;
m is 0 or 1 ;
p is 0 or 1 ;
t is 0, 1 or 2;
y is 1 or 2;
z is 0,1 or 2;
E is S, O, NH, NOH, NNO2, NCN, NR, NOR or NSO2R;
X1is CR1 when m is 1 or N when m is 0;
X2 is O, -NH, -CHr. SO2, NH-SOziCHtCrCe) aikyl or-NR2 ;
X3 is O, -NH, -CH2-, CO, - CH(CrC6) alkyl, SO2NH, -CO-NH- or-NR3;
X4 is CR4R5, CH2 CR4R5or CH2 -(CrC6) alkyl-CR4Rs;
X5 is a direct bond, O, S, SO2, CR4R5; (CrC6)alkyl, (CrCeJalkyloxy, (Ci-Ce)alkenyl, (Cr C6)alkenyloxy;
R is (C6-C12)aryl, (C2-C9)heteroaryl, (C;-Cejalkyl, (C2-Cg)heteroaryl(Ci_Ce)alkyl;
R1 is H,CN, (CrCeJalkylcarbonyl, or (CrCe)alkyl;
R2 and R3 are each independently -H, (Ci-C6)alkyl optionally substituted by one or more substituents selected from the group consisting of halogen, (CrC6)alkyl, (C6-C12)aryl, (C2Cgjheteroaryl, (CrCejalkyKCe-C^Jaryl, halo(Ce-C12)aryl, and halo(C2-Cg)heteroaryl, or optionally when X2 is -NR2 and X3 is -NR3, R2 and R3 may be taken together with the nitrogen atoms to which they are attached form a non-aromatic heterocyclic ring optionally substituted by with one or more substituents selected from halogen, (CrC6)alkyl, (C6-C12)aryl, (C2-C9)heteroaryl, (Ci-C6)alkyl(C6C12)aryl, halo(C6-C12)aryl, and halo(C2-Cg)heteroaryl;
R4 and R5 are independently selected from H, (Ci-C6)alkyl, or taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring;
R6 is -H, halogen, -CN, (C6-C12)aryl, (C6-Ci2)aryloxy, (Ci-C6)alkyloxy;
(CrCeJalkyl optionally substituted by one to four halo or (CrCeJalkyl;
A1 is (C2-Ce)alkynyl; (C6-Ci2)aryl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl or benzo(C2Cg)heterocycloalkyi optionally substituted with one or more substituents selected from the group consisting of halo, (CrC6)alkyl optionally substituted by one to three halo; (CpCeJalkenyl, amino, (Cr C6)alkylamino, (Ci-C6) dialkylamino, (Ci-C6)alkoxy, nitro, CN, -OH, (Ci-C6)alkyloxy optionally substituted by one to three halo; (CrC6)alkoxycarbonyl, and (CrCe) alkylcarbonyl;
A2 is H, (C6-C12)aryl, (C2-C9)heteroaryl, (C2-C9)heterocycloalkyl or benzo(C2C9)heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of halo, (Ci-C6)alkyl optionally substituted by one to three halo; (C^C^alkylenyl, amino, (CrCe) alkylamino, (CrCeJdialkylamino, (Ci-C6)alkoxy, O(C3-C6 cycloalkyl), (Cs-Ce) cycloalkoxy, nitro, CN, OH, (CrC6)alkyloxy optionally substituted by one to three halo; (C3-C6) cycloalkyl, (Ci-C6) alkoxycarbonyl, (CpCg) alkylcarbonyl, (CrCe) haloalkyl;
with the proviso that the sum of n +1 + y + z is not greater than 6;
with the proviso that when p is 0; X2 is NH-SO2 and X3 is NH;
with the proviso that when n is 1 ; t is 0; y is 1 ; z is 1 ; X2 is NH; E is Ο; X3 is NH; A2 is H and X5 is a direct bond; A1 is not unsubstituted phenyl, halophenyl or isopropenyl phenyl;
with the proviso that when n is 1 ; t is 0; y is 1 ; z is 1 ; X2 is O; E is Ο; X3 is NH; A1 is (C6C12)aryl and X5 is a direct bond; A2 is H and R4is H then R5is not cyclohexyl; and with the proviso that when n is 1 ; t is 0; y is 1 ; z is 1 ; X2 is NH; E is Ο; X3 is CH2; R4 and R5 are both hydrogen; A2 is H and X5 is a direct bond; then A1 is not unsubstituted phenyl. Certain aspects of the invention include administering the foregoing compound to a patient as part of combination therapy that includes an enzyme replacement therapy (ERT) and small molécule therapy (SMT) to reduce the amount of and/or inhibit substrate accumulation in a patient diagnosed with a lysosomal storage disease.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; t is 0; y is 1 and z is 1.
The présent invention further relates to the compound of Formula I, wherein n is 1; t is 1; y is 1 and z is 1.
The présent invention further relates to the compound of Formula I, wherein n is 2; t is 0; y is 1 and zis 1.
The présent invention further relates to the compound of Formula I, wherein n is 2; t is 1; y is 1 and z is 1.
The présent invention further relates to the compound of Formula I, wherein n is 3; t is 0; y is 1 and zis 1.
The présent invention further relates to the compound of Formula I, wherein n is 1; t is 2; y is 1 and z is 1.
The présent invention further relates to the compound of Formula I, wherein n is 1; t is 0; y is 1 and z is 0.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; t is 1 ; y is 1 and z is 0.
The présent invention further relates to the compound of Formula I,wherein n is 2; t is 0; y is 1 and z is 0.
The présent invention further relates to the compound of Formula I, wherein n is 2; t is 1 ; y is 1 and z is 0.
The présent invention further relates to the compound of Formula I, wherein n is 3; t is 0; y is 1 and z is 0.
The présent invention further relates to the compound of Formula I, wherein n is 1; t is 2; y is 1 and z is 0.
The présent invention further relates to the compound of Formula I, wherein n is 1; t is 1; y is 2 and z is 0.
The présent invention further relates to the compound of Formula I, wherein n is 2; t is 0; y is 2 and z is 0.
The présent invention further relates to the compound of Formula I, wherein m is 1 and X1 is CR1.
The présent invention further relates to the compound of Formula I, wherein m is 0 and X1 is N.
The présent invention further relates to the compound of Formula I, wherein m is 1; E is O; X2isOand X3isNH.
The présent invention further relates to the compound of Formula I, wherein m is 1; E is O; X2 is NH and X3is NH.
The présent invention further relates to the compound of Formula I, wherein m is 1 ; E is O; X2 is CH2 andX3isNH.
The présent invention further relates to the compound of Formula I, wherein m is 1; E is O; X2 isNHand X3is CH2.
The présent invention further relates to the compound of Formula I, wherein m is 1; E is S; X2 is NH andX3is NH.
The présent invention further relates to the compound of Formula I, wherein m is 0; E is O; X1 isNHand X’isNH.
The présent invention further relates to the compound of Formula I, wherein m is 1; E is O; X2 isNHandX3is CO-NH.
The présent invention further relates to the compound of Formula I, wherein m is 1 ; p is 0; X2 is NH-SO2 and X3is NH.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are each (Ci-C6)alkyl or taken together with the carbon to which they are attached to form a spiro (C3Cio)cyclo- alkyl ring or a spiro (C3-Ci0)cycloalkoxy ring.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are each methyl.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are taken together with the carbon to which they are attached to form a spîro cyclopropyl ring.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are taken together with the carbon to which they are attached to form a spiro (Ca-Cwjcycloalkoxy ring.
The présent invention further relates to the compound of Formula I, wherein A1 is (C2CB)alkynyl or (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein A1 is (C2Ca)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein A1 is thiophene, thiazole, isothiazole, furane, oxazole, isoxazole, pyrrole, imidazole, pyrazole, triazole, pyridine, pymiridine, pyridazine, indole, benzotiazole, benzoisoxazole, benzopyrazole, benzoimidazole, benzofuran, benzooxazole or benzoisoxazole.
The présent invention further relates to the compound of Formula I, wherein A1 is (C2Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein A1 is pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, azetidinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepînyl, piperazinyl, piperizin-2-onyl, piperizin-3-onyl, chromanyl, 2-pyrrolinyl, 3-pyrrolinyl, imidazolidinyl, 2imidazolidinyl, 1,4-dioxanyl, 8-azabicyclo[3.2.1]octanyl, 3-azabicyclo[3.2.1]octanyl, 3,8diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2,5-diazabicyclo[2.2.2]octanyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[4.1.0]heptanyl, 3-azabicyclo[3.1.0]hexanyl 2 azaspiro[4.4]nonanyl, 7-oxa-1-aza-spiro[4.4]nonanyl, 7-azabicyclo[2.2.2]heptanyl or octahydro-1 Hindolyl.
The présent invention further relates to the compound of Formula I, wherein A1 is benzo(C2Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein A1 is 2,3dihydrobenzo[b][1,4] dioxine or 2,2-difluorobenzo[d][1,3]dioxole.
The présent invention further relates to the compound of Formula I, wherein Re is H,
The présent invention further relates to the compound of Formula I, X5 is a direct bond.
The présent invention further relates to the compound of Formula I, X5 is a CR4R5.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are each methyl.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are taken together with the carbon to which they are attached to form a spiro cyclopropyl ring.
The présent invention further relates to the compound of Formula I, wherein R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkoxy ring.
The présent invention further relates to the compound of Formula I, wherein A2 is (C6C12)aryl.
The présent invention further relates to the compound of Formula I, wherein A2 is(C2C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein A2 is pyridine.
The présent invention further relates to the compound of Formula I, wherein A2 is (C2Cfl)heterocycloa Ikyl.
The présent invention further relates to the compound of Formula I, wherein A2 is pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, azetidinyl, oxiranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morphoîinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, piperizin-2-onyl, piperizin-3-onyl, chromanyl, 2-pyrrolinyl, 3-pyrrolinyl, imidazolidinyl, 2imidazolidinyl, 1,4-dioxanyl, 8-azabicycio[3.2.1]octanyl, 3-azabicyclo[3.2.1]octanyl, 3,8diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]heptany!l 2,5-diazabicyclo[2.2.2]octanyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[4.1 .OJheptanyl, 3-azabicyclo[3.1.0]hexanyl 2azaspiro[4.4]nonanyl, 7-oxa-1-aza-spiro[4.4]nonanyl, 7-azabicyclo[2.2.2]heptanyl or octahydro-1Hindolyl.
The présent invention further relates to the compound of Formula I, wherein A2 is benzo(C2Cgjheterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein A2 is ...
The présent invention further relates to the compound of Formula I, where R1 is hydrogen or methyl.
The présent further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Cio)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; Rs is a hydrogen or methyl; A1 is (C2Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (CrCgJheteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (Ce-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (Cs-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (Ce-C12)aryl; X5 is a direct bond, O or
CR4R5and A2 is (Ce-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E ts Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Ca)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9) heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (Ce-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4Rsand A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C9-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R® is a hydrogen or methyl; A1 is (C9-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (Ce-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R'1 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4 R5 and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R6 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (CB-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (CB-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (CB-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1 ; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E Is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (Cs-C^Jcycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (Cî-C^heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (CB-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-CB)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t îs 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; Xz is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R® is a hydrogen or methyl; A1 îs (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (Ce-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heteroaryl,
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 îs (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (Ce-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and Rsare each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is N H; R4 and Rs are taken together with the carbon to which they are attached to form a spîro (C3-C10)cycloalkyl ring or spiro (C3C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (Ce-C12)aryl; X5 is a direct bond, O or CR4R5 and A3 is (C3~C^2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5 and A2 is (Ce-C^Jaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3Cio)cycloalkoxy ring; R5 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5 and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; Xs is a direct bond, O or CR4R5 and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (CrCwJcycloalkyl ring or spiro (C3C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; Xs is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R6and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (Ce-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cs)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is O; X3is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2CB)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; Rs is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R'1 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or
CR4R5and A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is Oor 1; zis 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-Cg)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (Ce-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-Cg)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Ce)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C8)heterocycloalkyl; X5 is a direct bond, O or CR4Rsand A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (Ca-C^cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R® is a hydrogen or methyl; A1 is (C6-C12)aryl; Xs is a direct bond, O or CR4R5and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Ca)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 ts a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; Rs is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5 and A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R® is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5 and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R® is a hydrogen or methyl; A1 is (C2-Cg)heterocycloalkyl; X5 is a direct bond, O or CR4Rsand A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cfl)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C0)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C2C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 rs (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Cto)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2Cg)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (CrC9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 ts CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Ce)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CHZ; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heterocycîoalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (Ca-C^cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; Xs is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; Xs is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1 ; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (Ca-C^icycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; Xe is a direct bond, O or CR4R5and A2 is (C2-C9) heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalky! ring or spiro (C3Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C0)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond,
O or CR4R5and A2 is (C2-C9)heterocycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heterocycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-Cg)heterocycloalkyl; Xs is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula l, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3C10)cyc!oalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond,
O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro {C3-Cio)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; Xs is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E îs Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond,
O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (Ce-C-i2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl,
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-Cw)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (Ce-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or
CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; zis 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4Rsand A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X6 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R5 is a hydrogen or methyl; A1 is (C3-Ci0)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n Is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-Ci0)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4Rsand A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (CrCioJcycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cyc1oalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-Ci0)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-Ci2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5 and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5 and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is N; m îs 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R5 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C6-Ci2)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C6-C12)aryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (Qj-CioJcycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C6-C-i2)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (Ce-C12)aryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-Ci0)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1 ; m is 1 ; p is 1 ; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-Ci0)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; Xs is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 Is CR1; m is 1; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; Xs is a direct bond, O or CR4R5and A2 is (C3-C.|o)cycloalkyL
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CH2; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; Xs is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4Rsand A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9) heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is CH2; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1 ; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and Rs are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (Ca-CioJcycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is S; X2 is NH; X3 is NH; R4 and Rs are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring; R® is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; Xs is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1 ; E is SO2; X2 is NH; X3 is NH; R4 and Rs are each independently methyl; R® is a hydrogen or methyl; A1 is (C2-Cfl)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-Cw)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C0)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1; m is 1; E is SO2; X2 is NH; X3 is NH; R4 and R5 are each independently methyl; R® is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-C10)cycloalkyl ring or spiro (C3C10)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C2-CB)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-Ci0)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is N H; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3Ci0)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-Cg)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is N; m is 0; E is Ο; X3 is NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; Xs is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl,
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (Cs-Ciojcycloalkoxy ring; Re is a hydrogen or methyl; A1 is (C2-C9)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1 ; z is 0, 1 or 2; X1 is CR1; m is 1 ; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-C0)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C3-C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein n is 1 ; 2 or 3; t is 0, 1 or 2; y is 0 or 1; z is 0,1 or 2; X1 is CR1;mis1;Eis Ο; X2 is NH; X3 is CO-NH; R4 and R5 are taken together with the carbon to which they are attached to form a spiro (C3-Ci0)cycloalkyl ring or spiro (C3-Cio)cycloalkoxy ring; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein n is 1; 2 or 3; t is 0, 1 or 2; y is 0 or 1 ; z is 0,1 or 2; X1 is CR1; m is 1; E is Ο; X2 is NH; X3 is CO-NH; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C3-C10)cycloalkyl; X5 is a direct bond, O or CR4R5and A2 is (C2-C9)heteroaryl.
The présent invention further relates to the compound of Formula I, wherein A1 is (C3C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, wherein A2 is (C3C10)cycloalkyl.
The présent invention further relates to the compound of Formula I, or a pharmaceutically acceptable sait or prodrug thereof, selected from the group consisting of: 1-azabicyclo[2.2.2]oct-3-yl [2-(2,4’-difluorobiphenyl-4-yl)propan-2-yl]carbamate;
1-azabicyclo[2.2.2]oct-3-yl {2-[4-(1,3-benzothiazol-6-yl)phenyl]propan-2-yl}carbamate;
-azabicyclo[3.2.2]non-4-yl {1 -[5-(4-fluorophenyl)pyrïdin-2-yl]cyclopropyl}carbamate;
-azabicyclo[2.2.2]oct-3-yl {1 -[3-(4-fluorophenoxy)phenyl]cyclopropyl)carbamate;
1-azabicyclo[2.2.2]oct-3-yl {1-[4-(1,3-benzothiazol-5-yl)phenyl]cyclopropyl)carbamate;
-azabicyclo[2.2.2]oct-3-yl [1 -(4'-fiuoro-3'-methoxybiphenyl-4yl)cyclopropyl]carbamate;
1-azabicyclo[2.2.2]oct-3-yl [3-(4'-fluorobiphenyl-4-yl)oxetan-3-yl]carbamate;
-azabicyclo[2.2.2]oct-3-yl {1 -[6-(4-fluorophenoxy)pyridin-2-yl]cyclopropyl)carbamate;
1-azabicyclo[2.2.2]oct-3-yl [3-(4'-fluorobiphenyl-4-yl)pentan-3-yl]carbamate;
-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-2H-indazol-6-yl]propan-2 yl}carbamate;
1-azabicyclo[2.2.2]oct-3-yl {2-(2-(1 H-pyrrol-1-yl)pyridin-4-yl]propan-2-yl}carbamate;
1-(3-ethyl-1-azabicyclo[2.2.2]oct-3-yl)-3-[1-(4'-fluorobiphenyl-4-yl)cyclopropyl]urea; N-(1-azabicyclo[2.2.2]oct-3-yl)-N'-[1-(4'-fluorobiphenyl-4yl)cyclopropyl]ethanediamide;
-azabicyclo[2.2.2]oct-3-yl (1 -{4[(4,4difluorocyclohexyl)oxy]phenyl)cyclopropyl) carbamate;
1 -(4-methyl-1 -azabicyclo[3.2.2]non-4-yl)-3-[1 -(5-phenylpyridin-2-yl)cyclopropyl]urea;
1-[1-(4'-fluorobiphenyl-4-yl)cyclopropyl]-1-methyl-3-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)urea;
1-[1-(4'-fluorobiphenyl-4-yl)cyclopropyl]-1 -methyl-3-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)urea;
1- {2-[4'-(2-methoxyethoxy)biphenyl-4-yl]propan-2-yl}-3-(3-methyi-1-azabicyclo[2.2.2]oct-3-yl)urea;
2- (1-azabicyclo[3.2.2]non-4-yl)-N-[1-(5-phenylpyridin-2-yl)cyclopropyl]acetamîde;
3-(4'-fluorobiphenyl-4-yl)-3-methyl-N-(4-methyl-1 -azabicyclo[3.2.2]non-4-yl)butanamide;
N-[2-(biphenyl-4-yl)propan-2-yl]-N'-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)sulfuric diamide; N-[2-(4'-fluorobiphenyl-4-yl)propan-2-yl]-N’-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)sulfuric diamide;
-(3-butyl-1 -azabicyclo[2.2.2]oct-3-yl)-3-{2-[1 -(4-fluorophenyl)-1 H-pyrazol-4-yl]propan-2-yl}urea;
1-azabicyclo[2.2.2]oct-3-yl [4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl]carbamate;
1-(3-butyl-1-azabicyclo[2.2.2]oct-3-yl)-3-[4-(4-fluorophenyl)-2-methylbut-3-yn-2-yl]urea;
N-[1-(4‘-fluorobiphenyl-4-yl)cyclopropyl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide;
1-{2-(4’-fluoro-[1,r-biphenyl]-4-yl)propan-2-yl)-3-(3-methyl-1-azabicyc!o[3.2.2]nonan-3-yl)urea;
1-(2-(4'-fluoro-[1,T-biphenyl]-4-yl)propan-2-yl)-3-(4-methyl-1-azabicyclo[4.2.2]decan-4-yl)urea;
1-(2-(4'-fluoro-[1,T-biphenyl]-4-yl)propan-2-yl)-3-(3-methyl-1-azabicyclo[4.2.2]decan-3-yl)urea; and
1-(2-(4'-fluoro-[1,T-biphenyl]-4-yl)propan-2-yl)-3-(5-methyl-1-azabicyclo[4.2.2]decan-5-yl)urea.
The présent invention further relates to a pharmaceutical composition for treatîng a disease or disorder mediated by glucosylceramide synthase (GCS) or a disease or disorder in which GCS is implicated in a subject in need of such treatment comprising administering to the subject an effective amount of the compound of Formula I.
The présent invention further relates to a method for treatîng a disease or disorder mediated by glucosylceramide synthase (GCS) or a disease or disorder in which GCS is implicated in a subject in need of such treatment comprising administering to the subject an effective amount of the compound of Formula I.
The présent invention further relates to a method for treating a disease or disorder such as cancer.
The présent invention further relates to a method for treating a disease or disorder such as a metabolic disorder.
The présent invention further relates to a method for treating a disease or disorder such as a neuropathie disease.
The présent invention further relates to a method wherein the neuropathie disease is Alzheimers disease.
The présent invention further relates to a method wherein the neuropathie disease is Parkinsons disease.
The présent invention further relates to the method for inducing decreased glucosylceramide synthase catalytic activity in a cell, in vitro, comprising contacting the cell with an effect amount of the compound of Formula I.
The présent invention further relates to the compound of forumula I, represented by the following stsructural formula, or a pharmaceutically acceptable sait or prodrug thereof.
The présent invention further relates to the compound of forumula I, represented by the following stsructural formula,
F
or a pharmaceutically acceptable sait or prodrug thereof.
The présent invention further relates to a method of treating a subject diagnosed as having a lysosomal storage disease, the method including administering to the subject an effective amount of the compound of formula I, and in certain embodiments the compound is represented by following
or a pharmaceutically acceptable sait or prodrug thereof, or
or a pharmaceutically acceptable sait or prodrug thereof.
In certain embodiments of the invention, the lysosomal storage disease results from a defect in the glycosphingolipid pathway.
In certain embodiements of the invention, the lysosomal storage disease is Gaucher, Fabry, GMi-gangliosidosis, GM2 Activator deficiency, Tay-Sachs or Sandhoff.
The présent invention further relates to a method of treating a subject diagnosed as having a lysosomal storage disease, the method including administering to the subject an effective amount of the compound of formula I and administering to the subject a therapeutically effective amount of a lysosomal enzyme.
In certain embodiments of the invention, the lysosomal enzyme is glucocerebrosidase, alpha-galactosidase A, Hexosaminidase A, Hexosaminidase B or GMi-ganglioside-p-galactosidase.
In certain embodiements of the invention, the subject has eleveated levels of a lysosomal substrate prior to treatment and once undergoîng treatment the subject has lower combined amounts of the lysosomal substrate in the urine and plasma than a subject treated with either the lysosomal enzyme or compound alone.
In certain embodiements of the invention, the substrate is globotriaosylceramide or lysoglobotriaosylceramide, and combinations thereof.
The présent invention further relates to a method of reducing glucosylceramide synthase (GCS) activity in a subject diagnosed as having a lysosomal storage disease, including administering to the patient an effective anomount of the compound of formula I, either alone or as a combination therapy with an enzyme replacement therapy.
The présent invention further relates to a method of reducing accumulation of a GCS-derived material in a subject diagnosed as having a lysosomal storage disease, including administering to the patient an effective amount of the compound of formula I, either alone or as a combination therapy with an enzyme replacement therapy.
This invention provides a method of combination therapy for treatment of a subject diagnosed as having a lysosomal storage disease comprising altemating between administration of an enzyme replacement therapy and a small molécule therapy.
This invention provides a method of combination therapy for treatment of a subject diagnosed as having a lysosomal storage disease comprising simultaneously administering an enzyme replacement therapy and a small molécule therapy.
In the various combination thérapies of the invention, it will be understood that administering small molécule therapy may occur prior to, concurrently with, or after, administration of enzyme replacement therapy. Similarly, administering enzyme replacement therapy may occur prior to, concurrently with, or after, administration of small molécule therapy.
Définitions
As used herein, the term “pharmaceutically acceptable sait means either a pharmaceutically acceptable acid addition sait or a pharmaceutically acceptable base addition sait of a currently disclosed compound that may be administered without any résultant substantial undesirable biological effect(s) or any résultant deleterious interaction(s) with any other component of a pharmaceutical composition in which it may be contained.
As used herein, the term prodrug means a pharmacological dérivative of a parent drug molécule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. For example, prodrugs are variations or dérivatives of the compounds of Formula I that hâve groups cleavable under certain metabolic conditions, which when cleaved, become the compounds of Formula I, Such prodrugs then are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic dégradation. Prodrug compounds herein may be called single, double, triple, etc., depending on the number of biotransformation steps required to release the active drug within the organism, and the number of functionalities présent in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (See, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman,
The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academie Press, San Diego, Calif., 1992). Prodrugs commonly known in the art include well-known acid dérivatives, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, amides prepared by reaction of the parent acid compound with an amine, basic groups reacted to form an acylated base dérivative, etc. Of course, other prodrug dérivatives may be combined with other features disclosed herein to enhance bioavailability. As such, those of skill in the art will appreciate that certain of the presently disclosed compounds having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds having an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of the presently disclosed compounds. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gammaaminobutyric acid, citrulline homocystéine, homoserine, ornithine and méthionine sulfone. Prodrugs also include compounds having a carbonate, carbamate, amide or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.
As used herein, the term (Ci-C6)alkyr means a saturated linear or branched free radical consisting essentially of 1 to 6 carbon atoms and a corresponding number of hydrogen atoms. Exemplary (Ci-C6)alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, etc. Of course, other (Ct-CeJalkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term “(C3-C10)cycloalkyr means a nonaromatic saturated free radical forming at least one ring consisting essentially of 3 to 10 carbon atoms and a corresponding number of hydrogen atoms. As such, (C3-C10)cycloalkyl groups can be monocyclic or multicyclic. Individual rings of such multicyclic cycloalkyl groups can hâve different connectivities, e.g., fused, bridged, spiro, etc. in addition to covalent bond substitution. Exemplary (C3-Ci0)cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornanyl, bicyclo[3.2.1]octanyl, octahydro-pentalenyl, spiro[4.5]decanyl, cyclopropyl substituted with cyclobutyl, cyclobutyl substituted with cyclopentyl, cyclohexyl substituted with cyclopropyl, etc. Of course, other (C3C10)cycloalkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term (C2-C9)heterocycloalkyr means a nonaromatic free radical having 3 to 10 atoms (i.e., ring atoms) that form at least one ring, wherein 2 to 9 of the ring atoms are carbon and the remaining ring atom(s) (i.e., hetero ring atom(s)) is selected from the group consisting of nitrogen, sulfur, and oxygen. As such, (C2-C9)heterocycloalkyl groups can be monocyclic or multicyclic. Individual rings of such multicyclic heterocycloalkyl groups can hâve different connectivities, e.g., fused, bridged, spiro, etc. in addition to covalent bond substitution. Exemplary (C2-C9)heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyi, pyranyl, thiopyranyl, aziridinyl, azetidinyl, oxrranyl, methylenedioxyl, chromenyl, barbituryl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2yl, 1,3-pyrazolidin-1 -yl, piperidinyl, thiomorpholinyl, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3-tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, piperizin-2-onyl, piperizin-3-onyl, chromanyl, 2-pyrrolinyl, 3pyrrolinyl, imidazolidinyl, 2-imidazolidinyl, 1,4-dioxanyl, 8-azabicyclo[3.2.1]octanyl, 3azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 2,5diazabicyclo[2.2.2]octanyl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[4.1 .OJheptanyl, 3azabicyclo[3.1.0]hexanyl
2-azaspiro[4.4]nonanyl, 7-oxa-1 -aza-spiro[4.4]nonanyl, 7-azabicyclo[2.2.2]heptanyl, octahydro-1 Hindolyl, etc. In general, the (C2-C9)heterocycloalkyl group typically is attached to the main structure via a carbon atom or a nitrogen atom. Of course, other (C2-C9)heterocycloalkyl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term “(C2-Cg)heteroaryr’ means an aromatic free radical having 5 to 10 atoms (i.e., ring atoms) that form at least one ring, wherein 2 to 9 of the ring atoms are carbon and the remaining ring atom(s) (i.e., hetero ring atom(s)) is selected from the group consisting of nitrogen, sulfur, and oxygen. As such, (C2-Cg)heteroaryl groups can be monocyclic or multicyclic.
Individual rings of such multicyclic heteroaryl groups can hâve different connectivities, e.g., fused, etc. in addition to covalent bond substitution. Exemplary (C2-Cg)heteroaryl groups include furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadîazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-trîazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5,6,7,8-tetrahydro-quinolin-3-yl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalînyl, quinazolinyl and benzoxazinyl, etc. In general, the (C2-C9)heteroaryl group typically is attached to the main structure via a carbon atom, however, those of skill in the art will realize when certain other atoms, e.g., hetero ring atoms, can be attached to the main structure. Of course, other (C2-C9)heteroaryl groups will be readily apparent to those of skill in the art given the benefit of the présent disclosure.
As used herein, the term “(Cs-C10)aryl means phenyl or naphthyl.
As used herein, the term “halo” means fluorine, chlorine, bromine, or iodine.
As used herein, the term “amino” means a free radical having a nitrogen atom and 1 to 2 hydrogen atoms. As such, the term amino generally refers to primary and secondary amines. In that regard, as used herein and in the appended daims, a tertiary amine is represented by the general formula RR’N-, wherein R and R’ are carbon radicals that may or may not be identical. Nevertheless, the term “amino” generally may be used herein to describe a primary, secondary, or tertiary amine, and those of skill in the art will readily be able to ascertain the identification of which in view of the context in which this term is used in the présent disclosure.
As used herein, the term “combination therapy” means treating a patient with two or more therapeutic platforms (e.g., enzyme replacement therapy and small molécule therapy) in rotating, alternatîng and/or simultaneous treatment schedules. Examples of treatment schedules may include, but are not limited to: (1) enzyme replacement therapy, then small molécule therapy; (2) small molécule therapy, then enzyme replacement therapy; (3) enzyme replacement therapy concurrent with small molécule therapy, and (4) and any combination of the foregoing. Combination therapy may provide a temporal overlap of therapeutic platforms, as needed, depending on the clinical course of a given storage disease in a given subject.
As used herein, the term “enzyme replacement therapy, or ERT” means administering an exogenously-produced natural or recombinant enzyme to a patient who is in need thereof. In the case of a lyosomal storage disease, for example, the patient accumulâtes harmful levels of a substrate (i.e., material stored) in lysosomes due to a deficiency or defect in an enzyme responsible for metabolizing the substrate, or due to a deficiency in an enzymatic activator required for proper enzymatic fonction. Enzyme replacement therapy is provided to the patient to reduce the levels of (i.e., debulk) accumulated substrate in affected tissues. Table 1 provides a list of lysosomal storage diseases and identifies the correponding enzyme deficiency and accumulated substrate for each disease. Enzyme replacement thérapies for treating lysosomal storage diseases are known in the art. In accordance with a combination therapy of the invention, the lysosomal enzymes identified in Table 1 can be used for enzyme replacement therapy to reduce the levels of corresponding substrate in a patient diagnosed with the respective lysosomal storage disease.
As used herein, effective amount of an enzyme or small molécule, when delivered to a subject in a combination therapy of the invention, is an amount suffirent to improve the clinical course of a lysosomal storage disease, where clinical improvement is measured by any of the variety of defined parameters well known to the skilled artisan.
Abbreviations
ACN refers to acetonitrile.
DMF refers to N,N-dimethylformamide.
DMSO refers to dimethylsulfoxide.
EtOAc refers to ethyl acetate.
EtOH refers to éthanol.
Hunig's Base refers to diisopropylethyl amine (DIPEA).
MeOH refers to methanol.
NaOH refers to sodium hydroxide.
THF refers to tetrahydrofuran.
TFA refers to trifluoroacetic acid.
Additional features and advantages of compounds disclosed herein will be apparent from the following detailed description of certain embodiments.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 Présents the metabolic pathway for the potential synthesîs of Gb3 and Iyso-Gb3.
Documented synthetic pathways are shown with black arrows and undocumented (potential) pathways are shown with grey arrows.
FIG. 2A Chemical structure of (S)-Quînuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2yl)carbamate
FIG. 2B Chemical structure of Quinuclidin-3-yl (2-(4‘-fluoro-[1,T-biphenyl]-3-yl)propan-2yl)carbamate
FIG. 3
Gb3 concentration in kidney (A) and heart (B) from 12 month old Fabry mice treated with 300mg/kg/day (1R,2R)-Octanoic acid[2-(2’,3'-dihydro-benzo [1,4] dioxin-6’-yl)-2-hydroxy-1pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid sait (“GZ 638) or 60 mg/kg/day (S)-Quinuclidin-3yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate sait (“GZ 452).
FIG. 4A
Study timeline showing Fabry mice sterling treatment with 60 mg/kg/day GZ 452 starting at 3, 8 and 12 months of âge. Periodic blood-draws, urine collection, hot-plate and activity chamber assays were performed as indicated.
FIG. 4B
Gb3 concentration in urine (A) and plasma (B) from Fabry mice starting treatment with 60 mg/kg/day GZ 452 at either 3 or 8 months of âge. Drug treatment (Rx) was for either 2 or 4 months..
FIG. 5
Gb3 (A) and Iyso-Gb3 (B) concentration in kidney tissue from 12 month old Fabry mice that were either untreated (UNT) or treated with 60 mg/kg/day GZ 452 for 4 months (SRT).
FIG. 6A
Study timeline showing Fabry mice being treated with alpha-galactosidase A (1 mg/kg every 2 months) or with 60 mg/kg/day GZ 452 or a combination of the 2 treatments starting at 3 months of âge. Periodic blood-draws, urine collection and hot-plate assays were performed as indicated.
FIG. 6B
Plasma (A&C) and urine (B&D) Gb3 (A&C) and Iyso-Gb3 (C&D) concentrations from 5 month old Fabry mice treated with alpha-galactosidase A alone (ERT), GZ 452 alone (SRT) or a combination of the two (E+S) for 2 months.
FIG. 7
N-linked acyl chain isoform analysis of Gb3 isolated from Fabry mouse plasma, urine and kidney.
FIG. 8
Latency (time to respond) to a heat stimulus (55°C hotplate) of 10 month old Fabry mice following 7 months treatment with alpha-galactosidase A (ERT), GZ 452 (SRT) or a combination of the two (E+S) relative to untreated mice (UNT) and wild-type mice (WT).
FIG. 9 Glucosyl ceramide (GluCer) and Glucosyl sphingosine (GluSph) are significantly elevated in the brains of néonatal K14 mice. Mass spectrometry analysis of glucosyl- and galactosylceramides shows that (A) GluCer was elevated 10-fold in K14 mice (an animal model of Néonatal Gaucher disease, aîso known as Gaucher disease Type 2) compared to WT mice through the first 2 weeks of life, (B) GalCer levels were similar over time for both K14 and WT mice, (C) GluSph levels were >1O-fold higher in K14 mice than age-matched WT mice over the first 2 weeks of life; GluSph levels in WT animais were below the level of détection (<0.3 ng/mg). (D) There were no significant différences in brain weights between K14 and WT mice over the first 2 weeks of life. Data points represent mean values and errer bars SEM for N=4.
FIG. 10 Systemic administration of Quinuclidin-3-yl (2-(4'-fluoro-[1,T-biphenyl]-3-yl)propan-2yl)carbamate (GZ 161”) reduces GluCerand GluSph levels in the K14 mouse brain. K14 and WT mice were treated daily (IP) beginning at P4 with vehicle or 5 mg/kg GZ 161, and brains analyzed for GluCerand GluSph at P10. GZ 161-treated animais were asymptomatic atthis time. Treatment with GZ 161 reduced K14 (A) GluCer levels by -70% and (B) GluSph levels by -60%. Posttreatment levels of both glycosphingolipids remained significantly elevated compared to theirWT littermates and génotypes were confirmed by post-mortem DNA analysis. *p<0.05. N=4/group.
FIG. 11 Systemic administration of GZ 161 reduces CD68 staining throughout the brain of K14 mice. (Upper panels) Représentative immunohistochemical CD 68 staining at P10 in the hippocampus, thalamus, brainstem and cerebellum of K14 mice treated daily (IP) beginning at postnatal day 4 (P4) with vehicle or GZ 161 and WT mice. (Lower panels) QuantÎtation of staining in the groups shown above, showing that systemic treatment with GZ 161 results in significant réductions the CD68+ cells in ali brain régions. Similar réductions were observed in other structures such as the olfactory bulb and frontal cortex (data not shown). **p<0.01. N=4/group
FIG. 12 Systemic administration of GZ 161 reduces F4/80 staining in some brain régions of K14 mice. (Upper panels) Représentative immunohistochemical F4/80 staining at P10 in the hippocampus, thalamus, brainstem and cerebellum of K14 mice treated daily (IP) beginning at P4 with vehicle or GZ 161, and WT mice. (Lower panels) QuantÎtation of staining in the groups shown above, showing that systemic treatment with GZ 161 results in significant réductions the F4/80+ cells in the thalamus and brainstem. Similar réductions were observed in other structures such as the olfactory bulb and frontal cortex; statistical différences were observed in both structures (data not shown). *p<0.05. N=4/group
FIG. 13 Systemic administration of GZ 161 decreases gliosis in K14 mice. (Upper panels) Représentative immunohistochemical GFAP staining at P10 in the hippocampus, thalamus, brainstem and cerebellum of K14 mice treated daily (IP) beginning at P4 with vehicle or GZ 161, and WT mice. (Lower panels) Quantitation of staining in the groups shown above, showing that systemic treatment with GZ 161 results in significant réductions the GFAP+ cells in the hippocampus and cerebellum; statistical différences were observed in both structures (data not shown).
FIG. 14 Systemic administration of GZ 161 increases the médian lifespan of K14 mice. K14 mice were injected (IP) daily beginning at P4 with vehicle or GZ 161 or given a combined treatment of three intracerebroventricular (ICV) injections of rhGC at P1, 2, 3 together with daily (IP) injections of GZ 161 beginning at P4. Vehicle treated mice had a 15 day médian lifespan (N=25); GZ 161 treated mice had an 18 day médian lifespan (N=12; p<0.0001 compared to vehicle-treated); mice coadministered GZ 161 and rhGC had a 26 day médian lifespan (N=13)
FIG. 15 GZ 161 appears to cross the blood/placental barrier. Systemic administration (20 mg/kg/day in food) of GZ 161 to prégnant WT mice reduces the GluCer load in whole brain homogenates of mice at birth (PO). N=7; p<0.0001 )
FIG. 16 Treating K14 mice with GZ 161 in utero has a minimal effect on survival. K14 mice treated daily (IP) beginning at P4 with vehicle had a médian lifespan of 14 days (N=13). Systemic administration (20 mg/kg/day in food) of GZ 161 to prégnant K14 mice and then daily systemic (IP) administration of GZ 161 (5 mg/kg) to the pups beginning at PO extended lifespan to 19 days (N=13), a resuit similar to treating pups daily systemically (IP) with GZ 161 at 5 mg/kg beginning at P4 (N-12).
FIG. 17 Gb3 levels in kidney tissue from 12 month old male and female Fabry mice treated with
GZ 452, GZ 161 and GZ 638. Mice began treatment at -8 months old and were treated for 4 months with: 60 mg/kg/day GZ 452, 120 mg/kg/day GZ 452, 20 mg/kg/day GZ 161,300 mg/kg/day GZ 638, plus WT and UNT controls.
DETAILED DESCRIPTION
Although spécifie embodiments of the présent disclosure will now be described with reference to the préparations and schemes, it should be understood that such embodiments are by way of example only and merely illustrative of but a small number of the many possible spécifie embodiments which can represent applications of the principles of the présent disclosure. Various changes and modifications will be obvious to those of skill in the art given the benefit of the présent disclosure and are deemed to be within the spirit and scope of the présent disclosure as further defined in the appended daims.
Unless defined otherwise, ail technical and scientific terms used herein hâve the same meaning as commonly understood by one having ordinary skill in the art to which this disclosure belongs. Although other compounds or methods can be used in practice or testing, certain preferred methods are now described in the context of the following préparations and schemes.
PREPARATION A
6
PREPARATION B
PREPARATION C
PREPARATION D
PREPARATION E
D-2
SCHEME 1
SCHEME 2
A-1 or A-2 or B-1
V
SCHEME 3
A-3
In reaction 1 of Préparation A, the compound of formula A-7 is converted to the corresponding compound of formula A-1, wherein X is OH, by reducing A-7 with a reducing agent, preferably lithium aluminum hydride in aprotic solvent such tetrahydrofuran. The reaction is stirred at a température between 0°C and room température for a time period between about 15 minutes to about 2 hours, preferably about 30 minutes, Alternatively, the compound of formula A-7 is converted to the corresponding compound of formula A-1, wherein X is OH, by reducing A-7 under approximately 1 atmosphère of hydrogen in presence of a catalyst, preferably platinum oxide, and a polar solvent such methanol or éthanol for a period of 2 hours to 6 hours, preferably 4 hours. Alternatively, the compound of formula A-7 is converted to the corresponding compound of formula A-1, wherein X is NH, by reacting A-7 with hydroxylamine hydrochloride and sodium acetate in a polar solvent such éthanol, methanol, isopropanol, preferably isopropanol. The reaction mixture is stirred at a température between 50-80°C for a period of 2 hours to 7 hours, preferably 3 hours. Subsequently, the compound so formed above is converted to compound of formula A-1 with a reducing agent, preferably sodium metallic in a polar protic solvent such éthanol, methanol, propanol, preferably n-propanol. The reaction is stirred overnight at 50-80°C, preferably solvent reflux température.
In reaction 2 of Préparation A, the compound of formula A-7 is converted to the corresponding compound of formula A-5, wherein R1, n and z are as defined above, by adding a solution of R1-magnésium bromide in ether to a solution of A-7 in a aprotic solvent, such as ether, at a température between about -60° C to about -90° C, preferably about -78° C for a time period between about 1 hour to about 4 hours, preferably about 2 hours. Alternatively, the compound of formula A-7 can be reacted with R1-lithium to afford the compound of formula A-5.
In reaction 3 of Préparation A, the compound of formula A-5 is converted to the corresponding compound of formula A-4, wherein R1, n and z are as defined above, by treating A-5 with a strong acid, preferably sulfuric acid, in the presence of acetonitrile. The reaction is stirred overnight at room température.
In reaction 4 of Préparation A, the compound of formula A-4 is converted to the corresponding compound of formula A-3, wherein R1, n and z are as defined above, by treating A-4 with an acid, preferably hydrochloric acid. The reaction is stirred at reflux for a period of 18 hours to 72 hours, preferably 24 hours and basified to pH=8 by treatment with an inorganic base in aqueous solution, such as sodium hydroxide.
In reaction 5 of Préparation A, the compound of formula A-7 is converted to the corresponding compound of formula A-6, wherein R1, n and z are as defined above, by reacting A7 with a triphenyl phosphonium ylide to give the corresponding alkene compound of formula A-6, The reaction is stirred at room température for overnight.
In reaction 6 of Préparation A, the compound of formula A-6 is converted to the corresponding compound of formula A-3, wherein R1, n and z are as defined above, by reducing A6 under approximately 1 atmosphère of hydrogen in the presence of a catalyst, preferably palladium on carbon, and a polar solvent, such as methanol, éthanol or ethyl acetate. The reaction is stirred at room température for a time period between about 2 hours to about 24 hour, preferably about 18 hours. Subsequently, the compound so formed is treated with a base, preferably lithium hydroxide, in a mixture of solvent such tetrahydrofuran, methanol and water to afford the compound of A-3. The reaction is stirred overnight at room température.
In reaction 1 of Préparation B, the compound of formula B-2 is converted to the corresponding compound of formula B-1, by reducing B-2 with a reducing agent, preferably lithium aluminum hydride in aprotic solvent such tetrahydrofuran. The reaction is stirred at a température between 0°C and room température for a time period between about 15 minutes to about 2 hours, preferably about 30 minutes.
In reaction 1 of Préparation Ç, the compound of C-4 is converted to the corresponding compound of formula C-3, wherein X is bromine or chloride, by reacting C-4 with boronic acid in the presence of a catalyst, preferably 1,T-bis(diphenylphosphino)ferrocene-palladium(ll)-dichloride, and potassium carbonate. The reaction is microwaved in a mixture of dimethoxyethane and water at a température between about 130° C to about 170° C, preferably about 150° C, for a time period between about 15 min to about 1 hour, preferably about 30 min. Alternatively, the reaction can be performed using solvent such dioxane and stirred overnight at 100° C under conventional heating.
In reaction 2 of Préparation Ç, the compound of C-3 is converted to the corresponding compound of formula C-1, wherein f is 1 to 8 and A1, X5 and A2 are as defined above, by adding ethyl magnésium bromide dropwise to a mixture of C-3 and titanium isopropoxide in ether. The reaction is stirred at a température between about -50° C to about -90° C, preferably about -70° C.
The resulting reaction mixture is allowed to warm to about 20° C to about 30° C, preferably about 25° C, and allowed to stirfor an additional time period between about 30 minutes to about 2 hours, preferably about 1 hour, Boron trifluoride diethyl etherate is then added to the mixture dropwise at a température between about 20° C to about 30° C, preferably about 25° C.
In reaction 3 of Préparation Ç, the compound of C-3 is converted to the corresponding compound of formula C-2, wherein A1, X5 and A2 are as defined above, by first stirring a suspension of cérium (III) chloride in an aprotic solvent, such as tetrahyrofuran, at room température for time period between about 30 minutes to about 2 hours, preferably about 1 hour. The resulting suspension is cooled to a température between about -60° C to about -90° C, preferably about -78° C and an organolithium agent is added, preferably methyl lithium in an ether solution, The resulting organocerium complex is allowed to form for a time period between about 30 minutes to about 2 hours, preferably about 1 hour, followed by the addition of C-3 in an aprotic solvent, such as tetrahydrofuran, The resulting réaction mixture is then warmed to room température and allowed to stir for time period between about 16 hours to about 20 hours, preferably about 18 hours.
In reaction 1 of Préparation D, the compound of D-5, wherein R is CO2Et or CN and X is bromine or chloride, is converted to the corresponding compound of formula D-3, by reacting D-5 with an alkyl dihalide such 1,2-dibromoethane. Subsequently, the compound so formed is treated with an inorganic base such lithium hydroxide or potassium hydroxide, in a mixture of solvent such tetrahydrofuran, methanol, glycol and water to afford the compound of D-3, wherein f is 1 to 8. The reaction is stirred overnight at a température between 25°C and 130°C. Alternative^, to form the corresponding compound of formula D-3, wherein X is X5-A2, D-5 must first be reacted according to the procedure discussed above in reaction 1 of Préparation Ç.
In reaction 2 of Préparation D, the compound of D-3 is converted to the corresponding compound of formula D-1 by reacting D-3 with a base such triethylamine and diphenylphosphoryl azide in aprotic solvent such toluene. The reaction was heated to a température range between 80°C-110°C, preferably at 110°C for 15 min to 1 hour, preferably 30 minutes. The so formed intermediate is then treated with ferf-butyl alcohol for overnight period at 60-110 °C, preferably 90 °C. Subsequently, the so formed carbamate is converted to the corresponding compound of formula D-1, wherein f is 1 to 8, by a treatment under acidic media using preferably trifluoroacetic acid in dichloromethane at room température for a period of 30 min to 5 hours, preferably 2 hours.
In reaction 3 of Préparation D, the compound of D-5, wherein R is CO2Et or CN and X is bromine or chloride, is converted to the corresponding compound of formula D-4, by reacting D-5 with an alkyl halide such Mel. Subsequently, the compound so formed is treated with an inorganic base such lithium hydroxide or potassium hydroxide, in a mixture of solvent such tetrahydrofuran, methanol, glycol and water to afford the compound of D-4. The reaction is stirred overnight at a température between 25°C and 130°C. Alternatively, to form the corresponding compound of formula D-4, wherein X is X5-A2, D-5 must first be reacted according to the procedure discussed above in reaction 1 of Préparation Ç.
In reaction 4 of Préparation D, the compound of D-4 is converted to the corresponding compound of formula D-2, by reacting D-4 with a base such triethylamine and diphenylphosphoryl azide in aprotîc solvent such toluene. The reaction was heated to a température range between 80°C-110°C, preferably at 110°C for 15 min to 1 hour, preferably 30 minutes. The so formed intermediate is then treated with tert-butyl alcohol for overnight period at 60-110 °C, preferably 90 °C. Subsequently, the so formed carbamate is converted to the corresponding compound of formula D-1 by a treatment under acidic media using preferably trifluoroacetic acid in dichloromethane at room température for a period of 30 min to 5 hours, preferably 2 hours.
In reaction 1 of Préparation E, the compound of formula E-2, wherein X is bromide or chloride, is converted to the corresponding compound of formula E-1, by reacting E-2 with methyl magnésium bromide in ether, at a température between about -60° C to about -90° C, preferably about -78° C for a time period between about 30min to about 3 hours, preferably about 2 hours. Alternatively, to form the corresponding compound of formula E-1, wherein X is X5-A2, E-2 must first be reacted according to the procedure discussed above in reaction 1 of Préparation Ç.
In reaction 2 of Préparation E, the compound of formula E-1 is converted to the corresponding compound of D-2 by treating E-1 with a strong acid, preferably sulfuric acid, in the presence of chloroacetonitrile. The reaction is stirred overnight at room température. Subsequently, the so formed compound is treated with thiourea in a polar protic solvent such éthanol for an overnight period at 80°C to form the corresponding compound of formula D-2. Alternatively, E-1 is treated with sodium azide and trifluoroacetic acid in an aprotic solvent such dichloromethane at a température range of -10°C to room température, preferably 0°C. The so formed compound is reduced in presence of triphenylphosphine in a solution of tetrahydrofuran and water to form corresponding compound of formula D-2. The reaction is stirred at a température range 25-80°C, preferably at room température for a period of 2 hours to 24 hours, preferabiy 18 hours.
In reaction 1 of Scheme 1, the compounds of formula A-1 or A-2 are converted to the corresponding compounds of Formula II, wherein f is 1 to 8, or III, respectively, by adding triphosgene to a suspension of C-1 or C-2 and triethylamine in a aprotic solvent, such as tetrahydrofuran. The reaction is stirred at room température for a time period between about 5 minutes to about 20 minutes, preferably about 15 minutes, and a small amount of ether was added. The triethylammonium sait generated is filtered off. Separately, sodium hydride is added to a suspension of A-1 or A-2, wherein X is OH or NH, in an aprotic solvent, such as tetrahydrofuran, at 0°C or room température. The reaction is stirred at room température for a time period between about 5 minutes to about 20 minutes, preferably about 15 minutes, and the isocyanate tetrahydrofuran/ether solution so formed above is added dropwise. Alternatively, the compounds of Formula II and III may be formed by reacting the compounds of D3 or D4 with A-1 and A-2 in presence of a base such triethylamine and diphenylphosphoryl azide in aprotic solvent such toluene as described in procedure discussed above in reaction 4 of Préparation D.
In reaction 1 of Scheme 2, the compounds of formula A-1, A-2 or B-1 are converted to the corresponding compounds of Formula IV, V, VI and VII, wherein f is 1 to 8, respectively, by adding triphosgene to a suspension of C-1, C-2, D-1 or D-2 and triethylamine in a aprotic solvent, such as tetrahydrofuran or toluene. The reaction is stirred at room température for a time period between about 5 minutes to about 20 minutes, preferably about 15 minutes, and a small amount of ether was added. Subsequently, A-1 or A-2, wherein X is NH, is added to the isocyanate solution so formed above and the reaction is stirred at a température range of 25-100°C, preferably at room température for a period of about 2 hours to 24 hours, preferably 18 hours.
In reaction 1 of Scheme 3, the compound of formula A-3 is converted to the corresponding compounds of Formula VIII, wherein f is 1 to 8, and IX, respectively by reacting A3 with C1, C-2, D1 or D-2 via peptidic coupling using carbodiimide coupling agent such 1 -ethyl-3-(3dimethylaminopropyl) carbodiimide and 1-hydroxy-benzotrîazole or2-(1H-7-Azabenzotriazol-1-yl)1,1,3,3-tetramethyl uranium hexafluorophosphate in solvent such tetrahydrofuran or dimethylformamide. The reaction is stirred at room température for overnight.
Although spécifie embodiments of the présent disclosure will now be described with référencé to the préparations and schemes, it should be understood that such embodiments are by way of example only and merely illustrative of but a small number of the many possible spécifie embodiments which can represent applications of the principles of the présent disclosure. Various changes and modifications will be obvious to those of skill in the art given the benefit of the présent disclosure and are deemed to be within the spirit and scope of the présent disclosure as further defined in the appended daims.
(Jnless defined otherwise, ail technical and scientifîc terms used herein hâve the same meaning as commonly understood by one having ordinary skill in the art to which this disclosure belongs. Although other compounds or methods can be used in practice or testing, certain preferred methods are now described in the context of the following préparations and schemes.
Al! pharmaceutically acceptable salts, prodrugs, tautomers, hydrates and solvatés of the compounds presently disclosed are also within the scope of the présent disclosure.
Presently disclosed compounds that are basic in nature are generally capable of forming a wide variety of different salts with various inorganic and/or organic acids. Although such salts are generally pharmaceutically acceptable for administration to animais and humans, it is often désirable in practice to initially isolate a compound from the reaction mixture as a pharmaceutically unacceptable sait and then simply couvert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition sait. The acid addition salts of the base compounds can be readily prepared using conventional techniques, e.g., by treating the base compound with a substantially équivalent amount of the chosen minerai or organic acid in an aqueous solvent medium or in a suitable organic solvent such as, for example, methanol or éthanol. Upon careful évaporation of the solvent, the desired solid sait is obtained.
Acids which can be used to prépare the pharmaceutically acceptable acid addition salts of the base compounds are those which can form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as chloride, bromide, iodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1’methylene-bis-(2-hydroxy-3-naphthoate)] salts.
Presently disclosed compounds that are acidic in nature, e.g., contain a COOH ortetrazole moiety, are generally capable of forming a wide variety of different salts with various inorganic and/or organic bases. Although such salts are generally pharmaceutically acceptable for administration to animais and humans, it is often désirable in practice to initially isolate a compound from the reaction mixture as a pharmaceutically unacceptable sait and then simply convert the latter back to the free acid compound by treatment with an acidic reagent, and subsequently convert the free acid to a pharmaceutically acceptable base addition sait. These base addition salts can be readily prepared using conventional techniques, e.g., by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they also can be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali métal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields of the desired solid sait.
Bases which can be used to préparé the pharmaceutically acceptable base addition salts of the base compounds are those which can form non-toxic base addition salts, i.e., salts containing pharmacologically acceptable cations, such as, alkali métal cations (e.g., potassium and sodium), alkaline earth métal cations (e.g., calcium and magnésium), ammonium or other water-soluble amine addition salts such as N-methylglucamine-(meglumine), lower alkanolammonium and other such bases of organic amines.
Isotopically-labeled compounds are also within the scope of the présent disclosure. As used herein, an isotopically-labeled compound refers to a presently disclosed compound including pharmaceutical salts and prodrugs thereof, each as described herein, in which one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds presently disclosed include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 1BO, 17O, 31P, 32P, 35S, 1SF, and 36CI, respectively.
By isotopically-labeling the presently disclosed compounds, the compounds may be useful in drug and/or substrate tissue distribution assays. Tritiated (3H) and carbon-14 (14C) labeled compounds are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium (2H) can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds presently disclosed, including pharmaceutical salts and prodrugs thereof, can be prepared by any means known in the art.
Stereoisomers (e.g., cis and trans isomers) and ail optical isomers of a presently disclosed compound (e.g., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers are within the scope of the présent disclosure.
The compounds, salts, prodrugs, hydrates, and solvatés presently disclosed can exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and géométrie isomers and mixtures thereof. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer prédominâtes. Even though one tautomer may be described, ail tautomers are within the scope of the présent disclosure.
Atropisomers are also within the scope of the présent disclosure. Atropisomers refer to compounds that can be separated into rotationally restricted isomers.
The présent disclosure also provides pharmaceutical compositions comprising at least one presently disclosed compound and at least one pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can be any such carrier known in the art including those described in, for example, Remingtorïs Pharmaceutical Sciences, Mack Publishing Co., (A. R. Gennaro edit. 1985). Pharmaceutical compositions of the compounds presently disclosed may be prepared by conventional means known in the art including, for example, mixing at least one presently disclosed compound with a pharmaceutically acceptable carrier.
Presently disclosed pharmaceutical compositions can be used in an animal or human. Thus, a presently disclosed compound can be formulated as a pharmaceutical composition for oral, buccal, parentéral (e.g., intravenous, intramuscular or subcutaneous), topical, rectal or intranasal administration or in a form suitable for administration by inhalation or insufflation.
The compounds presently disclosed may also be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,119,742, 3,492,397, 3,538,214, 4,060,598, and 4,173,626.
For oral administration, the pharmaceutical composition may take the form of, for example, a tablet or capsule prepared by conventional means with a pharmaceutically acceptable excipient(s) such as a binding agent (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); filler (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricant (e.g., magnésium stéarate, talc or silica); disintegrant (e.g., potato starch or sodium starch glycolate); and/or wetting agent (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid préparations for oral administration may take the form of a, for example, solution, syrup or suspension, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid préparations may be prepared by conventional means with a pharmaceutically acceptable additive(s) such as a suspending agent (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicle (e.g., almond oil, oily esters or ethyl alcohol); and/or preservative (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).
For buccal administration, the composition may take the form of tablets or lozenges formulated in a conventional manner.
Presently disclosed compounds may be formulated for parentéral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or émulsions in oily or aqueous vehicles, and may contain a formulating agent such as a suspending, stabilizing and/or dispersing agent recognized by those of skill in the art. Alternative^, the active ingrédient may be in powder form for reconstitution with a suitable vehicle, e.g., stérile pyrogen-free water, before use.
For topical administration, a presently disclosed compound may be formulated as an ointment or cream.
Presently disclosed compounds may also be formulated in rectal compositions such as suppositories or rétention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
For intranasal administration or administration by inhalation, presently disclosed compounds may be conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aérosol spray présentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aérosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the presently disclosed compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a presently disclosed compound and a suitable powder base such as lactose or starch.
A proposed dose of a presently disclosed compound for oral, parentéral or buccal administration to the average adult human for the treatment or prévention of a TPO-related disease state is about 0.1 mg to about 2000 mg. In certain embodiments, the proposed dose is from about 0.1 mg to about 200 mg of the active ingrédient per unit dose. Irrespective of the amount of the proposed dose, administration of the compound can occur, for example, 1 to 4 times per day.
Aérosol formulations for the treatment or prévention of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or “puff” of aérosol contains about 20mg to about 10,000mg, preferably, about 20mg to about 1000mg of a presently disclosed compound. The overall daily dose with an aérosol will be within the range from about 100mg to about 100 mg. In certain embodiments, the overall daily dose with an aérosol generally will be within the range from about 100mg to about 10 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1,2 or 3 doses each time.
Aérosol combination formulations for the treatment or prévention of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or “puff of aérosol contains from about 0.01 mg to about 1000 mg of a combination comprising a presently disclosed compound. In certain embodiments, each metered dose or “puff of aérosol contains about 0.01 mg to about 100 mg of a combination comprising a presently disclosed compound. In certain embodiments, each metered dose or “puff of aérosol contains about 1 mg to about 10 mg of a combination comprising a presently disclosed compound. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1,2 or 3 doses each time.
Pharmaceutical compositions and methods of treatment or prévention comprising administering prodrugs of at least one presently disclosed compound are also within the scope of the présent disclosure.
Glucosylceramide Synthase Assay
An enzyme assay using microsomes as a source of glucosylceramide synthase activity. Fluorescent ceramide substrate is delivered to membrane-bound enzyme as a complex with albumin. After reaction, ceramide and glucosylceramide are separated and quantitated by reversephase HPLC with fluorescence détection.
Procedure
Préparation of Microsomes from A375 human melanoma cells:
Cell suspension was sonicated on ice to complété cell lysis followed by centrifugation at spin down at 10,000 g for 10 min. at 4qC
Supernatant was cleared by centrifugation again at 100,000 g for 1 hour at 4°C in the.
Pellet was resuspended in lysis buffer, aliquoted and stored at -80°C.
Glucosylceramide Synthase Assay
Substrate and microsome were combined 1:1, mix well on a plate shaker seal the plate and incubate 1 hour at room température in the dark
The was stop with stop solution into the reaction plate and transferred analysis plate;
RP-HPLC Analysis
- column: MercuryMS™ (Phenomenex) replaceable cartridge (Luna Ca, 3 Dm. 20 x 4 mm)
- System: Agilent 1100 with Agilent 1200 sériés fluorescence detector
- mobile phase: 1% formic acid in 81% methanol, 19% water, flow rate 0.5 mL/min, isocratic run, 4 min
- sample diluent: 0.1 mM C8 ceramide (adsorption blocker) in 50% isopropanol, 50% water (v/v)
- fluorescence détection: Oex = 470 nm, Dem = 530 nm
- under these conditions, NBD C6 GluCer had a rétention time of about 1.7 min and NBD C0 Cer ran at about 2.1 min; the peaks were clearly separate to the baseline and were integrated automatically by the HPLC software
- %conversion of substrate to product was used as the readout for inhibitor testing to avoid variability due to dilution error or sample évaporation
Ail of the exemplified compounds had an IC50 value of less than 5μΜ in the Reporter Assay.
EXPERIMENTAL
General procedure A: Carbamate/urea formation with triphosqene
To a suspension of amine hydrochloride (1 équivalent) and triethylamine (3-4 équivalents) in a THF (concentration - 0.2M) at room température was added triphosgene (0.35 équivalent). The reaction mixture was stirred for 10 min and small amount of ether (1-2 mL) was added. The triethylammonium sait was filtered off to afford a clear solution of isocyanate in THF/ether.
To a solution of alcohol (1.5 équivalents) in THF (concentration - 0.2M) at room température was added NaH [60%, oil] (1.5 équivalents). The reaction mixture was stirred for 15 min and the above solution (isocyanate in THF/ether) was added dropwise.
In a standard workup, the reaction was quenched with brine. The solution was extracted with EtOAc and the organic layer was dried over Na2SO^, filtered and concentrated. The crude material was purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding carbamate.
Alternatively: To a suspension of amine hydrochloride A (1 équivalent) and triethylamine (34 équivalents) in a THF (concentration ~ 0.2M) at room température was added triphosgene (0.35 équivalent). The reaction mixture was stirred for 10 min and small amount of ether (1-2 mL) was added. The triethylammonium sait was filtered off to afford a clear solution of isocyanate in THF/ether.
To a solution of amine B (1 équivalent) in THF (concentration - 1,0M) at room température was added the above solution (isocyanate in THF/ether) dropwise. The reaction was stirred for a period of 18 h and concentrated. The crude material was purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding urea.
General procedure B: Alkylation with orqanocerium
A suspension of CeCI3 (4 équivalents) in THF (concentration - 0.2M) was stirred at room température for 1 h. The suspension was cooled to -78°C and MeLi /Ether [1.6M] (4 équivalents) was added dropwise. The organocerium complex was allowed to form for a period of 1 h and a solution of nitrite (1 équivalent) in THF (concentration 2.0M) was added dropwise. The reaction mixture was warmed up to room température and stirred for 18 h. The solution was cooled to 0 °C and quenched with water (- 1 mL) followed by addition of 50% aqueous solution of ammonium hydroxide (~ 3 mL) until precipitated formed and settled to the bottom of the flask. The mixture was filtered through a pad of celite and concentrated. The crude material was treated with a solution of
HCI/dioxane [4.0M]. The intemnediate arylpropan-2-amine hydrochloride was triturated in ether and used as is for the next step. Alternatively, the crude free base amine was purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding arylpropylamîne.
General procedure C: Urea formation with carbonvl diimidazole (CPI)
A solution of amine A (1 équivalent) and CDI (1.3 équivalent) in THF (concentration ~ 0.15M) was stirred at reflux for 1 h. A solution of amine B (1.3 équivalent) in THF was added and the reaction mixture was stirred for an additional 1.5 h. The reaction was cooled to room température and diluted with ether. The desired compound precipitated and was filtered off. The crude material was purified on combiflash (basic AI2O3 cartridge, CHCI3 and MeOH) or (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding urea.
General procedure D: Urea formation with triphosqene
To a suspension of amine A (1 équivalent) and triethylamine (4 équivalents) in a THF (concentration ~ 0.15M) at room température was added triphosgene (0.35 équivalent). The reaction mixture was stirred for 15 min and amine B (1.1 équivalent) was added. The reaction mixture was stirred at room température for 18 h and then diluted with EtOAc. The organic layer was washed with aqueous NaOH [1.0 M], dried over Na2SO4. filtered and concentrated. The crude material was purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding urea.
General procedure E: Suzuki coupling
To a solution of aryl halide (1 équivalent) in a mixture of DME/water [4:1] (concentration 0.2M) was added boronic acid (2 équivalents), palladium catalyst (0.1-0.25 équivalent) and sodium carbonate (2 équivalents). The reaction mixture was microwaved 25 min at 150 °C. After filtering through a celite plug and concentrating, the crude product was purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding coupling adduct.
Alternatively: To a solution of aryl halide (1 équivalent) in a mixture of toluene/water [20:1] (concentration - 0.2 M) was added boronic acid (1.3-2.5 équivalents), palladium catalyst (0.05-0.15 équivalent), tricyclohexylphosphine (0.15-0.45 équivalent) and potassium phosphate (5 équivalents). The reaction mixture was microwaved 25 min at 150° C. After filtering through a celite plug and concentrating, the crude product was purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding coupling adduct.
General procedure F: Hydrogénation
To a solution of substrate in methanol, éthanol or EtOAc (concentration ~ 0.2M) was added palladium catalyst (20% w/w of substrate). The reaction mixture was stirred at room température under 1 atm of H2 until completion. The reaction was filtered through a celite plug followed by two rinses with chloroform. The crude product was concentrated and purified on combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the hydrogenated product. Alternatively, the final material was purified by précipitation or recristallization.
General procedure G: Cyclopropanation
To a mixture of arylnîtrile (1 équivalent) and Ti(Oi-Pr)4 (1.7 équivalents) stirring at -70 °C, was added dropwise EtMgBr [3.0 M in ether] (1.1 équivalents). The reaction mixture was allowed to warm to 25 °C and stirred for 1 h. To the above mixture was added BF3-Et2O (3 équivalents) dropwise at 25 °C. After the addition, the mixture was stirred for another 2 h, and then quenched with aqueous HCl [2M]. The resulting solution was then basified by adding aqueous NaOH [2M], The organic material was extracted with ethyl ether. The organic layers were combined, dried over Na2SO4, filtered and concentrated. The crude material was purified by silica gel column chromatography (eluting with petroleum ether/EtOAc: 10/1 to 1/1) to give the corresponding 1 -arylcyclopropanamine.
General procedure H: Coupling via in-situ Curtius rearrangement
A mixture of acid (1 équivalent), triethylamine (2.5 équivalents), DPPA (1.0 équivalent) in toluene (concentration ~ 0.3M) was refluxed for 30 min. The mixture was cooled to room température and alcohol (1 équivalent) was added. After addition, the mixture was heated at 90 °C for 18 h. The reaction was cool down to room température, diluted with EtOAc and washed with saturated aqueous sodium dicarbonate. The organic phase was dried over Na2SO4, concentrated and purified by prep-TLC (EtOAc/MeOH 5:1, containing 1% of TEA) to afford the corresponding carbamate.
General procedure I: Amide formation using EPCI
To a solution of amine (1 équivalent) in DMF or THF (concentration ~ 0.3M) was added EDCI (1.2-2.5 équivalents), HOBT (1.2-2.5 équivalents), DIPEA (1.2-2.5 équivalents) and triethylamine (few drops). The reaction mixture was stirred and the acid (1.2 équivalents) was added. The reaction was stirred at room température for 18 h and then concentrated. The residue was dissolved in EtOAc and washed with brine. The organic layer was dried over Na2SO4 and concentrated. The crude material was purified by prep- HPLCMS or by combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH).
Préparation A
Intermediate 1
2-(3-bromophenyl)propan-2-amine hydrochloride
To a solution of methyl 3-bromobenzoate (15.0 g, 69.8 mmol) in THF (140 ml_) at -78 °C was added dropwise a solution of MeMgBr/diethyl ether [3.0M] (58 mL). The reaction mixture was warmed up to room température and stirred for 2 h. The solution was poured to an aqueous saturated solution of ammonium chloride and the organic material was extracted with EtOAc. The organic layer was dried over Na2SO<, filtered and concentrated to afford the corresponding alcohol (14.9 g) which was used without further purification.
To a solution of 2-(3-bromophenyl)propan-2-ol (17.2 g, 79.8 mmol) in chloroacetonitrile (160 mL) was added acetic acid (14 mL). The reaction mixture was cooled to 0 °C and H2SO4 (14 mL) was added dropwise. The reaction mixture was warmed to room température and stirred for 18 h.
The reaction was then poured înto ice and extracted with EtOAc. The organic layer was washed with aqueous NaOH [1.0M] solution and brine, dried over Na2SO4 and concentrated to afford the corresponding chloroacetamide (21.4 g) which was used without further purification.
To a solution of N-(2-(3-bromophenyl)propan-2-yl)-2-chloroacetamide (20.3 g) in éthanol (120 mL) was added acetic acid (20 mL). The reaction mixture was stirred at reflux for 18 h. The solution was cooled to room température and the precipitate was filtered off on a celite pad. The filtrate was concentrated and the residue was dissolved in EtOAc. The organic layer was treated with aqueous NaOH [1.0M] solution, dried over Na2SO4 and concentrated. The crude material was treated with a solution of HCI/dioxane [4M]. The intermediate 2-(3-bromophenyi)propan-2-amine hydrochloride was triturated in ether and used as is for the next step (7.50 g, 43%). 1H NMR (400 MHz, CD3OD) δ 7.69 (q, J= 1.8 Hz, 1H), 7.55 (ddd, J =1.0, 1.8, 7.9 Hz, 1 H), 7.49 (ddd, J =1.0, 2.0, 8.0 Hz, 1 H), 7.38 (t, J = 8.0 Hz, 1 H), 1.71 (s, 6H) ppm.
Préparation B
Intermediate 2
2-(5-bromo-2-fluorophenyl)propan-2-amine hydrochloride
To a solution of 5-bromo-2-fluorobenzoic acid (4.85 g, 22.8 mmol) in methanol (45 mL) was added H2SO4 (4.5 mL). The reaction mixture was stirred at room température for 18 h and the solution was concentrated. The residue was treated with an aqueous NaOH [10% w/v] solution and the organic material was extracted with CHCI3. The organic layer was dried over Na2SO4, filtered and concentrated to afford the corresponding ester (4.69 g, 91%) which was used without further purification.
The ester intermediate (4.69 g, 20.1 mmol) was converted to intermediate 2 using the same procedure reported in example intermediate 1 to afford the corresponding ammonium sait (3.94 g, 67% overall yield) as a white solid. Ή NMR (400 MHz, CD3OD) δ 7.67 - 7.57 (m, 2H), 7.21 (dd, J = 8.7,12.3 Hz, 1H), 1.77 (s. 6H) ppm.
Intermediate 3
2-(3-bromo-4-fluorophenyl)propan-2-amine hydrochloride
5-Bromo-2-fluorobenzoic acid was transformed to intermediate 3 using the same procedure reported in example intermediate 2 to afford the corresponding ammonium sait (2.79 g, 49% overall yield) as a white solid.
Intermediate 4
2- (3-bromo-2-fluorophenyl)propan-2-amine
3- Bromo-2-fluorobenzoic acid was transformed to intermediate 4 using the same procedure reported in example intermediate 2 to afford the corresponding amine as pale yellow oil.
Intermediate 5
2-(4-bromophenyl)propan-2-amine hydrochloride
Using general procedure B, bromobenzonitrile (2.00 g, 11.0 mmol) was converted to the corresponding 2-(4-bromophenyl)propan-2-amine, which was afforded as a brown oil (1.20 g, 51 %).
Préparation C
Intermediate 6
1,4-Diazabicyclo[3.2.2]nonane
To a stirred solution of 1,4-diazabicyclo[3.2.2]nonan-3-one (1.0 g, 7.2 mmol) in 1,4-dioxane (7.2 mL) at room température was added lithium aluminum hydride [2.0M/THF] (4.1 mL, 8.2 mmol). The reaction mixture was then heated at reflux for 6 hours before cooling to room température.
The reaction was quenched by the stepwise addition of 200 DL of H2O, 200 DL of 15% aqueous NaOH, and 600 DL of H2O. The mixture was filtered through Celite which was subsequently washed with EtOAc. The combined filtra te was concentrated in vacuo to afford the product (0.82 g, 90%) which was used without further purification. 1H NMR (400 MHz, CDCI3) δ 3.28-3.25 (m, 1H), 2.99-2.95 (m, 8H), 1.86-1.80 (m, 3H), 1.69-1.64 (m, 2H) ppm.
Préparation D
Intermediate 7
2-Methylquinuclidin-3-ol
A solution of potassium carbonate (11.4g, 82.8 mmol) and quinuclidine hydrate (5.00 g, 20.4 mmol) was dissolved in H2O (15.6 mL), When completely dissolved, dichloromethane (20.4 ml_) was added and the reaction was stirred at room température overnight. The organic phase was separated and the aqueous phase extracted with chloroform (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The product was used without further purification. 1H NMR (400 MHz, CDCI3) 2.79 (s, 1H), 5.19 (s, 1 H), 3.14-3.06 (m, 2H), 2.992.91 (m, 2H), 2.57-2.55 (m, 1H), 1.98-1.93 (m, 4H) ppm.
The 2-methylenequinuclidin-3-one (3.50 g) in éthanol (30 mL) was reduced over 10% Pd/C (50 wt%) under a H2 atmosphère. When judged complété by TLC (~3 days), the catalyst was filtered off and the fil ter cake washed with ethyl acetate. The solvent was removed in vacuo to afford the desired product (2.80 g, 80%) was obtained and used without further purficiation. 1H NMR (400 MHz , CDCI3) 3.37-3.31 (m, 1 H), 3.21-3.13 (m, 2H), 3.09-3.00 (m, 1H), 2.97-2.89 (m, 1 H), 2.46-2.43 (m, 1 H), 2.05-1.91 (m, 4H), 1.34 (d, J = 7.6 Hz, 3H) ppm.
To 2-methylquinuclidin-3-one (0.50g, 3.60 mmol) in 1,4-dioxane (18 mL) at room température was added lithium aluminum hydride [1.0M/THF] (4.1,4.1 mmol). The reaction mixture was stirred at room température for 15 minutes. The reaction was quenched by the stepwise addition of 116 DL of H2O, 116 DL of 15% aqueous NaOH, and 348 OL of H2O. The mixture was filtered through Celite which was subsequently washed with EtOAc. The solvent was removed in vacuo to afford the product (0.48 g, 95%) which was used without further purification as a 2:1 mixture of diastereomers.
Préparation E
Intermediate 8
-azabicyclo[3.2.2]nonan-4-ol
To 1-azabicyclo[3.2.2]nonan-4-one (0.20 g, 1.4 mmol) in 1,4-dioxane (2.8 ml_) at 0 °C was added lithium aluminum hydride [1.0M/THF] (1.7 mL, 1.7 mmol). The reaction mixture was maintained at 0 °C for 15 minutes. The reaction was quenched by the stepwise addition of 46 DL of H2O, 46 OL of 15% aqueous NaOH, and 138 üL of H2O. The mixture was filtered through Celite which was subsequently washed with EtOAc. The solvent was removed in vacuo to afford the product (0.19 g, 96%) which was used without further purification. 1H NMR (400 MHz, CDCI3) δ 3.90-3.86 (m, 1H), 3.09-3.03 (m, 1H), 2.96-2.91 (dd, J = 9.2, 6.8 Hz, 1H), 2.86-2.75 (m, 3H), 2.712.64 (m, 1H), 2.34-2.27 (bs s, 1H), 1.98-1.86 (m, 3H), 1.71-1.59 (m, 3H), 1.51-1.35 (m, 1H) ppm.
Préparation F
Intermediate 9
1-Azabicyclo[2.2.1]heptan-3-ol
To a mixture of sodium methoxide (2.00 g, 37.9 mmol) in methanol (9 mL) at 0 °C was added glycine methyl ester hydrochloride (4.76 g, 37.9 mmol) and dimethyl itaconate (5.00 g, 31.6 mmol.) The reaction was heated at reflux for 16 hours before cooling to room température. The solid was filtered off and washed with dichloromethane. The flltrate was concentrated and the residue diluted with 5N HCl (50 mL). The aqueous layer was extracted with dichloromethane (4 x 50mL), dried over MgSO4, filtered and concentrated in vacuo. The product was used without further purification. 1H NMR (400 MHz, CDCI3) δ 4.04 (dd, J = 82.0, 17.6 Hz), 3.74-3.64 (m, 8H), 3.32-3.24 (m, 1H), 2.77-2.63 (m, 2H) ppm.
To methyl 1-(2-methoxy-2-oxoethyl)-5-oxopyrrolidine-3-carboxylate (3.40 g, 16.0 mmol) in THF (20 mL) at 0 °C was added borane-THF [1.0M/THF] (32.0 mL, 32.0 mmol). The reaction was stirred at reflux for 1 hour and then cooled to room température where it was allowed to stir an additional 12 hours. The reaction was quenched by the addition of a saturated solution of potassium carbonate (5.52 g in 20 mL H2O) and heated at reflux for an additional 1 hour before cooling to room température. The solvent was removed in vacuo and the residue made acidic by the addition of 5N HCl (25 mL). The aqueous layer was extracted with dichloromethane (2 x 30 mL). The pH of the aqueous layer was then made basic by the addition of solid potassium carbonate. The aqueous layer was further extracted with dichloromethane (5 x 30 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The product was used without further purification. 1H NMR (400 MHz, CDCI3) δ 3.66 (s, 3H), 3.63 (s, 3H), 3.29 (ABq, 2H, 7=24.0, 16.8 Hz), 3.06-3.02 (m, 2H), 2.87-2.81 (m, 1 H), 2.71-2.65 (m, 1H), 2.56-2.50 (m, 1H), 2.09-2.04 (m, 2H) ppm.
To a refluxing solution of potassium tert-butoxide (2.46 g, 22.0 mmol) in toluene (32 mL) was added dropwise a solution of methyl 1-(2-methoxy-2-oxoethyl)pyrrolidine-3-carboxylate (2.00 g, 10.0 mmol) in toluene (10 mL) over 1 hour. The reaction was allowed to stir and additional 3 hours at reflux before first cooling to room température then cooling to -10 °C. Acetic acid (1.3 mL) was then added with stirring. The toluene layerwas extracted with 5N HCl ( 4 x 50mL). The combined aqueous layers were heated at 110 °C for 8 hours. The reaction was then cooled to room température and the volume reduced by half in vacuo. The pH of the reaction mixture was made basic by the addition of solid potassium carbonate. The aqueous layer was extracted with dichloromethane (5 x 50mL) and the combined organic layers were concentrated in vacuo. To the crude product was added ethyl ether. The solid filtered off to afford the desired product (0.30 g, 27%) which was used without further purification. 1H NMR (400 MHz, CDCI3) δ 3.05-2.96 (m, 3H), 2.76 (s, 2H), 2.72-2.66 (m, 2H), 2.09-2.01 (m, 1 H), 1.78-1.71 (m, 1H) ppm.
The 1-azabicyclo[2.2.1]heptan-3-one (0.30 g, 2.7 mmol) in éthanol (2-3 mL) was reduced over PtO2 (50 wt%) under a H2 atmosphère. After stirring 4 hours, the catalyst was filtered off and the filtercake washed with éthanol. The éthanol was removed in vacuo to afford the desired product (0.29 g, 95%). 1H NMR (400 MHz, CDCI3) δ 4.36-4.35 (m, 1H), 3.10-3.05 (m, 1H), 2.952.88 (m, 1H), 2.72-2.66 (m, 1H), 2.63-2.57 (m, 2H), 2.48-2.44 (dd, J= 10.0, 3.2 Hz, 1 H), 2.11-2.05 (m, 2H), 1.51-1.44 (m, 1H) ppm.
Préparation G
Intermediate 10 (R)-3-methylquinuclidin-3-amine and (S)-3-methylquinuclidin-3-amine
To a well-stirred solution of MeLi [3.0M/diethyl ether] (67.0 mL, 201 mmol) in anhydrous diethyl ether (150 mL) at-78 °C was added, dropwise, a solution of quînuclidin-3-one (12.5 g, 100 mmol) in diethyl ether (100 mL). The resulting solution was maintained at -78 °C for 1 hour, then at room température for 18 hours. Water (60 mL) was added dropwise at 0 °C and the mixture was concentrated in vacuo to give a residue, which was purified by neutral aluminum oxide column chromatography (0-20% MeOH in CHCI3) to give 3-methylquinuclidin-3-ol (10.0 g, 71%) as a light 85 yellow solid. To stirred acetonitrile (250 mL) at 0 °C was slowly added concentrated sulfuric acid (100 mL). The resulting solution was added dropwise to a mixture of 3-methylquinuclidin-3-ol (9.10 g, 64.5 mmol) in acetonitrile (250 mL) at 0 °C. The reaction mixture was stirred at room température for 60 hours, then cooled with an ice bath and basified with aqueous sodium hydroxide solution to pH 10. The mixture was extracted with 5:1 (v/v) CHCI;j//-PrOH. The organic layer was concentrated to afford a residue which was diluted with 2N aq. HCl and washed with 5:1 (v/v) CHCyZ-PrOH. The remaining aqueous layer was then basified with 2N NaOH and extracted with 5:1 (v/v) CHCI3/ÎPrOH. The combined organic layers were washed with water, dried (Na2SO4) and concentrated to give 9.5 g (82%) of the desired compound as a light yellow oil. The 2 enantiomers of the above intermediate are separated from each other by using chiral column on supercritical fluid chromatography (SFC) System.
A solution of the above chiral acetamide intermediate (9.50 g, 52.0 mmol) in conc. HCl (100 mL) was refluxed for 3 days, cooled with an ice bath and neutralised with aqueous sodium hydroxide solution to pH 1. The mixture was washed with 5:1 (v/v) CHCI3//-P1OH. The aqueous layer was then basified with 2N NaOH and extracted with 5:1 (v/v) CHCIa/Z-PrOH). The combined extracts were washed with water, dried (Na2SO4) and concentrated to give 5.00 g (69%) of the desired chiral compound as a light yellow semi-solid. 1H NMR (500 MHz, DMSO-d6) δ 2.72-2.39 (m, 6H), 2.01-1.96 (m, 1H), 1.67-1.61 (m, 1H), 1.43-1.36 (m, 2H), 1.23-1.17 (m, 1H), 1.09 (s, 3H) ppm. 13C NMR (125 MHz, DMSO-d6) δ 65.3, 48.3, 46.6, 46.4, 34.2, 30.0, 24.8, 22.8 ppm. Purity: > 99% (GC-MS); rétention time 6,63 min; (M) 140.1.
Préparation H
Intermediate 11
2-(3-(4-fluorophenyl)isothiazol-5-yl)propan-2-amine
To a stirred suspension of 4-fluorobenzamide (70.00 g, 503.1 mmol) in toluene (900 mL) was added chlorocarbonyl sulfenyl chloride (83.0 mL, 1.00 mol). The mixture was heated overnight at 60 °C and concentrated. The resulting tan solid was triturated with methylene chloride (200 mL), collected by suction filtration and rinsed with additional methylene chloride (4 x 70 mL). The crude product was impregnated onto silica (100 g) and chromatographed in a large filter funnel dry loaded with silica using a hexane/ethyl acetate gradient. The product 5-(4-fluorophenyl)-1,3,4-oxathiazol2-one was afforded as an off-white solid (55.98 g, 56%).
To a stirred solution of 5-(4-fluorophenyl)-1,3,4-oxathiazol-2-one (42.80 g, 217.1 mmol) in odichlorobenzene (600 mL) was added ethyl propiolate (66.0 mL, 651 mmol). The mixture was heated overnight at 135 °C and concentrated. The residual oil was purified by flash chromatography using a hexane/ethyl acetate gradient to afford ethyl 3-(4-fluorophenyl)isothiazole5-carboxylate as a pale golden solid (17.35 g, 32%). The more polar, ethyl 3-(4fluorophenyl)isothiazole-4-carboxylate isomer (generated in -57/43 ratio versus the desired product) was discarded.
To a stirred and cooled (0 °C) solution of ethyl 3-(4-fluorophenyl)isothiazole-5-carboxylate (38.50 g, 153.2 mmol) in THF (400 mL) was added a solution of méthylmagnésium bromide in diethyl ether (3.0 M, 128 mL, 384 mmol), dropwise over 20 minutes. After another 1.5 hours at 0 °C, the reaction was quenched by the slow addition of ethyl acetate (20 mL) and concentrated. The residue was taken up in aqueous NH4CI (400 mL) and extracted with ethyl acetate (2 x 150 mL). The combined extracts were dried (Na2SO4) and concentrated. The resulting amber syrup was purified by flash chromatography using a hexane/ethyl acetate gradient to afford 2-(3-(4fluorophenyl)isothiazol-5-yl)propan-2-ol as soft, golden solid (29.02 g, 80%).
2-(3-(4-Fluorophenyl)isothiazol-5-yl)propan-2-ol (29.00 g, 122.2 mmol) was taken up în thionyl chloride (75 mL). The mixture was cooled (ice bath) briefly and stirred. After 4 hours the reaction was concentrated and the residue was partitioned between ethyl acetate (200 mL) and aqueous NaHCO3 (300 mL). The organic layer was combined with a backextract of the aqueous layer (ethyl acetate, 1 x 100 mL), dried (Na2SO4) and concentrated to afford a mixture of 5-(2chloropropan-2-yl)-3-(4-fluorophenyl)isothiazole product and 3-(4-fluorophenyl)-5-(prop-1-en-2yl)isothiazole élimination byproduct (-63/39 ratio) as a dark amber oil (29.37 g). This material was used without purification in the next reaction.
To a stirred solution of the product of the previous step in DMSO (80 mL) was added sodium azide (14.89 g, 229.0 mmol). The mixture was heated at 50 °C overnight, diluted with ethyl acetate (250 mL) and washed with water (6 x 400 mL). The organic layer was dried (Na2SO4) and concentrated to afford a mixture of 5-(2-azidopropan-2-yl)-3-(4-fluorophenyl)isothiazole and 3-(4fluorophenyl)-5-(prop-1-en-2-yl)isothiazole (-56/44 ratio) as a dark amber oil (29.10 g). This material was used without purification in the next reaction.
The product of the previous step was combined with 10% palladium on carbon (50% water; 7.50 g) and taken up in methanol (350 mL). The stirred suspension was cycled between vacuum and a nitrogen purge three times. After an additional évacuation, the reaction was backfilled with hydrogen gas (balloon réservoir) and stirred overnight. The reaction was filtered through Celite. The filtrate was combined with methanol rinsings of the Celite and concentrated. The resulting dark amber oil purified by flash chromatography using a methylene chloride/methanol gradient to afford 2-(3-(4-fluorophenyl)isothiazol-5-yl)propan-2-amine as viscous, amber oil (14.23 g, 49% over3 steps).
Several approaches are being used or pursued for the treatment of LSDs, most of which focus on enzyme replacement therapy for use alone in disease management Numerous approved enzyme replacement thérapies are commercially available for treating LSDs (e.g., Myozyme® for Pompe disease, Aldurazyme® for Mucopolysaccharidosis I, Cerezyme® for Gaucher disease and Fabrazyme® for Fabry disease). Additionally, the inventors hâve identified a number of small molécules for use alone in the management of LSDs. The therapeutic methods of the invention described herein provide treatment options for the practitioner faced with management of various lysosomal storage diseases, as described in detail below.
In certain aspects of the invention, the compounds of the présent invention may be used to treat a metabolic disease, such as a lysosomal storage disease (LSD), either alone or as a combination therapy with an enzyme replacement therapy. In other aspects of the invention, the compounds of the présent invention may be used to inhibit or reduce GCS activity in a sujbect diagnosed with a metabolic disease, such as an LSD, either alone or as a combination therapy with an enzyme replacement therapy. In other aspects of the invention, the compounds of the présent invention may be used to reduce and/or inhibit the accumulation of a stored material (e.g., lysosomal substrate) in a subject diagnosed with a metabolic disease, such as an LSD. In certain embodiements of the foregoing aspects, the LSD is Gaucher (type 1, type 2 or type 3), Fabry, GMr gangliosidosis or GM2-gangliosidoses (e.g., GM2 Activator Deficiency, Tay-Sachs and Sandhoff). Table 1 lists numerous LSDs and identifies the corresponding déficient enzyme that may be used as an ERT in the foregoing aspects of the invention.
In other scénarios it may be necessary to provide SMT to a patient whose condition requires the réduction of substrates in the brain and thus is not treatable by systemic administration of ERT. While direct intracerebroventricular or intathecal administration can reduce substrate levels in the brain, systemic administration of ERT is not amenable for LSD’s with Central Nervous System (CNS) involvement due to its incapacity to cross the Blood Brain Barrier (BBB) and SMT may prove bénéficiai in patients having residual enzymatic activities in the CNS.
In accordance with the présent.invention, SMT is provided to a patient to treat a cancer and/or metabolic disease, such as, a lysosomal storage disease. The SMT may include one or more small molécules. The SMT includes administering to the patient compounds of the présent invention. In particular embodiments, the compound is (S)-Quinuclidin-3-yl (2-(2-(4fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate or Quinuclidin-3-yl (2-(4'-fluoro-[1,1'-biphenyl]-3yl)propan-2-yl)carbamate, or combinations thereof.
In certain embodiments, compounds of the invention, such as, for example, (S)-Quinuclidin3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate and Quinuclidin-3-yl (2-(4’-fluoro-[1,Tbiphenyl]-3-yl)propan-2-yl)carbamate may be used for treatment of virtually any storage disease resulting from a defect in the glycosphingolipid pathway (e.g. Gaucher (i.e., type 1, type 2 type 3), Fabry, GMi-gangliosidosis, GM2-ganglrosidoses (e.g., GM2 Activator Deficiency, Tay-Sachs and Sandhoff)). In a particularly preferred embodiment, (S)-Quinuclidin-3-yl (2-(2-(4fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate or a pharmaceutically acceptable sait or prodrug thereof is used to inhibit and/or reduce the accumulation of Gb3 and/or Iyso-Gb3 in a patient with Fabry disease, either alone or as a combination therapy with enzyme replacement therapy (see Examples). In a preferred embodiment, the enzyme replacement therapy includes administering alpha-galactosidase A to the Fabry patient. Indeed, the Examples below demonstrate that a GCS inhibitor of the invention effectively reduces Gb3 and Iyso-Gb3 storage in a mouse model of Fabry disease, thus supporting its use as a viable approach for the treatment of Fabry disease. Furthermore, in vivo combination therapy data provided in the Examples strongly suggest that a combined therapeutic approach could be both additive and complementary.
In certain embodiments, compounds of the invention, such as, for example, (S)-Quinuclidin3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate and Quinuclidin-3-yl (2-(4'-fluoro-[1,1 'biphenyl]-3-yl)propan-2-yl)carbamate may be used for reducing the level of GluCer and GluSph in the brain of a subject diagnosed with neuropathie Gaucher disease, either alone or in combination with ERT (e.g., glucocerebrosidase administration).
Dosage regimens for a small molécule therapy component of a combination therapy of the invention are generally determined by the skilled clinician and are expected to vary significantly depending on the particular storage disease being treated and the clinical status of the particular affected individual. The general principles for determining a dosage regimen fora given SMT of the invention for the treatment of any storage disease are well known to the skilled artisan. Guidance for dosage regimens can be obtained from any of the many well known references in the art on this topic. Further guidance is available, inter alia, from a review of the spécifie references cited herein. In certain embodiments, such dosages may range from about 0.5 mg/kg to about 300 mg/kg, preferably from about 5 mg/kg to about 60 mg/kg (e.g., 5 mg/kg, 10 mg/kg, 15, mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg and 60 mg/kg) by intraperitoneal, oral or équivalent administration from one to five times daily. Such dosages may range from about 5 mg/kg to about 5 g/kg, preferably from about 10 mg/kg to about 1 g/kg by oral, intraperitoneal or équivalent administration from one to five times daily. In one embodiment, doses range from about about 10 mg/day to about 500 mg/day (e.g., 10 mg/day, 20 mg/day, 30 mg/day, 40 mg/day, 50 mg/day, 60 mg/day, 70 mg/day, 80 mg/day, 90 mg/day, 100 mg/day, 110 mg/day, 120 mg/day, 130 mg/day, 140 mg/day, 150 mg/day, 160 mg/day, 170 mg/day, 180 mg/day, 190 mg/day, 200 mg/day, 210 mg/day, 220 mg/day, 230 mg/day, 240 mg/day, 250 mg/day, 260 mg/day, 270 mg/day, 280 mg/day, 290 mg/day, 300 mg/day). A particularly preferred oral dose range is from about 50 mg to about 100 mg, wherein the dose is administered twice daily. A particular oral dose range for a compound of the présent invention is from about 5 mg/kg/day to about 600 mg/kg/day. In a particular oral dose range for a compound of the présent invention is from about 1 mg/kg/day to about 120 mg/kg/day, e.g., 1 mg/kg/day , 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day, 20 mg/kg/day, 25 mg/kg/day, 30 mg/kg/day, 35 mg/kg/day, 40 mg/kg/day, 45 mg/kg/day, 50 mg/kg/day, 55 mg/kg/day or 60 mg/kg/day, 65 mg/kg/day, 70 mg/kg/day, 75 mg/kg/day, 80 mg/kg/day, 85 mg/kg/day, 90 mg/kg/day, 95 mg/kg/day, 100 mg/kg/day, 105 mg/kg/day, 110 mg/kg/day ,115 mg/kg/day or 120 mg/kg/day.
In certain embodiments, the invention relates to combination thérapies of SMT using compounds of the invention and ERT therapy for the treatment of lysosomal storage diseases. A partial list of known lysosomal storage diseases that can be treated in accordance with the invention is set forth in Table 1, including common disease name, material stored, and corresponding enzyme deficiency (adapted from Table 38-4 of Kolodny et al., 1998, ld.).
TABLE 1
Lysosomal Storage Diseases
Disease
Material Stored
Enzyme Deficiency
Sphinqolipidoses
Gaucher
Niemann-Pick
Niemann-Pick B
Farber
GMi-gangliosidosis
GM2-gangliosidosis (Sandhoff)
Tay-Sachs
Glucocerebroside, glucosylsphingosine
Sphingomyelin
Sphingomyelin
Ceramide
Givn-ganglioside, glycoprotein
GM2-ganglioside, globoside
GM2-ganglioside
Glucocerebrosidase
Sphingomyelinase
Sphingomyelinase
Ceramidase
GMi-ganglioside-βgalactosidase
Hexosaminidase A and B
Hexosaminidase A
Krabbe
Galactosylceramide β-Galactocerebrosidase
Mucopolysaccharidoses
Hurler-Scheie (MPS l)Dermatan sulfate, heparin a-L-iduronidase
Sulfate
Hunter (MPS II)
Dermatan sulfate, heparin Iduronate sulfatase sulfate
Sanfilippo (MPS III)
Type A
Heparan sulfate
Heparan-N-sulfatase
Type B
Heparan sulfate
N-acetyl-a-glucosaminidase
Type C
Heparan sulfate
Acetyl CoA:a-glucosaminide acetyl-transferase
Type D
Heparan sulfate
N-acetyl-a-glucosamine-6sulfatase
Marguio (MPS IV)
Type A Keratan sulfate
Galactosamine-6-sulfatase
Type B Keratan sulfate β-galactosidase
Maroteaux-Lamy (MPS VI)
Sly(MPS VII)
Mucosulfatidosis
Mucolipidoses
Sialidoses
Mucolîpidosis II
Mucolipidosis III
Mucolîpidosis IV
Dermatan sulfate
Dermatan sulfate, heparan
Sulfate
Sulfatides, mucopolysaccha rides
Sialyloligosaccharides, glycoproteins
Sialyloligosaccharides, glycoproteins, glycolipids
Glycoproteins, glycolipids
Glycolipids, glycoproteins
Other Diseases of Complex Carbohydrate Metabolism
Galactosamine-4-sulfatase (arylsulfatase B) β-glucuronidase
Arylsulfatase A, B and C, other sulfatases a-neuraminidase
High sérum, low fibroblast enzymes; N-acetylglucosamine-1 -phosphate transferase
Same as above
Mcolnl transm protein
Fabry Globotriaosylceramide{Gb3), α-galactosidase A
Iyso-Gb3
Schindler
Pompe
Sialic acid storage disease
Fucosidosis
Mannosidosis
Aspartylglucosaminuria
Wolman
O-linked glycopeptides
Glycogen
Free sialic acid
Fucoglycolipids, fucosyloligosaccha rides
Mannosyloligosaccharides
Aspartylglucosamine
Cholesteryl esters,
Triglycérides a-N-acetylgalactosaminidase a-glucosidase
Unknown a-fucosidase a-mannosidase
Aspartylglucosamine amidase
Acid lipase
Neuronal Ceroid Lipofuscinoses (NCLs)*
Granular osmophilic deposits,
Saposins A and D thioesterase
Infintile NCL
Late Infantile
Curvilinear profiles,
ATP synthase subunit c
Palmitoyl-protein thioesterase (PPT1)
Tripeptidyl protease 1 (TPP1)
Finnish variant Fingerprint/Rectilinear profiles, CLN5
ATP synthase subunit c
Variant | Fingerprint/Rectilinear profiles, ATP synthase subunit c | CLN6 |
Juvénile | Fingerprint profile, ATP synthase subunit c | CLN3 |
Adult | Variable | Unknown |
Northem Epilepsy | Rectilinear profile, ATP synthase subunit c | CLN8 |
Turkish variant | Fingerprint/Rectilinear profiles - constituents unknown | Unknown |
Lysosomal diseases of cholestérol transport and metabolism
Niemann-Pick type C Unesterified cholestérol NPC1 or NPC2 * Davidson et al., The Neuronal Ceroid Lipofuscinosis, Clinical Features and Molecular Basis of Disease. In Barranger JA and Cabrera-Salazar MA (Eds) Lysosomal Storage Disorders. 2007. pp. 371-388, Springer, New York, U.S.A.
Any method known to the skilled artisan may be used to monitor disease status and the effectiveness of a combination therapy of the invention. Clinical monitors of disease status may include but are not limited to organ volume (e.g. liver, spleen), hemoglobin, érythrocyte count, hematocrit, thrombocytopenia, cachexia (wasting), and plasma chitinase levels (e.g.
chitotriosidase). Chitotriosidase, an enzyme of the chitinase family, is known to be produced by macrophages in high leveîs in subjects with lysosomal storage diseases (see Guo et al., 1995, J. Inherit. Metab. Dis. 18, 717-722; den Tandt et al., 1996, J. Inherit. Metab. Dis. 19, 344-350; Dodelson de Kremer et al., 1997, Medicina (Buenos Aires) 57, 677-684; Czartoryska et al., 2000, Clin. Biochem. 33, 147-149; Czartoryska et al., 1998, Clin. Biochem. 31,417-420; Mistry et al., 1997, Baillieres Clin. Haematol. 10, 817-838; Young et al., 1997, J. Inherit. Metab. Dis. 20, 595602; Hollak et al., 1994, J. Clin. Invest. 93, 1288-1292). Chitotriosidase is preferably measured in conjuction with angiotensin converting enzyme and non tartrate résistant acid phosphatase to monitor response to treatement of Gaucher patients.
Methods and formulations for administering the combination thérapies of the invention include ail methods and formulations well known in the art (see, e.g., Remingtorïs Pharmaceutical Sciences, 1980 and subséquent years, 16th ed. and subséquent éditions, A. Oslo editor, Easton Pa.; Controlled Drug Delivery, 1987, 2nd rev., Joseph R. Robinson & Vincent H. L. Lee, eds., Marcel Dekker, ISBN: 0824775880; Encyclopedia of Controlled Drug Delivery, 1999, Edith Mathiowitz, John Wiley & Sons, ISBN: 0471148288; U.S. Pat. No. 6,066,626 and references cited therein; see also, references cited in sections below).
According to the invention, the following general approaches are provided for combination therapy in the treatment of lysosomal storage diseases. Each general approach involves combining enzyme replacement therapy with small molécule therapy in a manner consistent with optimizing clinical benefit while minimizing disadvantages associated with using each therapy alone.
In one embodiment of the invention, enzyme replacement therapy (alone or in combination with small molécule therapy) is administered to initiate treatment (i.e., to de-bulk the subject), and small molécule therapy is administered after the de-bulking phase to achieve and maintain a stable, long-term therapeutic effect without the need for frequent intravenous ERT injections. For example, enzyme replacement therapy may be administered intravenously (e.g. over a one to two hour period) once, on a weekly basis, once every two weeks, or once every two months, for several weeks or months, or longer (e.g., until an involved indicator organ such as spleen or liver shows a decrease in size). Moreover, the ERT phase of initial de-bulking treatment can be performed alone or in combination with a small molécule therapy. A small molécule therapeutic component is particularly preferred where the small molécule is compatible with oral administration, thus providing further relief from frequent intravenous intervention.
Alternating among ERT and SMT, or supplementîng SMT with ERT as needed, provides a strategy for simultaneously taking advantage of the strengths and addressing the weaknesses associated with each therapy when used alone. An advantage of ERT, whether used for de-bulking and/orfor more long-term care, is the much broader clinical expérience available to inform the practitioner's decisions. Moreover, a subject can be effectively titrated with ERT during the debulking phase by, for example, monitoring biochemical métabolites in urine or other body samples, or by measuring affected organ volume. A disadvantage of ERT, however, is the frequency of the administration required, typically involving intravenous injection on a weekly or bi-weekly basis due to the constant re-accumulation of the substrate. The use of small molécule therapy to reduce the amount of or inhibit substrate accumulation in a patient can in turn reduce the administration frequency of ERT. For example, a bi-weekly enzyme replacement therapy dosing regimen can be offered an ERT holiday (e.g., using a SMT) so that frequent enzyme injections are not required therapy. Furthermore, treating a lysosomal storage disease with combination therapy can provide complementary therapeutic approaches. Indeed, as demonstrated in the Examples below, a combination therapy of SMT and ERT can provide significant improvements over either therapeutic platform alone. These data suggest that combination therapy using SMT and ERT can be both additive and complementary. In one embodiment, ERT may be used as a de-bulking strategy (i.e., to initiate treatment), followed by or simultaneously supplemented with SMT using a compound of the présent invention. In another embodiment, a patient is first treated with SMT using a compound of the présent invention, followed by or simultaneously supplemented with ERT. In other embodiments, a SMT is used to inhibit or reduce further accumulation of substrate (or reaccumulation of substrate if used after debulking with ERT) in a patient with a lysosomal storage disease, and optionally provided ERT as needed to reduce any further substrate accumulation. In one embodiment, this invention provides a method of combination therapy for treatment of a subject diagnosed as having a lysosomal storage disease comprising alternating between administration of an enzyme replacement therapy and a small molécule therapy. In another embodiment, this invention provides a method of combination therapy for treatment of a subject diagnosed as having a lysosomal storage disease comprising simultaneously administering an enzyme replacement therapy and a small molécule therapy. In the various combination thérapies of the invention, it will be understood that administering small molécule therapy may occur prior to, concurrently with, or after, administration of enzyme replacement therapy. Similarly, administering enzyme replacement therapy may occur prior to, concurrently with, or after, administration of small molécule therapy.
In any of the embodiments of the invention, the lysosomal storage disease is selected from the group consisting of Gaucher (types 1,2 and 3), Niemann-Pick, Farber, GM1-gangliosidosis, GM2gangliosidoses (e.g., GM2 Activator Deficiency, Tay-Sachs and Sandhoff), Krabbe, Hurler-Scheie (MPS I). Hunter (MPS II), Sanfilippo (MPS III) Type A, Sanfilippo (MPS III) Type B, Sanfilippo (MPS III) Type C, Sanfilippo (MPS III) Type D, Marquio (MPS IV) Type A, Marquio (MPS IV) Type B, Maroteaux-Lamy (MPS VI), Sly (MPS VII), mucosulfatidosis, sialidoses, mucolipidosis II, mucolipidosis III, mucolipidosis IV, Fabry, Schindler, Pompe, sialicacid storage disease, fucosidosis, mannosidosis, aspartylglucosaminuria, Wolman, and neuronal ceroid lipofucsinoses.
Further, the ERT provides an effective amount of at least one of the following enzymes; glucocerebrosidase, sphingomyelinase, ceramidase, GMi-ganglioside-beta-galactosidase, hexosaminidase A, hexosaminidase B, beta-galactocerebrosidase, alpha-L-iduronidase, iduronate sulfatase, heparan-N-sulfatase, N-acetyl-alpha-g!ucosaminidase, acetyl CoA:alpha-glucosaminide acetyl-transferase, N-acetyl-alpha-glucosamine-6-sulfatase, galactosamine-6-sulfatase, betagalactosidase, galactosamine-4-sulfatase (arylsulfatase B), beta-glucuronidase, arylsulfatase A, arylsulfatase C, alpha-neuraminidase, N-acetyl-glucosamine-1 -phosphate transferase, alphagalactosidase A, alpha-N-acetylgalactosaminidase, alpha-glucosidase, alpha-fucosidase, alphamannosidase, aspartylglucosamine amidase, acid lipase, palmitoyl-protein thioesterase (CLN-1), PPT1, TPP1, CLN3, CLN5, CLN6, CLN8, NPC1 or NPC2 .
In accordance with the invention, the SMT and/or ERT produce a diminution in at least one of the following stored materials; glucocerebroside, sphingomyelin, ceramide, GM1-ganglioside, GM2ganglioside, globoside, galactosylceramide, dermatan sulfate, heparan sulfate, keratan sulfate, sulfatides, mucopolysaccharides, sialyloligosaccharides, glycoproteins, sialyloligosaccharides, glycolipids, globotriaosylceramide, O-linked glycopeptides, glycogen, free sialic acid, fucoglycolipids, fucosyloligosaccharides, mannosyloligosaccharides, aspartylglucosamine, cholesteryl esters, triglycérides, granular osmophilic deposits - Saposins A and D, ATP synthase subunit c, NPC1 or NPC2.
In certain embodiments of the invention, the smail molécule therapy comprises administering to the subject an effective amount of (S)-Quinuclîdin-3-yl (2-(2-(4fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (see Fig. 2A). In other embodiments, the small molécule therapy comprises administering to the subject an effective amount of Quinuclidin-3-yl (2(4'-fluoro-[1,T-biphenyl]-3-yl)propan-2-yl)carbamate (see Fig. 2B). The small molécule therapy may include admininstering to a subject one or more compounds. In certain embodiments, at least one of the compounds is a compound of the présent invention, such as those shown in Figs. 2A and/or 2B.
Enzyme replacement therapy can provoke unwanted immune responses. Accordingly, immunosuppressant agents may be used together with an enzyme replacement therapy component of a combination therapy of the invention. Such agents may also be used with a small molécule therapy component, but the need for intervention here is generally less likely. Any immunosuppressant agent known to the skilled artisan may be employed together with a combination therapy of the invention. Such immunosuppressant agents include but are not limited to cyclosporine, FK506, rapamycin, CTLA4-lg, and anti-TNF agents such as etanercept (see e.g. Moder, 2000, Ann. Allergy Asthma Immunol. 84, 280-284; Nevins, 2000, Curr. Opin. Pediatr. 12, 146-150; Kurlberg et al., 2000, Scand. J. Immunol. 51, 224-230; Ideguchi et al., 2000, Neuroscience 95, 217-226; Potteret al., 1999, Ann. N.Y. Acad. Sci, 875, 159-174; Slavik et al., 1999, Immunol. Res. 19, 1-24; Gaziev et al., 1999, Bone Marrow Transplant. 25, 689-696; Henry,
1999, Clin. Transplant. 13, 209-220; Gummert et al., 1999, J. Am. Soc. Nephrol. 10, 1366-1380; Qi et al., 2000, Transplantation 69,1275-1283). The anti-lL2 receptor (.alpha.-subunit) antibody daclizumab (e.g. Zenapax.TM.), which has been demonstrated effective in transplant patients, can also be used as an immunosuppressant agent (see e.g. Wiseman et al., 1999, Drugs 58,10291042; Beniaminovitz et al., 2000, N. Engl J. Med. 342, 613-619; Ponticelli et al., 1999, Drugs R. D. 1,55-60; Berard et al., 1999, Pharmacotherapy 19, 1127-1137; Eckhoff et al., 2000, Transplantation 69,1867-1872; Ekberg et al., 2000, Transpi. Int. 13, 151-159). Additional immunosuppressant agents include but are not limited to anti-CD2 (Branco et al., 1999, Transplantation 68,1588-1596; Przepiorka et al., 1998, Blood 92, 4066-4071), anti-CD4 (MarinovaMutafchieva et al., 2000, Arthritis Rheum. 43, 638-644; Fishwild et al., 1999, Clin. Immunol. 92, 138-152), and anti-CD40 ligand (Hong et al., 2000, Semin. Nephrol. 20, 108-125; Chirmule et al.,
2000, J. Virol. 74, 3345-3352; Ito et al., 2000, J. Immunol. 164, 1230-1235).
Any combination of immunosuppressant agents known to the skilled artisan can be used together with a combination therapy of the invention. One immunosuppressant agent combination of particular utility is tacrolimus (FK506) plus sirolimus (rapamycin) plus daclizumab (anti-IL2 receptor .alpha.-subunit antibody). This combination is proven effective as an alternative to steroids and cyclosporine, and when specifically targeting the liver. Moreover, this combination has recently been shown to permit successful pancreatic islet cell transplants. See Denise Grady, The
New York Times, Saturday, May 27, 2000, pages A1 and A11. See also A. M. Shapiro et al., Jul. 27, 2000, Islet Transplantation In Seven Patients With Type 1 Diabètes Mellitus Using A Glucocorticoid-Free Immunosuppressive Regimen, N. Engl. J. Med. 343, 230-238; Ryan et al., 2001, Diabètes 50, 710-719. Plasmaphoresis by any method known in the art may also be used to remove or deplete antibodies that may develop against various components of a combination therapy.
Immune status indicators of use with the invention include but are not limited to antibodies and any of the cytokines known to the skilled artisan, e.g., the interleukins, CSFs and interferons (see generally, Leonard et al., 2000, J. Allergy Clin. Immunol. 105, 877-888; Oberholzer et al., 2000, Crit. Care Med. 28 (4 Suppl.), N3-N12; Rubinstein et al., 1998, Cytokine Growth Factor Rev. 9,175-181). For example, antibodies specifically îmmunoreactive with the replacement enzyme can be monitored to détermine immune status of the subject. Among the two dozen or so interleukins known, particularly preferred immune status indicators are IL-1.alpha., IL-2, IL-4, IL-8 and IL-10. Among the colony stimulating factors (CSFs), particularly preferred immune status indicators are GCSF, GM-CSF and M-CSF. Among the interferons, one or more alpha, beta or gamma interferons are preferred as immune status indicators.
In the sections which follow, various components that may be used for eight spécifie lysosomal storage diseases are provided (i.e., Gaucher (including types 1,2 and 3), Fabry, Niemann-Pick B, Hunter, Morquio, Maroteaux-Lamy, Pompe, and Hurler-Scheie). In subséquent sections, further enabling disclosure for enzyme replacement therapy and small molécule therapy components of a combination therapy of the invention are provided.
Gaucher
As noted above, Gaucher's disease is caused by the deficiency of the enzyme glucocerebrosidase (beta-D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45) and accumulation of glucocerebroside (glucosylceramide). For an enzyme replacement therapy component of a combination therapy of the invention for the treatment of Gaucher's disease, a number of référencés are available which set forth satisfactory dosage regimens and other useful information relating to treatment (see Morales, 1996, Gaucher's Disease: A Review, The Annals of Pharmacotherapy 30, 381-388; Rosenthal et al., 1995, Enzyme Replacement Therapy for Gaucher Disease: Skeletal Responses to Macrophage-targeted Glucocerebrosidase, Pediatrics 96, 629-637; Barton et al., 1991, Replacement Therapy for Inherited Enzyme Deficiency-Macrophage-targeted
100
Glucocerebrosidase for Gaucher's Disease, New England Journal of Medicine 324, 1464-1470; Grabowski et al., 1995, Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-terminated Glucocerebrosidase from Natural and Recombinant Sources, Annals of Internai Medicine 122, 33-39; Pastores et al., 1993, Enzyme Therapy in Gaucher Disease Type 1: Dosage Efficacy and Adverse Effects in 33 Patients treated for 6 to 24 Months, Blood 82, 408-416); and Weinreb et al., Am. J. Med.; 113(2):112-9 (2002).
In one embodiment, an ERT dosage regimen of from 2.5 units per kilogram (U/kg) three times a week to 60 U/kg once every two weeks is provided, where the enzyme is administered by intravenous infusion over 1-2 hours. A unit of glucocerebrosidase is defined as the amount of enzyme that catalyzes the hydrolysis of one micromole of the synthetic substrate para-nitrophenylp-D-glucopyranoside per minute at 37 °C. In another embodiment, a dosage regimen of from 1 U/kg three times a week to 120 U/kg once every two weeks is provided. In yet another embodiment, a dosage regimen of from 0.25 U/kg daily or three times a week to 600 U/kg once every two to six weeks is provided.
Since 1991, alglucerase (Ceredase®) has been available from Genzyme Corporation. Alglucerase is a placentally-derived modified form of glucocerebrosidase. In 1994, imiglucerase (Cerezyme®) also became available from Genzyme Corporation. Imiglucerase is a modified form of glucocerebrosidase derived from expression of recombinant DNA in a mammalian cell culture System (Chinese hamster ovary cells). Imiglucerase is a monomeric glycoprotein of 497 amino acids containing four N-linked glycosylation sites. Imiglucerase has the advantages of a theoretically unlimited supply and a reduced chance of biological contaminants relative to placentally-derived aglucerase. These enzymes are modified at their glycosylation sites to expose mannose residues, a maneuver which improves lysosomal targeting via the mannose-6-phosphate receptor, Imiglucerase differs from placental glucocerebrosidase by one amino acid at position 495 where histidine is substituted for arginine. Several dosage regimens of these products are known to be effective (see Morales, 1996, ld.; Rosenthal et al., 1995, ld.; Barton et al., 1991, ld.; Grabowski et al., 1995, ld.; Pastores et al., 1993, ld.). For example, a dosage regimen of 60 U/kg once every two weeks is of clinical benefit in subjects with moderate to severe disease. The references cited above and the package inserts for these products should be consulted by the skilled practitioner for additional dosage regimen and administration information. See also U.S. Pat. Nos. 5,236,838 and 5,549,892 assigned to Genzyme Corporation.
101
As noted above, Gaucher Disease results from a deficiency of the lysosomal enzyme glucocerebrosîdase (GC). In the most common phenotype of Gaucher disease (type 1), pathology is limited to the réticuloendothélial and skeletal Systems and there are no neuropathie symptoms. See Barranger, Glucosylceramide lipidosis: Gaucher disease. In: Scriver CR BA, Sly WS, Valle D, editor. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill. pp. 3635-3668 (2001). In neuropathie Gaucher disease (nGD), subdivided into type 2 and type 3 Gaucher disease, the deficiency of glucocerebrosîdase (GC) causes glucosylceramide (GluCer; GL-1) and glucosylsphingosine (GluSph) to accumulate in the brain, leading to neurologie impairment. Type 2 Gaucher disease is characterized by early onset, rapid progression, extensive pathology in the viscera and central nervous System, and death usually by 2 years of âge. Type 3 Gaucher disease, also known as subacute nGD, is an intermediate phenotype with varying âge of onset and different degrees of severity and rates of progression. Goker-Alpan et al., The Journal of Pediatrics 143: 273-276 (2003). A recent development has produced the K14 Inl/lnl mouse model of type 2 Gaucher disease (hereinafter, the “K14 mouse); this mouse model closely récapitulâtes the human disease showing ataxia, seizures, spasticity and a reduced médian lifespan of only 14 days. Enquist et al., PNAS 104: 17483-17488 (2007).
As in patients with nGD, several mouse models of the disease hâve increased levels of GluCer and GluSph in the brain due to the deficiency in GC activity. Liu et al., PNAS 95: 2503-2508 (1998) and Nilsson, J. Neurochem 39: 709-718 (1982). The “K14 mice display a neuropathie phenotype that shares many pathologie features with type 2 Gaucher disease, such as neurodegeneration, astrogliosis, microglial prolifération, and increased levels of GluCer and GluSph in spécifie brain régions. Enquist et al. (2007).
Clinical management of patients affected by nGD poses a challenge for treating physicians both because of the severity of type 2 disease and the inability of the current thérapies to cross the blood brain barrier (BBB). Current treatment of non-nGD relies on the intravenous delivery of recombinant human glucocerebrosîdase (Imiglucerase; Cerezyme™) to replace the missing enzyme or the administration of glucosylceramide synthase inhibitors to attenuate substrate (GL-1) production. However, these drugs do not cross the blood brain barrier, and thus are not expected to provide therapeutic benefit for nGD patients. Current small molécule glucosylceramide synthase inhibitors in the clinic are not likely to address the neuropathie phenotypes of nGD. An évaluation of a compound of the présent invention, Quinuclidin-3-yl (2-(4'-fluoro-[1,1'-biphenyl]-3-yl)propan-2102 yljcarbamate (hereinafter, “Gz161), in the K14 mouse model of type 2 Gaucher disease demonstrated that it could indeed reduce brain GluCer and GluSph (see Examples 122-125). It also reduced brain neuropathology and extended the lifespan of this model. Moreover, a combined approach using both enzyme replacement and small molécule substrate réduction may represent a superior therapy for type 2 Gaucher disease.
Fabry
As noted previously, Fabry's disease is caused by the deficiency of the lysosomal enzyme alpha-galactosidase A. The enzymatic defect leads to systemic déposition of glycosphingolipids having terminal alpha-galactosyl moieties, predominantly globotriaosylceramide (GL3 or Gb3) and, to a lesser extent, galabiosylceramide and blood group B glycosphingolipids.
Several assays are available to monitor disease progression and to détermine when to switch from one treatment modality to another. In one embodîment, an assay to détermine the spécifie activity of alpha-galactosidase A in a tissue sample may be used. In another embodîment, an assay to détermine the accumulation of Gb3 may be used. In another embodîment, the practitioner may assay for déposition of glycosphingolipid substrates in body fluids and in lysosomes of vascular endothélial, perithelial and smooth muscle cells of blood vessels. Other clinical manifestations which may be useful indicators of disease management include proteinuria, or other signs of rénal impairment such as red cells or lipid globules in the urine, and elevated érythrocyte sédimentation rate. One can also monitor anémia, decreased sérum iron concentration, high concentration of beta-thromboglobulin, and elevated réticulocyte counts or platelet aggregation. Indeed, any approach for monitoring disease progression which is known to the skilled artisan may be used (See generally Desnick RJ et al., 1995, .alpha.-Galactosidase A Deficiency: Fabry Disease, In: The Metabolic and Molecular Bases of Inherited Disease, Scriver et al., eds., McGraw-Hill, N.Y., î.sup.th ed., pages 2741-2784). A preferred surrogate marker is pain for monitoring Fabry disease management. Other preferred methods include the measurement of total clearance of the enzyme and/or substrate from a bodily fluid or biopsy specimen. A preferred dosage regimen for enzyme replacement therapy in Fabry disease is 1-10 mg/kg i.v. every other day. A dosage regimen from 0.1 to 100 mg/kg i.v. at a frequency of from every other day to once weekly or every two weeks can be used.
Niemann-Pick B
103
As previously noted, Niemann-Pick B disease is caused by reduced activity of the lysosomal enzyme acid sphingomyelinase and accumulation of membrane lipid, primarily sphingomyelin. An effective dosage of replacement acid sphingomyelinase to be delivered may range from about 0.01 mg/kg to about 10 mg/kg body weight at a frequency of from every other day to weekly, once every two weeks, or once every two months. In other embodiments an effective dosage may range from about 0.03 mg/kg to about 1 mg/kg; from about 0.03 mg/kg to about 0.1 mg/kg; and/or from about 0.3 mg/kg to about 0.6 mg/kg. In a particular embodiment, a patient is administering acid sphingomyelinase in an escalating dose regimen at the following sequential doses: 0.1 mg/kg; 0.3 mg/kg; 0.6 mg/kg; and 1.0 mg/kg, wherein each dose of acid sphingomyelinase is administered at least twice, and each dose is administered at two week intervals, and wherein the patient is monitored for toxic side effects before elevating the dose to the next level (See U.S. Patent Application Publication No. 2011/0052559.
Hurler-Scheie (MPS I)
Hurler, Scheie, and Hurler-Scheie disease, also known as MPS I, are caused by inactivation of alpha-iduronidase and accumulation of dermatan sulfate and heparan sulfate. Several assays are available to monitor MPS I disease progression. For example, alpha-iduronidase enzyme activity can be monitored in tissue biopsy specimens or cultured cells obtained from peripheral blood. In addition, a convenient measure of disease progression in MPS I and other mucopolysaccharidoses is the urinary excrétion of the glycosaminoglycans dermatan sulfate and heparan sulfate (see Neufeld étal., 1995, ld.). In a particularembodiment, alpha-iduronidase enzyme is administered once weekly as an intravenous infusion at a dosage of 0.58 mg/kg of body weight.
Hunter (MPS II)
Hunter’s disease (a.k.a. MPS II) is caused by inactivation of îduronate sulfatase and accumulation of dermatan sulfate and heparan sulfate. Hunter's disease présents clinically in severe and mild forms. A dosage regimen of therapeutic enzyme from 1.5 mg/kg every two weeks to 50 mg/kg every week is preferred.
Morquio (MPS IV)
Morquio's syndrome (a.k.a. MPS IV) results from accumulation of keratan sulfate due to inactivation of either of two enzymes. In MPS IVA the inactivated enzyme is galactosamine-6sulfatase and in MPS IVB the inactivated enzyme is beta-galactosidase. A dosage regimen of
104 therapeutic enzyme from 1.5 mg/kg every two weeks to 50 mg/kg every week is preferred.
Maroteaux-Lamy (MPS VI)
Maroteaux-Lamy syndrome (a.k.a. MPS VI) is caused by inactivation of alactosamine-4sulfatase (arylsulfatase B) and accumulation of dermatan sulfate.
A dosage regimen of from 1.5 mg/kg every two weeks to 50 mg/kg every week is a preferred range of effective therapeutic enzyme provided by ERT. Optimally, the osage employed is less than or equal to 10 mg/kg per week. A preferred surrogate marker for MPS VI disease progression is roteoglycan levels.
Pompe
Pompe's disease is caused by inactivation of the acid alpha-glucosidase enzyme and accumulation of glycogen. The acid alpha-glucosidase gene résides on human chromosome 17 and is designated GAA. H. G. Hers flrst proposed the concept of inborn lysosomal disease based on his studies of this disease, which he referred to as type II glycogen storage disease (GSD II) and which is now also termed acid maltase deficiency (AMD) (see Hers, 1965, Gastroenterology 48, 625). In a particular embodiment, GAA is administered every 2 weeks as an intravenous infusion at a dosage of 20 mg/kg body weight.
Several assays are available to monitor Pompe disease progression. Any assay known to the skilled artisan may be used. For example, one can assay for intra-lysosomal accumulation of glycogen granules, particularly in myocardium, liver and skeletal muscle fibers obtained from biopsy. Alpha-glucosidase enzyme activity can also be monitored in biopsy specimens or cultured cells obtained from peripheral blood. Sérum élévation of creatine kinase (CK) can be monitored as an indication of disease progression. Sérum CK can be elevated up to ten-fold in infantile-onset patients and is usually elevated to a lesser degree in adult-onset patients. See Hirschhorn R, 1995, Glycogen Storage Disease Type II: Acid alpha-Glucosidase (Acid Maltase) Deficiency, In: The Metabolic and Molecular Bases of Inherited Disease, Scriver et al., eds., McGraw-Hill, N.Y., 7.sup.th ed., pages 2443-2464.
Enzyme Replacement Therapy
The following sections set forth spécifie disclosure and alternative embodiments available for the enzyme replacement therapy component of a combination therapy of the invention. Generally, dosage regimens for an enzyme replacement therapy component of a combination
105 therapy of the invention are generally determined by the skilled clinician. Several examples of dosage regimens for the treatment of Gaucher's disease with glucocerebrosidase are provided above. The general principles for determining a dosage regimen for any given ERT component of a combination therapy of the invention for the treatment of any LSD will be apparent to the skilled artisan from publically available information, such as, for example, a review of the spécifie references cited in the sections for each spécifie LSD. An ERT may be administered to a patient by intravenous infusion. Intracerebroventricular and/or intrathecal infusion may be used (e.g., in addition to intravenous infusion) to administer ERT to a patient diagnosed with a lysosomal storage disease having CNS manifestations.
Any method known in the art may be used for the manufacture of the enzymes to be used in an enzyme replacement therapy component of a combination therapy of the invention. Many such methods are known and include but are not limited to the Gene Activation technology developed by Shire pic (see U.S. Pat. Nos. 5,968,502 and 5,272,071).
Small Molécule Therapy
The following section also sets forth spécifie disclosures and alternative embodiments available for the small molécule therapy component of a combination therapy of the invention. Dosage regimens for a small molécule therapy component of a combination therapy of the invention are generally determined by the skilled clinician and are expected to vary significantly depending on the particular storage disease being treated and the clinical status of the particular affected individual. The general principles for determining a dosage regimen for a given SMT component of any combination therapy of the invention for the treatment of any storage disease are well known to the skilled artisan. Guidance for dosage regimens can be obtained from any of the many well known references in the art on this topic. Further guidance is available, inter alia, from a review of the spécifie references cited herein.
Generally, compounds of the présent invention, such as, for example, (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate and Quinuclidin-3-yl (2-(4'-fluoro-[1,1 biphenyl]-3-yl)propan-2-yl)carbamate may be used in the combination thérapies of the invention for treatment of virtually any storage disease resulting from a lésion in the glycosphingolipid pathway (e.g. Gaucher, Fabry, GM1-gangliosidosis and GM2-gangliosidoses (e.g., GM2 Activator Deficiency, Tay-Sachs and Sandhoff)). Likewise, aminoglycosides (e.g. gentamicin, G418) may be used in the combination thérapies of the invention for any storage disease individual having a prématuré stop
106 codon mutation (i.e., nonsense mutation). Such mutations are particularly prévalent in Hurler syndrome. A small molécule therapy component of a combination therapy of the invention is particularly preferred where there is a central nervous System manifestation to the storage disease being treated (e.g., Sandhoff, Tay-Sachs, Niemann-Pick Type A, and Gaucher types 2 and 3), since small molécules can generally cross the blood-brain barrier with ease when compared to other thérapies.
Preferred dosages of substrate înhibitors used in a combination therapy of the invention are easily determined by the skilled artisan. In certain embodiments, such dosages may range from about 0.5 mg/kg to about 300 mg/kg, preferably from about 5 mg/kg to about 60 mg/kg (e.g., 5 mg/kg, 10 mg/kg, 15, mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg and 60 mg/kg) by intraperitoneal, oral or équivalent administration from one to five times daily. Such dosages may range from about 5 mg/kg to about 5 g/kg, preferably from about 10 mg/kg to about 1 g/kg by oral, intraperitoneal or équivalent administration from one to five times daily. In one embodiment, doses range from about about 10 mg/day to about 500 mg/day (e.g., 10 mg/day, 20 mg/day, 30 mg/day, 40 mg/day, 50 mg/day, 60 mg/day, 70 mg/day, 80 mg/day, 90 mg/day, 100 mg/day, 110 mg/day, 120 mg/day, 130 mg/day, 140 mg/day, 150 mg/day, 160 mg/day, 170 mg/day, 180 mg/day, 190 mg/day, 200 mg/day, 210 mg/day, 220 mg/day, 230 mg/day, 240 mg/day, 250 mg/day, 260 mg/day, 270 mg/day, 280 mg/day, 290 mg/day, 300 mg/day). A particularly preferred oral dose range is from about 50 mg to about 100 mg, wherein the dose is administered twice daily. A particular oral dose range for a compound of the présent invention is from about 5 mg/kg/day to about 600 mg/kg/day. In a particular oral dose range for a compound of the présent invention is from about 1 mg/kg/day to about 100 mg/kg/day, e.g., 1 mg/kg/day, 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day, 20 mg/kg/day, 25 mg/kg/day, 30 mg/kg/day, 35 mg/kg/day, 40 mg/kg/day , 45 mg/kg/day, 50 mg/kg/day , 55 mg/kg/day or 60 mg/kg/day, 65 mg/kg/day, 70 mg/kg/day, 75 mg/kg/day, 80 mg/kg/day, 85 mg/kg/day, 90 mg/kg/day, 95 mg/kg/day or 100 mg/kg/day.
A rotating combination of therapeutic platforms (i.e., enzyme replacement and small molécule therapy) is preferred. However, subjects may also be treated by overlapping both approaches as needed, as determined by the skilled clinician. Examples of treatment schedules may include but are not limited to: (1) SMT followed by ERT; (2) ERT followed by SMT; and (3) ERT and SMT provided at about the same time. As noted previously, temporal overlap of
107 therapeutic platforms may also be perfomned, as needed, depending on the clinical course of a given storage disease in a given subject.
Treatment intervals for various combination thérapies can vary widely and may generally be different among different storage diseases and different individuals depending on how aggressively storage products are accumulated. For example, Fabry storage product accumulation may be slow compared to rapid storage product accumulation in Pompe. Titration of a particular storage disease in a particular individual is carried out by the skilled artisan by monitoring the clinical signs of disease progression and treatment success.
The various macromolecules that accumulate in lysosomal storage diseases are not uniformly distributed, but instead are deposited in certain preferred anatomie sites for each disease. However, an exogenously supplied enzyme is generally taken up by cells of the réticuloendothélial System and sorted to the lysosomal compartment where it acts to hydrolyze the accumulated substrate. Moreover, cellular uptake of therapeutic enzyme can be augmented by certain maneuvers to increase lysosomal targeting (see e.g. U.S. Pat. No. 5,549,892 by Friedman et al., assigned to Genzyme Corporation, which describes recombinant glucocerebrosidase having improved pharmacokinetics by virtue of remodeled oligosaccharide side chains recognized by cell surface mannose receptors which are endocytosed and transported to lysosomes).
Some treatment modalities target some affected organs better than others. In Fabry, for example, if ERT does not reach the kidney well enough for a satisfactory clinical outcome, SMT can be used to reduce the substrate levels in the kidney. As demonstrated in Example 112 and Fig. 6B, SMT effectively reduced Gb3 levels (i.e., the substrate accumulated in Fabry patients) in the urine of a Fabry mouse model to a greater extent than ERT. The kidneys are believed to be the major source of urine Gb3. In contrast, Fig. 6B shows ERT effectively reduced the Gb3 levels in the plasma to a greater extent than SMT. These results demonstrate that a combination therapy of ERT and SMT provides a complementary therapeutic strategy that takes advantage of the strengths and addresses the weaknesses associated with each therapy employed alone. SMT is able to cross the BBB, providing a powerful approach, when combined with ERT, for treating LSDs having CNS manifestations, such as Niemann Pick Type A and Neuropathie Gaucher disease (nGD). Moreover, substrate réduction by SMT combined with enzyme replacement address the storage problem at separate and distinct intervention points which may enhance clinical outcome.
108
It will be understood that reference to simultaneous or concurrent administration of two or more thérapies does not require that they be administered at the same time, just that they be acting în the subject at the same time.
Example 1 quinuclidin-3-yl 1 -phenylcyclobutylcarbamate
Using general procedure A, 1-phenylcyclobutanamine hydrochloride (100 mg, 0.540 mmol) and quinuclidin-3-ol (103 mg, 0.810 mmol) gave quinuclidin-3-yl 1-phenylcyclobutylcarbamate (76 mg, 47%) as a white solid. 1H NMR (400 MHz, CDCI3) 5 7.43 (d, J = 7.9 Hz, 2H). 7.34 (t, J = 7.7 Hz, 2H), 7.23 (t, J = 7.3 Hz, 1 H), 5.75 - 5.25 (m, 1 H), 4.60 (br s, 1 H), 3.25-2.22 (m, 9H), 2.16 2.03 (m, 1H), 2.02- 0.94 (m, 6H), 0.88 (t, J = 6.8 Hz, 1H) ppm. 13C NMR (100 MHz, CDCI3) δ 158.1,
128.5, 126.9, 125.6, 71.4, 59.4, 55.7, 47.5, 46.6, 34.0, 31.8, 29.9, 25.5, 24.7, 22.9, 19.7, 15.3, 14.4 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 0.62 min; (M+1 ) 331.
Example 2 quinuclidin-3-yl 2-(benzo[d][1,3]dioxol-5-yl)propan-2-ylcarbamate
Using general procedure B, benzo[d][1,3]dioxole-5-carbonitrile (1.00 g, 6.81 mmol) was converted to 2-(benzo[d][1,3]dioxol-5-yl)propan-2-amine hydrochloride (692 mg, 47%).
Using general procedure A, the above ammonium chloride intermediate (150 mg, 0.695 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(benzo[d][1,3]dioxol-5-yl)propan-2 ylcarbamate (125 mg, 54%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 6.91 (dd, J= 1.9 Hz, 1H), 6.87 (dd, J = 1.9, 8.2 Hz, 1H), 6.75 (d, J =8.2 Hz, 1H), 5.93 (s, 2H), 5.12 (s, 1H), 4.69-4.66 (m, 1H), 3.26-2.11 (m, 7H), 2.03-1.07 (m, 4H), 1.63 (s, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 156.7,147.9, 118.0,
108.1, 106.1, 101.2, 71.2, 55.9, 55.3, 47.6, 46.7, 29.9, 29.7, 25.6, 24.8,19. 8 ppm. Purity; 97.5% UPLCMS (210 nm); rétention time 0.65 min; (M+1) 333.
Example 3 quinuclidin-3-yl 2-(naphthalen-1-yl)propan-2-ylcarbamate
109
Using general procedure A, 2-(naphthalen-1-yl)propan-2-amine hydrochloride (100 mg, 0.450 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(naphthalen-1-yl)propan-2-ylcarbamate (115 mg, 59%) asa white solid. 1H NMR (400 MHz, CDCI3) δ 8.79-8.46 (m, 1H), 7.99-7.72 (m, 2H), 7.69-7.36 (m, 4H), 5.86 -5.37 (m, 1H), 4.72 -4.34 (m, 1H), 3.25-2.20 (m, 6H), 2.16-0.41 (m, 5H), 1.93 (s, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 154.6,135.2, 130.7, 129.7, 128.8, 125.9, 125.3, 123.9, 72.2, 71.1, 56.5, 55.7, 47.6, 46.6, 31.8, 31.2, 25.5, 24.8, 22.9, 19.7, 14.4 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.80 min; (M+1) 339.
Préparation I
Example 4 (R)-quinuclidin-3-yl 2-(3-(prop-1-en-2-yl)phenyl)propan-2-ylcarbamate
To a solution of (R)-quinuclidin-3-ol (194 mg, 1.52 mmol) in THF (5 mL) at room température was added NaH [60%, oil] (64 mg, 1.6 mmol). The reaction mixture was stirred for 15 min and 1-(2-isocyanatopropan-2-yl)-3-(prop-1-en-2-yl)benzene (302 uL, 1.53 mmol) was added dropwise. The reaction was stirred for a period of 30 min and quenched with brine. The solution was extracted with EtOAc and the organic layer was dried over Na2SO4 and concentrated. The crude material was purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding carbamate (475 mg, 95%) as a clear oil. ’H NMR (400 MHz, CDCI3) δ 7.49 (s, 1H), 7.31 (brs, 3H), 5.33 (s, 1H), 5.17 (s, 1H), 5.08 (s, 1H), 4.77-4.61 (m, 1H), 3.33-2.27 (m, 5H), 2.14 (s, 3H), 2.25-0.75 (m, 6H), 1.68 (brs, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 154.7, 147.2,143.7, 141.6, 128.5, 124.2, 122.1, 112.8, 70.9, 55.7, 55.5, 47.5, 46.6, 32.2, 31.5, 29.9, 29.6,
25.5, 24.6, 22.9, 22.2,19.6 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.84 min; (M+1)
329.2. Anal. Calcd. for C20H28N2O2-0.06 (CHCI3): C, 71.59; H, 8.40; N, 8.58. Found: C, 71.51; H, 9.05; N, 8.60.
Préparation J
Example 5 quÎnuclidin-3-yl 2-(3-îsopropoxyphenyl)propan-2-ylcarbamate
A solution of 3-cyanophenol (1.00 g, 8.39 mmol), 2-iodopropane (839 uL, 8.39 mmol) and césium carbonate (2.73 g, 8.39 mmol) in 1:1 CH2CI2/CH3CN (16 mL) was stirred at reflux for 18 h.
110
The réaction mixture was cooled to room température and filtered through Celite. The filtrate was concentrated and the crude material purified on a combiflash (SiO2 cartridge, CH2CI2) to afford the corresponding ether (763 mg, 57%) as a white solid.
Using general procedure B, 3-isopropoxybenzonitrile (763 mg, 4.24 mmol) was converted to the corresponding 2-(3-isopropoxyphenyl)propan-2-amine (362 mg, 45%) as a clear oil.
Using general procedure A, the above amine (100 mg, 0.520 mmol) and quinuclidin-3-ol gave quînuclidin-3-yl 2-(34sopropoxyphenyl)propan-2-ylcarbamate (110 mg, 61%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.17 (t, J = 7.9 Hz, 1 H), 6.92 (d, J = 7.8 Hz, 1 H), 6.89 (t, J = 2.1 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H), 5.38-5.13 (m, 1H), 4.58 ( br s, 1H), 4.49 (hept, J = 6.1 Hz, 1H), 3.31-2.04 (m, 6H), 2.00-0.79 (m, 5H) 1.60 (br s, 6H), 1.28 (d, J = 6.1 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 158.1, 129.5, 117.2, 113.6, 71.1, 69.9, 55.8, 55.4, 47.6, 46.6, 29.4, 25.6, 24.8, 22.3, 19.7 ppm. Purity; >99.9% UPLCMS (210 nm); rétention time 0.83 min; (M+1) 347.
Example 6 quinuclidin-3-yl 2-(3-bromo-2-fluorophenyl)propan-2-ylcarbamate
Using general procedure A, 2-(3-bromo-2-fluorophenyl)propan-2-amine (1.0 g, 4.3 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(3-bromo-2-fluorophenyl)propan-2-ylcarbamate (957 mg, 58%) as a white solid. Ή NMR (400 MHz, CDCI3) δ 7.45 (ddd, J = 1.6, 6.3, 7.9 Hz, 1 H), 7.31 (td, J = 1.6, 7.7 Hz, 1 H), 6.99 (td, J = 1.0, 8.0 Hz, 1 H), 5.31 -5.15 (br s, 1 H), 4.59 (br s, 1 H), 3.252.19 (m, 6H), 2.06-0.81 (m, 5H), 1.73 (s, 3H), 1.71 (s, 3H) ppm. 13C NMR (100 MHz. CDCI3) δ
158.1, 155.6, 132.5, 127.1, 127.0, 124.8, 124.8, 110.6, 110.4, 71.5, 55.7, 54.2, 47.5, 46.7, 29.9,
28.4, 25.5, 24.8, 19.7 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 0.79 min; (M+1) 385.
Example 7 (+/-) quinuclidin-3-yl (1 R,2S)-2-phenylcyclopropylcarbamate
Using general procedure A, (+/-)((1 S,2R)-2-isocyanatocyclopropyl)benzene (117 uL, 0.780 mmol) and quinuclidin-3-ol gave (+/-) quinuclidin-3-yl (1R,2S)-2-phenylcyclopropylcarbamate (63 mg, 28%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.30-7.05 (m, 5H), 5.43 (br s, 1H), 4.77 (br
I 11 s, 1H), 3.23 (dd, J = 9.0,14.0 Hz, 1H), 2.97-2.65 (m, 6H), 2.15-1.12 (m, 8H)ppm.13C NMR (100 MHz, CDCI3) δ 157.1, 140.7, 140.2, 128.5, 126.8, 126.3, 71.5, 55.7, 47.5, 46.6, 32.7, 25.6, 25.2,
24.5,19.5, 16.2 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 0.67 min; (M+1) 287.
Example 8 quinuclidin-3-yl 1 -phenylcyclohexylcarbamate
Using general procedure A, 1-phenylcyclohexanamine (36 mg, 0.21 mmol) and quinuclidin3-ol gave quinuclidin-3-yl 1-phenylcyclohexylcarbamate (40 mg, 58%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.41 (d, J~ 7.4 Hz, 2H), 7.32 (t, J~ 7.7 Hz, 2H), 7.21 (t, J= 7.3 Hz, 1H), 5.194.98 (br s, 1 H), 4.70-4.56 (s, 1 H), 3.34-0.83 (m. 21 H) ppm. 13C NMR (100 MHz. CDCI3) δ 158.4,
128.3, 126.5, 124.9, 57.2, 46.3, 36.1, 25.4, 24.2, 22.0, 19.2, 15.2 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 0.84 min; (M+1) 329.
Préparation K
Example 9 (R)-1-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)-3-(quinuclidin-3-yl)urea
To a solution of (R)-quinuclidin-3-amine dihydrochloride (120 mg, 0.603 mmol) and 1-(2isocyanatopropan-2-yl)-3-(prop-1-en-2-yl)benzene (119 mg, 0.597 mmol) in THF (3 mL) was added triethylamine (168 uL, 1.21 mmol). The reaction mixture was stirred at room température for 18 h and then quenched with brine. The mixture was extracted with CHCI3 and the organic layer was dried (Na2SO4) and concentrated. The crude material was purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding urea (163 mg, 50%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.62 (t. J = 1.6 Hz, 1 H), 7.44 (dt, J = 1.9, 7.0 Hz, 1 H), 7.41 - 7.33 (m, 2H), 5.35 (br s, 1 H), 5.11 (p, J = 1.4 Hz, 1 H), 4.84 (s, 1 H), 4.21 (d, J = 7.5 Hz, 1 H), 3.70-3.61 (m, 1H), 3.13 (ddd, J = 2.3, 9.3, 14.2 Hz, 1H), 2.71 -2.54 (m, 3H), 2.30-2.22 (m, 1H), 2.15 (dd, J = 0.8,
1.4, 3H), 2.05-1.96 (m, 1H), 1.65 (s, 3H), 1.64 (s, 3H), 1.65-1.60 (m, 1H) 1.54-1.45 (m, 2H), 1.221.12 (m, 1H), 0.95-0.80 (m, 1H) ppm. 13C NMR (400 MHz, CDCI3) δ 157.4, 148.5, 143.8, 141.3,
128.4.124.4, 123.8, 122.2, 112.6, 55.2, 53.4, 46.2, 46.1, 44.5, 30.5, 30.4, 25.0, 22.2, 17.7, 8.9 ppm. Purity: 97.5% UPLCMS (210 nm); rétention time 0.83 min; (M+1) 328.
112
Example 10
1-(2-(naphthalen-2-yl)propan-2-yl)-3-(quinuclidin-3-yl)urea
Using general procedure B, naphthalene-2-carbonitrile (1.00 g, 6.53 mmol) was converted to the corresponding 2-(naphthalen-2-yl)propan-2-amine (294 mg, 25%) as a clear oil.
Using general procedure C, quinuclidin-3-amine (102 mg, 0.808 mmol), CDI (131 mg, 0.808 mmol) and 2-(naphthalen-2-yl)propan-2-amine (150 mg, 0.819 mmol) gave 1-(2-(naphthalen-2yl)propan-2-yl)-3-(quinuclidin-3-yl)urea (132 mg, 49%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.94-7.78 (m, 4H), 7.69 (dd, J~ 2.0, 8.7 Hz, 1 H), 7.53-7.46 (m, 2H), 4.84 (s, 1H), 4.23 (d, J = 8.0 Hz, 1H), 3.68-3.54 (m, 1H), 3.07 (ddd, J = 2.3, 9.3, 14.1 Hz, 1H), 2.61-2.51 (m, 2H), 2.42-2.32 (m, 1 H), 1.95-1.83 (m, 2H), 1.75 (s, 3H), 1.74 (s, 3H), 1.58-1.54 (m, 1 H), 1.46-1.40 (m, 2H), 1.03-0.91 (m, 1H), 0.72-0.60 (m, 1H) ppm. 13CNMR(100 MHz, CDCI3) δ 157.5,143.7, 133.4, 132.8,129.3,
128.1, 127.8, 126.9, 126.7, 124.4, 124.0, 57.0, 55.0, 47.1,47.1, 46.6, 30.5, 30.3, 26.0, 25.9, 20.0 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 0.71 min; (M+1) 338.
Example 11 1-(2-methyl-2-(m-tolyl)propyl)-3-(3-methylquinuclidin-3-yl)urea
Using general procedure D, 2-methyl-2-(m-tolyl)propan-1-amine hydrochloride (100 mg, 0.501 mmol), triethylamine (279 uL, 2.00 mmol), triphosgene (47 mg, 0.18 mmol) and 3methylquinuclidin-3-amine 2,2,2-trifluoroacetate (140 mg, 0.550 mmol) gave 1-(2-methyl-2-(mtolyl)propyl)-3-(3-methylquinuclidin-3-yl)urea (41 mg, 25%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.23 (t, J = 7.7 Hz, 1H), 7.18-7.12 (m, 2H), 7.04 (d, >7.5 Hz, 1H), 4.12 (s, 1H), 4.08 (t, J = 6.0 Hz, 1H), 3.39-3.22 (m, 2H), 2.81-2.62 (m, 6H), 2.34 (s, 3H), 1.98-1.89 (m, 1H), 1.80-1.63 (m, 2H), 1.51 -1.23 (m, J = 26.9 Hz, 2H), 1.37 (s, 3H), 1.30 (s, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ
157.9.147.1, 138.2, 128.6, 127.1, 127.1, 123.3, 64.0, 52.2, 52.1,46.9, 46.7, 39.2, 31.2, 27.1,26.8,
25.4, 23.5, 22.7, 21.9. Purity: >99.9% UPLCMS (210 nm); rétention time 0.79 min; (M+1) 330.
Example 12
1-(2-(3-methoxyphenyl)propan-2-yl)-3-(quinuclidin-3-yl)urea
113
Using general procedure C, quinuclidin-3-amine (380 mg, 3.01 mmol), CDI (489 mg, 3.01 mmol) and 2-(3-methoxyphenyl)propan-2-amine (506 mg, 3.07 mmol) gave 1-(2-(3methoxyphenyl)propan-2-yl)-3-(quinuclidin-3-yl)urea (560 mg, 59%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.35-7.29 (m, 1H), 7.14-7.07 (m, 2H), 6.87-6.81 (ddd, 1H), 4.76 (s, 1H), 4.19 (d, 1H), 3.81 (s, 3H), 3.70-3.62 (m, 1 H). 3.19-3.10 (m, 1H), 2.74-2.59 (m, 3H), 2.37-2.26 (m, 1H), 2.071.98 (dd, 1 H), 1.80 (br s, 1 H), 1.69-1.63 (m, 1 H), 1.63 (s, 3H), 1.62 (s, 3H), 1.58-1.44 (m, 2H), 1.281.14 (m, 1H), 1.02-0.90 (m, 1H) ppm. 13C NMR (100 MHz, CDCI3) δ 160.0, 157.5, 148.4, 129.9, 117.7, 112.0, 111.9, 56.7, 55.3, 54.6, 47.2, 46.8, 46.4, 30.1,25.8, 20.0 ppm. Purity: >99.4% UPLCMS (210 nm); rétention time 1.73 min; (M+1) 318.
Example 13 quinuclidin-3-yl 2-(3-methoxyphenyl)propan-2-ylcarbamate
Using general procedure A, 1-(3-methoxyphenyl)propan-2-amine (327 mg, 1.98 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(3-methoxyphenyl)propan-2-ylcarbamate (370 mg, 59%) as a white solid. 'H NMR (400 MHz. CDCI3) δ 7.30-7.20 (m, 1H), 7.03-6.97 (m, 1H), 6.97-6.93(m, 1H), 6.80-6.74 (dd, 1H), 5.18-5.00 (brs, 1H), 4.67-4.57 (m, 1H), 3.80 (s, 3H), 3.30-2.12 (brm, 7H), 2.021.00 (m, 10H) ppm. 13C NMR (100 MHz, CDCI3) δ 159.7, 154.5, 149.0, 129.3, 117.2, 111.4, 111.0, 70.9, 55.7, 55.1,47.4, 46.5, 29.4, 25.4, 24.6, 19.6 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 1.85 min; (M+1) 319.
Example 14 quinuclidin-3-yl 2-(3-methoxyphenyl)propan-2-ylcarbamate
Using general procedure A, 1-(4-methoxyphenyl)propan-2-amine hydrochloride (316 mg, 1.57 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(3-methoxyphenyl)propan-2-ylcarbamate (370 mg, 59%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.33 (d, 2H), 6.86 (d, 2H), 5.155.01(brs, 1H), 4.66-4.57 (m, 1H), 3.79 (s, 3H), 3.33-2.12 (m, 7H), 2.10-0.96 (m, 10H) ppm. 13C NMR (100 MHz, CDCI3) δ 158.1, 154.5, 139.2, 125.8, 113.5, 70.7, 55.7, 55.2, 54.6, 47.2, 46.3,
31.2, 29.4, 25.3, 24.5, 19.4 ppm. Purity: >94.1% UPLCMS (210 nm); rétention time 1.81 min; (M+1) 319.
Example 15
H4 quinuclidin-3-yl 2-(4-tert-butylphenyl)propan-2-ylcarbamate
Using general procedure A, 1-(4-tert-butylphenyl)propan-2-amine (348 mg, 1.82 mmol) and quinuclîdin-3-oî gave quinuclidin-3-yl 2-(4-tert-butylphenyl)propan-2-ylcarbamate (427 mg, 68%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.34 (s, 4H), 5.09 (br s, 1H), 4.69-4.52 (m, 1H), 3.47-2.05 (m, 7H), 3.33-2.12 (m, 7H), 2.00-0.80 (m, 20H) ppm. 13C NMR (100 MHz, CDCI3) δ 156.2, 149.4, 144.5, 125.3, 124.5, 70.9, 55.8, 55.1, 47.5, 46.6, 34.4, 31.4, 29.8,
29.3, 25.5, 24.6,19.6 ppm. Purity: >98.2% UPLCMS (210 nm); rétention time 2.29 min; (M+1) 345.
Example 16 quinuclidin-3-yl 2-(4-isopropylphenyl)propan-2-ylcarbamate
Using general procedure A, 1-(4-isopropylphenyl)propan-2-amine (158 mg, 0.891 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(4-isopropylphenyl)propan-2-ylcarbamate (205 mg, 70%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.33 (d, J= 7.3 Hz, 2H), 7.19 (s, 1H), 7.17 (s, 1 H), 5.09 (s, 1 H) 4.69-4.51 (br s, 1 H) 3.30-1.30 (m, 17 H), 1,24(s, 3H), 1.22 (s, 3H), 1.06-0.77 (m, 1H) ppm. 13C NMR (100 MHz, CDCI3) δ 156.2,147.1, 144.4, 126.4,124.7, 70.9, 55.7, 55.0, 47.4,
46.5, 33.6, 29.8, 29.4, 25.4, 24.6, 24.0, 19.5 ppm. Purity: >98.3% UPLCMS (210 nm); rétention time 2.19 min; (M+1) 331.
Example 17 quinuclidin-3-yl 2-(4-ethylphenyl)propan-2-yicarbamate
Using general procedure A, 1-(4-ethylphenyl)propan-2-amine (230 mg, 1.41 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(4-ethylphenyl)propan-2-yîcarbamate (248 mg, 56%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.33 (d, J = 7.3 Hz, 2H), 7.19 (s. 1H), 7.17 (s, 1 H). 5.09 (s, 1H) 4.69-4.51 (br s, 1H) 3.34-0.73 (m, 22 H) ppm. 13C NMR (100 MHz, CDCI3) δ 154.5,144.3,
142.4, 127.8, 124.7, 71.0, 55.6, 55.1,47.4, 46.5, 29.6, 28.3, 25.4, 24.6, 19.5, 15.8,15.4 ppm. Purity: >99.5% UPLCMS (210 nm); rétention time 2.07 min; (M+1) 317.
115
Example 18 qufnuclidln-3-yI 2-o-tolylpropan-2-ylcarbamate
Using general procedure A, 2-o-tolylpropan-2-amine (230 mg, 1.52 mmol) and quinuclidin-3ol gave quinuclidin-3-yl 2-o-tolylpropan-2-ylcarbamate (200 mg, 44%) as a white solid. 1H NMR (400 MHz, CDCIa) (rotamers) δ 7.33 (s, br, 1H), 7.15-7.10 (m, 3H), 5.35-5.20 (m, 1H), 4.60 (brs, 1H), 3.20-2.60 (m, 5H), 2.5 (s, 3H), 2.15 (br s, 1H), 1.80-1.30 (m, 10 H). 13C NMR (100 MHz, CDCI3) (rotamers) δ 154.2,144.5, 140.2, 133.0,127.1, 126.2, 126.1,72.2, 71,56.0, 46.6, 46.7, 31.0, 29.0, 26.0, 24.7, 22.3, 19.7. Purity: >95 % UPLCMS (210 nm); (M+1 ) 303.
Example 19 quinuclidin-3-yl 2-(2-methoxyphenyl)propan-2-ylcarbamate
Using general procedure A, 2-(2-methoxyphenyl)propan-2-amine (150 mg, 0.908 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 2-(2-methoxyphenyl)propan-2-ylcarbamate (60 mg, 21%) as a white solid. 1H NMR (400 MHz, CDCI3) (rotamers) δ 7.3 (m, 1H), 7.2 (m, 1H), 6.9 (m, 2H), 5.4 (s. br, 1H), 4.6 (m, 1H), 3.8 (s, 1H), 3.1 (m, 1H), 2.4-2.8 (m, 5H), 1.9 (s, 1H), 1.3-1.7 (m, 10H). 13C NMR (100 MHz, CDCI3) (rotamers) δ 157,155,140,134, 129,127,121, 111, 70, 56, 55, 48, 47, 29, 26, 25, 20. Purity: > 99 % UPLCMS (210 nm); (M+1) 319.
Préparation L
Example 20
1-(3-cyanoquinuclidin-3-yl)-3-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)urea
3-Amino-3-cyanoquinuclidine was prepared as described in the literature (Fernandez, M. A.; Gonzalez, G.; Martinez, M.; Galvez, E. Anales de la Real Academia de Farmacia 1988, 54, 502).
To a solution of 3-amino-3-cyanoquinuclidine (100 mg, 0.661 mmol) in CH2CI2 (5 mL) was added, dropwise, 3-isoprenyl-LJ,ü-dimethylbenzyl isocyanate (0.13 mL, 0.66 mmol). The reaction mixture was stirred at room température for 18 hours, concentrated and subjected to flash chromatography oversilica gel (19:1 CH2CI2/7M NH3(CH3OH)). The title product was obtained as a
116 white solid (155 mg, 67%). 1H NMR (400 MHz, CD3OD) δ 7.52 (s, 1H), 7.35-7.25 (m, 3H), 5.34 (s, 1H), 5.05 (s, 1H), 2.60-3.41 (m, 6H), 2.25-2.32 (m, 1H), 2.13 (s, 3H). 1.42-2.10 (m, 4H), 1.64 (s, 6H) ppm. 13C NMR (100 MHz, CD3OD) δ 157.0, 147.9, 144.0, 141.4,128.1, 124.0, 123.4, 121.9,
121.7,111.5, 61.0, 55.1, 50.4, 30.9, 23.3, 22.5, 21.0 19.0 ppm. Purity: >99.9% UPLCMS (210 nm); rétention time 0.82 min; (M+1) 353.
Préparation M
Example 21
1-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-3-{2-[3-(prop-1-en-2-yl)phenyl]propan-2-yl}urea
To a suspension of (S)-(-)-3-aminoquinculidine dihydrochloride (120 mg, 0.603 mmol) and triethylamine (168 uL, 1.21 mmol) in THF (2 ml_) at room température was added 3-isopropenyl□.□-dimethylbenzyl-isocyanate (121 mg, 0.601 mmol). The reaction mixture was stirred for 18 hr and then washed with saturated aqueous NaHCO3. The organic phase was dried over Na2SO4 and concentrated. The crude material was purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the title compound (29 mg, 47%) as an off-white solid. 1H NMR (400 MHz, CD3OD) δ 7.51 (dt, J = 2.5, 1.2 Hz, 1H), 7.41-7.14 (m, 3H), 5.32 (dd, J= 1.6, 0.8 Hz, 1H), 5.06 (s, 1H), 3.74-3,60 (m, 1H), 3.31-3.29 (m, 2H), 3.19 (ddd, J= 13.7, 9.5, 1.6 Hz, 1H), 2.88-2.50 (m, 4H), 2.37 (ddd, J= 14.0, 4.9, 2.2 Hz, 1H), 2.14 (ddd, J=2.3, 1.8, 1.0 Hz, 3H), 1.81-1.63 (m, 4H), 1.62 (d, J = 6.2 Hz, 6H), 1.55-1.38 (m, 1H) ppm. 13C NMR (100 MHz, CD3OD) δ 158.4, 148.4, 144.0,
141.3, 128.0, 124.1, 123.3, 121.9, 111.4, 55.7, 54.7, 46.7, 46.4, 46.0, 29.6, 29.4, 28.4, 26.1,25.1, 21.0, 19.4 ppm. Purity: >96% UPLCMS (210 nm); rétention time 0.81 min; (M+1) 329.5.
Préparation N
Example 22
1-(1-azabîcyclo[2.2.2]oct-3-yl)-3-{2-[3-(propan-2-yl)phenyl]propan-2-yl}urea
To a solution of 3-aminoquinuclidine (150 mg, 1.19 mmol) in THF (5 mL) was added 3isopropenyl-D,ü-dimethylbenzylisocyanate. The solution was stirred at room température for 30 min, then concentrated onto silica gel and purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford an off-white solid (299 mg, 77%).
117
Using general procedure F, the above isoprenyl urea (150 mg, 1.19 mmol) and palladium hydroxide (30 mg, 20 wt.% on carbon) gave 1-(1-azabicyclo[2.2.2]oct-3-yl)-3-(2-[3-(propan-2yl)phenyl]propan-2-yl)urea (116 mg, 77%) as an off-white solid. 1H NMR (400 MHz, CDCI3) δ 7.387.28 (m, 3H), 7.16 (dt, 7= 6.9, 1.6 Hz, 1H), 4.93 (s, 1H), 4.26 (d, 7 = 7.5 Hz, 1H), 3.70-3.58 (m, 1H), 3.11 (ddd, 7= 14.1, 9.4, 2.3 Hz, 1H), 2.90 (hept, 7 = 6.9 Hz, 1H), 2.71-2.52 (m, 4H), 2.31-2.19 (m, 1H), 1.98 (dd, 7= 14.2, 2.9 Hz, 1H), 1.61 (d, 7 = 2.0 Hz, 6H), 1.52-1.43 (m, 2H), 1.23 (d, 7=6.9 Hz, 6H), 1.19-1.09 (m, 1H), 0.92-0.79 (m, 1H) ppm. 13C NMR (100 MHz, CDCI3) δ 157.6, 150.1,
146.1.129.2, 125.8, 124.1, 123.3, 57.1, 54.9, 47.4, 47.0, 46.6, 34.5, 30.7, 30.5, 26.1, 26.0, 24.3,
24.2, 20.3 ppm. Purity: 94% UPLCMS (210 nm); rétention time 0.87 min; (M+1) 329.3.
Example 23
1-(1-azabicyclo[2.2.2]oct-3-yl)-3-[1-(naphthalen-1-yl)ethyl]urea
3-Aminoquinculidene dihydrochloride (150 mg, 0.753 mmol) was mixed with THF (3 mL) and triethylamine (152 mg, 1.50 mmol) before adding 1-(1-naphthyl)ethylisocyanate (149 mg, 0.752 mmol). The mixture was stirred 48 h at room température. The reaction solution was concentrated and purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the title compound as an off-white solid (46 mg, 19%). 1H NMR (400 MHz, CDCI3) δ 8.20-8.05 (m, 1H), 7.85 (dd, 7= 7.9,1.5 Hz, 1H), 7.75 (d, 7= 8.1 Hz, 1H), 7.59-7.34 (m, 4H), 5.55 (hept, 1H), 5.35 5.19(m, 1 H),4.84 (dd, 1H), 3.70-3.53 (m, 1H),3.09 (ddd, 1H), 2.74-2.28 (m, 4H), 2.17(ddd,7 =
1.8, 4.5,14.1 Hz, 1 H), 1.75 - 1.62 (m, 1 H), 1.55 (dd, 7 = 1.8, 6.8 Hz, 3H), 1.52 - 1.06 (m, 4H) ppm. 13C NMR (100 MHz, CDCI3) δ 157.7, 140.0, 134.1, 130.9, 129.2, 128.3, 126.8, 126.7, 126.7, 126.0, 125.6, 123.2, 123.1, 122.8, 122.7, 56.9, 56.7, 47.4, 47.3, 46.7, 46.4, 26.1, 25.9, 22.7, 22.6, 20.1, 20.0 ppm. Purity: 97% UPLCMS (210 nm); rétention time 0.68 min; (M+1) 324.2
Example 24
1-(1-azabicyclo[2.2.2]oct-3-yl)-3-[2-(3-bromophenyl)propan-2-yl]urea
Using general procedure C, quinuclidin-3-amine (100 mg, 0.792 mmol), CDI (128 mg, 0.789 mmol) and 2-(3-bromophenyl)propan-2-amine (170 mg, 0.791 mmol) gave the title compound as a white solid (166 mg, 75%). 1H NMR (400 MHz, CDCI3) δ 7.50 (s, 1H), 7.30 (t, 7= 7.2 Hz, 2H), 7.15 (t, 7=7.9 Hz, 1H), 5.54 (d, 7 = 22.7 Hz, 1H), 5.16 (d, 7= 29.7 Hz, 1H), 3.60 (s, 1H), 3.14 (ddd, 7 =
13.3, 9.4, 1.6 Hz, 1H), 2.61 (d, 7 = 52.6 Hz, 4H), 2.18 (dd, 7 = 14.1,2.8 Hz, 1 H), 1.66 (d, 7 = 3.0 Hz,
2H), 1.51 (d, 7=7.6 Hz, 6H), 1.28 (s, 3H) ppm. 13C NMR (100 MHz, CDCI3) δ 157.1, 150.4, 130.3, 130.0, 128.6, 124.0, 123.0, 57.0, 54.6, 47.6, 47.2, 46.8, 30.5, 30.3, 26.3, 26.2, 20.2 ppm. Purity; 100% UPLCMS (210 nm); rétention time 0.66 min; (M+1) 367.8.
Example 25
1-(1-azabicyclo[2.2.2]oct-3-yl)-3-[2-(biphenyl-3-yl)propan-2-yl]urea
Using general procedure E, 1-(1-azabicyclo[2.2.2]oct-3-yl)-3-[2-(3-bromophenyl)propan-2yljurea (111 mg, 0.301 mmol), phenylboronic acid (78.8 mg, 0.606 mmol) and tetrakis(triphenylphosphine)palladium(0) gave the title compound as an off-white solid (21 mg, 11%). 'H NMR (400 MHz, CDCI3) δ 7,74 (s, 1H), 7.52-7.40 (m, 8H), 4.89 (s, 1H), 4.28 (d, J = 7.3 Hz, 1H), 3.75-3.59 (m, 1H), 3.15 (ddd, J= 1.9, 9.3, 13.9 Hz, 1H), 2.46 (m, 4H), 2.05 (dd, J= 3.5, 14.0 Hz, 1H), 1.68 (d, J= 4.7 Hz. 6H), 1.66-0.76 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 157.4, 146.9, 142.5, 141.1, 129.7, 129.1, 127.8, 127.4, 126.7,124.8, 124,7, 57.1, 55.1,30.7, 30.1,26.1, 26.0, 20.2 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.78 min; (M+1) 364.0.
Example 26
1-azabicyclo[2.2.2]oct-3-yl {2-[3-(propan-2-yl)phenyl]propan-2-yl}carbamate
Using general procedure F, 1-azabicyclo[2.2.2]oct-3-yl {2-[3-(prop-1-en-2-yl)phenyl]propan2-yl}carbamate (48.8 mg, 0.146 mmol) and palladium hydroxide (30 mg, 20 wt.% on carbon) gave the title compound as an off-white solid (16 mg, 33%). 1H NMR (400 MHz, CDCI3) δ 7.24 (d, J = 5.1Hz, 3H), 7.10 (d, 1H), 5.12 (s. 1H), 4.63 (s, 1H), 3.54-2.96 (m, 1H), 2.89 (s, 1H), 2.68 (s, 5H), 2.17-1.75 (m, 2H), 1.67 (s, 6H), 1.62-1.30 (m, 2H), 1.24 (d, J = 6.9 Hz. 6H), 1.15-0.85 (m, 1H) ppm. 13C NMR (100 MHz, CDCI3) δ 149.1, 128.5, 124.9, 123.1, 122.5, 55.8, 55.6, 46.6, 34.5, 25.6, 24.6,
24.3, 19.7 ppm. Purity: 94% UPLCMS (210 nm); rétention time 0.89 min; (M+1) 331.1.
Example 27
1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromophenyl)propan-2-yl]carbamate
119
Using general procedure A, 2-(3-bromophenyl)propan-2-amine hydrochloride (2.00 g, 7.89 mmol) and quinuclidin-3-ol gave the title compound as a white solid (2.23 g, 76%). 1H NMR (400 MHz, CDCI3) δ 7.54 (s, 1H), 7.41-7.30 (m, 2H), 7.19 (t, J = 7.9 Hz, 1H), 5.11 (s, 1H), 4.68-4.54 (m, 1H), 3.51-2.11 (m, 6H), 2.04-1.68 (m, 2H), 1.63 (d, J= 10.2 Hz, 6H), 1.51-0.67 (m, 3H) ppm. 13C NMR (100 MHz, CDCI3) δ 156.0, 154.7, 150.6, 149.7, 130.2, 130.0, 128.4, 123.7, 72.5, 71.6, 71.5,
55.8, 55.1, 47.6, 46.7, 31.2, 29.9, 29.8, 29.5, 25.6, 24.8, 19.7 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.69 min; (M+1) 368.8.
Example 28
1-azabicyclo[2.2.2]oct-3-yl [2-(3-cyclopropylphenyl)propan-2-yl]carbamate
Using general procedure E, 11-azabicyclo[2.2.2]oct-3-yl [2-(3-bromophenyl)propan-2yljcarbamate (44.3 mg, 0.121 mmol), cyclopropyl boronic acid (14 mg, 0.16 mmol) and palladium (II) acetate gave the title compound as an off-white solid (21 mg, 11%). 1H NMR (400 MHz, CDCI3) δ 7.54 (s, 1H), 7.41-7.30 (m, 2H), 7.19 (t, J = 7.9 Hz, 1H), 5.11 (s, 1H), 4.68-4.54 (m, 1H), 3.51-2.11 (m, 6H), 2.04-1.68 (m, 2H), 1.63 (d, J = 10.2 Hz, 6H), 1.36 (d, J = 9.5 Hz, 3H) ppm. 13C NMR (100 MHz, CDCI3) δ 147.2, 144.2, 128.6, 128.4, 125.0, 123.7, 122.8, 122.1, 110.0, 72.2, 71.4,
55.9, 55.4, 47.7, 47.3, 46.7, 33.1, 31.6, 30.0, 29.6, 25.6, 24.8, 19.8, 19.3,15.8. 9.5 ppm. Purity; 91% UPLCMS (210 nm); rétention time 0.75 min; (M+1) 329.0.
Example 29
1-azabicyclo[2.2.2]oct-3-yl [2-(biphenyl-3-yl)propan-2-yl]carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromophenyl)propan-2yljcarbamate (600 mg, 1.63 mmol), phenylboronic acid (398 mg, 3.27 mmol) and palladium (II) acetate gave the title compund as a white solid (379 mg, 64%). 1H NMR (400 MHz, CDCI3) δ 7.61 (s, 1 H), 7.56 (d, J= 7.4 Hz, 2H), 7.50-7.38 (m, 4H), 7.34 (m, 2H), 5.16 (s, 1 H), 4.63 (s, 1H), 3.392.09 (m, 6H), 1.72 (s, 6H), 2.02-0.73 (m, 5H) ppm. 13C NMR (100 MHz, CDCIa) δ 154.8,147.8, 141.6, 129.0, 129.0, 128.6, 127.5, 125.8, 125.0, 124.0, 71.6, 71.3, 55.9, 55.5, 47.6, 46.8, 31.5,
30.2, 30.0, 29.5, 25.6, 24.8,19.8 ppm. Purity: 99% UPLCMS (210 nm); rétention time 0.84 min; (M+1) 365.0. Anal. Calcd. for C23H28N2O2-0.29(CHCI3): C, 70.02; H, 7.14; N, 7.01. Found: C, 70.02; H, 7.37; N, 6.84.
120
Example 30
1-azabîcyclo[2.2.2]oct-3-yl {2-[3-(2-methylpropyl)phenyl]propan-2-yl}carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromophenyl)propan-2yljcarbamate (75 mg, 0.20 mmol), 2-methylpropyl boronic acid (28.1 mg, 0.276 mmol) and palladium (II) acetate gave the title compound as a white solid (50 mg, 71%). 1H NMR (400 MHz, CDCI3) δ 7.21 (d, J = 4.9 Hz, 2H), 7.16 (s, 1H), 7.00 (s, 1H), 5.17 (s, 1H), 4.60 (s, 1H), 3.35-2.10 (m, 6H), 2.45 (d, J= 7.1 Hz, 2H), 1.82 (dt, J= 6.8, 13.5 Hz, 1H), 2.03-0.94 (m, 5H), 1.65 (s, 6H), 0.89 (d, J=6.6 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 172.6, 172.1,170.8, 170.2, 160.1, 160.0, 157.8, 157.7, 140.4, 139.8, 130.5, 130.4, 130.0, 129.8, 129.5, 129.3, 127.9, 127.7, 120.8,
120.7,120.3, 113.9, 113.6, 113.2, 113.0, 110.5, 110.4, 66.6, 66.5, 56.8, 56.3, 55.4, 55.4, 54.0, 53.7, 51.1,46.6, 43.8, 43.7, 42.0, 38.4, 37.8, 37.7, 33.8, 33.2, 27.4, 27.0, 25.7, 25.5, 20.9, 20.9 ppm. Purity: 90% UPLCMS (210 nm); rétention time 0.89 min; (M+1) 345.
Example 31
1-azabicyclo[2.2.2]oct-3-yl [2-(5-bromo-2-fluorophenyl)propan-2-yl]carbamate
Using general procedure A, 2-(5-bromo-2-fluorophenyl)propan-2-amine hydrochloride (100 mg, 0.372 mmol) and quinuclidin-3-ol gave the title compound as a white solid (90.3 mg, 98%). 1H NMR (400 MHz, CDCI3) δ 7.45 (dd, J = 2.3, 7.3 Hz, 1H), 7.31 (ddd, J= 2.5, 4.2, 8.6 Hz, 1H), 6.88 (dd, J = 8.6,11.9 Hz, 1 H), 5.38 (s, 1 H), 4.82-4.33 (m, 1 H), 3.28-2.28 (m, 6H), 1.68 (d, J - 9.0 Hz, 6H), 1.98-1.27 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 161.1, 158.6,131.7, 131.6,131.0, 131.0, 118.6. 118.3, 116.8, 55.8, 54.0, 47.6, 46.7, 28.5, 25.6, 24.8, 19.7 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.81 min; (M+1) 386.7. Anal. Calcd. for C17H22BrFN2O2-0.37(CHCI3): C, 52.20; H, 5.66; N, 7.14. Found: C, 52.21; H, 5.57; N, 7.13.
Example 32
1-azabicyclo[2.2.2]oct-3-yl [2-(4'-fluorobiphenyl-3-yl)propan-2-yl]carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromophenyl)propan-2yljcarbamate (600 mg, 1.63 mmol), 4-fluorophenyl boronic acid (457 mg, 3.27 mmol) and palladium (II) acetate gave the title compound as a white solid (373 mg, 60%). 1H NMR (400 MHz,
121
CDCI3) δ 7.56 (s, 1H), 7.52 (dd, 7=5.4, 8.4 Hz, 2H), 7.42-7.38 (m, 3H), 7.12 (m, 2H), 5.18 (s, 1H), 4.62 (s, 1H), 2.66 (m, 6H), 1.72 (s, 6H), 2.01-0.83 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 125.0,124.0, 123.8, 116.0, 116.0, 71.3, 55.9, 55.5, 47.6, 46.7, 29.6, 25.6, 24.8,19.8 ppm. Purity: 98.0% UPLCMS (210 nm); rétention time 0.95 min; (M+1) 382.9. Anal. Calcd. for C23H27FN2O2-0.37(CHCI3): C, 65.86; H, 6.47; N, 6.57. Found: C, 65.85; H, 6.69; N, 6.49.
Example 33
1-azabicyclo[2.2.2]oct-3-yl [2-(4-fluorobiphenyl-3-yl)propan-2-yl]carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(5-bromo-2-fluorophenyl)propan2-yl]carbamate (990 mg, 2.57 mmol), phenylboronic acid (209 mg, 1.71 mmol) and palladium (II) acetate gave the title compound as a white solid (257 mg, 26%). 1H NMR (400 MHz, CDCI3) δ 7.58-7.49 (m, 3H), 7.44-7.38 (m. 3H), 7.35-7.29 (m, 1H), 7.08 (dd, J~ 8.4, 12.1 Hz, 1H), 5.30 (s, 1H), 4.75-4.42 (m, 1H), 2.89 (d, J= 10.2 Hz, 6H), 1.81-1.66 (m, 6H), 2.04-1.18 (m, 5H) ppm.13C NMR (100 MHz, CDCI3) δ 161.7, 159.3, 140.7, 137.3, 137.3, 131.7, 131.7,131.0, 129.0, 127.5,
127.3, 126.7, 117.1, 116.9, 71.4, 55.8, 54.3, 47.6, 46.7, 28.6, 25.6, 24.8, 19.8 ppm. Purity: 92.0% UPLCMS (210 nm); rétention time 0.95 min; (M+1) 382.9. Anal. Calcd. for C23H27FN2O2O.4(CHCI3): C, 65.39; H, 6.43; N, 6.52. Found: C, 65.39; H, 6.51; N, 6.42.
Example 34
1-azabîcyclo[2.2.2]oct-3-yl {2-[2-fluoro-5-(2-methylpropyl)phenyl]propan-2yl}carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(5-bromo-2-fluorophenyl)propan2-yl]carbamate (120 mg, 0.312 mmol), 2-methylpropylboronic acid (79.4 mg, 0.779 mmol) and palladium (II) acetate gave the title as a white solid compound (37 mg, 33%). 1H NMR (400 MHz, CDCI3) δ 7.08 (dd, J = 2.0, 8.2 Hz, 1 H), 6.95 (d, J = 4.9 Hz, 1 H), 6.93-6.85 (m, 1 H), 5.23 (s, 1 H), 4.72-4.52 (m, 1H), 3.20-2.47 (m, 6H), 2.41 (d, J= 7.1 Hz, 2H), 1.89-1.76 (m, 1H), 2.02-1.26 (m, 5H), 1.70 (d, J = 7.6 Hz, 6H), 0.88 (d, J = 6.6 Hz, 6H) ppm. 13C NMR (100 MHz, CDC!3) δ 160.4, 158.0,137.1, 137.1, 129.2, 129.1, 128.1, 116.2, 116.0, 71.2, 55.8, 54.2, 47.6, 46.7, 45.1,30.5,
29.9, 28.6, 27.0, 25.6, 24.8, 22.5,19.8, 19.5 ppm. Purity: 95.0% UPLCMS (210 nm); rétention time 1.02 min; (M+1) 363.
122
Example 35
1-azabicyclo[2.2.2]oct-3-yl [2-(5-cyclopropyl-2-fluorophenyl)propan-2-yl]carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(5-bromo-2-fluorophenyl)propan2-yl]carbamate (750 mg, 0.649 mmol), cyclopropylboronic acid (139 mg, 1.62 mmol) and palladium (II) acetate gave the title compound as a white solid (727 mg, 86%). ’H NMR (400 MHz, CDCI3) δ 7.08 (d, J = 6.4 Hz, 1 H), 6.97-6.78 (m, 2H), 5.19 (s, 1 H), 4.65-4.57 (m, 1 H), 2.66 (s, 6H), 1.85 (tt, J = 5.1, 8.4 Hz, 1H), 2.00-1.17 (m, 5H), 1.71 (d, J= 8.7 Hz, 6H), 0.92 (ddd, J = 4.6, 6.3, 8.4 Hz, 2H), 0.62 (dt, J = 4.7, 6.4 Hz, 2H) ppm. 13C NMR (100 MHz. CDCI3) δ 160.2, 157.8, 139.2, 139.2, 125.6, 125.5, 125.4, 116.5, 116.3, 71.3, 55.8, 54.2, 47.6, 46.7, 29.9, 29.6, 28.6, 25.6, 24.8, 19.6, 15.2, 9.1 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.87 min; (M+1) 347.2. Anal. Calcd. for C20H27FN2O2-0.07(CHCI3): C, 68.00; H, 7.70; N, 7.90. Found: C, 67.99; H, 7.86; N, 7.81.
Example 36
1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan-2-yl]carbamate
Using general procedure A, 2-(3-bromo-4-fluorophenyl)propan-2-amine hydrochloride (1.00 g, 3,72 mmol) and quinuclidin-3-ol gave the title compound as a white solid (434 mg, 30%). 1H NMR (400 MHz, CDCI3) δ 7.57 (s, 1H), 7.38-7.25 (m, 1 H), 7.06 (t, J= 8.5 Hz, 1H), 5.62 (s, 1H), 4.86-4.32 (m, 1H), 3.33-2.12 (m, 6H), 1.73 (t, J= 7.2 Hz, 5H), 1.61 (d, J= 9.6 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 159.1, 156.7, 154.6, 130.4, 125.8, 125.7, 116.4, 116.2, 109.1, 108.9,
71.3, 55.7, 54.7, 47.4, 46.5, 29.9, 29.6, 25.5, 24.6, 22.9, 19.6 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.79 min; (M+1) 387.8. Anal. Calcd. for C17H22BrFN2O2-0.27(CHCI3): C, 49.68; H, 5.38; N, 6.71. Found: C, 49.67; H. 5.39; N, 6.74.
Example 37
1-azabicyclo[2.2.2]oct-3-yl [2-(6-fIuorobiphenyl-3-yl)propan-2-yl]carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (750 mg, 1.95 mmol), phenyl boronic acid (418 mg, 4.87 mmol) and palladium (II) acetate gave the title compound as a white solid (195 mg, 29%). 1H NMR (400 MHz, CDCI3) δ 7.49 (s, 2H), 7.46-7.38 (m, 3H), 7.35 (dd, J~ 4.3,11.7 Hz, 2H), 7.08 (dd, J- 8.6, 10.1 Hz, 1H),
123
5.10 (s, 1H), 4.60 (s, 1H), 3.33-2.10 (m, 6H), 1.67 (d, J = 7.9 Hz, 6H), 1.67 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 159.9, 157.4, 136.2, 129.3, 129.0, 128.7, 127.9,127.6, 125.7, 125.6, 71.0, 66.1, 55.7, 55.1, 47.5, 46.6, 29.9, 29.6, 25.5, 24.5, 19.5, 15.5 ppm. Purity: 98% UPLCMS (210 nm); rétention time 0.95 min; (M+1) 382.9. Anal. Calcd. for C23H27FN2O2-0.29(CHCl3): C, 67.08; H, 6.60; N, 6.72. Found: C. 67.09; H, 6.95; N, 6.37.
Example 38
1-azabicyclo[2.2.2loct-3-yl{2-[4-fluoro-3-(2-methylpropyl)phenyl]propan-2yljcarbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (125 mg, 0.324 mmol), 2-methylpropylboronic acid (66 mg, 0.65 mmol) and palladium (II) acetate gave the title compound as a white solid (27 mg, 23%). 1H NMR (400 MHz, CDCI3) δ 7.23-7.11 (m, 2H), 7.04-6.82 (m, 1 H), 5.11 (s, 1 H), 4.59 (s, 1 H), 3.32-2.12 (m, 6H), 2.48 (d, J = 7.2 Hz, 2H), 1.86 (d, J = 6.7, Hz, 1 H), 2.05-0.96 (m, 5H). 1.62 (d, J = 5.8 Hz, 6H), 0.90 (d, J = 6.6 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 161.4, 159.0, 154.7, 142.5, 128.3, 124.0, 115.1,
114.9, 71.2, 66.1,55.8, 55.0, 47.6, 46.7, 38.7, 29.9, 29.6, 25.6, 24.8, 22.6,19.7, ppm. Purity; 85% UPLCMS (210 nm); rétention time 1.0 min; (M+1) 362.9.
Example 39
1-azabicyclo[2.2.2]oct-3-yl [2-(4',6-difluorobiphenyl-3-yl)propan-2-yl]carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (125 mg, 0.324 mmol), 4-fluoroboronic acid (64 mg, 0.46 mmol) and palladium (II) acetate gave the title compound as a white solid (76 mg, 56%). 1H NMR (400 MHz, CDCI3) δ 7.48 (t, 2H), 7.44-7.29 (m, 2H), 7.21-7.00 (m, 3H), 5.27 (s, 1H), 4.68-4.55 (m, 1H), 3.29-2.10 (m, 6H), 1.67 (d, J = 9.4 Hz, 6H), 2.01-0.69 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 163.9, 161.4,159.8,
157.3, 154.8, 143.5, 132.2, 130.9, 127.9, 127.8, 127.4, 125.9, 125.8, 116.2, 116.0,115.7, 115.5, 71.4, 66.1,55.9, 47.6, 46.7, 30.0, 39.7, 25.6, 24.8,19.8 ppm. Purity: 98% UPLCMS (210 nm); rétention time 0.96 min; (M+1) 400.9.
Example 40
124
1-azabicyclo[2.2.2]oct-3-yl {2-[4-fluoro-3-(pyrimidin-5-yl)phenyl]propan-2yl}carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (150 mg, 0,389 mmol), pyrimidine-5-boronic acid (75.9 mg, 0.613 mmol) and tris(dibenzylideneacetone)dipalladium(0) gave the title compound as a white solid (49 mg, 31%). 1H NMR (400 MHz, CDCI3) 6 9.22 (s, 1H). 8.92 (s, 2H), 7.55-7.41 (m, 2H), 7.19 (dd, J= 8.7, 9.9 Hz, 1H), 5.37 (s, 1H), 4.72-4.49 (m, 1H), 3.34-2.04 (m, 6H), 2.04-0.98 (m, 5H), 1.66 (t, J= 10.9 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 159.9, 157.9, 157.4, 156.6, 154.7, 130.2, 127.85, 127.77, 126.9,122.0, 121.8, 116.7, 116.5, 116.2, 71.6, 55.9, 54.9, 47.6, 46.7, 30.3,29.6,25.6, 24.8, 19.8 ppm. Purity: 93% UPLCMS (210 nm); rétention time 0.63 min; (M+1) 384.9
Example 41
1-azabicyclo[2.2.2]oct-3-yl {2-[4-fluoro-3-(pyridin-3-yl)phenyl]propan-2-yl}carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (110 mg, 0.286 mmol), pyridine-3-boronic acid (53 mg, 0.43 mmol) and tris(dibenzylideneacetone)dipalladium(0) gave the title compound as a white solid (42 mg, 39%). 1H NMR (400 MHz, CDCI3) δ 8.78 (s, 1H), 8.62 (d, J= 3.5 Hz, 1H), 7.86 (s, 1H), 7.46 (d, J= 7.2 Hz, 2H), 7.38 (dd, J = 4.9, 7.9 Hz, 1 H), 7.15 (dd, J = 8.7, 9.9 Hz, 1 H), 5.32 (s, 1 H), 4.69-4.57 (m, 1 H), 2.68 (s, 6H), 1.70 (d, J= 11.3 Hz, 6H), 2.08-0.94 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 160.0, 157.5, 149.9, 149.0, 136.6, 132.1, 127.3, 126.8, 126.7, 125.5, 125.3,123.5, 116.4,116.2, 71.5,
55.9, 55.0, 47.6, 46.7, 30.1,29.66, 25.6, 24.8, 19.7 ppm. Purity: 100% UPLCMS (210 nm); rétention time 0.54 min; (M+1) 367.8.
Example 42
1-azabicyclo[2.2.2]oct-3-yl {2-[4-fluoro-3-(furan-3-yl)phenyllpropan-2-yl}carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (110 mg, 0.296 mmol), furan-3-boronic acid (47.9 mg, 0.428 mmol) and tris(dibenzylideneacetone)dipalladium(0) gave the title compound as a white solid (47 mg, 44%). 1H NMR (400 MHz, CDCI3) δ 7.88 (ddd, J= 0.9, 1.5, 2.5 Hz, 1H), 7.53 (dd, J= 2.5, 7.1 Hz, 1H),
125
7.50 (t, J = 1.7 Hz, 1H), 7.31-7.23 (m, 1 H), 7.08 (dd, J = 8.6, 10.6 Hz, 1H),6.76 (dt, J= 0.8, 1.7 Hz, 1 H). 5.22 (s, 1 H), 4.62 (s, 1 H), 3.40-2.11 (m, 6H), 2.02-0.87 (m, 5H), 1.59 (dd, J = 11.6, 70.3 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 160.0, 157.5, 150.2, 143.9, 127.44, 127.36, 127.0, 126.1,
123.8, 116.6, 116.4, 71.5, 55.9, 55.0, 47.6, 46.7, 30.1,29.9, 25.6, 24.8, 19.8 ppm. Purity; 96% UPLCMS (210 nm); rétention time 0.85 min; (M+1) 372.9.
Example 43
1-azabicyclo[2.2.2]oct-3-yl {2-[4-fluoro-3-(pyridin-4-yl)phenyl]propan-2-yl}carbamate
Using general procedure E, 1-azabicyclo[2.2.2]oct-3-yl [2-(3-bromo-4-fluorophenyl)propan2-yl]carbamate (130 mg, 0.291 mmol), pyridine-4-boronic acid (54 mg, 0.43 mmol) and tris(dibenzylideneacetone)dipalladium(0) gave the titie compound as a white solid (46 mg, 41%). 1H NMR (400 MHz, CDCI3) δ 8.68 (dd, J = 1.6, 4.5 Hz, 2H), 7.61-7.39 (m, 4H), 7.15 (dd, J = 8.6, 10.2 Hz, 1 H), 5.31 (s, 1 H), 4.69-4.57 (m, 1 H), 3.40-2.07 (m, 6H), 1.69 (d, J = 10.8 Hz, 6H), 2.060.74 (m, 5H) ppm. 13CNMR(100 MHz, CDCl3) δ 160.0, 157.6, 143.3, 141.6, 141.5, 126.7, 126.6,
124.9, 124.8, 120.1, 119.9, 116.1, 115.9, 115.4, 115.1, 109.2, 71.4, 55.9, 55.0, 47.6, 46.7, 29.9, 25.6, 24.8, 19.8 ppm. Purity; 97% UPLCMS (210 nm); rétention time 0.82 min; (M+1) 384.6,
Example 44
1-(1-azabicyclo[2.2.2]oct-3-yl)-3-(2-phenylpropan-2-yl)urea
Using general procedure C, quinuclidin-3-amine (102 mg, 0.6 mmol), CDI (131 mg, 0.789 mmol) and cumylamine (95 mg, 0.70 mmol) gave the title compound as a white solid (21 mg, 10%). 1H NMR (400 MHz, CDCI3) δ 7.61-7.47 (m. 2H), 7.44-7.37 (m, 2H), 7.34-7.28 (m, 1H), 4.86 (s, 1H), 4.20 (d, J= 7.3 Hz, 1H), 3.71-3.60 (m, 1H), 3.14 (ddd, J = 2.3, 9.4,14.2 Hz, 1H), 2.79-1.89 (m, 6H), 1.64 (d, J= 3.3 Hz, 6H), 1.58-1.10 (m, 5H) ppm. 13C NMR (100 MHz, CDCI3) δ 157.4, 146.2, 129.3, 127.8,125.8, 57.1, 54.9, 47.7, 47.1,46.7, 30.6, 30.5, 26.0, 20.3 ppm. Purity: 79% UPLCMS (210 nm); rétention time 0.61 min; (M+1) 288.2.
Préparation O
Example 45
126
3-cyano-1-azabîcyclo[2.2.2]oct-3-yl {2-[3-{prop-1-en-2-yl)phenyl]propan-2yl}carbamate
To a solution of 3-hydroxyquinuclidine-3-carbonitrile (38 mg, 0.25 mmol) in acetonitrile/dioxane (3 mL) at room température was added triethylamine (7.0 uL, 0.05 mmol). The reaction mixture was stirred for 15 min and 1-(2-isocyanatopropan-2-yl)-3-(prop-1-en-2-yl)benzene (49.0 uL, 0.248 mmol) was added dropwise. The reaction was stirred for a period of 18 h at 65 °C and concentrated. The crude material was purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding carbamate as a clear oil (57 mg, 65%). 1H NMR (400 MHz, CDCI3) δ 7.42-7.20 (s, 5H), 6.61 (s, 1H), 5.11 (s, 1H), 3.29 (d, J= 12.0 Hz, 1H), 3.09 (d, J = 12.0 Hz, 1H), 2.93 (d, J= 4.0 Hz, 2H), 2.79-2,68 (m, 2H), 2.13 (s, 6H) 2.05-2.00 (m, 2H),1.91 (s, 3H), 1.87 (s, 2H),1.50-1.37 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 135.4, 128.7, 125.2, 124.5, 124.0, 122.0, 112.9, 61.2, 47.0, 46.2, 32.4, 31.8, 29.9, 29.4, 29.2, 26.6, 25.7, 23.7, 22.8, 22.2, 19.2 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.81 min; (M+1) 354.
Préparation P
Example 46
N-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)-1,4-diazabicyclo[3.2.2]nonane-4carboxamide
To a solution of 1,4-diazabicyclo[3.2.2]nonane (350 mg, 2.77 mmol) and 1-(2isocyanatopropan-2-yl)-3-(prop-1-en-2-yl)benzene (1.09 mL, 5.55 mmol) in chloroform (2 mL) was added 3-4 pièces of molecular sieves. The reaction mixture was stirred at room température for 18 h and then concentrated. The crude material was purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding urea as an off-white solid (650 mg, 36%). 1H NMR (400 MHz, CDCI3) δ 7.48 (s, 1H), 7.31-7.26 (m, 3H), 5.34(s, 1 H), 5.07 (s, 1H), 4.73 (brs, 1H), 4.03 (BR s, 1H), 3.64 (m, 2H), 3.14-3.03 (m, 6H), 2.15 (s, 3H) 2.06 (m, 2H), 1.72 (m, 8H) ppm. 13C NMR (100 MHz, CDCI3) δ 155.7, 148.3, 143.8, 141.3, 128.5, 124.1, 123.9, 122.0, 112.5, 57.8, 55.8, 48.1,46.4 (2x), 41.2, 30.2 (2x), 27.3 (2x), 22.1 ppm. Purity; >98% UPLCMS (210 nm); rétention time 0.71 min; (M+1) 328
Example 47
127 biphenyl-2-yl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate
Biphenyl-2-yl carbonochloridate (83.0 mg, 0.358 mmol) was treated with 1,4diazabicyclo[3.2.2] nonane (113 mg, 0.896 mmol) using the same procedure reported in example 46 to afford the title compound as an off-white solid (17 mg, 15%). Purity: >99% UPLCMS (210 nm); rétention time 0.75 min; (M+1 ) 323.
Example 48
N-{2-[3-(propan-2-yl)phenyl]propan-2-yl)-1,4-diazabîcyclo[3.2.2]nonane-4carboxamide
Using general procedure F, N-(2-(3-(prop-1-en-2-yl)phenyl)propan-2-yl)-1,4diazabicyclo[3.2.2]nonane-4-carboxamide (100 mg, 0.305 mmol) and palladium, (20 mg, 20 wt.% on carbon) gave the title compound as an off-white solid (60 mg, 57%). 1H NMR (400 MHz, CDCI3) Ô 7.28-7.21 (m, 3H), 7.11 (d, J = 8.0 Hz, 1 H), 4.71 (s, 1 H), 4.02 (s, 1H), 3.66 (t, J =8.0 Hz, 2H) 3.15 (m, 7H), 2.06 (br s, 2H), 1.77 (s, 7H) 1.26 (d, J = 4.0 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 155,8, 148.9, 148.5, 128.5.1, 124.7, 123.1, 122.4, 57.8, 56.0, 48.1,46.4, 41.2, 34.5, 32.2, 30.4, 30.0, 29.9, 27.3, 24.3, 22.9 ppm. Purity: >91% UPLCMS (210 nm); rétention time 0.74 min; (M+1) 330.
Préparation Q
Example 49 (+/-)-(3S,4S)-1-azabicyclo[2.2.1]heptan-3-yl-2-(3-(prop-1-en-2-yl)phenyl)propan-2ylcarbamate
To a solution of (+/-)-(3S,4S)-1-azabicyclo[2.2.1]heptan-3-ol (294 mg, 2.6 mmol) in THF (5 mL) at room température was added NaH [60%, oil] (107 mg, 2.67 mmol). The reaction mixture was stirred for 15 min and 1-(2-isocyanatopropan-2-yl)-3-(prop-1-en-2-yl)benzene (344 uL, 1.73 mmol) was added dropwise. The reaction was stirred for a period of 30 min and quenched with brine. The solution was extracted with EtOAc and the organic layer was dried over Na2SO4 and concentrated. The crude material was purified on a combiflash (SiO2 cartridge, CHCI3 and 2N NH3 in MeOH) to afford the corresponding carbamate as a clear oil (140 mg, 26%). 1H NMR (400 MHz,
128
CDCI3) δ 7.26-7.20 (m, 3H), 7.11 (m, 1H), 5.18 (s, 1H), 5.19 (br s, 1H), 5.01 (s, 1H), 4.81 (brs, 1H), 2.99 (br s, 1H), 2.82(br s, 1H), 2.70 (br s, 1H), 2.53 (br s, 2H), 2.33 (br s, 1H), 2.02 (s, 3H), 1.76 (br s, 1 H) 1.61 (br s, 6H), 1.52 (br s, 1 H), 1.37 (br s, 1 H) ppm. 13C NMR ( 100 MHz, CDCI3) δ
147.1, 143.7, 141.5, 128.5, 124.1, 122.1, 112.7, 75.6, 60.6, 59.4, 55.4, 54.3, 53.9, 41.5, 29.9, 29.8, 29.4, 22.2, 21.6 ppm. Purity: >98% UPLCMS (210 nm); rétention time 0.83 min; (M+1) 315
Example 50 (+/-)-(3S,4S)-1 -azabîcyclo[2.2.1]hept-3-yl{2-[3-(propan-2-yl)phenyl]propan-2yl}carbamate
Using general procedure F, (+/-)-(3S,4S)-1-azabicyclo[2.2.1]heptan-3-yl 2-(3-(prop-1-en-2yl)phenyl)propan-2-ylcarbamate (110 mg, 0.350 mmol) and palladium (20 mg, 20 wt.% on carbon) gave the title compound as an off-white solid (36 mg, 46%). 1H NMR (400 MHz, CDCI3) δ 7.257.19 (m, 3H), 7.11 (d, J = 8.0 Hz, 1H),5.19(s, 1H), 4.91 (s, 1H), 3.44 (t, J = 4.0 Hz, 2H) 3.19 (brs, 1 H), 3.02 (br s, 1 H), 2.89 (m, 2H), 2.69 (br s, 1 H), 2.39 (br s, 1 H), 1.91 (br s, 1 H), 1.66 (br s, 7H) 1.26 (d, J = 4.0 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 128.5 (2x), 124.8,123.1 (2x), 122.4(2x), 77.4, 60.6, 59.4, 55.5, 41.5, 34.5, 29.9, 29.9, 29.5, 24.3 (2x), 21.6 ppm. Purity: >95% UPLCMS (210 nm); rétention time 0.88 min; (M+1) 317.
Example 51
N-[2-(3-bromo-4-fluorophenyl)propan-2-ylJ-1,4-diazabicyclo[3.2.2]nonane-4carboxamide
Using general procedure A, 2-(3-bromo-4-fluorophenyl)propan-2-amine hydrochloride (1.00 g, 3.72 mmol) and 1,4-diazabicyclo[3.2.2]nonane gave the title compound as a white solid (265 mg, 18%). 1H NMR (400 MHz, CDCI3) δ 7.54-7.52 (m, 1H), 7.31-7.25 (m, 1H), 7.04 (t, J = 8.0 Hz, 1 H), 4.71 (s, 1 H), 3.99 (br s, 1 H), 3.59 (t, J = 8.0 Hz, 2H), 3.13-2.95 (m, 6H), 2.04-1.97 (m, 2H) 1.77-1.67 (m, 2H), 1.65 (s, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 158.9,156.4, 155.4, 145.9,
130.2, 125.6, 116.2, 57.8, 54.9, 48.3, 46.6, 46.6, 41.6, 30.5, 30.5, 27.6, 27.6 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.73 min; (M+1) 384.
Example 52
129
N-[2-(6-fluorobiphenyl-3-yl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
Using general procedure E, N-[2-(3-bromo-4-fluorophenyl)propan-2-yl]-1,4diazabicyclo[3.2.2]nonane-4-carboxamide (100 mg, 0.261 mmol), phenylboronic acid (79 mg, 0.65 mmol) and palladium (II) acetate gave the title compound as an off-white solid (66 mg, 66%). 1H NMR (400 MHz, CDCI3) δ 7.54 (m, 2H), 7.44-7.40 (m, 5H), 7.08(m, 1H), 4.78(brs, 1H), 4.00 (brs, 1H), 3.60 (m, 2H), 3.11-2.92 (m, 6H). 2.00 (m, 2H) 1.67(m, 7H), 1.26 (s, 1H) ppm. 13C NMR (100 MHz, CDCI3) δ 159.6, 155.6, 144.6, 136.5, 129.3, 128.6, 128.5, 127.8, 127.5, 125.7, 125.6, 116.1,
115.9, 57.9, 55.3, 48.2, 46.4, 46.4, 41.6, 30.6, 30.5, 29.9, 27.6 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.88 min; (M+1 ) 382.
Example 53
N-[2-(4',6-difluorobiphenyl-3-yl)propan-2-yl]-1,4-diazabîcyclo[3.2.2]nonane-4carboxamide
Using general procedure E, N-[2-(3-bromo-4-fluorophenyl)propan-2-yl]-1,4diazabicyclo[3.2.2]nonane-4-carboxamide (100 mg, 0.261 mmol), 4-fluorophenyl boronîc acid (91 mg, 0.65 mmol) and palladium (II) acetate gave the title compound as an off-white solid (64 mg, 62%). 1H NMR (400 MHz, CDCI3) δ 7.48 (m, 2H), 7.37-7.30 (m, 2H), 7.10-7.03 (m, 3H), 4.77 (s, 1 H), 3.99 (brs, 1H), 3.58 (m, 2H), 3.10-2.90 (m, 6H), 1.98 (m, 2H) 1.71 (m, 8H) ppm. 13C NMR (100 MHz, CDCI3) δ 163.7, 161.3, 159.5, 157.1, 155.6, 144.6, 131.0, 130.9, 127.4, 127.2, 125.7, 116.1,115.6, 57.9, 55.2, 48.2, 46.4, 46.4, 41.5, 30.6, 30.6, 27.6, 27.6 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.90 min; (M+1) 400.
Example 54
N-[2-(naphthalen-1-yl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
Using general procedure A, 2-(naphthalen-1-yl)propan-2-amine hydrochloride (227 mg, 1.23 mmol) and 1,4-diazabicyclo[3.2.2]nonane gave the title compound as a white solid (206 mg, 50%). 1H NMR (400 MHz, CDCI3) δ 8.63-8.60 (m, 1H), 7.90-7.87 (m, 1H), 7.78 (d. J= 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz. 1 H), ), 7.47-7.42 (m, 3H), 4.86 (s, 1 H), 3.94 (br s, 1 H), 3.61 (m, 2H), 3.11-2.88 (m,
130
7H), 2.01-1.91 (m, 7H), 1.68-1.62 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 176.2, 155.5, 142.6,
135.3, 130.6, 129.9, 128.8, 126.3, 125.4, 125.2, 123.9, 57.3, 57.1,47.7, 45.8, 45.8, 40.7, 29.4,
29.4, 26.9, 26.9 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.72 min; (M+1) 338.
Example 55
N-(2-(5-bromo-2-fluorophenyl)propan-2-yl)-1,4-diazabicyclo[3.2.2]nonane-4carboxamide
Using general procedure A, 2-(5-bromo-2-fluorophenyl)propan-2-amine hydrochloride (100 mg, 0.372 mmol) and 1,4-diazabicyclo[3.2.2]nonane gave the title compound as a white solid (70 mg, 49%). 1H NMR (400 MHz, CDCI3) δ 7.48 (m, 1H), 7.28 (m, 1H), 6.86 (m, 1H), 4.85 (s, 1H), 3.98 (br s, 1H), 3.56 (m, 2H), 3.14-2.91 (m, 7H), 1.99 (m, 2H) 1.71 (m, 7H) ppm. 13C NMR (100 MHz, CDCI3)ô 161.1, 158.6,155.7, 131.3, 113.1, 118.3, 118.0 57.8, 54.0, 48.1, 46.4, 46.4, 41.5,
29.1, 29.1, 27.5, 27.5 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.73 min; (M+1) 384.
Example 56
N-[2-(4-fluorobiphenyi-3-yl)propan-2-yl]-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
Using general procedure E, N-(2-(5-bromo-2-fluorophenyl)propan-2-yl)-1,4diazabicyclo[3.2.2]nonane-4-carboxamide (100 mg, 0.261 mmol), phenyl boronic acid (30 mg, 0.25 mmol) and palladium (II) acetate gave the title compound as an off-white solid (27 mg, 39%). 1H NMR (400 MHz, CDCI3) δ 7.56-7.51 (m, 3H), 7.41-7.37 (m, 3H), 7.32-7.30 (m, 1H), 7.03 (m, 1H), 4.90 (s, 1H), 4.00 (br s, 1H), 3.59 (m, 2H), 3.11-2.92 (m, 6H), 2.04-1.98 (m. 2H) 1.78 (s, 6H), 1.731.67 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 161.8, 159.4, 155.9, 140.9, 137.2, 134.6, 128.9,
127.4, 127.3, 127.2, 127.1, 127.0, 116.9, 57.9, 54.4, 48.1,46.5, 46.5, 41.4, 29.9, 29.3, 27.5, 27.5 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.90 min; (M+1) 400.
Example 57
N-(2-(3-isopropoxyphenyl)propan-2-yl)1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
131
Using general procedure A, 2-(3-isopropoxyphenyl)propan-2-amine hydrochloride (60 mg, 0.31 mmol) and 1,4-diazabicyclo[3.2.2]nonane gave the title compound as a white solid (70 mg, 57%). 1H NMR (400 MHz, CDCI3) δ 7.17 (t, J = 8.0 Hz, 1H), 6,92-6.87 (m, 2H), 6.69 (d, J = 8.0 Hz, 1 H) 4.66 (br s, 1 H), 4.48 (m, 1 H), 3.94 (br s, 1 H) 3.56 (m, 2H), 3.08-2.90 (m, 5H), 1.96 (m, 2H) 1.69-1.60 (m, 7H), 1.27 (d, J = 8.0 Hz, 6H), 1.17 (br s. 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 158.0, 155.7, 150.3, 129.4, 117.1, 113.4, 113.1,77.5, 69.8, 55.7, 48.2, 46.4, 46.4, 46.3, 41.5, 30.3, 30.0, 29.9, 27.6, 22.3 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.75 min; (M+1) 346.
Example 58
N-(biphenyl-3-yl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
Using general procedure A, biphenyl-3-amine (100 mg, 0.592 mmol) and 1,4diazabicyclo[3.2.2]nonane gave the title compound as an off white solid (93 mg, 49%). 1H NMR (400 MHz, CDCI3) δ 7.60 (m, 1H), 7.56-53 (m. 2H). 7.39-7.21 (m, 6H), 6.67 (br s, 1H), 4.85 (s, 1H), 4.16 (br s, 1H), 3.66- 3.61 (m, 2H), 3.07-2.86 (m, 6H), 1.97 (m, 2H) 1.68 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 154.7, 142.0, 141.1, 139.9, 129.3,128.8. 128.8, 127.5, 127.3, 127.3, 122.0,
119.4, 119.2, 57.5, 48.4, 46.3, 46.3, 42.1, 27.5, 27.5 ppm. Purity: >96% UPLCMS (210 nm); rétention time 0.75 min; (M+1) 333.
Example 59
N-(2-[2-fluoro-5-(2-methylpropyl)phenyl]propan-2-yl}-1,4-diazabicyclo[3.2.2]nonane-4carboxamide
Using general procedure E, N-(2-(5-bromo-2-fluorophenyl)propan-2-yl)-1,4-diazabicyclo [3.2.2]nonane-4-carboxamide (100mg, 0.261 mmol), with isopropyl boronicacid (66 mg, 0.65 mmol) and palladium (II) acetate gave the title compound as an off-white solid (27 mg, 39%). 1H NMR (400 MHz, CDCI3) δ 7.08 (d, J= 8.0 Hz, 1H), 6.93-6.81 (m, 2H), 4.85 (s, 1H), 3.96 (br s, 1 H), 3.65 (q, J = 8.0 Hz, 1H), 3.55 (t, J = 8.0 Hz, 2H), 3.09-2.90 (m, 5H), 2.40 (d, J = 4.0 Hz, 1H), 2.01-1.92 (m, 2H) 1.81-1.61 (m, 8H), 1.22-1.17 (m, 2H), 0.87 (d, J = 8.0 Hz, 6H) ppm. 13C NMR (100 MHz, CDCI3) δ 160.5, 158.0, 155.9, 137.0, 133.6, 128.8, 116.0, 57.9, 54.3, 48.1, 46.4 (2x),
45.2, 41.4, 30.5, 29.9, 29.2, 29.2, 27.5, 22.6, 22.6 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.94 min; (M+1) 362.
132
Example 60
N-(biphenyl-2-yl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
Using general procedure A, 1-isocyanatobiphenyl (50 mg, 0.26 mmol) and 1,4diazabicyclo[3.2.2]nonane gave the title compound as a white solid (55mg mg, 65%). 1H NMR (400 MHz, CDCI3) δ 8.15 (d, J = 8.0 Hz, 1H), 7.45-7.31 (m, 6H), 7.16 (d, J= 8.0 Hz, 1H), 7.04 (t, J= 8.0 Hz, 1H), 6.47 (brs, 1H), 3.63 (br s, 1H), 3.57 (t, J = 8.0 Hz, 2H), 3.00-2.80 (m, 6H), 1.68 (m, 2H) 1.43 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 154.2,138.9, 136.6, 131.7, 129.7, 129.5, 129.5,
129.3, 129.3, 128.7, 128.1, 122.6, 120.5, 57.6, 48.5, 46.2, 46.2, 41.6, 29.9, 27.3 ppm. Purity; >99%
UPLCMS (210 nm); rétention time 0.64 min; (M+1) 322.
Example 61
N-(naphthalen-1-yl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide
Using general procedure A, 1-isocyanatonaphthalene (208 mg, 1.23 mmol) and 1,4diazabicyclo[3.2.2]nonane gave the title compound as a white solid (150 mg, 48%). 4H NMR (400 MHz, CDCI3) δ 7.80-7.72 (m, 2H), 7.64 (d, J= 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.44-7.35 (m, 3H), 6.65 (br s, 1H), 4.18 (br s, 1H), 3.64 (t, J = 8.0 Hz, 2H), 3.09-2.91 (m, 6H), 2.08-1.93 (m, 2H) 20 1.74-1.66 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 155.3, 134.4,134.3, 128.9, 128.2, 126.2,
126.1,126.0, 125.1, 121.2, 121.0, 57.6, 48.7, 46.4, 46.4, 42.2, 27.6, 27.6 ppm. Purity: >99% UPLCMS (210 nm); rétention time 0.53 min; (M+1) 296.
Example 62 (S)-quinuclidin-3-yl 2-(biphenyl-4-yl)propan-2-yicarbamate
Using general procedure B, bromobenzonitrile (2.00 g, 11.0 mmol) was converted to the corresponding 2-(4-bromophenyl)propan-2-amine (1.20 g, 51%) as a brown oil.
Using general procedure A, 2-(4-bromophenyl)propan-2-amine (1.0 g, 4.7 mmol) and (S)30 quinuclidin-3-ol gave (S)-quinuclidin-3-yl 2-(4-bromophenyl)propan-2-ylcarbamate (1.0 g, 58%) as a brown oil.
133
Using general procedure E, the above bromide (200 mg, 0.540 mmol), phenylboronic acid (133 mg, 1.10 mmol) and [PdCI2(pddf)]CH2CI2 gave the titie compound as a white solid (70 mg, 35%). 1H NMR (500 MHz, CDCI3) δ 7.60-7.53 (m, 4H), 7.47 (d, J = 8.5 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (t, J=7.5 Hz, 1H), 5.26 (brs, 1H), 4.64 (m, 1H), 3.33-3.15 (m, 1H), 3.10-2.45 (m, 5H), 2.40-1.80 (m, 2H), 1.78-1.58 (m, 7H), 1.55-1.33 (m, 2H) ppm. 13C NMR (125 MHz, CDCI3) δ 154.5, 146.1, 140.8, 139.5, 128.7, 127.2, 127.1, 127.1, 125.2, 70.9, 55.5, 55.1, 47.4, 46.4, 31.1,29.5,
25.3, 24.5,19.5 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.56 min; (M+1) 365.
Example 63 quinuclidin-3-yl 2-(4-(pyrimidin-5-yl)phenyl)propan-2-ylcarbamate
Using general procedure E, quinuclidin-3-yl 2-(4-bromophenyl)propan-2-ylcarbamate (200 mg, 0.540 mmol), pyrimidin-5-ylboronic acid (136 mg, 1.12 mmol) and [PdCI2(pddf)]CH2CI2 gave the titie compound as a white solid (80 mg, 40%). 1H NMR (500 MHz, CDCI3) δ 9.17 (s, 1H), 8.92 (s, 2H), 7.58-7.51 (m, 4H), 5.34 (s, 1H), 4.61 (m, 1H), 3.20-3.10 (m, 1H), 2.92-2.41 (m, 5H), 2.00-1.76 (m, 2H), 1.72-1.53 (m, 7H), 1.52-1.32 (m, 2H) ppm. 13C NMR (125 MHz, CDCI3) δ 157.4,154.8,
154.5, 148.2, 134.0, 132.5, 127.0, 126.0, 71.2, 55.6, 55.0, 47.4, 46.3, 29.7, 29.4, 25.4, 24.5, 19.5 ppm. Purity: > 96 % LCMS (214 nm & 254 nm); rétention time 1.34 min; (M+1) 366.
Example 64 quinuclidin-3-yl 1-(biphenyl-4-yl)cyclopropylcarbamate
Using general procedure G, bromobenzonitrile (3.00 g, 16.5 mmol) was converted to the corresponding 1-(4-bromophenyl)cyclopropanamine (1.80 g, 51 %) as a yellow solid.
Using general procedure A, 1-(4-bromophenyl)cyclopropanamine (1.0 g, 4.7 mmol) and quinuclidin-3-ol gave quinuclidin-3-yl 1-(4-bromophenyl)cyclopropyl-carbamate (1.3 g, 75 %) as a white semî-solid.
Using general procedure E, the above carbamate (400 mg, 1.12 mmol), phenylboronic acid (267 mg, 2.22 mmol) and [PdCI2(pddf)]CH2CI2 the titie compound as a viscous oil (100 mg, 25%). 1H NMR (500 MHz, CDCI3) δ 7.47 (d, J = 7.5 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 7.33 (t, J = 7.5 Hz, 2H), 7.26-7.15 (m, 3H), 5.93 (brs, 0.6H), 5.89 (brs, 0.4H), 4.67 (m, 1H), 3.20-3.06 (m, 1H), 2.882.42 (m, 5H), 1.98-1.08 (m, 9H) ppm. 13CNMR(125 MHz, CDCI3) δ 155.0, 141.0, 139.7, 138.2,
134
127.7, 126.1, 126.0, 124.8, 124.1,70.0, 54.5, 46.3, 45.4, 34.1, 24.3, 23.2, 18.3, 17.0 ppm. Purity: 100 % LCMC (214 nm & 254 nm); rétention time 1.52 min; (M+1) 363.
Préparation R
Example 65 quinuclidin-3-yl 1-(4-(pyridin-2-yl)phenyl)cyclopropylcarbamate
To a solution of quinuclidin-3-yl 1-(4-bromophenyl)cyclopropylcarbamate (870 mg, 2.43 mmol) in 30 mL 1,4-dioxane, was added bis(pinacolato)diboron (1.81 g, 7.22 mmol), CH3COOK (2.10 g, 21.4 mmol), and [PdCI2(pddf)]CH2Ci2 (97 mg, 0.12 mmol). The mixture was stirred at 80 °C for 18 h. The solvent was evaporated and the residue was extracted with EtOAc. The extracts were concentrated and purified by silica gel column chromatography (eluting with EtOAc/m éthanol from 20/1 to 10/1, containing 1% of TEA) to give quînuclidin-3-yl 1-(4-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)phenyl)cyclopropylcarbamate (260 mg, 33%) as a brown semi-solid.
Using general procedure E, the above boronate (260 mg, 0.632 mmol), 2-bromopyridine (149 mg, 0.941 mmol) and Pd2(dba)3 (32.0 mg, 0.036 mmol) gave the title as a white semi-solid compound (70 mg, 31%). 1H NMR (500 MHz, CDCI3) δ 8.58 (d, J = 4.5 Hz, 1H), 7.82 (d, J = 7.0 Hz, 2H), 7.66-7.57 (m, 2H), 7.23-7.15 (m, 2H), 7.11 (t, J= 5.0 Hz, 1H), 6.16 (brs, 0.6H), 5.97 (br s, 0.4H), 4.63 (m, 1H), 3.17-3.02 (m, 1H), 2.90-2.38 (m, 5H), 1.90-1.10 (m, 9H) ppm. 13C NMR (125 MHz, CDCI3) δ 156.1, 155.2, 148.6, 143.0, 136.3, 135.7, 125.9, 124.5, 120.9, 119.4, 70.3, 54.6,
46.3, 45.4, 34.1, 24.4, 23.5,18.5,17.3 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.18 (M+H) 364.
Example 66 quinuclidin-3-yl 1-(4-(pyrimidin-5-yl)phenyl)cyclopropylcarbamate
Using general procedure E, the above quinuclidin-3-yl 1-(4-bromophenyl)cyclopropylcarbamate (400 mg, 1.10 mmol), pyrimidin-5-ylboronic acid (204 mg, 1.64 mmol) and [PdCI2(pddf)]CH2CI2 gave the title compound as a viscous oil (110 mg, 28 %). 1H NMR (500 MHz, CDCI3) δ (s, 1H), □ □□□□(s, 2H), 7.44 (d, J= 8.5 Hz, 2H), 7.33-7.25 (m, 2H), 6.02 (br s, 0.7H), 6.02 (brs, 0.3H), 4.65 (m, 1H), 3.20-3.05 (m, 1H), 2.86-2.40 (m, 5H), 1.98-1.12 (m, 9H) ppm. 13C
135
NMR (125 MHz, CDCI3) δ 156.3, 155.1, 153.7, 143.3, 132.9, 131.1,126.0, 125.3, 70.5, 54.7, 46.4,
45.4, 34.1, 24.4, 23.5, 18.5, 17.5 ppm. Purity: 100 % LCMS (214 nm &254 nm); rétention time 1.29 min; (M+1) 365.
Example 67 (S)-quinuclidîn-3-yl 1-(4'-fluorobiphenyl-4-yl)cyclopropylcarbamate
Using general procedure E, (S)-quinuclidin-3-yl 1-(4-bromophenyl)cyclopropyl carbamate, 4-F-phenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (45%). 1H NMR (500 MHz, DMSO-d6) δ 8.06-7.83 (d, 1H), 7.69-7.66 (m, 2H), 7.59-7.55 (m, 2H), 7.29-7.22 (m, 4H), 4.56-4.54 (m, 1H), 3.13-2.32 (m, 6H), 1.91-1.19 (m, 9H) ppm. 13C NMR (125 MHz, DMSOd6) δ 163.2, 161.2, 156.4, 143.7,136.9, 128.9, 128.8, 126.8, 125.6, 116.2, 116.0, 70.7, 55.8, 47.4,
46.4, 34.8, 25.7, 24.6, 19.6, 18.7, 18.6 ppm. Purity: > 97 % LCMS (214 nm & 254 nm); rétention time 1.96 min; (M+1) 381.2.
Example 68
1-azablcyclo [3.2.2] nonan-4-yl 1-(4’-fluorobiphenyl-4-yl) cyclopropylcarbamate
Using general procedure E, 1-azabicyclo[3.2.2]nonan-4-yl 1-(4-bromophenyl)-cyclopropyl carbamate, 4-F-phenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (27%). 1H NMR (500 MHz, CDCI3) δ 7.52-7.48 (m, 4H), 7.33-7.28 (m, 2H), 7.14-7.11 (t, J = 8.5 Hz, 2H), 5.47-5.33 (d, 1H), 4.93-4.89 (m, 1H), 3.15-2.75 (m, 6H), 2.10-0.88 (m, 11 H) ppm. 13C NMR (125 MHz, CDCI3) δ 163.4, 161.4, 155.7, 142.1, 138.3, 136.9, 128.5, 128.5, 127.0, 125.9, 125.4,115.7, 115.5, 78.8, 51.7, 48.3, 44.9, 35.2,33.7, 30.6, 29.7, 24.8, 22.2, 18.1 ppm. Purity: > 99 % LCMS (214 nm & 254 nm); rétention time 1.56 min; (M+1) 395.2.
Example 69 (S)-quinuclidin-3-yl 1-(4-(5-fluoropyridin-2-yl)phenyl)cyclopropylcarbamate
Using general procedure E, (S)-quinuclidin-3-yl (1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropyl)carbamate, 2-bromo-5-fluoropyridine and [PdCI2(pddf)]CH2CI2 gave
136 the title compound as a white solid (34%). 1H NMR (500 MHz, CDCI3) δ 8.51-8.52 (d, J = 3.5 Hz, 1H), 7.87-7.85 (d, J= 10.5 Hz, 2H), 7.69-7.67 (m, 1H), 7.47-7.42 (m, 1H), 7.32-7.27 (m, 2H), 5.795.66 (d, 1H), 4.73-4.71 (t, J= 5.0 Hz ,1H), 3.22-3.19 (m, 1H), 2.87-2.61 (m, 5H), 2.01-1.22 (m, 9H) ppm. 13C NMR (125 MHz, CDCI3) δ 160.8, 157.4,156.1, 153.5, 144.4, 137.8, 136.3, 126.7, 125.7,
124.9, 123.6, 121.1, 71.6, 55.7, 47.4, 46.5, 35.3, 29.7, 25.4, 24.8, 19.4 ,18.2 ppm. Purity: > 99 % LCMS (214 nm & 254 nm); rétention time 1.41 min; (M+1) 382.2.
Préparation S
Example 70 (S)-1-(1-(4'-fluorobiphenyl-4-yl)cyclopropyl)-3-(3-methylquinuclidin-3-yl)urea
In a three-necked round-bottomed flask fitted with two pressure-equalizing addition tunnels and a rubbertube connected with a gas flowmeter, a suspension of 1-(4’-fluoro-[1,T-biphenyl]-4yl)cyclopropanamine (1.50 g, 7.07 mmol) in a mixture of 20 mL of water and 1 mL of conc. HCl was stirred for 10 min. Toluene (10 mL) was added and the solution was maintained under vigorous stirring and cooled down to 0 °C. A solution of triphosgene (3.10 g, 10.6 mmol) in 20 mL of toluene and 40 mL of saturated aqueous NaHCO3was added dropwise over 1h period. The reactionnai mixture was stirred for an additional 30 min. The stirring was stopped and the upper toluene layer was then separated out, dried (Na2SO4) and concentrated to afford the corresponding isocyanate which is used in the next step without further purification.
To a solution of the above isocyanate (134 mg, 0.571 mmol) in 15 mL of toluene was added (S)-3-methylquinuclidin-3-amine (80 mg, 0.57 mmol). The resulting mixture was heated at reflux overnight, cooled to ambient température and concentrated in vacuo to give a residue, which was purified by reverse phase chromatography on a combiflash (0-20% MeCN in water) to afford the title compound as a white solid (73 mg, 33%). 1H NMR (500 MHz CDCI3) δ 7.52-7.48 (m, 4H), 7.27-7.25 (d, J = 10.0 Hz, 2H), 7.13-7.09 (m, 2H), 5.39 (s, 1H), 4.78 (s, 1H), 2.95-2.71 (m, 5H), 2.65-2.64 (m, 1H), 1.94-1.93 (m, 1H), 1.69-1.68 (m, 1H), 1.46-1.38 (m, 5H), 1.36-1.33 (m, 4H), 1.26-1.23 (m, 1H) ppm. 13C NMR (125 MHz CDCI3) δ 163.5, 161.5, 157.5, 141.5, 138.5, 136.6,
136.6,128.5, 128.4, 127.2, 124.7, 115.8, 115.6, 63.8, 52.3, 46.6, 46.3, 34.9, 31.0, 25.0, 23.2, 22.5,
20.2, 20.0 ppm. Purity: > 99 % LCMS (214 nm & 254 nm); rétention time 1.51 min; (M+H+) 394.2.
Example 71
137 (S)-1 -azabicyclo[2.2,2]oct-3-yl [1 -(2',4'-difluorobiphenyl-4-yl)cyclopropyl]carbamate
Using general procedure E, (S)-quinuclidin-3-yl 1-(4-bromophenyl)cyclopropylcarbamate (0.446 g, 1.22 mmol), 2,4-difluorophenyl boronic acid (0.386 g, 2.44 mmol) and Pd(OAc)2 (0.015 g, 0.067 mmol) gave the title compound as a tan solid (0.111 g, 23%). 1H NMR (CDCI3) δ 7.43 (dd, J = 8.4, 1.6 Hz, 2H), 7.40-7.33 (m, 1H), 7.31 (d, J = 7.7 Hz, 2H), 6.99-6,81 (m, 2H), 5.54 (d, 7 = 48.0 Hz, 1H), 4.82-4.65 (m, 1H), 3.30-3.07 (m, 1H), 2.98-2.44 (m, 5H), 1.97 (d, J = 32.7 Hz, 1H), 1.83 (d, J= 10.3 Hz, 1H), 1.64 (s, 1H), 1.52 (s, 1H), 1.39 (s, 1H), 1.31 (d, 7 = 6.8 Hz, 4H) ppm. 13C NMR major rotomer (CDCI3) δ 162.2 (dd, 7= 12.8, 249.1 Hz), 159.8 (dd, 7 = 11.8, 251.0 Hz), 156.9, 156.0,142.6, 133.1, 131.3 (m), 128.9, 125.6, 124.9, 111.5 (dd, 7 = 3.9, 21.2 Hz) 104.4 (dd, 7 =
25.2, 29.4 Hz), 72.1, 71.6, 55.7, 47.4, 46.5, 35.7, 35.3, 25.5, 24.6, 24.4,19.5, 18.1 ppm. Purity: LCMS > 99.3 % (214 nm & 254 nm); rétention time 0.90 min; (M+1) 399.0
Example 72
1-azabicyclo[2.2.2]oct-3-yl [1-(4'-methoxybiphenyl-4-yl)cyclopropyl]carbamate
Using general procedure E, quinuclidin-3-yl 1-(4-bromophenyl)cyclopropylcarbamate (0.485 g, 1.33 mmol), 4-methoxyphenyl boronic acid (0.404 g, 2.66 mmol) and Pd(OAc)2 (0.016 g, 0.071 mmol) gave the title compound as a grey solid (0.337 mg, 65%). ’H NMR (CDCI3) δ 7.48 (dd, 7 = 8.6, 5,5 Hz. 4H), 7.29 (d, 7 = 7.6 Hz, 2H), 6.96 (d, 7 = 8.8 Hz, 2H), 5.58 (d, 7 = 48.7 Hz, 1 H), 4.834.63 (m, 1 H), 3.84 (s, 3H), 3.20 (dd, 7 = 24.0, 15.5 Hz, 1 H), 2.97-2.42 (m, 5H), 1.97 (d, 7 = 30.9 Hz, 1 H), 1.81 (s, 1 H), 1.75-1.33 (m, 3H), 1.28 (d, 7 = 6.8 Hz. 4H) ppm. 13C NMR major rotomer (CDCI3) δ 159.1, 156.0, 141.4, 139.0, 133.4, 128.0, 126.7,125.9, 114.2, 71.5, 55.7, 55.3, 47.4, 46.5, 35.3,
25.5, 24.6, 19.6, 17.8 ppm. Purity; LCMS >97.1 % (214 nm & 254 nm); rétention time 0.88 min; (M+1) 393.4.
Préparation T
Example 73 quinuclidin-3-yl 2-(5-(4-fluorophenyl)thiophen-3-yl)propan-2-ylcarbamate
To a stirred and cooled (0 °C) solution of ethyl 5-bromothiophene-3-carboxylate (13.30 g, 56.57 mmol) in THF (100 mL) was added a solution of méthylmagnésium bromide in diethyl ether [3.0 M] (55.0 mL, 165 mmol), dropwise over 20 minutes. After 2 hours, the reaction solution was concentrated. The residue was taken up in aqueous NH4CI (200 mL) and extracted with ethyl
138 acetate (2 x 100 mL). The combined extracts were dried (Na2SO4) and concentrated. The resulting amber oil was purified by flash chromatography using a hexane/ethyl acetate gradient to afford 2-(5-bromothiophen-3-yl)propan-2-ol as a pale amber oil (8.05 g, 64%).
To a stirred solution of 2-(5-bromothiophen-3-yl)propan-2-ol (8.03 g, 36.3 mmol) in methylene chloride (80 mL) was added sodium azide (7.08 g, 109 mmol) followed by trifluoroacetic acid (8.0 mL; dropwise over 5-6 minutes). The thickening suspension was stirred for 1.5 hour before diluting with water (350 mL) and extracting with ethyl acetate (1 x 200 mL). The organic layer was washed with aqueous NaHCO3 (1 x 250 mL), dried (Na2SC>4) and concentrated to afford the crude azide product. To a stirred solution of this material in THF (160 mL) was added water (11 mL) followed by triphenylphosphine (23.8 g, 90.7 mmol). The reaction was stirred for 2 days before concentrating. The resulting residue was dissolved in ethyl acetate (250 mL) and extracted with 1 N aqueous HCl (4 x 75 mL). The combined extracts were basified with concentrated NH4OH and extracted with ethyl acetate (2 x 100 mL). These extracts were, in turn, dried (Na2SO4) and concentrated. The resulting amber oil was purified by flash chromatography using a methylene chloride/methanol/ammonia gradient to afford a mixture of 2-(5-bromothiophen-3-yl)propan-2-amine and triphenylphosphine oxide (-70/30 ratio) as a viscous amber oil (1.32 g, 17%).
To a stirred solution of 3-quinuclidinol (3.00 g, 23.6 mmol) in THF (100 mL) was added 4nitrophenyl chloroformate (5.94 g, 29.5). After stirring for 4 hours, the precipitate was filtered off, rinsed with THF and air dried on the frit under house vacuum. The filtercake was dissolved in ethyl acetate (150 mL) and washed with aqueous NaHCO3 (1 x 150 mL) and water (2 x 150 mL). The organic layer was dried (Na2SO4) and concentrated to afford crude 4-nitrophenyl quinuclidin-3-yl carbonate product, which was used in the next step without purification.
To a stirred solution of 2-(5-bromothiophen-3-yl)propan-2-amine (0.366 g, 1.66 mmol) in THF (10 mL) was added 4-nitrophenyl quinuclidin-3-yl carbonate (0.571 g, 1.95 mmol) and a few granules of 4-(dimethylamino)pyridine. The mixture was refluxed overnight, concentrated and partitioned between ethyl acetate (50 mL) and aqueous NaHCO3 (50 mL). The organic layer was washed again with aqueous NaHCO3 (1 x 50 mL), dried (Na2SO4) and concentrated. The resulting dirty yellow gum was purified by flash chromatography using a chloloform/methanol/ammonia gradient to afford quinuclidin-3-yl (1-(5-bromothiophen-3-yl)cyclopropyl)carbamate as an off-white solid (0.305 g, 49%).
139
Using general procedure E, quinuclidin-3-yl (1-(5-bromothiophen-3yl)cyclopropyl)carbamate (0.227 g, 0.742 mmol), 4-fluorophenyl boronic acid (0.208 g, 1.49 mmol), tricyclohexylphosphine (0.021 g, 0.075 mmol), potassium phosphate (0.866, 4.08 mmol) and palladium acetate (8.0 mg, 36 ümol) gave the title compound as a gray solid (0.142 g, 49%). 1H NMR (400 MHz, CDCI3) δ 7.60-7.45 (m, 2H), 7.24-7.19 (m, 1H), 7.10-6.97 (m, 3H), 5.23 (br s, 1H), 4.72-4.61 (m, 1H), 3.30-3.04 (m, 1H), 3.03-2.25 (m, 5H), 2.09-1.02 (m, 11H) ppm. 13C NMR (400 MHz, CDCI3) δ 162.3 (d, J = 247.1 Hz), 154.5,149.8,143.6, 130.7,127.4 (d, J = 8.1 Hz), 121.8, 118.9,115.8 (d, J= 21.6 Hz), 70.8, 55.5, 53.4, 47.3, 46.4, 29.0, 25.4, 24.4, 19.4 ppm. Purity: 95.8 % UPLCMS (210 nm & 254 nm); rétention time 0.90 min; (M+1) 389.
Préparation U
Example 74 (S)-quinuclidin-3-yl 2-(3-(4-fluorophenyl)isothiazol-5-yl)propan-2-ylcarbamate
To stirred solution of 2-(3-(4-fluorophenyl)isothiazol-5-yl)propan-2-amine (1.21 g, 5.12 mmol) in toluene was added a solution of phosgene in toluene [—1.9 M] (10.8 mL, 20.5 mmol). The reaction was heated at reflux for two hours and then concentrated. The residue was coevaporated with toluene (2x15 mL) to afford the crude isocyanate intermediate as golden oil. This material was taken up in toluene (10 mL) and treated with (S)-3-quinuclidinol (0.749 g, 5.89 mmol). The reaction was heated at reflux overnight and concentrated. The residue was purified by flash chromatography using a chloloform/methanol/ammonia gradient to afford the title compound as a white solid (0.971 g, 49%). 1H NMR (400 MHz, DMSO-d6) δ 8.09-8.00 (m, 2H), 7.87 (br s, 1 H), 7.75 (s, 1H), 7,35-7.25 (m, 2H), 4.54-4.45 (m, 1H), 3.14-2.92 (m, 1H), 2.87-2.17 (m, 5H), 1.98-0.98 (m, 11H)ppm. 13C NMR (400 MHz, DMSO-de) δ 180.1,165.6, 162.6 (d, J = 246.4 Hz), 154.7, 131.2 (d, J = 3.0 Hz), 128.7 (d, J = 8.4 Hz), 118.2, 115.7 (d, J = 21.8 Hz), 70.6, 55.3, 52.8, 46.9,
45.9, 29.9, 25.2, 24.2,19.2 ppm. Purity: 100 % UPLCMS (210 nm & 254 nm); rétention time 0.82 min; (M+1) 390.
Préparation V
Example 75 (S)-quinuclîdin-3-yl 2-(2-(4-fluorophenyl)thiazol-4-yi)propan-2-ylcarbamate
140
To a stirred solution of 4-fluorothiobenzamide (8.94 g, 57.6 mmol) in éthanol (70 mL) was added ethyl 4-chloroacetoacetate (7.8 mL, 58 mmol). The reaction was heated at reflux for 4 hours, treated with an addition aliquot of ethyl 4-chloroacetoacetate (1.0 mL, 7.4 mmol) and refluxed for an additional 3.5 hours. The reaction was then concentrated and the residue was partitioned between ethyl acetate (200 mL) and aqueous NaHCO3 (200 mL). The organic layer was combined with a backextract of the aqueous layer (ethyl acetate, 1 x 75 mL), dried (Na2SO4) and concentrated. The resulting amber oil was purified by flash chromatography using a hexane/ethyl acetate gradient to afford ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate as a low melting, nearly colorless solid (13.58 g, 89%).
To a stirred solution of ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)acetate (6.28 g, 23.7 mmol) in DMF (50 mL) was added sodium hydride [60% dispersion in minerai oil] (2.84 g, 71.0 mmol). The frothy mixture was stirred for 15 minutes before cooling in an ice bath and adding iodomethane (4.4 mL, 71 mmol). The reaction was stirred overnight, allowing the cooling bath to slowly warm to room température. The mixture was then concentrated and the residue partitioned between ethyl acetate (80 mL) and water (200 mL). The organic layer was washed with a second portion of water (1 x 200 mL), dried (Na2SO4) and concentrated. The resulting amber oil was purified by flash chromatography using a hexane/ethyl acetate gradient to afford ethyl 2-(2-(4-fluorophenyl)thiazol-4yl)-2-methylpropanoate as a colorless oil (4.57 g, 66%).
To a stirred solution of ethyl 2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropanoate (4.56 g, 15.5 mmol) in 1:1:1 THF/ethanol/water (45 mL) was added lithium hydroxide monohydrate (2.93 g, 69.8 mmol). The reaction was stirred overnight, concentrated and redissolved in water (175 mL). The solution was washed with ether (1 x 100 mL), acidified by the addition of 1.0 N HCl (80 mL) and extracted with ethyl acetate (2 x 70 mL). The combined extracts were dried (Na2SO4) and concentrated to afford 2-(2-(4-fluorophenyl)thiazol-4-yl)-2-methylpropanoic acid as a white solid (4.04 g, 98%). This material was used in the next step without purification.
To a stirred and cooled (0 °C) solution of 2-(2-{4-fluorophenyl)thiazol-4-yl)-2methylpropanoic acid ( 4.02 g, 15.2 mmol) in THF (100 mL) was added triethylamine (4.2 mL, 30 mmol) followed by isobutyl chloroformate (3.0 mL, 23 mmol). The reaction was stirred cold for another 1 hour before adding a solution of sodium azide (1.98 g, 30.5 mmol) in water (20 mL). The
141 reaction was stirred overnight, allowing the cooling bath to slowly warm to room température. The mixture was then diluted with water (100 mL) and extracted with ethyl acetate (2 x 60 mL). The combined extracts were washed with aqueous NaHCO3 (1 x 150 mL) and brine (1 x 100 mL), dried (Na2SO4) and concentrated. After coevaporating with toluene (2 x 50 mL), the resulting white solid was taken up in toluene (100 mL) and refluxed for 4 hours. (S)-3-quinuclidinol (3.87 g, 30.4 mmol) was then added and reflux was continued overnight. The reaction was concentrated and the residue partitioned between ethyl acetate (100 mL) and aqueous NaHCO3 (150 mL). The organic layer was washed with water (1 x 150 mL), dried (Na2SO4) and concentrated. The resulting offwhite solid was purified by flash chromatography using a chloloform/methanol/ammonia gradient to afford the title compound as a white solid (4.34 g, 73%). 1H NMR (400 MHz, CDCI3) 6 7.96-7.88 (m, 2H), 7.16-7.04 (m, 3H), 5.55 (br s, 1H), 4.69-4.62 (m, 1H). 3.24-3.11 (m, 1 H), 3.00-2.50 (m, 5H), 2.01-1.26 (m, 11 H) ppm. 13CNMR(400 MHz, CDCI3) δ 166.4, 165.1, 163.8 (d, J = 250.3 Hz),
162.9, 155,0, 130.1 (d, J =3.3 Hz), 128.4 (d, J = 8.5 Hz), 115.9 (d, J = 22.3 Hz), 112.5, 71.2, 55.7,
54.2, 47.5, 46.5, 28.0, 25.5, 24.7, 19.6 ppm. Purity: 100 % UPLCMS (210 nm & 254 nm); rétention time 0.83 min; (M+1) 390.
Préparation W
Example 76 (S)-quinuclidin-3-yl 2-(4-(4-fluorophenyl)thiazol-2-yl)propan-2-ylcarbamate
To a stirred solution of ethyl 3-amino-3-thioxopropanoate (20.00g, 135.9 mmol) in éthanol (120 mL) was added 2-bromo-4’-fluoroacetophenone (29.49 g, 135.9 mmol). The mixture was refluxed for 1 hour, concentrated and partitioned between ethyl acetate (300 mL) and aqueous NaHCO3 (400 mL). The organic layer was combined with a backextract of the aqueous layer (ethyl acetate, 1 x 100 mL), dried (Na2SO4) and concentrated. The resulting light brown solid was purified by flash chromatography using a hexane/ethyl acetate gradient to afford ethyl 2-(4-(4fluorophenyl)thiazol-2-yl)acetate as an off-white solid (29.92 g, 83%).
To a stirred and cooled (-78 °C) solution of ethyl 2-(4-(4-fluorophenyl)thiazol-2-yl)acetate (10.00 g, 37.69 mmol) in THF (250 mL) was added a solution of potassium t-butoxîde in THF (1.0 M] (136 mL, 136 mmol), dropwise over 15 minutes, followed by 18-crown-6 (1.6 mL, 7.5 mmol). After an additional 30 minutes at -78 °C, iodomethane (8.5 mL) was added, dropwise over 5 minutes. The reaction was stirred cold for another 2 hours before pouring into water (450 mL) and
142 extracting with ethyl acetate (2 x 150 mL). The combined extracts were washed with brine (1 x 200 mL), dried (Na2SO4) and concentrated. The resulting brown oil was purified by flash chromatography using a hexane/ethyl acetate gradient to afford ethyl 2-(4-(4-fluorophenyl)thiazol-2yl)-2-methylpropanoate as a pale amber oil (8.64 g, 78%).
To a stirred solution of ethyl 2-(4-(4-fluorophenyl)thiazol-2-yl)-2-methylpropanoate (0.900 g, 3.07 mmol) in 1:1:1 THF/ethanol/water (15 mL) was added lithium hydroxide monohydrate (0.451 g, 10.7 mmol). After overnight stirring, the reaction was concentrated and redissolved in water (80 mL). The solution was washed with ether (1 x 50 mL), acidified with the addition of 1 N HCl (15 mL) and extracted with ethyl acetate (2 x 50 mL). The combined extracts were dried (Na2SO4) and concentrated to afford 2-(4-(4-fluorophenyl)thiazol-2-yl)-2-methylpropanoic acid as a pale golden solid (0.808 g, 99%).
To stirred and cooled (0 °C) solution of 2-(4-(4-fluorophenyl)thiazol-2-yl)-2-methylpropanoic acid ( 0.784 g, 2.96 mmol) in THF (25 mL) was added triethylamine (0.82 mL, 5.9 mmol) followed by isobutyl chloroformate (0.58 mL, 4.4 mmol). The reaction was stirred cold for another 1 hour before adding a solution of sodium azide (0.385 g, 5.92 mmol) in water (7 mL). The reaction was stirred overnight, allowing the cooling bath to slowly warm to room température. The mixture was then diluted with water (100 mL) and extracted with ethyl acetate (2 x 60 mL). The combined extracts were washed with aqueous NaHCO3 (1 x 150 mL) and brine (1 x 100 mL), dried (Na2SO4) and concentrated. After coevaporating with toluene (2 x 30 mL), the resulting off-white solid was taken up in toluene (25 mL) and refluxed for 4 hours. (S)-3-quinuclidinol (0.753 g, 5.92 mmol) was then added and reflux was continued for 3 hours. The reaction was concentrated and the residue was purified by flash chromatography using a chloloform/methanol/ammonia gradient to afford the title compound as a white solid (0.793 g, 69%). 1H NMR (400 MHz, CDCI3) δ 7.90-7.81 (m, 2H), 7.32 (s, 1H), 7.14-7.05 (m, 2H), 5.76 (brs, 1H), 4.72-4.65 (m, 1H), 3.26-3.10 (m, 1H), 3.03-2.37 (m, 5H), 2.05-1.23 (m, 11 H) ppm. 13C NMR (400 MHz, CDCI3) δ 177.6, 162.6 (d, J = 248.4 Hz), 154.8, 153.6, 130.8 (d, J = 3.2 Hz), 128.1 (d, J = 8.1 Hz), 115.9 (d, J = 21.7 Hz), 112.2, 71.6, 55.7, 47.4, 46.5, 29.1, 25.4, 24.7,19.6 ppm. Purity: 100 % UPLCMS (210 nm & 254 nm); rétention time 0.82 min; (M+1) 390.
Example 77 quinuclidin-3-yl 1-(4-(benzyloxy)phenyl)cyclopropylcarbamate
143
A mixture of 4-cyanophenol (5.0 g, 42 mmol), benzylbromide (8.6 g, 50 mmol), potassium carbonate (11.6 g, 84.0 mmol) in DMF (40 mL) was stirred at 100 °C for 3 h. The precipitate was filtered off and the filtrate was diluted with EtOAc and washed with water. The organic layer was dried (NaîSCU) and concentrated. The resulting crude product was purified by silica gel column chromatography (eluting with petroleum ether/EtOAc from 20/1 to 5/1) to give 4(benzyloxy)benzonitrile as a white solid (8.1 g, 92%).
Using general procedure G, 4-(benzyloxy)benzonitrile (6.00 g, 28.7 mmol) was converted to the corresponding 1-(4-(benzyloxy)phenyl)cyclopropanamine as a yellow solid (1.8 g, 26%).
Using general procedure A, 1-(4-(benzyloxy)phenyl)cyclopropanamine (600 mg, 2.51 mmol) and quinuclidin-3-ol gave the title compound as a viscous oil (170 mg, 17%). 1H NMR (500 MHz, CDCI3) δ 7.34 (d, J = 7.0 Hz, 2H), 7.30 (t, J = 7.0 Hz, 2H), 7.25 (t, J =7.0 Hz, 1 H), 7.16 (d, J = 8.5 Hz, 1 H), 7.07 (d, J = 7.0 Hz, 1 H), 6.83 (d, J = 8.0 Hz, 2H), 5.50 (br s, 0.6H), 5.40 (br s, 0.4H), 4.96 (s, 2H), 4.64 (m, 1H), 3.20-3.15 (m, 1H), 2.88-2.50 (m, 5H), 1.95-1.05 (m, 9H) ppm. 13C NMR (125 MHz, CDCI3) δ 156.6, 154.8, 136.0, 134.2, 127.6, 126.9, 126.4, 125.4, 113.7, 70.0, 69.0, 54.5,
46.3, 45.4, 34.2, 24.3, 23.3, 18.3, 15.8 ppm. Purity: > 90 % LCMS (214 nm & 254 nm); rétention time 1.57 min; (M+1) 393.
Example 78 quinuclidin-3-yl biphenyl-3-ylmethylcarbamate
To a stirred and cooled (0 °C) solution of triphosgene (0.80 g, 2.7 mmol) in THF (20 mL) was added, dropwise, a mixture of (3-bromophenyl)methanamine (1.0 g, 5.4 mmol) and triethylamine (1.08 g, 10.7 mmol) in THF (30 mL) over 2 h. After the addition was complété, the mixture was refluxed for 1 h and then cooled to room température. Quinuclidin-3-ol (1.40 g, 10.7 mmol) was added, and the mixture was refluxed for 18 h. The solvent was removed in vacuo, and the residue was dissolved in EtOAc, washed with water, dried over Na2SO4, and concentrated. The crude residue was purified by silica gel column chromatography (eluting with EtOAc/methanol = 10/1) to give quinuclidin-3-yl 3-bromobenzylcarbamate as a colourless liquid (0.68 g, 37%).
144
Using general procedure E, quinuclidin-3-yl 3-bromobenzylcarbamate (237 mg, 0.700 mmol), phenylboronic acid (171 mg, 1.4 mmol) and [PdCI2(pddf)]CH2CI2 gave the title compound as a viscous semi-solid (110 mg, 47 %). 1H NMR (500 MHz, CDCI3) δ 7.57 (d, J= 7.5 Hz, 2H), 7.50 (m, 2H), 7.62-7.38 (m, 3H), 7.35 (t, J= 7.5 Hz, 1 H), 7.28 (d, J= 8.0 Hz, 1H). 5.32-5.17 (m, 1H), 7.78 (m, 1H), 4.42 (d, J = 6.0 Hz, 2H), 3.26 (m, 1H), 2.95-2.65 (m, 5H), 2.05 (m, 1H), 1.84 (m, 1H), 1.70 (m, 1H), 1.58 (m, 1H), 1.42 (m, 1H) ppm. 13C NMR (125 MHz, CDCI3) δ 155.2, 140.7, 139.8, 138.0, 128.1, 127.8, 126.4, 126.1, 125.5, 125.4, 125.3, 70.1, 54.4, 46.2, 45.3, 44.1, 24.3, 23.1, 18.2 ppm. Purity: > 98 % LCMS (214 nm & 254 nm); rétention time 1.44 min; (M+1) 337.
Example 79 quinuclidin-3-yl 3-(pyrimidin-5-yl)benzylcarbamate
Using general procedure E, quinuclidin-3-yl 3-bromobenzylcarbamate (203 mg, 0.600 mmol), pyrimidin-5-ylboronic acid (149 mg, 1.2 mmol) and [PdCI2(pddf)]CH2CI2 gave the title compound as a viscous semi-solid (110 mg, 54%). 1H NMR (500 MHz, CDCI3) δ 9.20 (s, 1H), 8.94 (s, 2H), 7.51 (m, 3H), 7.40 (m, 1H), 5.62 (m, 1H), 4.81 (m, 1H), 4.50-4.40 (m, 2H), 3.30 (m, 1H), 2.97-2.65 (m, 5H), 2.12 (m, 1H), 1.92-1.82 (m, 1H), 1.79-1.69 (m, 1H), 1.65-1.56 (m, 1H), 1.50-1.42 (m, 1H)ppm. 13C NMR (125 MHz, CDCI3) δ 157.6, 156.2, 154.9, 140.1, 134.7, 134.1,129.8, 128.2,
126.2, 70.9, 55.2, 47.2, 46.2, 44.8, 25.2, 23.8, 19.0 ppm. Purity: > 95 % LCMS (214 nm & 254 nm); rétention time 1.22 min; (M+1) 339.
Example 80 quïnuclidin-3-yl 3-(benzyloxy)benzylcarbamate
A mixture of 2-(3-hydroxyphenyl)acetic acid (0.6 g, 3.95 mmol), benzyl bromide (0.710 g, 4,14 mmol), potassium hydroxide (0.550 g, 9.87 mmol), Kl (13 mg, 0.079 mmol) in THF (20 mL) was refluxed for 18 h. The solvent was removed and the residue was dissolved in 50 mL of water and extracted with ether. The aqueous layer was acidified with aqueous 1N HCl and the white precipitate that formed was filtered off to afford 2-(3-(benzyloxy)phenyl)acetic acid as a gray solid (0.87 g, 91%).
Using general procedure H, 2-(3-(benzyloxy)phenyl)acetic acid (242 mg, 1.00 mmol) and quinuclidin-3-ol gave the title compound as a viscous semi-solid (200 mg, 55%). ’H NMR (500
145
MHz, CDCI3) δ 7.42 (d, J = 7.5 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.0 Hz, 1 H), 7.24 (d, J =
7.5 Hz, 1H), 6.92 (s, 1H), 6.88 (d, J - 7.0 Hz, 2H), 5.30 (m, 1H), 5.05 (s, 2H), 4.75 (m, 1H), 4.32 (d, J = 6.0 Hz, 2H), 3.23 (m, 1H), 2.93-2.60 (m, 5H), 2.08-1.96 (m, 1H), 1.88-1.75 (m, 1H), 1.72-1.62 (m, 1H), 1.60-1.50 (m, 1H), 1.42-1.34 (m, 1H)ppm. 13C NMR (125 MHz, CDCI3) δ 159.1, 156.3,
140.2, 136.8, 129.7, 128.6, 128.0, 127.5, 120.0, 114.1, 113.6, 71.3, 70.0, 55.5, 47.3, 46.4, 45.0,
25.4, 24.3, 19.3 ppm. Purity: > 95 % LCMS (214 nm & 254 nm); rétention time 1.51 min; (M+1) 367
Example 81 quinuclidin-3-yl 4-phenoxybenzylcarbamate
Using general procedure H, 2-(3-phenoxyphenyl)acetic acid (228 mg, 1.00 mmol), and quinuclidin-3-ol gave the title compound as a viscous semi-solid (70 mg, 20%). 4H NMR (500 MHz, CDCI3) δ 7.29-7.18 (m, 3H), 7.03 (t, J= 7.5 Hz, 1H), 6.96-6.90 (m, 3H), 6.86 (s, 1 H), 6.82 (d, J =
8.5 Hz, 1H), 5.40-5.15 (m, 1 H). 4.70 (m, 1H), 4.25 (d, J = 6.0 Hz, 2H), 3.18 (m, 1H), 2.90-2.60 (m, 5H), 2.03-1.92 (m, 1H), 1.82-1.74 (m, 1H), 1.68-1.60 (m, 1H), 1.57-1.45 (m, 1H), 1.40-1.32 (m, 1H) ppm. 13C NMR (125 MHz, CDCI3) δ 156.6, 155.9, 155.1, 139.6, 129.0, 128.8, 122.4, 121.1, 118.0, 116,7, 69.7, 54.1,46.1,45.2, 43.7, 24.2, 22.7, 18.0 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.50 min; (M+1) 353.
Example 82 quinuclidin-3-yl 3-isopropoxybenzylcarbamate
A mixture containing 2-(3-hydroxyphenyl)acetic acid (0.800 g, 5.26 mmol), 2-bromopropane (0.971 g, 7.89 mmol), potassium hydroxide (0.740 g, 13.2 mmol), Kl (18 mg, 0.11 mmol) in 20 mL EtOH was refluxed for 18 h. The solvent was removed and the residue was dissolved in 50 mL of water and extracted with ether. The aqueous layer was acidified with aqueous 1N HCl and extracted with EtOAc. The organic layers were dried (Na2SO4) and concentrated to afford a residue which was purified by silica gel chromatography (petroleum ether/EtOAc 4:1) to get 2-(3(benzyloxy)phenyl)acetic acid as a white solid (0.45 g, 44%).
Using general procedure H, 2-(3-isopropoxyphenyl)acetic acid (291 mg, 1.50 mmol), and quinuclidin-3-ol gave the title compound as a viscous semi-solid (120 mg, 25%). ’H-NMR (500
146
MHz, CDCI3) δ 7.23 (t, J= 7.5 Hz, 1H), 6.86-6.77 (m, 3H), 5.16-5.00 (m, 1H), 4.78 (m, 1H), 4.55 (m, 1H), 4.32 (d, J = 5.0 Hz, 2H), 3.26 (m, 1H), 2.95-2.70 (m, 5H), 2.10-2.05 (m, 1H), 1.90-1.80 (m, 1 H), 1.75-1.65 (m, 1 H), 1.63-1.53 (m, 1 H), 1.47-1.37 (m, 1 H), 1.33 (d, J = 5.5 Hz, 6H) ppm. 13C NMR (125 MHz, CDCI3) δ 158.1, 156.2, 140.1, 129.7, 119,6, 115.2, 114.6,71.0, 69.8, 55.3,47.2,
46.3, 45.0, 25.3, 24.1, 22.0, 19.2 ppm. Purity: > 90 % LCMS (214 nm & 254 nm); rétention time 1.42 min; (M+1) 319.
Example 83 quinuclidin-3-yl 3-isobutoxybenzylcarbamate
A mixture containing 2-(3-hydroxyphenyl)acetic acid (1.0 g, 6.6 mmol), 1-bromo-2methylpropane (1.08 g, 7.91 mmol), potassium hydroxide (0.920 g, 16.4 mmol), Kl (22 mg, 0.13 mmol) in EtOH (20 mL) was refluxed for 18 h. The solvent was removed and the residue was dissolved in 50 mL of water and extracted with ether. The aqueous layer was acidified with aqueous 1N HCl and extracted with EtOAc. The organic layers were dried (Na2SO4) and concentrated to afford a residue which was purified by silica gel chromatography (petroleum ether/EtOAc 4:1 ) to get 2-(3-(benzyloxy)phenyl)acetic acid as a white solid (0.42 g, 31 %).
Using general procedure H, 2-(3-isobutoxyphenyl)acetic acid (208 mg, 1.00 mmol) and quinuclidin-3-ol gave the title compound as a viscous semi-solid (130 mg, 39%). ’H NMR (500 MHz, CDCI3) δ 7.23 (t, J - 7.5 Hz, 1H), 6.86-6.76 (m, 3H), 5.35-5.10 (m, 1H), 4.77 (m, 1H), 4.31 (d, J =5.5 Hz, 2H), 3.69 (d, J= 6.5 Hz, 2H), 3.26 (m, 1H), 2.95-2.70 (m, 5H), 2.10-2.00 (m, 2H), 1.881.80 (m, 1H), 1.75-1.63 (m, 1H), 1.62-1.52 (m, 1H), 1.45-1.36 (m, 1H), 1.01 (d, J = 6.5 Hz, 6H) ppm. 13C NMR (125 MHz, CDCI3) δ 159.6, 156.1, 139.9, 129.7, 119.6, 113.9, 113.4, 74.4,70.9,
55.3, 47.2, 46.3, 45.1,28.3, 25.3, 23.9, 19.3, 19.1 ppm. Purity: > 95 % LCMS (214 nm & 254 nm); rétention time 1.50 min; (M+1) 333.
Example 84 quinuclidin-3-yl 3-(cyclopropylmethoxy)benzylcarbamate
A mixture containing 2-(3-hydroxyphenyl)acetic acid (1.0 g, 6.6 mmol), (bromomethyl) cyclopropane (0.97 g, 7.2 mmol), potassium hydroxide (0.920 g, 16.4 mmol), Kl (22 mg, 0.13 mmol)
147 in EtOH (20 mL) was refluxed for 18 h. The solvent was removed in vacuo, and the residue was dissolved in 50 mL of water and extracted with ether. The aqueous layer was acidified with aqueous 1N HCl and extracted with EtOAc. The organic layers were dried (Na2SO4) and concentrated to afford a residue which was purifted by silica gel chromatography (petroleum ether/EtOAc 4:1 ) to get 2-(3-(cyclopropylmethoxy)phenyl)acetic acid as a white solid (0.80 g, 59%).
Using general procedure H, 2-(3-(cyclopropylmethoxy)phenyl)acetic acid (300 mg, 1.50 mmol) and quinuclidin-3-o! gave the title compound as a viscous oil (90 mg, 19%). 1H NMR (500 MHz, CDCI3) δ 7.24 (t, J= 7.5 Hz, 1H), 6.88-6.78 (m, 3H), 5.13-4.95 (m, 1H), 4.74 (m, 1H), 4.33 (d, J = 6.0 Hz, 2H), 3.79 (d, J = 7.0 Hz, 2H), 3.23 (m, 1 H), 2.93-2.63 (m, 5H), 2.04-1.98 (m, 1 H), 1.851.76 (m, 1H), 1.72-1.60 (m, 1H), 1.58-1.50 (m, 1H), 1.41-1.22 (m, 2H), 0.68-0.62 (m, 2H), 0.37-0.32 (m, 2H) ppm. 13C NMR (125 MHz, CDCI3) δ 158.2, 155.5,139.3, 128.6, 118.6,112.8, 112.3, 71.7,
70.4, 54.5, 46.2, 45.3, 43.9, 24.4, 23.5,18.5, 9.3, 2.2 ppm. Purity: > 95 % LCMS (214 nm & 254 nm); rétention time 1.44 min; (M+1) 331.
Préparation X
Example 85
N-(2-(biphenyl-4-yl)propan-2-yl)-2-(quinuclidin-3-yl)acetamide
To a solution of 2-(quinuclidin-3-yl)acetic acid hydrochloride (0.97 g, 4.7 mmol) in DMF (30 mL) was added HATU (1.79 g, 4.72 mmol), 2-(4-bromophenyl)propan-2-amine (1.0 g, 4.7 mmol), and triethylamine (3.9 mL, 28 mmol). The resulting mixture was stirred at 60 °C for 16 h. The mixture was concentrated in vacuo, diluted with EtOAc and washed with brine. The organic layer was dried over Na2SO4 and evaporated to afford crude product, which was purified by silica gel column chromatography (EtOAc/methanol 50/1 to 3/1) to obtain N-(2-(4-bromophenyl)propan-2-yl)2-(quinuclidin-3-yl)acetamide as a yellow solid (1.3 g, 76%).
Using general procedure E, N-(2-(4-bromophenyl)propan-2-yl)-2-(quinuclidin-3-yl)acetamide (200 mg, 0.550 mmol), phenylboronic acid (134 mg, 1.00 mmol) and [PdCI2(pddf)]CH2CI2 gave the title compound as a viscous brown oil (58 mg, 32%). 1H NMR (500 MHz, CDCI3) δ 7.58-7.50 (m, 4H), 7.44-7.37 (m, 4H), 7.31 (t, J= 7.0 Hz, 1H), 6.50 (s, 1H), 3.16 (m, 1H), 3.02 (m, 1H), 2.92-2.78 (m, 3H), 2.60 (m, 1H), 2.40-2.20 (m, 3H), 1.47-1.90 (m, 11 H) ppm. 13C NMR (125 MHz, CDCI3) δ
148
170.5, 146.1, 140.7, 139.2, 128.8, 127.2, 127.0 125.2, 55.6, 53.1,46.8, 46.2, 40.3, 31.7, 29.3, 29.2, 26.0, 24.4,19.7 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.55 min; (M+1) 363.
Example 86 quinuclidin-3-yl biphenyl-3-ylcarbamate
To a solution of quinuclidin-3-ol (635 mg, 5.00 mmol) in THF (15 mL) was added NaH [60% dispersion in minerai oïl] (260 mg, 6.50 mmol) at room température. The mixture was stirred for 15 min and 3-bromophenyl isocyanate (990 mg, 5.00 mmol) was added under stirring. The resulting mixture was stirred at room température for 18 h, quenched with brine and extracted with EtOAc. The organic layers were combined, dried over Na2SO4 and concentrated. The crude product was purified by silica gel column chromatography (eluting with EtOAc/methanol 3:1) to give quinuclidin3-yl 3-bromophenylcarbamate as a white solid (0.70 g, 43%).
Using general procedure E, above carbamate intermediate (130 mg, 0.402 mmol), phenylboronic acid (72 mg, 0.6 mmol) and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (75 mg, 58%). Ή NMR (500 MHz, CDCI3) δ 7.67 (br s, 1 H), 7.59 (d, J = 7.5 Hz, 2H), 7.43 (t, J = 7.5 Hz, 2H), 7.41-7.28 (m, 4H), 6.77 (brs, 1H), 4.85 (m, 1H), 3.30 (m, 1H), 2.98-2.75 (m, 5H), 2.12 (m, 1H),1.93-1.68 (m, 2H), 1.64-1.55 (m, 1H), 1.47-1.40 (m, 1H) ppm. 13C NMR (125 MHz, CDCI3) 6 153.3,142.3, 140.7,138.3, 129.5, 128.8, 127.5, 127.2, 122.3, 117.4, 72.1, 55.4, 47.4,
46.5, 30.9, 25.4, 24.5,19.5 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.53 min; (M+1) 323.
Example 87 quinuclidin-3-yl 2'-methoxybiphenyl-3-ylcarbamate
Using general procedure E, quinuclidin-3-yl 3-bromophenylcarbamate, 2-methoxyphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (75 mg, 58%). 1H NMR (500 MHz, CDCI3) δ 7.49 (brs, 1H), 7.41 (brs, 1H), 7.37-7.28 (m, 3H), 7.23 (d, J =7.5 Hz, 1H), 7,04-6.94 (m, 3H), 4.83 (m, 1H), 3.80 (s, 3H), 3.29 (m, 1H), 2.97-2.70 (m, 5H), 2.10 (m, 1H), 1.91-1.82 (m, 1H), 1.74-1.65 (m, 1H), 1.62-1.53 (m, 1H), 1.46-1.37 (m, 1H)ppm. 13C NMR (125 MHz, CDCI3) δ 156.4, 153.4, 139.4, 137.6,130.9, 130.2, 128.8, 128.6, 124.8, 120.8, 119.9, 117.3,
149
111.2, 72.0, 55.6, 55.4, 47.4, 46.5, 25.4, 24.5, 19.5 ppm. Purity: > 95 % LCMS (214 nm & 254 nm); rétention time 1.52 min; (M+1) 353.
Example 88 quinuclidin-3-yl 2'-ethylbiphenyl-3-ylcarbamate
Using general procedure E, quinuclidin-3-yl 3-bromophenylcarbamate, 2ethylphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title vcompound as a white solid (110 mg, 78%). ’H NMR (400 MHz, CDCI3) δ 7.42-7.28 (m, 5H), 7.25-7.16 (m, 2H), 7.03-7.00 (m, 1H), 6.88 (br s, 1H), 4.83 (m, 1H), 3.27 (m, 1H), 2.98-2.70 (m, 5H), 2.61 (q, J= 7.6 Hz, 2H), 2.08 (m, 1H), 1.92-1.80 (m, 1H). 1.75-1.65 (m, 1H), 1.63-1.55 (m, 1H), 1.46-1.37 (m, 1H), 1.10 (t, J = 7.6 Hz, 3H)ppm. 13C NMR (100 MHz, CDCI3) δ 152.1, 141.7, 140.4, 139.9, 136.4,128.6, 127.5, 127.4,
126.4, 124.3, 123.2, 118.4,115.9, 71.0, 54.3, 46.2, 45.3, 25.0, 24.2, 23.4,18.3,14.5 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.61 min; (M+1) 351.
Example 89 quinuclidin-3-yl 3'-methoxybiphenyl-3-ylcarbamate
Using general procedure E, quinuclidin-3-yl 3-bromophenylcarbamate, 3methoxyphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (100 mg, 71%). 1H NMR (500 MHz, CDCI3) δ 7.63 (br s, 1H), 7.40-7.27 (m, 4H), 7.17 (d, J = 8.0 Hz, 1H), 7.11 (m, 1H), 7.07 (br s, 1H), 6.89 (dd. J= 8.0, 2.0 Hz, 1H), 4.85 (m, 1H), 3.85 (s, 3H), 3.30 (m, 1H), 2.99-2.70 (m, 5H), 2.12 (m, 1H), 1.92-1.84 (m, 1H), 1.75-1.68 (m, 1H), 1.62-1.55 (m, 1H), 1.48-1.40 (m, 1H) ppm. 13C NMR (125 MHz, CDCI3) δ 159.9, 153.4, 142.3, 142.1, 138.4, 129.8,
129.4,122.3, 119.7, 117.7, 112.9,112.8, 72.0, 55.4, 55.3, 47.4, 46.5, 25.4, 24.5, 19.5 ppm. Purity: > 97 % LCMS (214 nm & 254 nm); rétention time 1.52 min; (M+1) 353
Example 90 quinucltdin-3-yl 3'-ethyibiphenyl-3-ylcarbamate
150
To a solution of 1-bromo-3-ethylbenzene (370 mg, 2.00 mmol) in 5 mL 1,4-dioxane, was added bis(pinacolato)diboron (609 mg, 2.40 mmol), CH3COOK (589 mg, 6.02 mmol), and [PdCI2(pddf)]CH2CI2 (75 mg, 0.09 mmol). The mixture was stirred at 80 °C for 5 h. The mixture was cooled, dîluted with water, and extracted with EtOAc. The combined extracts were dried (Na2SO4) and concentrated to afford the crude boronate (410 mg, >100%), which was used without purification in the next step.
Using general procedure E, quinuclidin-3-yl 3-bromophenylcarbamate, 3-ethylphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the titie compound as a white solid (78 mg, 56%). 1H NMR (500 MHz, CDCI3) δ 7.64 (br s, 1H), 7.43-7.27 (m, 6H), 7.24 (br s, 1H), 7.18 (d, J = 8.0 Hz, 1H), 4.85 (m, 1H), 3.30 (m, 1H), 2.99-2.73 (m, 5H), 2.70 (q, J= 7.5 Hz, 2H), 2.12 (m, 1H), 1.92-1.84 (m, 1H), 1.75-1.67 (m, 1H), 1.62-1.55 (m, 1H), 1.48-1.38 (m, 1H), 1.27 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (125 MHz, CDCI3) δ 153.5, 144.8, 142.4, 140.8, 138.4,129.4, 128.8, 127.1, 126.8,124.6, 122.3,
117.4, 72.1, 55.4, 47.4, 46.5, 29.0, 25.4, 24.5, 19.5, 15.7 ppm. Purity: > 98 % LCMS (214 nm & 254 nm); rétention time 1.66 min; (M+1) 351.
Example 91 quinuclidin-3-yl blphenyl-2-ylcarbamate
To a solution of quinuclidin-3-ol (382 mg, 3.00 mmol) in THF (15 mL) was added NaH [60% dispersion in minerai oil] (156 mg, 3.90 mmol) at room température. The mixture was stirred for 15 min and 2-bromophenyl isocyanate (594 mg, 3.00 mmol) was added under stirring. The resulting mixture was stirred at room température for 18 h, quenched with brine and extracted with EtOAc. The organic layers were combined, dried over Na2SO4 and concentrated. The resulting crude product was purifled by silica gel column chromatography (EtOAc/methanol 3:1) to give the product quinuclidin-3-yl 2-bromophenylcarbamate as viscous oil (0.80 g, 82%).
Using general procedure E, quinuclidin-3-yl 2-bromophenylcarbamate (130 mg, 0.400 mmol), phenylboronic acid (96 mg, 0.8 mmol) and [PdCI2(pddf)]CH2CI2 gave the titie compound as a white solid (112 mg, 87%). 1H NMR (400 MHz, CDCI3) δ 8.07 (brs, 1H), 7.55-7.33 (m, 6H), 7.257.21 (dd, J= 7.6 & 1.6 Hz, 1H), 7.43 (td, J=8.0, 1.2 Hz, 1H), 6.65 (brs, 1H), 4.78 (m, 1H), 3.24 (m, 1H), 2.90-2.68 (m, 5H), 2.04 (m, 1H),1.80-1.62 (m, 2H), 1.61-1.50 (m, 1H), 1.41-1.30 (m, 1H)ppm. 13C NMR (100 MHz, CDCI3) δ 151.2, 135.9,132.5, 129.5, 128.0, 127.0,126.9, 126.2, 125.7, 121.4,
151
117.9, 69.9, 53.1,45.1, 44.3, 23.1, 22.3, 17.2 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.47 min; (M+1) 323.
Example 92 quinucltdin-3-yl 2'-methoxybiphenyl-2-ylcarbamate
Using general procedure E, quinuclidin-3-yl 2-bromophenylcarbamate, 2methoxyphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (102 mg, 72%). 1H NMR (500 MHz, CDCI3) δ 7.95 (brs, 1H), 7.42 (t, J= 7.5 Hz, 1H), 7.37 (t, J= 7.5 Hz, 1 H), 7.25 (d, J = 7.5 Hz, 1 H), 7.15 (t, J = 7.5 Hz, 1 H), 7.09 (t, J = 7.5 Hz, 1 H), 7.04 (d, J = 8.5 Hz, 1H), 6.72 (brs, 1H), 4.76 (m, 1H), 3.82 (s, 3H), 3.23 (m. 1H), 2.90-2.64 (m, 5H), 1.98-2.08 (m, 1H), 1.81-1.63 (m, 2H), 1.60-1.50 (m, 1H), 1.42-1.30 (m, 1H) ppm.13C NMR (125 MHz, CDCI3) δ 156.2,
153.8, 135.6, 132.1, 130.9, 129.7, 128.3, 127.1, 123.8, 121.5, 111.3, 71.8, 55.7, 55.5, 47.3, 46.5,
25.3, 24.5, 19.4 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.48 min; (M+1) 353.
Example 93 quinuclidin-3-yl 2'-ethylbiphenyl-2-ylcarbamate
Using general procedure E, quinuclidin-3-yl 2-bromophenylcarbamate, 2-ethylphenylboronic and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (71 mg, 51%). ’H NMR (500 MHz, CDCI3) δ 8.11 (br s, 1H), 7.43-7.34 (m, 3H), 7.33-7.28 (m, 1H), 7.18-7.08 (m, 3H), 6.24 (br s, 1H), 4.75 (m, 1H), 3.23 (m, 1H), 2.85-2.65 (m, 5H), 2.40 (m, 2H), 2.02 (m, 1H), 1.73-1.62 (m, 2H), 1.61-1.50 (m, 1 H), 1.40-1.30 (m, 1 H), 1.05 (m, 3H) ppm. 13C NMR (125 MHz, CDCI3) δ 153.3,
142.9.136.4, 135.3, 130.6, 130.3, 130.1, 129.0, 128.7, 128.4, 126.4,123.0, 119.1,72.1, 55.2, 47.3,
46.4, 26.0, 25.3, 24.5,19.3,15.2 ppm. Purity: > 98 % LCMS (214 nm & 254 nm); rétention time 1.55 min; (M+1) 351.
Example 94 quinuclidin-3-yl 3'-methoxybiphenyl-2-ylcarbamate
152
Using general procedure E, quinuclidin-3-yl 2-bromophenylcarbamate, 3methoxyphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (120 mg, 85%). 1H NMR (500 MHz, CDCI3) δ 8.08 (br s, 1 H), 7.40 (t, J = 7.5 Hz, 1 H), 7.36 (t, J = 7.5 Hz, 1 H), 7.23 (dd, J = 7.5, 1.5 Hz, 1 H), 7.13 (td, J = 7.5,1.5 Hz, 1 H), 6.96 (dd, J = 8.0, 2.0 Hz, 2H), 6.91 (t, J = 1.5 Hz, 1H), 6.73 (brs, 1H), 4.79 (m, 1H), 3.84 (s, 3H), 3.24(m, 1H), 2.90-2.70 (m, 5H), 2.05 (m, 1H), 1.80-1.70 (m, 2H), 1.62-1.52 (m, 1H), 1.41-1.32 (m, 1H)ppm. nCNMR(125 MHz, CDCI3) δ 160.1, 153.4, 139.5, 134.7, 131.5, 130.1, 130.1, 128.5, 123.5, 121.4, 119.9, 114.7, 113.6, 72.1, 55.3, 55.3, 47.3, 46.5, 25.3, 24.5,19.4 ppm. Purity: > 98 % LCMS (214 nm & 254 nm); rétention time 1.48 min; (M+1) 353
Example 95 quinuclidin-3-yl 3'-ethylbiphenyl-2-ylcarbamate
Using general procedure E, quinuclidin-3-yl 2-bromophenylcarbamate, 3-ethylphenylboronic acid and [PdCI2(pddf)]CH2CI2 gave the title compound as a white solid (120 mg, 86%). 1H NMR (500 MHz, CDCI3) δ 8.09 (br s, 1 H), 7.41 (t, J = 7.5 Hz, 1 H), 7.36 (t, J = 7.5 Hz, 1 H), 7.26-7.18 (m, 4H), 7.14 (t, J =7.5 Hz, 1H), 6.71 (brs, 1H), 4.79 (m, 1H), 3.25 (m, 1H), 2.90-2.65 (m, 7H), 2.05 (m, 1H), 1.80-1.64 (m, 2H), 1.62-1.52 (m, 1H), 1.40-1.32 (m, 1H), 1.28 (t, J=7.5Hz, 3H) ppm. 13C NMR (125 MHz, CDCI3) δ 153.4, 145.2, 138.1, 134.7, 131.8, 130.2, 129.1, 128.8, 128.4, 127.5, 126.6, 123.5, 120.1,72.0, 55.3, 47.3, 46.4, 28.9, 25.3, 24.5, 19.4, 15.7 ppm. Purity: > 95 % LCMS (214 nm & 254 nm); rétention time 1.55 min; (M+1 ) 351.
Préparation Y
Example 96 quinucIidin-3-yl 2-isopropoxyphenylcarbamate
To a mixture of 3-aminophenol (1.50 g, 13.8 mmol), isopropanol (3.3 g, 55 mmol), and triphenylphosphine (14,4 g, 54.9 mmol) in THF (15 mL), was added dropwise diethylazodicarboxylate (9.60 g, 55.0 mmol) over a 30 min period. The mixture was stîrred at room température for 3 h and concentrated. The residue was diluted with water, acidified with aqueous 2N HCl and extracted with ether. The aqueous phase was basified with aqueous 2N NaOH and extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated. The
153 resulting crude product was purified by silica gel column chromatograph (petroleum ether/EtOAc 10:1 to 5:1) to afford 3-isopropoxybenzenamine as yellow oil (1.3 g, 64%).
Using general procedure A, 3-isopropoxybenzenamine (300 mg, 2.00 mmol) and quinuclidin-3-ol gave the title compound as a viscous oil (130 mg, 22%). ’H NMR (500 MHz, CDCIg) δ 7.20 (brs, 1H), 7.09 (t, J = 8.5 Hz, 1H), 7.05 (brs, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.51 (d, J = 8.5 Hz, 1H), 4.75 (m, 1H), 4.46 (m, 1H), 3.26-3.18 (m, 1H), 2.92-2.65 (m, 5H), 2.04 (m, 1H). 1.80 (m, 1H), 1.63 (m, 1H), 1.52 (m, 1H), 1.35 (m, 1H), 1.28 (d, J = 5.5Hz, 6H) ppm. 13C NMR (125 MHz, CDCh) δ 157.5, 152.2, 138.2, 128.7, 110.1, 109.6, 105.1, 70.7, 68.9, 54.3, 46.3, 45.4, 28.7,
24.3, 23.3, 21.0,18.3 ppm. Purity: > 90 % LCMS (214 nm & 254 nm); rétention time 1.43 min; (M+1) 305.
Example 97 quinuclidin-3-yl 2-isobutoxyphenylcarbamate
To a mixture of 3-aminophenol (500 mg, 4.60 mmol), 2-methylpropan-1-ol (1.40 g, 18.9 mmol) and triphenylphosphine (4.80 g, 16.2 mmol) in THF (10 mL) was added dropwise diethylazodicarboxylate (3.20 g, 18.3 mmol) over a 30 min period. The mixture was stirred at room température for 3 h. The solvent was evaporated and the residue was diluted with water, acidified with aqueous 2N HCl and extracted with ether. The aqueous phase was basified with aqueous 2N NaOH and extracted with EtOAc. The combined organic layers were dried (NaîSO4) and concentrated. The resulting crude product was purified by silica gel column chromatograph (petroleum ether/EtOAc 15:1) to afford 3-isobutoxybenzenamine as yellow oil (330 mg, 45%).
Using general procedure A, 3-isobutoxybenzenamine (330 mg, 2.00 mmol) and quinuclidin3-ol gave the title compound as a viscous oil (140 mg, 22%). 1H NMR (500 MHz, CDCI3) δ 7.17 (t, J = 8.0 Hz, 1H), 7.15 (brs, 1H), 6.81 (d, J = 8.5 Hz, 1H), 6.80 (br s, 1H), 6.61 (d, J= 8.5 Hz, 1H), 4.83 (m, 1 H), 3.71 (d, J = 6.5 Hz, 2H), 3.34-3.21 (m, 1 H), 2.97-2.72 (m, 5H), 2.12-2.04 (m, 2H), 1.90-1.84 (m, 1H), 1.75-1.67 (m, 1H), 1.55-1.63 (m. 1H), 1.46-1.38 (m, 1H), 1.01 (d, J = 6.5Hz, 6H) ppm.13C NMR (100 MHz, CDCI3) δ 159.9, 153.4, 139.3, 129.6, 110.6, 109.7, 105.0, 74.4, 72.0,
55.4, 47.3, 46.5, 28.3, 25.4, 24.5, 19.5,19.3 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.56 min; (M+1) 319.
154
Example 98 quinuclidin-3-yl 2-(cyclopropy!methoxy)phenylcarbamate
To a mixture of 3-aminophenol (300 mg, 2.70 mmol), cyclopropylmethanol (793 mg, 11.0 mmol) and triphenylphosphine (2.90 g, 11.0 mmol) in THF (6 mL) was added dropwise diethylazodicarboxylate (1.90 g, 11.0 mmol) over a 30 min period. The mixture was stirred at room température for 3 h. The solvent was evaporated and the residue was diluted with water, acidified with aqueous 2N HCl and extracted with ether. The aqueous phase was basified with aqueous 2N NaOH and extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated. The resulting crude product was purified by silica gel column chromatograph (petroleum ether/EtOAc 15:1) to afford 3-(cyclopropylmethoxy)benzenamine as a brown oïl (260 mg, 58%).
Using general procedure A, 3-(cyclopropylmethoxy)benzenamine (260 mg, 1.60 mmol) and quinuclidin-3-ol gave the title compound as a viscous oil (80 mg, 16%). 1H NMR (400 MHz, CDCI3) δ 7.72 (br s, 1H), 7.14 (br s, 1 H), 7.13 (t, J = 8.0 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 6.57 (dd, J = 8.0, 2.0 Hz, 1H), 4.85 (m, 1H), 3.75 (d, J = 6.8 Hz, 2H), 3.35-3.26 (m, 1H), 3.05-2.78 (m, 5H), 2.18-2.12 (m, 1H), 1.97-1.86 (m, 1H), 1.80-1.67 (m, 1H), 1.66-1.55 (m, 1H), 1.52-1.42 (m, 1H), 1.26-1.15 (m, 1H), 0.61-0.55 (m, 2H), 0.31-0.26 (m, 2H) ppm. 13C NMR (100 MHz, CDCI3) δ 158.6, 152.1, 138.3, 128.6,109.9, 108.9, 104.0, 71.7, 69.7, 53.8, 46.0, 45.2, 28.7, 24.1, 22.4,17.8, 9.2, 2.2 ppm. Purity: 100 % LCMS (214 nm & 254 nm); rétention time 1.46 min; (M+1) 317.
Example 99
1-benzyl-3-(quinuclldin-3-yl)imidazolidin-2-one
To a stirred solution of quinuclidin-3-amine hydrochloride (324 mg, 0.199 mmol) in DMF (30 ml) was added triethylamine (3 drops) followed by (isocyanatomethyl)benzene (275 mg, 2.10 mmol) carefully. The résultant mixture was stirred at 25 °C for 18 h. After HPLC séparation, 1-benzyl-3(quinuclidin-3-yl)urea (283 mg, 55%) was obtained.
To a solution of 1-benzyl-3-(quinuclidin-3-yl)urea (260 mg, 1.00 mmol) in DMF (30 ml) was added NaH [60% dispersion in minerai oil] (96 mg, 2.4 mmol) with ice bath cooling. The résultant
155 mixture was stirred for 2 h before BrCH2CH2Br (0.75 g, 4.0 mmol) was added carefully. The reaction was stirred for an additional 18 h at about 25 °C. After HPLC séparation, the aqueous layer was lyophilized and purified by prep-TLC (CHCI3 to 5% MeOH in CHCI3 to 5% 2N NH3(MeOH) in CHCI3) to give the title compound (81 mg, 28%). 1H NMR (400 MHz, CDCI3) δ 7.19-7.22 (m, 4H), 7.11-7.14 (m, 1H), 6.09 (dd, J= 15.2, 8.4 Hz, 1H), 5.45 (dd, J= 15.6, 4.0 Hz, 1H), 5.30 (dd, J=8.0,
3.6 Hz, 1H), 4.17-4.29 (m, 4H), 3.66-3.75 (m, 2H), 3.47 (d, J= 12.4 Hz, 1H), 3.19-3.27 (m, 3H), 2.34 (br s, 1 H), 2.22 (d, J = 2.4 Hz, 1 H), 1.92 (br s, 2H), 1.75 (br s, 1 H) ppm. 13C NMR (400 MHz. CDCI3) δ 158.9,141.1, 140.4, 128.7, 127.4,127.3, 113.6, 63.6, 57.1,56.0, 45.6, 43.9, 25.2, 23.0, 18.8 ppm. Purity: 93.8% HPLCMS (210 nm); rétention time 1.84 min; (M+1) 286.
Example 100
N-(1aza-bicyclo[2.2.2]oct-3-yl)-4-p-toly!-butyramide
Usîng general procedure 1,1-aza-bicyclo[2.2.2]oct-3-ylamine (200 mg, 1.00 mmol) and -ptolyl-butyric acid (220 mg, 1.2mmol) gave N-(1-aza-bicyclo[2.2.2]oct-3-yl)-4-p-tolyl-butyramide (114 mg, 40%) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.06 (s, 4H), 4.19 (m, 1H), 3.66-3.73 (t, J = 8.4 Hz, 1 H), 3.29-3.33 (m, 4H), 2.91 (dd, J ~ 8.0, J = 3.6 Hz, 1 H), 2.59 (t, J = 7.6 Hz, 2H), 2.28 (s, 3H), 2.24 (t, J =7.6 Hz, 2H), 2.15-2.16 (m, 1 H), 2.02-2.14 (m, 1H), 1.92-2.01 (m, 2H), 1.81-1.91 (m, 3H) ppm. 13C NMR (400 MHz, CDCI3) δ 175.1, 138.6, 135.1, 128.8, 128.2, 52.7, 47.4, 47.3, 44.5,
34.8, 27.3, 24.3, 21.6,19.8,17.1 ppm. Purity: 99.7% HPLCMS (210 nm); rétention time 1.76 min; (M+1) 287.
Example 101
N-(1-aza-bicyclo[2.2.2]oct-3-yl)-4-(4-methoxy-phenyl)-butyramide
Using general procedure 1,1-aza-bicyclo[2.2.2]oct-3-ylamine (200 mg, 1.00 mmol) and 4-(4methoxy-phenyl)-butyric acid gave the title compound as a white solid (85 mg, 28%). 1H NMR (400 MHz, CD3OD) δ 7.08 (d, J = 8.4 Hz, 2H), 6.81 (d, J = 8.4 Hz, 2H), 4.18 (br s, 1 H), 3.74 (s, 3H), 3.68 (d, J= 11.6 Hz, 1H), 3.24-3.33 (m, 4H), 2.98-3.03 (m, 1H), 2.57 (t, J~ 7.6 Hz, 2H), 2.24 (t, J= 7.6 Hz, 2H), 2.03-2.16 (m, 2H), 2.02 (br s, 2H), 1.85-1.91 (m, 3H) ppm. 13C NMR (400 MHz, CD3OD) δ
175.2,158.3, 133.6, 129.2, 113.6, 54.5, 52.6, 47.2, 46.4, 44.5, 34.9, 34.2, 27.5, 24.4, 21.5, 17.1 ppm. Purity: 96.4% HPLCMS (210 nm); rétention time 1.76 min; (M+1) 303.
I56
2-(1-aza-bicyclo[2.2.2]oct-3-yl)-N-[1-(3-isopropyl-phenyl)-1-methyl-ethyl]-acetamtde
To a solution of 1-(1-isocyanato-1-methyl-ethyl)-3-isopropenyl-benzene (10 g, 50 mmol) in tBuOH (1000 mL) was added KOH (40.0 g, 71.6 mmol). The mixture was stirred at reflux for 3 h. The résultant mixture was cooled down to room température, concentrated and dissolved in CH2CI2. Solid residue was filtered off and the organic layer was adjusted to pH<7 using conc. HCl. The ammonium sait was extracted with water. The aqueous layer was made basic using an aqueous NaOH solution [5% w/w, 200 ml] and free based amine was then extracted with CH2CI2. The organic layers were combined, dried over Na2SO4, filtered and concentrated under reduced pressure to give 1-(3-isopropenyl-phenyl)-1-methyl-ethylamine (3.3 g, 63%).
A solution of the above compound (8.5 g, 48 mmol) and PtO2 (1.8 g, 8.0 mmol) in EtOH (600 mL) was stirred at room température under 1 atm of H2 for 18 h. The reaction was filtered through Celite and concentrated under reduced pressure to give 1-(3-isopropyl-phenyl)-1-methylethylamine (5.0 g, 58%).
Using general procedure I, (1-aza-bicyclo[2.2.2]oct-3-yl)-acetic acid (200 mg, 1.20 mmol) and 1-(3-isopropyl-phenyl)-1-methyl-ethylamine gave the title compound as a white solid (42 mg, 10%). 1H NMR (400 MHz, DMSO-de) δ 7.15-1.20 (m. 3H), 7.05 (d, J= 8.4 Hz, 1H), 3.41-3.45 (m, 1H), 3.26 (s, 2H), 3.15-3.22 (m, 2H), 2.71-2.82 (m, 2H), 2.41-2.47 (m, 3H), 2.05-2.12 (m, 1H), 1.791.90 (m, 4H), 1.61 (d, J = 8.0 Hz, 6H), 1.21 (d, J = 6.4 Hz, 6H) ppm. 13C NMR (400 MHz, DMSO-c/6) δ 171.1, 148.7, 147.3, 128.1, 123.9, 122.8, 122.2, 55.6, 52.1, 46.5,45.9, 38.8, 34.5, 30.7, 28.9,
28.5, 23.8, 23.4, 18.0 ppm. Purity: 96.8% HPLCMS (210 nm); rétention time 1.93 min; (M+1) 329.
Example 107
2-(1-aza-bicyclo[2.2.2]oct-3-yl)-N-[2-(2-methoxy-phenyl)-ethyl]-acetamide
Using general procedure I, (1-aza-bicyclo[2.2.2]oct-3-yl)-acetic acid (200 mg, 1.20 mmol) and 2-(2-methoxy-phenyl)-ethylamîne gave the title compound as a white solid (60 mg, 15%). 1H NMR (400 MHz, CD3OD) δ 7,17 (t, J= 7.2 Hz, 1H), 7.08 (d, J = 7.2 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.84 (t, J= 7.6 Hz, 1H), 3.89 (s, 3H), 3.35-3.45 (m, 3H), 3.21-3.31 (m, 3H), 2.76-2.83 (m, 3H), 2.29-2.45 (m, 3H), 1.82-2.01 (m, 3H), 1.72-1.81 (m, 2H) ppm. 13C NMR (400 MHz, CD3OD) δ 172.0, 158.0, 130.4, 127.8, 127.2, 120.2, 110.4, 54.6, 52.0, 46.4, 45.9, 39.1, 38.3, 30.7, 30.2, 23.8, 17.9 ppm. Purity: 92.4% HPLCMS (210 nm); rétention time 1.59 min; (M+1) 303.
159
Example 102
Biphenyl-3-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide
Using general procedure I, 1-aza-bicyclo[2.2.2]oct-3-ylamine (200 mg, 1.00 mmol) and biphenyl-3-carboxylic acid gave the title compound as a white solid (211 mg, 68%). 1H NMR (400 MHz, CD3OD) δ 7.86 (s, 1 H), 7.59 (d, J = 7.6 Hz, 1 H), 7.53 (d, J = 8.0 Hz, 1 H), 7.40 (d, J = 7.6 Hz, 2H), 7.28 (t, J ~ 7.6 Hz, 1 H), 7.19 (t, J = 7.6 Hz, 2H), 7.11 (t, J = 7.6 Hz, 1 H), 4.21 (br s, 1 H), 3.56 (t, J= 11.6 Hz, 1 H), 3.11-3.22 (m, 1H), 3.05-3.10 (m, 4H), 2.10 (q, J = 3.2 Hz, 1H), 1.95 (brs, 1H), 1.79-1.83 (m, 2H), 1.59-1.20 (m, 1H) ppm. 13C NMR (400 MHz, CD3OD) δ 169.6, 141.6, 140.2,
134.5,130.3, 129.0, 127.7, 126.9, 126.3, 125.9, 51.9, 46.4, 46.0, 45.6, 24.6, 21.6, 17.3 ppm. Purity: 99.8% HPLCMS (210 nm); rétention time 1.60 min; (M+1) 307.
Example 103
N-(1-aza-bicyclo[2.2.2]oct-3-yl)-2-biphenyl-4-yl-acetamide
Using general procedure I, 1-aza-bicyclo[2.2.2]oct-3-ylamine (200 mg, 1.00 mmol) and biphenyl-4-yl-acetic acid gave the title compound as a white solid (140 mg, 44%). 1H NMR (400 MHz, CD3OD) δ 7.56 (t, J = 8.0 Hz, 4H), 7.29-7.41 (m, 5H), 4.19 (br s, 1 H), 3.70 (t, J = 7.2 Hz, 1 H), 3.58 (s, 2H), 3.24-3.31 (m, 5H), 3.12-3.19 (m, 1H), 2.16-2.17 (m, 2H), 1.95-1.98 (m, 2H), 1.82 (br s, 1H) ppm. 13C NMR (400 MHz, CD3OD) δ 173.1, 140.8, 140.0, 134.7, 129.4, 128.7, 126.9, 52.3, 46.4, 45.9, 44.3, 41.9, 24.4, 21.5, 17.1 ppm. Purity: 93.9% HPLCMS (210 nm); rétention time 2.87 min; (M+1) 321.
Préparation Z
Example 104
2-(quinuclidin-3-yl)-N-(1-p-tolylcyclopropyl)acetamide
To a solution of methyl 2-(dimethoxyphosphoryl)acetate (2.70 g, 14.8 mmol) in THF (200 ml) at 0 °C was added NaH [60% dispersion in minerai oil] (600 mg, 15.0 mmol). After 1 h of stirring, quinuclidin-3-one (2.00 g, 12.4 mmol) was added and the résultant mixture was stirred at
157 room température for 18 h. The reaction was quenched with 50 ml water at 0 °C and the mixture was extracted with EtOAc. The organic layers were combined and concentrated under reduced pressure to afford crude methyl 2-(quinuclidin-3-ylidene)acetate, which was used in next step without purification (1.2 g, 70%).
A mixture of methyl 2-(quinuclidin-3-ylidene)acetate (70 mg, 0.38 mmol) and Pd/C (100 mg, 20% w/w) in EtOH (10 mL) was stirred under H2 (20 psi) at room température for 18 h. The reaction solution was filtered through Celite and the filtrate was concentrated under reduced pressure to afford crude methyl 2-(quinuclidin-3-yl)acetate (60 mg, 85%), which was used with purification in the next step.
A mixture of methyl 2-(quinuclidin-3-yl) acetate (1.1g, 6.0 mmol) and 50 mL of conc. HCl [12M] was stirred at 70°C for 18 h. The reaction mixture was concentrated under reduced pressure to afford crude 2-(quinuclidin-3-yl)acetic acid, which was used without purification in the next step (900 mg, 86%).
Using general procedure I, 2-(quinuclidin-3-yl)acetic acid (169 mg, 1.00 mmol) and 1-ptolylcyclopropanamine (149 mg, 1.10 mmol) gave the title compound as a white solid (60 mg, 18%). 1H NMR (400 MHz, CDCI3) δ 7.86 (s, 1H), 6.96-7.07 (m, 4H), 3.22-3.37 (m, 2H), 2.85-3.05 (m, 4H), 2.39-2.45 (m, 2H), 2.21 (s, 3H), 1.45-1.92 (m, 5H), 1.07-1.23 (m, 5H) ppm. 13C NMR (400 MHz, CDCI3) δ 171.6, 139.8, 136.1,129.2, 125.6, 52.1,50.9, 46.5, 46.0, 39.2, 34.9, 30.8, 24.5, 21.1,
18.7,17.6 ppm. Purity; 96.2% HPLCMS (210 nm); rétention time 1.21 min; (M+1) 299.
Example 105
N-(2-(3-methoxyphenyl)propan-2-yl)-2-(quinuclidin-3-yl)acetamide
Using general procedure I, 2-(quinuclidin-3-yl)acetic acid (169 mg, 1.00 mmol) and 2-(3methoxyphenyl)propan-2-amine (182 mg, 1.10 mmol) gave the title compound as a white solid (126 mg, 40%). 1H NMR (400 MHz, CDCI3) δ 7.39 (s, 1 H), 7.20 (t, J = 8.0 Hz, 1 H), 6.92 (d, J = 8.0 Hz, 1H), 6.87 (d, J = 2.0 Hz, 1 H). 6.71 (dd, J= 8.0, 2.0 Hz, 1H), 3.75 (s, 3H), 3.31-3.42 (m, 2H), 3.003.19 (m, 4H), 2.47-2.60 (m, 2H), 2.27 (dd, J= 14.0, 6.0 Hz, 1H), 1.83-2.06 (m, 4H), 1.64-1.74 (m, 1 H), 1.61 (d, J = 12.4 Hz, 6H) ppm. 13C NMR (400 MHz, CDCI3) δ 170.0, 159.7, 149.3, 129.5,
117.5,111.8, 111.0, 55.9, 55.4, 52.0, 50.6, 46.6, 46.0, 39.7, 30.9, 29.7, 29.1, 24.3, 18.8 ppm. Purity: 93.7% HPLCMS (210 nm); rétention time 0.76 min; (M+1) 317.
Example 106
158
Example 108
1- (1-aza-bicyclo[2.2.2]oct-3-yl)-3-[1-(3-isopropyl-phenyl)-cyclopropyl]-urea
A mixture of 3-isopropyl-benzoic acid (5.00 g, 30.4mmol) in SOCI2(50ml) was stirred at 100 °C for 2 h. The reaction mixture was concentrated to give 3-isopropyl-benzoyl chloride (5.00 g, 91%).
Into a solution of the above acid chloride (5.00 g, 27.0 mmol) in CH2CI2(20 ml) at -70 °C was added, dropwise, a solution of NH3/CH2CI2 (200 mL). The mixture was stirred at room température for 18 h and then concentrated to give 3-îsopropyl-benzamide (4.2 g, 93%).
A solution of the above amîde (4.20 g, 25.7 mmol) in POCI3(36.0 g, 236 mmol) was stirred at 80 °C for 18 h. The solution was concentrated and the residue was poured into water (100 mL). The mixture was exacted with EtOAc. The organic layers were combined, washed by brine, dried over Na2SO4 and concentrated to give 3-isopropyl-benzonitrile (3.00 g, 80%).
Using general procedure G, 3-isopropyl-benzonitrile (3.00 g, 20.6 mmol) was converted to the corresponding 1-(3-isopropyl-phenyl)-cyclopropylamine (0.80 g, 22%).
Using general procedure C, the above amine (300 mg, 1.71 mmol), quinuclidin-3-amine (215 mg, 1.71 mmol) and CDI (290 mg, 2.05 mmol) gave the title compound as a white solid (88 mg, 46%). 1H NMR (400 MHz, CD3OD) δ 7.18 (t, J- 8.0 Hz, 1H), 7,12 (s, 1H), 7.01 (dd, J= 19.2,
7.6 Hz, 2H), 3.74-3.77 (m, 1H). 3.18-3.24 (m, 1H), 2.71-2.87 (m, 5H), 2.42-2.47 (m, 1H), 1.63-1.82 (m, 4H), 1.45 (br s, 1H), 1.21-1.26 (m, 10H) ppm. 13C NMR (400 MHz, CD3OD) δ 193.0,168.7, 160.1, 128.2, 122.7, 121.9, 55.3, 46.8, 46.1.34.1.25.9, 25.0, 23.5, 19.6,18.2 ppm. Purity: 92.4% HPLCMS (210 nm); rétention time 2.53 min; (M+1) 328.
Example 109
2- (1 -aza-bicyclo[2.2.2]oct-3-yl)-N-[1 -(3-isopropyl-phenyl)- cyclopropyl]-acetamide
160
Using general procedure 1,1-(3-isopropyl-pheny!)-cyclopropylamine (278 mg, 1.58 mmol) and (1-aza-bicyclo[2.2.2]oct-3-yl)-acetic acid (267 mg, 1.58 mmol) gave the title compound as a white solid (70 mg, 14%). 1H NMR (400 MHz, CD3OD) δ 7.16 (t, J= 8.0 Hz, 1H), 7.07 (s, 1H), 6.97 (dd, J= 19.2, 7.6 Hz, 2H), 3.16-3.23 (m, 1H), 2.79-2.97 (m, 5H), 2.51-2.58 (m, 1H), 2.23-2.41 (m, 3H), 1.83-1.92 (m, 1H), 1.68-1.81 (m, 3H), 1.54-1.62 (m, 1H), 1.15-1.25 (m, 10H) ppm. 13C NMR (400 MHz, CD3OD) δ 173.6, 148.5, 142.4, 127.8, 123.6,123.1, 122.0, 73.0, 53.1,46.6, 45.9, 39.3, 34.1, 32.3, 28.1,26.4, 24.4,19.7, 16.8 ppm. Purity: 96.9% HPLCMS (210 nm); rétention time 2.55 min; (M+1) 327.
Example 110 [1 -(3-isopropyl-phenyl)-cyclopropyl]-carbamic acid 1-aza-bicyclo[2.2.2]oct-3-yl ester
Using general procedure A, 1-(3-isopropyl-phenyl)-cyclopropylamine (278 mg, 1.58 mmol) and quinuclidin-3-ol gave the title compound as a white solid (75 mg, 22%). 1H NMR (400 MHz, CD3OD) δ 7.17 (m, 1H), 7.09 (s, 1H), 6.97-7.08 (m, 2H), 4.72-4.79 (m, 1H), 3.36-3.42 (m, 1H), 2.79-3.08 (m, 5H), 1.93-2.17 (m, 2H), 1.81-1.90 (m, 1H), 1.67-1.78 (m, 2H), 1.31-1.54 (m, 1H), 1.13-1.28 (m, 10H) ppm. 13C NMR (400 MHz, CD3OD) δ 157.1, 148.4, 143.1,128.1, 123.9, 123.0, 122.4, 69.2, 54.4, 46.7, 45.7, 34.7, 34.3, 24.9, 23.3, 22.0, 18.0, 17.3 ppm. Purity: 99.2% HPLCMS (210 nm); rétention time 1.83 min; (M+1) 329.
Example 111
In vivo efficacy studies of small molécule therapy using (S)-Quinuclidin-3-yl (2-(2-(4fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate sait on Fabry mouse model
Here, in vivo experiments are described using a GCS inhibitor in a Fabry mouse model and demonstrate that substrate réduction therapy (SRT) is equally effective at reducing the levels of both Gb3 and Iyso-Gb3 in the plasma, kidney and urine of Fabry mice. The study was designed to evaluate whether substrate inhibition (i.e. substrate réduction therapy) using a compounds of the invention types could reduce the accumulation of the storage material globotriaosylceramide (Gb3) and lysoglobotriaosylceramide (Iyso-Gb3). Recently it has been proposed that urinary Iyso-Gb3 may represent a reliable biomarker of clinical relevance for Fabry disease (Aerts et al., PNAS USA 105:2812-2817 (2008); and Auray-Blais et al., Clin Chim Acta 411:1906-1914 (2010)), The
I61 metabolic origin of the Iyso-Gb3 is not known and can conceivably be derived through either déacylation of Gb3 or through anabolic synthesis from glucosylsphingosine.
In Fig. 2, black arrows indicate demonstrated pathways, gray arrows are undocumented pathways. ERT using α-Galactosidase A is known to dégradé both Gb3 and Iyso-Gb3. Accordingly, SRT using a GCS inhibitor would be most effective at limiting Iyso-Gb3 accumulation if the lysoGb3 is generated primarily through déacylation of Gb3, a GCS dépendent pathway. These experiements demonstrate that SRT using GCS inhibitors in a mouse model of Fabry disease reduced both Gb3 and Iyso-Gb3, thus supporting the use of compounds of the invention as viable therapeutic options for Fabry patients.
In the following experiments, mice dosed with GCS inhibitors at either -60 mg/kg/day of (S)Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (S)-2-hydroxysuccinate sait (hereinafter “GZ 452) or -300 mg/kg/day of (1 R,2R)-Octanoic acid[2-(2’,3'-dihydro-benzo [1,4] dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide-L-tartaric acid sait (hereinafter “GZ 638”) as a component of the pelleted food diet provided ad libitum. Lipid analysis was by ESI/MS as described in Marshall et al., PLoS ONE 5:e15033 (2010). As discussed in further detail below, treatment started when the mice were 3, 8 or 12 months of âge to test the efficacy at different disease severities. Blood and urine was collected monthly and periodic tissue harvests provided materials to evaluate efficacy of the therapy (Gb3 and Iyso-Gb3 levels). Previous studies demonstrated that earlier génération glucosylceramide synthase inhibitors (of the P4-like class) could delay the rate of Gb3 accumulation, however, as discussed below, treatment with Genz-452 could not only prevent or delay further accumulation but effected réductions of the absolute levels of both Gb3 and Iyso-Gb3 in the tissues tested (liver, heart, urine, plasma). As further discussed below, the efficacy of SMT was affected by the âge of the mice at the start of treatment. Generally, the older the mouse, the higher the levels of Gb3 stored and thus a longer period of treatment was required in order to affect similar therapeutic benefit (see Fig. 4). The experiments and results are described further below.
GCS Inhibitor Reduces Gb3 Levels In Fabry Mouse Viscéral Tissue
In this experiment, Fabry mice were treated with GCS inhibitors in their diet for 4 months starting at 8 months old. We hâve previously reported that eliglustat tartrate (GZ 638) at 300 mg/kg/day (SRT GZ 638) is effective at inhibiting further accumulation of tissue Gb3 (as shown
162 here by the non-significant changes in Gb3 relative to the starting levels UNT (start)). As shown in Fig. 3, a more potent GCS inhibitor, GZ 452, was also evaluated (at 60 mg/kg/day) (SRT-Gz452) and found not only to prevent further accumulation but also to significantly reduce stored Gb3 relative to the starting levels (UNT (start)). Age-matched wild-type levels (WT) are also shown. These results demonstrate that GZ 638 is a potent GCS inhibtor and effectively reduces Gb3 levels in viscéral tissues of the Fabry mouse.
SRT Reduces Urine And Plasma Gb3 In Both Younqer And Older Fabry Mice
In this experiment, Fabry mice were treated with GZ 452 in their diet (Rx:) for 2 or 4 months starting at either 3 or 8 months of âge (Age:) as indicated in Figs. 4A and 4B. The urine Gb3 levels of younger and older mice were equally responsive to SRT treatment, achieving -90% réduction with 2 months of treatment. Plasma levels of Gb3 were slower to respond to treatment, with older mice requiring twice the treatment time of younger mice (4 vs. 2 months) to achieve -50% réduction. These results demonstrate that GZ 638 effectively reduces Gb3 levels in urine and plasma in younger and older Fabry mice.
SRT Reduces both Gb3 and Lyso-Gb3 in Fabry Mouse Kidney
In this experiment, Fabry mice were treated with Genz-452 in their diet for 4 months starting at 8 months of âge. As shown in Fig. 5, kidney tissue was analyzed for (A) Gb3 and (B) Iyso-Gb3 from age-matched untreated Fabry mice (UNT), GZ 452-treated Fabry mice (SRT) and wild-type control mice (WT). SRT resulted in similar significant relative réductions in levels (60-70%) for both Gb3 and Iyso-Gb3. These results demonstrate that GZ 638 effectively reduces both Gb3 and LysoGb3 levels in kidney tissues of Fabry mice.
Example 112
In vivo efficacy studies of combination therapy on Fabry mouse model using GZ 452 and alpha-galactosidase A
Fabry mice were used to test the in vivo efficacy of combining enzyme replacement therapy with small molécule therapy in a concurrent treatment format. The study was designed to evaluate whether substrate inhibition (i.e. substrate réduction therapy) using the GZ 452 compound could reduce re-accumulation of the storage material Gb3 and Iyso-Gb3. The study protocol called for three distinct treatment groups of 3 month old male Fabry mice (Fig. 6A). The first group received intravenous injections of alpha-galactosidase A enzyme (ERT) at 1mg/kg to reduce Gb3 levels and
163
was repeated every 2 months. The second group received the same enzyme injections as group 1, but also were dosed with GZ 452 at ~60 mg/kg/day as a component of the pelleted diet. The third group received only the daily dosing of GZ 452 in their diet. A fourth group received no treatment to serve as vehicle controls and a fifth group of wild-type animais provided 'normal' Gb3 and Iyso-Gb3 values. Monthly urine and blood collections and three monthly tissue harvests provide materials to evaluate relative efficacy of the thérapies (Fig. 6A).
After 2 months (mice were 5 months old), plasma (Fig. 6B, panels A and C) and urine (Fig. 6B, panels B & D) were analyzed for Gb3 (Fig. 6B, panels A and B) and Iyso-Gb3 (Fig. 6B, panels C and D). In plasma, ERT and SRT reduced both Gb3 (panel A) and Iyso-Gb3 (panel C) levels, and combining ERT and SRT resulted in significant improvements over either therapeutic alone. Urine Gb3 levels were unaffected by ERT, but significantly reduced by SRT (panel B). Urine Iyso-Gb3 was similarly reduced by ail treatments (panel D), suggesting that urine Gb3 and Iyso-Gb3 may originale from distinct sources. The results from these studies show that the SMT was effective at reducing Gb3 in the kidney and urine. ERT was more effective than SMT at reducing Gb3 in the plasma, however the most effective therapy was derived from combining the two thérapies. SMT therapy alone or in combination with ERT was also capable of affecting (reducing accumulation) of Iyso-Gb3.
Example 113
Gb3 Acyl Chain Isoform ProfileThe relative abundance of the different carbon chain length amido-linked acyl groups was determined for Gb3 from plasma, urine and kidney of Fabry mice. As shown in Fig. 7, major plasma isoforms were C16:0 and C24:1. Urine and kidney isoform profiles were nearly identical, with C24:0 and 022:0 being the prédominant chain lengths. These data are consistent with urine Gb3 coming predominantly from the kidney - probably through epidermal exosomal shedding. Correlating these results with those in Fig. 6, in which ERT reduced plasma and urine Iyso-Gb3 but not urine Gb3, suggests that the Iyso-Gb3 in urine is derived from plasma filtrate. This différentiation of source for urine Gb3 and Iyso-Gb3, if also true for patients, may explain why Iyso-Gb3 is thought to be a more accurate predictor of disease severity and treatment efficacy than urine Gb3.
Example 114
SRT But Not ERT Significantly Delays Loss of Thermal Nociceptive Response
164
Three month old Fabry mice were treated with GZ 452 in their diet (SRT), agal once every 2 months (ERT), or a combination of the 2 treatments (E+S), as described above. After 6 months of combination therapy, the thermal nociceptive response time (latency) was evaluated by placing the mice on a 55°C hotplate and recording the time to respond (i.e., a distinctive hind-paw flick), As shown in Fig. 8, after 7 months of treatment (10 month old mice) the ERT-only treated group was not significantly different to the untreated group (UNT). The SRT and combination treated groups had significantly shorter response fîmes to the heat stimulus. These results demonstrate that SRT (but not ERT) delayed the loss of a thermal nociceptive response, a surrogate for the peripheral neuropathy often seen in Fabry patients.
Example 115 nGD mouse model for in vivo studies of SMT using Gz161
K14 Inl/lnl (abbreviated as K14) mice were obtained from Lund University (Enquist et al. (2007)) and bred under a protocol approved by the Institutional Animal Care and Use Committee. Pups obtained from hétérozygote matings were tail clipped and genotyped within one day of birth (by P1). The DNA was extracted using a lysis buffer of 5 mM EDTA, 0.2%SDS, 200 mM NaCI, 100 mM Tris pH 8.0 supplemented with 0.25 mg/ml Protéinase K (Invitrogen, Carlsbad, California), precipitated with 100% isopropanol and redissolved in 1X Tris EDTA buffer. The DNA was then used for polymerase chain reaction (PCR) to détermine the presence of the GC gene under the K14 keratin promoter (CRE) (Enquist et al. (2007)). To détermine the Neomycin résistance site disruption of the murine glucocerebrosidase gene (NEO) we used a three primer approach: GC WT Fwd 5’-TGTTCCCCAACACAATGCTCTTT-3'; Rev 5'-TCTGTGACTCTGATGCCACCTTG-3’ and Neo Rev 5’-AAGACAGAATAAAACGCACGG GTG-3' as previously described in Cabrera-Salazar et al., Experimental Neurology 225: 436-444 (2010).
Newborn mice received daily 5 mg/kg intraperitoneal injections of Quinuclidin-3-yl (2-(4’~ fluoro-[1,1'-biphenyl]-3-yl)propan-2-yl)carbamate (hereinafter “GZ 161) in a volume of 10 pl/gram of body weight starting at postnatal day 4. K14 mice and wild type littermates were humanely sacrificed at postnatal day 10 (pre-symptomatic) and at day 14 (humane endpoint) to evaluate glycosphingolipid (GSL) levels. Mice received a 150 mg/kg dose of pentobarbital (Euthasol, Virbac Inc, Forth Worth, TX) and were transcardially perfused with cold 0.9% NaCI solution. Brains were dissected and divided; one hemisphere was used for GSL analysis and the other was fixed in 4% paraformaldéhyde for 96 hours and processed for histology.
165
To détermine if further benefits could be achieved by prénatal exposure to GZ 161, a subset of prégnant K14 females received GZ 161 in food using a formulation calculated to provide 20 mg/kg/day during the final 5-7 days of gestation. Females receiving GZ 161 were switched to standard diet after delivery and the pups received daily IP injections of GZ 161 at a dose of 5 mg/kg (10 pi per gram of body weight) starting at P1. A set of WT pups born to females receiving the drug or standard formula was sacrificed immediately after birth to détermine whether in utero exposure to GZ 161 could reduce brain GSL levels.
Example 116
Glycosphingolipid quantitation
Quantitative sphingolipid analysis was performed by liquid chromatography and tandem mass spectrometry (LC/MS/MS) as previously described in Merrill et al., Methods 36: 207-224 (2005). Briefly, 10 μΙ of brain tissue homogenate (tissue weight/water:100 mg/ml) was extracted with 1.00 ml of an organic solvent mixture (97% acetonitrile, 2% methanol, and 1% acetic acid, v/v) and vortexed vigorously for 10 min. Extracted sphingolipids (GluCer and GluSph) were directly separated by hydrophilic liquid chromatography (Atlantis HILIC column, Waters Corp.) and analyzed by triple quadrupole tandem mass spectrometry (API 4000, Applied Biosystems/MDS SCIEX) and compared with sphingolipid standards (Matreya, LLC; Pleasant Gap, PA)
Example 117
Reformulation of recombinant human glucocerebrosidase
Recombinant human glucocerebrosidase (rhGC) was reformulated as previously described in Cabrera-Salazar et al. (2010). Briefly, rhGC was bound using a cation-exchange (CM Sepharose) and human sérum albumin (HSA) was added to the eluate as a stabilizer. The formulation for ICV administration was 2 mg/ml rhGC in a 10 mM sodium phosphate buffer at pH 7.2 containing 135 mM sodium chloride, 5 mg/ml HSA and 0.01% polysorbate 80.
Example 118
Intracerebroventricular injections
An animal model of neuropathie Gaucher disease (nGD) identified as K14 were cryoanesthesized and received 2 μΙ bilateral intracerebroventricular (ICV) injections of either rhGC
166 at 2 mg/ml or vehicle as previously described. (Cabrera-Salazar et al. (2010)) The injected pups were monitored for recovery and returned to the mother following the procedure.
Example 119
Hïstopathology
After génotype confirmation, animais were humanely sacrificed at 10 days of âge, At this âge K14 mice are asymptomatic. Mice received an intraperitoneal injection of 150 mg/kg sodium pentobarbital ((Euthasol, Virbac Inc, Forth Worth, TX) and were perfused by an intracardial infusion of chilled 0.9% sodium chloride. Brains were removed and post fixed in 4% paraformaldéhyde for 72 hours. Tissue was transferred to PBS and paraffin embedded. Sagital sections 5 pm thick were eut and stained as described below. Gliosis and the presence of cells of the macrophage lineage were evaluated by means of glial fibrillary acidic protein staining and expression of CD68 and F4/80 pan-macrophage markers using the Leica Bond Max Immunostainer system (Leica Microsystems, Wetzlar, Germany).
GFAP staining: Paraffin sections were placed on mounting slides and processed using the Bond Polymer Refine IHC System (Leica Microsystems, Wetlzar, Germany) blocked for 10 minutes in serum-free protein block (Dako Systems, Glostrup, Denmark), incubated for 30 minutes in a 1:1500 dilution of primary anti-GFAP antibody in Dako antibody diluent (Dako, Glostrup, Denmark), and stained using the Bond Polymer Refine détection kit (Leica Microsystems, Wetzlar, Germany).
F4/80 staining: Paraffin sections were placed on mounting slides and processed using the Bond Polymer Refine IHC system (Leica Microsystems, Wetlzar, Germany), incubated for 30 minutes in a 1:2500 dilution of rat anti- mouse F4/80 antibody (eBioscîence, San Diego, CA) or Rat lgG2a (eBioscience, San Diego, CA) as an isotype control. Slides were then incubated with a 1:250 dilution of rabbit anti-rat secondary antibody (Vector laboratories, Burlingame, CA) and stained using the Bond Polymer Refine détection kit (Leica Microsystems, Wetzlar, Germany).
CD 68 staining: Paraffin sections were placed on mounting slides and processed using the Bond Polymer Refîne IHC system (Leica Microsystems, Wetlzar, Germany), incubated for 30 minutes in a 1:2500 dilution of rat anti- mouse CD68 clone FA-11 antibody (AbD Serotec, Oxford, UK) or Rat lgG2a isotype control (AbD Serotec, Oxford, UK). Slides were then incubated with a
167
1:250 dilution of rabbit anti-rat secondary antibody (Vector laboratories, Burlingame, CA) and stained using the Bond Polymer Refine détection kit (Leica Microsystems, Wetzlar, Germany).
For each staining technique exposure-matched digital images were obtained from similar brain régions of each experimental group using the Aperio ScanScope XT system (Aperio Technologies, Vista, CA). Stained slides were digitalized in high resolution and six areas of interest were highlighted in each slide and analyzed independently by histomorphometry. Positively stained area and nuclei were determined and quantitative data were analyzed by a one-way analysis of variance followed by Tukey’s multiple comparison test using the Graph Pad Prism V 4.0 (GraphPad Software, San Diego, CA). Différences between group means with p<0.05 were considered significant.
Example 119
Survival
K14 mice received daily intraperitoneal injections of GZ 161 at a dose of 5 mg/kg of body weight as described above. A separate cohort of animais also received ICV injections of GC at postnatal days 1,2 and 3 followed by daily IP injections of GZ 161. Animais that reached weaning âge received GZ 161 in a spécial chow designed to provide a dose of 60 mg/kg/day. Ail animais were monitored daily for the development of neurological complications. Mice were sacrificed when they reached a humane endpoint (inability to right within 10 seconds after being placed in latéral recumbence) by an injection of 150 mg/kg sodium pentobarbital (Euthasol, Virbac Inc, Forth Worth, TX). This time point was recorded as end of life and analyzed using Kaplan-Meier plots.
Example 120
Statistical analysis
Values shown correspond to means and error bars represent standard error of the mean. Comparisons between groups were analyzed by a one-way analysis of variance followed by Tukey’s multiple comparison test. Comparison of substrate réduction in utero was analyzed by the unpaired t test with Welch’s correction. Kaplan-Meier survival curves were analyzed using the logrank test équivalent to the Mantel-Haenszel test. Ail statistical analyses were performed using GraphPad Prism v4.0 (GraphPad Software, San Diego, CA). Différences between group means with p<0.05 were considered significant.
168
Example 121
Substrate accumulation in K14 mouse brain
Before evaluating drug effects on brain lipids, we compared the time dépendent changes in GluCer, GalCer and GluSph levels in the K14 mouse brain to those of a wild type (WT) mouse control. Fig. 9, panels A and B show that in WT mouse brain, the prédominant GL-1 isomer in the first few days of life was GluCer; by postnatal day 14 (P14) the prédominant isomer was GalCer. These results are consistent with those of a study in rat brain, which found that GluCer is synthesized at a higher rate during the first week of life and is followed by an increased synthesis of GalCer starting at P8 (Brenkert et al., Brain Research 36: 183-193 (1972)). Fig. 9, panel A also shows that in K14 mice GluCer was elevated 10-fold relative to WT mice and that this increase was sustained through the first 2 weeks of life until the mice died around P14.
In agreement with prevîous mouse models of neuropathie Gaucher disease (Liu et al., PNAS 95: 2503-2508 (1998)), Fig. 9, panel C shows that at birth the lysoglycosphingolipid GluSph was elevated >20-fold in the brains of the K14 mouse model relative to WT mice. This increase was sustained through the first 2 weeks of life and was even higher in animais sacrificed at end stage (Fig. 9, panel C). In WT littermates of the K14 mice, GluSph levels were below the threshold of détection (0.3 ng/mg of tissue). Fig. 9, panel D shows that these elevated glycosphingolipids and lysoglycosphingolipids in the K14 mouse did not appearto hâve an impact on brain weight (relative to that of WT mice). Given the known toxicity of GluSph, therapeutic strategies geared towards reducing the accumulation of these substrates in the K14 mouse brain might be expected to hâve an impact on the pathologie features of the disease and the lifespan of the animais.
Example 122
Intraperitoneal administration of GZ 161 reduces GluCer and GluSph levels in the brains of K14 mice
Fig. 10 shows that compared to vehicle-treated K14 mice at the humane endpoint (14-15 days of âge), daily intraperitoneal (IP) administration of GZ 161 reduced brain levels of both GluCer and GluSph by >60%. K14 mice treated with GZ 161 were asymptomatic at this time point. Even though GZ 161 administration significantly reduced the levels of these glycosphingolipids, Fig. 10 shows that they nonetheless remained elevated several-fold over those of age-matched wild-type mice; GluSph was not detected in samples analyzed from WT or hétérozygote littermates. The réduction of brain glycosphingolipids as a conséquence of systemic drug administration strongly
169 suggests that GZ 161 is both capable of crossing the blood brain barrier and inhibiting its target enzyme, GCS.
Example 123
Intraperitoneal administration of Gz 161 reduces microqlial/macrophaqe staininq throuqhout the brain of K14 mice
Cells of the myeloid lineage can be detected in the murine brain using antibodies to antigens such as F4/80 and CD68. F4/80 is a transmembrane glycoprotein found on ramified (quiescent) microglia and macrophages, while CD68 is a lysosomal protein expressed at relatively high levels in macrophages and activated (reactive) microglia, and at lower levels in ramified microglia. Increased F4/80 and CD68 staining in the brain may occur through recruitment of monocytes or microglial prolifération, and is a normal response to injury and inflammation. Fig. 11 shows qualitatively and quantitatively that compared to wild type mice at 10 days of âge (P10), the K14 mouse brain has increased numbers of CD68+ cells in multiple locations (hippocampus, thalamus, brainstem, cerebellum). The greatest concentration of CD68+ cells was seen in the thalamus and brainstem, two sites that also show pathology in type 2 Gaucher patients. (Conradi et al., Acta Neuropathologica 65: 99-109(1984); Conradi et al., Acta Neuropathologica 82:152-157 (1991); and Wong et al., Molecular Genetics and Metabolism 82:192-207 (2004)). Fig. 11 also shows that systemic administration of GZ 161 reduces the numbers of CD68+ cells in ail of these locations; treatment also reduced CD68+ cells in the olfactory bulb and frontal cortex (data not shown). Consistent with the CD68 histopathology, Fig. 12 shows increased F4/80 staining relative to WT animais in vehicle treated K14 mice at P10. Daily IP injections of GZ 161 reduced the numbers of F4/80+ cells in the thalamus and brainstem, but had marginal effects in other brain régions. Taken together with the CD68 data, these results suggest that systemic treatment of the K14 mouse with GZ 161 results in decreased numbers of macrophages/microglia in multiple brain régions.
Example 124
Intraperitoneal administration of GZ 161 reduces gliosis in several brain régions of K14 mice
Astrocytes can undergo hypertrophy or proliferate in response to inflammation and neuronal damage or death, a process known as astrogliosis. Glial fibrillary acidic protein (GFAP) is an intermediate filament protein that is heavily expressed in activated (reactive) astrocytes, and can
170 therefore be used to monitor astrogliosis. Fig. 13 shows that at P10 GFAP staining was increased compared to WT levels in several brain régions (hippocampus, thalamus, brainstem, cerebellum) of the K14 mouse, indicating the presence of reactive astrocytes. Fig. 13 also shows that systemic treatment of K14 mice with GZ 161 led to decreased GFAP staining in the hippocampus and cerebellum at P10; staining was also decreased in the olfactory bulb and frontal cortex (data not shown). Thus, these GFAP results are consistent with the above macrophage/microglial data demonstrating that the K14 mouse likely has an ongoing inflammatory process that can be attenuated to some degree by systemic administration of GZ 161.
Example 125
Intraperitoneal administration of GZ 161 increases survival of K14 mice
Given the positive effects of GZ 161 treatment on brain glycosphingolipids and histopathology, we asked whether these effects translated into increased survival of the K14 mouse. Fig. 14 demonstrates that vehicle treated K14 mice hâve a médian lifespan of 15 days, consistent with our previous findings in this mouse model (Cabrera-Salazar et al. (2010)). Systemic (IP) treatment of K14 mice with GZ 161 resulted in an extension in médian lifespan to 18 days (p<0.0001 ), consistent with a benefit of the molecular and cellular effects of the drug in the brain shown above.
In previous experiments, it was shown in the K14 mouse that néonatal (P1-P3) întracerebroventricular injections of GC could extend médian survival even further, viz., to 23 days (Cabrera-Salazar et al. (2010)). Because GC and GZ 161 both hâve the potential to decrease levels of the same glycosphingolipid, namely GluCer (GC by degrading GluCer; GZ 161 by inhibiting ïts synthesis) we also asked whether the combination of Gz161 and întracerebroventricular (ICV) administration of GC would provide survival benefit superiorto that resulting from either individual agent. Fig. 14 demonstrates that the combination of ICV GC (at P1,2,3) and daily IP Gz161 led to a médian survival of 26 days, significantly greaterthan GZ 161 alone or ICV GC (p=0.0007). Thus, systemic administration of GZ 161 appears to be additive to ICV GC, and provides additional survival benefit
Example 126
Prénatal administration of GZ 161 fails to increase survival of K14 mice
171
Because the GluSph levels in the K14 mouse brain were found to be elevated at least 10fold over normal at P1, and it has been documented that GluSph is elevated in the brains of mîce and humans affected by nGD even prenatally (Orvisky et al., Pédiatrie Research 48: 233-237 (2000)), it was investigated whether a survival advantage could be gained by treating K14 mice with GZ 161 in utero. Fig. 15 shows that treating WT mouse dams with GZ 161 led to an — 5-fold decrease in GluCer levels in the newborn mouse brain (PO), suggesting that GZ 161 could cross the blood/placental barrier. However, giving K14 dams GZ 161 and then treating the resulting pups IP with GZ 161 failed to extend survival beyond that of mice given systemic GZ 161 postnatally alone (18 days) (Figs. 14 and 16). These data are thus consistent with the results described in Fig. 14, and imply that although GZ 161 can effect réductions in glycosphingolipids and neuropathology, the current treatment régime is insufficient to rescue the CNS. These results are consistent with our previous results in this model using intracerebroventricular injections of recombinant human glucocerebrosidase (Cabrera-Salazar et al. (2010)), and together suggest that more robust and continuous déplétion of glycosphingolipids such as GluCer will be necessary to improve survival further.
These data show both qualitatively and quantitatively that systemic (IP) administration of GZ 161 to néonatal K14 mice significantly reduces substrate load, améliorâtes the pathological features of the disease and increases médian lifespan. When combined with ICV-delivered rhGC, systemic administration of GZ 161 resulted in additive increases in lifespan, rmplying that such a combination might be more effïcacious than either monotherapy alone in nGD patients. Given the implications of these studies that GZ 161 can apparently cross the BBB and inhibit its target enzyme, glucosylceramide synthase, it is reasonable to assume that this molécule could also be used to treat other LSDs resulting from a buildup of substrates downstream from GluCer.
It is important to note that in the current studies, GZ 161 was administered to K14 mice in a time frame in which GluCer and GluSph were being produced in the developing mouse brain at relatively high levels compared to WT mice (Fig. 9); Brenkert et al., 1972). Daily IP treatment with GZ 161 successfully reduced, but did not normalîze GluCer and GluSph levels in the K14 brain (Fig. 10). There are several Unes of evidence suggesting that GluSph and other lysosphingolipids such as galactosyl sphingosine may contribute to CNS pathology by initiating the production of inflammatory mediators Gtri et al., Journal of lipid research 47:1478-1492 (2006) and Grâler et al., Molecular and Cell Biology of Lipids 1582: 168-174 (2002). The ability of GZ 161 to decrease GluSph levels and concurrently resuit in decreased macrophage/microglial and astrocyte staining
172 (Figs. 11-13) is consistent with this hypothesis, Because GluSph also has known neurotoxic properties (Schueler et al., Neurobiology of Disease 14: 595-601 (2003); Orvisky et al., Molecular Genetics and Metabolism 76: 262-270 (2002); Sun et al., Hum Mol Genet 19:1088-1097 (2010); and Pelled et al., Journal of Inherited Metabolic Disease 23:175-184 (2000)), the inability of GZ 161 treatment to normalize GluSph levels is consistent with GluSph as a potential contributor to the early death seen in this model.
Taken together, the preclinical results in the K14 mouse model shown here suggest that administration of GZ 161 may mitigate disease progression and neurologie symptoms in type 2 and type 3 Gaucher disease patients. However, it is difficult to predict the potential benefits of such a therapeutic approach in symptomatîc type 2 patients since it is known that their brains contain very high levels of GluSph that date back to prénatal life. Goker-Alpan et al., The Journal of Pediatrics 143: 273-276 (2003). Type 3 Gaucher disease may be more amenable to treatment since the brain levels of GluSph are lower (Nilsson, J Neurochem 39: 709-718 (1982), the progression of the disease is slower despite being part of a phenotypic continuum (Goker-Alpan et al. (2003)), and in some cases the patients can be identified by mutational analysis before the onset of the neuropathie phenotype (Ida et al., Human Genetics 105:120-126 (1999)). Based on the current results, it would appear that an early, aggressive approach will be needed to treat these patients. Small molécule inhibitors of glucosylceramide synthase may represent one arm of a comprehensive approach.
Example 127
SMT of male and female Fabry mice treated with GZ 452, GZ 161 and GZ 638.
Fabry mice began treatment at -8 months old and were treated for 4 months with: 60 mg/kg/day GZ 452 (Fab 452@ 60mkd), 120 mg/kg/day GZ 452 (Fab 452 @120mkd), 20 mg/kg/day GZ 161 (Fab 161 @20mkd), 300 mg/kg/day GZ 638 (Fab 638 @300 mkd). Kidney tissue from 12 month old male and female Fabry mice were tested for Gb3 levels. As shown in FIG. 17, GZ 161 and GZ 452 significantly reduced the amount of Gb3 présent in kidney tissue relative to untreated controls (Fab UNT 12mo).
173
Claims
Claims (20)
- Claims1. A compound represented by the following structural formula,E or a pharmaceutically acceptable sait or prodrug thereof, wherein:n is 1,2 or 3;m is 0 or 1 ;p is 0 or 1;t is 0, 1 or 2;y is 1 or 2;z is 0, 1 or 2;E is S, O, NH, NOH, NNO2, NCN, NR, NOR or NSO2R;X1is CR1 when m is 1 or N when m is 0;X2 is O, -NH, -CH2-, SO2, NH-SO^CHtCrCe) alkyl or -NR2 ;X3 is O, -NH, -CH2-, CO, - CH(CrCe) alkyl, SO2NH, -CO-NH- or-NR3;X4 is CR4R5, CH2 CR4R5or CH2 -(CrCe) alkyl-CR4R5;X5 is a direct bond, O, S, SO2, CR4R5; (CrCgJalkyl, (CrC6)alkyloxy, (CrCsJalkenyl, (Cr C6)alkenyloxy;R is (C6-C12)aryl, (C2-C9)heteroaryl, (Ci-C6)alkyl, (C2-Cg)heteroaryl(C1-C6)alkyl;R1 is H,CN, (Ci-C6)alkylcarbonyl, or (CrC6)alkyî;I74R2 and R3 are each independently -H, (Ci-Ce)alkyl optionally substituted by one or more substituents selected from the group consisting of halogen, (CrCeJalkyl, (C0-C12)aryl, (C2C9)heteroaryl, (CrCeJalkyKCs-C^Jaryl, halo(C6-C12)aryl, and halo(C2-Cg)heteroaryl, or optionally when X2 is -NR2 and X3 is -NR3, R2 and R3 may be taken together with the nitrogen atoms to which they are attached form a non-aromatic heterocyclic ring optionally substituted by with one or more substituents selected from halogen, (Ci-C6)alkyl, (C6-C12)aryl, (C2-C9)heteroaryl, (CrC^alkyKCeC12)aryl, halo(C6-Ci2)aryl, and halo(C2-C9)heteroaryl;R4 and R5 are independently selected from H, (CrCeJalkyl, or taken together with the carbon to which they are attached to form a spiro (C3-Cio)cycloalkyl ring or spiro (C3-Ci0)cycloalkoxy ring;R6 Îs-H, halogen, -CN, (Ce-C12)aryl, (C6-C12)aryloxy, (CrC6)alkyloxy;(CrCejalkyl optionally substituted by one to four halo or (CrC6)alkyl;A1 is (C2-C6)alkynyl; (C3-C10)cycloalkyl, (C6-C12)aryl, (CrCg)heteroaryl, (C2Cgjheterocycloalkyl or benzo(C2-C9)heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of halo, (CrC6)alkyl optionally substituted by one to three halo; (Ci-C6)alkenyl, amino, (CrCeJalkylamino, (CrC6)dialkylamino, (Ci-C6)alkoxy, nîtro, CN, OH, (CrCe)alkyloxy optionally substituted by one to three halo; (CrCeJalkoxycarbonyl, and (CrC6) alkylcarbonyl;A2 is H, (C3-C10)cycloalkyl, (C6-C12)aryl, (C2-C9)heteroaryl, ( C2-C9) h etero cycloalkyl or benzo(C2-C9)heterocycloalkyl optionally substituted with one or more substituents selected from the group consisting of halo, (CrCeJalkyl optionally substituted by one to three halo; (Ci-Ce)alkylenyl, amino, (CrCe) alkylamino, (CrCeJdialkylamino, (CpCejalkoxy, O(C3-C6 cycloalkyl), (C3-C6) cycloalkoxy, nitro, CN, OH, (CrC6)alkyloxy optionally substituted by one to three halo; (C3-C6) cycloalkyl, (Ci-C6) alkoxycarbonyl, (CrC6) alkylcarbonyl, (CpCe) haloalkyl;with the proviso that the sum of n +1 + y + z is not greater than 6;with the proviso that when p is 0; X2 is NH-SO2 and X3 is NH;with the proviso that when n is 1 ; t is 0; y is 1 ; z is 1 ; X2 is NH; E is Ο; X3 is NH; A2 is H and X5 is a direct bond; A1 is not unsubstituted phenyl, halophenyl or isopropenyl phenyl;with the proviso that when n is 1 ; t is 0; y is 1 ; z is 1 ; X2 is O; E is Ο; X3 is NH; A1 is (C6C12)aryl and X5 is a direct bond; A2 is H and R4 is H then R5is not cyclohexyl; and with the proviso that when n is 1 ; t is 0; y is 1 ; z is 1 ; X2 is NH; E is Ο; X3 is CH2; R4 and R5 are both hydrogen; A2 is H and X5 is a direct bond; then A1 is not unsubstituted phenyl.175
- 2. A compound according to claim 1, wherein n is 1 ; t is 0; y is 1 and z is 1.
- 3. A compound according to claim 1, wherein m is 1 and X1 is CR1.
- 4. A compound according to claim 1, wherein m is 0 and X1 is N.
- 5. A compound according to claim 1, wherein m is 1 ; E is Ο; X2 is O and X3 is NH.
- 6. A compound according to claim 1, wherein A1 is (C2-Cg)heteroaryl.
- 7. A compound according to claim 6, wherein A1 is thiophene, thiazole, isothiazole, furane, oxazole, isoxazole, pyrrole, imidazole, pyrazole, triazole, pyridine, pymiridine, pyridazine, indole, benzotiazole, benzoisoxazole, benzopyrazole, benzoimidazole, benzofuran, benzooxazole or benzoisoxazole.
- 8. A compound according to claim 1, wherein n is 1; 2 or 3; t is 0,1 or 2; y is 0 or 1; z is 0, 1 or 2; X1 is CR1; m is 1; p is 1; E is Ο; X2 is Ο; X3 is NH; R1 is H; R4 and R5 are each independently methyl; R6 is a hydrogen or methyl; A1 is (C2-Cg)heteroaryl; X5 is a direct bond, O or CR4R5and A2 is (C6-C12)aryl.
- 9. A compound according to claim 1, represented by the following structural formula, or a pharmaceutically acceptable sait or prodrug thereof.176
- 10. A compound according to claim 1, represented by the following structural formula, or a pharmaceutically acceptable sait or prodrug thereof.
- 11. A method of treating a subject diagnosed as having a lysosomal storage disease, comprising administering to the subject an effective amount of the compound according to claim 1.
- 12. The method of claim 11, wherein the lysosomal storage disease results from a defect in the glycosphingolipid pathway.
- 13. The method of claim 12, wherein the lysosomal storage disease is selected from the group consisting of Gaucher, Fabry, GMi-gangliosidosis, GM2 Activator deficiency, Tay-Sachs and Sandhoff.
- 14. The method of claim 13, wherein the lysosomal storage disease is Fabry.
- 15. The method of claim 11, further comprising the step of administering to the subject a therapeutically effective amount of a lysosomal enzyme.177
- 16. The method of claim 15, wherein the lysosomal enzyme is selected from the group consisting of glucocerebrosidase, alpha-galactosidase A, Hexosaminidase A, Hexosaminidase B and GMr ganglioside-p-galactosidase.
- 17. The method of claim 16, wherein the lysosomal enzyme is alpha-galactosidase A.
- 18. The method of claim 11, wherein the compound is represented by the following structural formula, or a pharmaceutically acceptable sait or prodrug thereof.
- 19. The method of claim 11, wherein the compound is represented by the following structural formula, or a pharmaceutically acceptable sait or prodrug thereof.
- 20. A method of reducing glucosylceramide synthase (GCS) activity in a subject diagnosed as having a lysosomal storage disorder, comprising administering to the patient an effecti the compound according to claim 1, either alone or as a combination therapy with a^Æ / I replacement therapy. / / 7*/
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/454,034 | 2011-03-18 | ||
US61/590,711 | 2012-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16599A true OA16599A (en) | 2015-11-20 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210261557A1 (en) | Glucosylceramide synthase inhibitors | |
US12060349B2 (en) | Glucosylceramide synthase inhibitors | |
US20220409595A1 (en) | Glucosylceramide synthase inhibitors | |
OA16599A (en) | Glucosylceramide synthase inhibitors. | |
SG193532A1 (en) | Glucosylceramide synthase inhibitors | |
NZ615857B2 (en) | Glucosylceramide synthase inhibitors |